



# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

VOLUME 20 • ISSUE 2 • MARCH 2019

## Original Articles

Regorafenib Results in Metastatic  
Colorectal Cancer

Şahin and Hacıoğlu. Van, Konya, Turkey

Ovarian Cancer

Kaban et al. İstanbul, Turkey

Abdominal Wall Endometriosis

Bacanakgil et al. İstanbul, Turkey

Cervical Length Measurement

Sezer et al. İstanbul, Turkey

The Diaphragm Thickness

Measurements on CT

Ufuk et al. Denizli, Turkey

Vitamin D Deficiency Among Female

University Students

Filiz Tuna. Edirne, Turkey

Lumbar Multifidus Muscle Change

Emrah Sayit. Samsun, Turkey

Pilonidal Disease and Liquid Phenol

Öztürk and Karaköse. İstanbul, Turkey

Superficial Laryngeal Nerve Injury

Özben et al. İstanbul, Turkey

Inflammation/Mortality in Geriatric  
Abdominal Pain

Öncül et al. Ankara, Turkey

RANKL and OPG in DM2

Gümüş et al. İstanbul, Turkey

Obesity Prevalence and Associated  
Factors

Özdenk and Özcebe. Kırşehir, Ankara, Turkey

Whom Should We Treat?

Ceylan et al. İstanbul, Turkey

[istanbulmedicaljournal.org](http://istanbulmedicaljournal.org)



# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

Owned by on behalf of the Health Sciences University İstanbul Training and Research Hospital  
Özgür YİĞİT

**Executive Editor**  
Tevfik Fikret ÇERMİK

**Editor in Chief**  
Tevfik Fikret ÇERMİK

Clinic of Nuclear Medicine, Health Sciences University İstanbul Training and Research Hospital, İstanbul, Turkey

**Associate Editors**

**Turgut KARABAĞ**

Department of Cardiology, Bülent Ecevit University School of Medicine, Zonguldak, Turkey

**Serkan SARI**

Clinic of General Surgery, Health Sciences University, İstanbul Training and Research Hospital, İstanbul, Turkey

**Behiye Pınar GÖKSEDEF**

Clinic of Obstetrics and Gynecology, Health Sciences University İstanbul Haseki Training and Research Hospital, İstanbul, Turkey

**Feray AKBAŞ**

Clinic of Internal Diseases, Health Sciences University İstanbul Training and Research Hospital, İstanbul, Turkey

**Owner**

**Özgür YİĞİT**

Clinic of Otorhinolaryngology, Health Sciences University İstanbul Training and Research Hospital, İstanbul, Turkey

**Publishing Manager**

**Tevfik Fikret ÇERMİK**

Clinic of Nuclear Medicine, Health Sciences University İstanbul Training and Research Hospital, İstanbul, Turkey



**Galenos Publishing House**  
Owner and Publisher  
Erkan Mor

**Publication Coordinator**  
Burak Sever

**Web Coordinators**  
Turgay Akpınar

**Graphics Department**  
Ayda Alaca  
Çiğdem Birinci  
Gülşah Özgül

**Project Coordinators**

Duygu Yıldırım  
Eda Kolukısa

Hatice Balta  
Melike Eren

Pelin Bulut  
Saliha Tuğçe Güdücü  
Zeynep Altındağ

**Project Assistants**

Gamze Aksoy  
Nurcan Acarçağ

**Finance Coordinator**  
Sevinç Çakmak

**Research&Development**  
Kerim Sancar Ölmez  
Mert Can Köse

**Publisher Contact**

Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1  
34093 İstanbul, Turkey

Phone: +90 (212) 621 99 25 Fax: +90 (212) 621 99 27

E-mail: info@galenos.com.tr/yayin@galenos.com.tr

Web: www.galenos.com.tr

Publisher Certificate Number: 14521

Printing at: Üniform Basım San. ve Turizm Ltd. Şti.  
Matbaacılar Sanayi Sitesi 1. Cad. No: 114 34204 Bağcılar, İstanbul, Turkey

Phone: +90 (212) 429 10 00

Certificate Number: 42419

Printing Date: March 2019

ISSN: 2619-9793 E-ISSN: 2148-094X

International periodical journal published three times in a year.



# İstanbul MEDICAL JOURNAL

İ S T A N B U L T I P D E R G İ S İ

## Advisory Board

N. Volkan ADSAY

Department of Pathology, Emory University Hospital,  
Atlanta GA, USA

Sedat ALTIN

Clinic of Chest Diseases, Health Sciences University Yedikule  
Chest Diseases and Chest Surgery Training and Research Hospital,  
İstanbul, Turkey

Ferihan ARAL

Department of Endocrine Diseases, İstanbul University  
İstanbul School of Medicine, İstanbul, Turkey

Baki ARPACI

Department of Neurology, Bakırköy Psychiatric Hospital,  
İstanbul, Turkey

Talip AŞİL

Department of Neurology, Bezmialem Vakıf University  
School of Medicine, İstanbul, Turkey

Ali ATAŞ

Department of Child Health and Diseases, Harran University  
School of Medicine, Şanlıurfa, Turkey

Yağmur AYDIN

Department of Plastic and Reconstructive Surgery, İstanbul  
University-Cerrahpaşa School of Medicine, İstanbul, Turkey

Mustafa BAŞBUĞ

Department of Gynecology and Obstetrics, Erciyes University  
School of Medicine, Kayseri, Turkey

Hasan BEKTAŞ

Clinic of General Surgery, Health Sciences University İstanbul  
Training and Research Hospital, İstanbul, Turkey

Levent CANSEVER

Health Sciences University, Yedikule Chest Diseases and Chest  
Surgery Training and Research Hospital, Clinic of Chest Surgery  
İstanbul, Turkey

Nil ÇAĞLAR

Clinic of Physical Therapy and Rehabilitation, Health Sciences  
University İstanbul Training and Research Hospital,  
İstanbul, Turkey

Gürhan ÇELİK

Clinic of General Surgery, Health Sciences University İstanbul  
Training and Research Hospital, İstanbul, Turkey

Oğuz ÇETİNKALE

Department of Plastic and Reconstructive Surgery, İstanbul  
University-Cerrahpaşa School of Medicine, İstanbul, Turkey

Fuat DEMİRKIRAN

Department of Gynecology and Obstetrics, İstanbul University-  
Cerrahpaşa School of Medicine, İstanbul, Turkey

Feza EKİZ

Department of General Surgery, Hepatobiliary Surgery and  
Gastrointestinal Surgery, İstanbul University İstanbul  
School of Medicine, İstanbul, Turkey

Murat ELEVİLİ

Clinic of Child Health and Diseases, Health Sciences University  
İstanbul Haseki Training and Research Hospital, İstanbul, Turkey

Haluk EMİR

Department of Pediatric Surgery, İstanbul University-Cerrahpaşa  
School of Medicine, İstanbul, Turkey

Veysel ERDEN

Clinic of Anesthesiology and Reanimation, Health Sciences  
University İstanbul Training and Research Hospital,  
İstanbul, Turkey

Fusun ERDENEN

Clinic of Internal Medicine, Health Sciences University  
İstanbul Training and Research Hospital, İstanbul, Turkey

Acar AREN

Clinic of General Surgery, Health Sciences University  
İstanbul Training and Research Hospital, Turkey

Elvan ERHAN

Department of Algology, Ege University School of Medicine,  
İzmir, Turkey

Selim GÖKÇE

Department of Pediatric Gastroenterology, Biruni University  
School of Medicine, İstanbul, Turkey

Gonca GÖKDEMİR

Clinic of Dermatology, Health Sciences University Şişli Hamidiye  
Etfal Training and Research Hospital, İstanbul, Turkey

Mehmet Salih GÜREL

Department of Dermatology, İstanbul Medeniyet University  
School of Medicine, İstanbul, Turkey

Abdil Cem İBİŞ

Department of General Surgery, Hepatobiliary Surgery, İstanbul  
University İstanbul School of Medicine, İstanbul, Turkey

Gökhan İPEK

Department of Cardiovascular Surgery, İstanbul University-  
Cerrahpaşa School of Medicine, İstanbul, Turkey

Sibel KALAÇA

Department of Public Health, Marmara University  
School of Medicine, İstanbul, Turkey



# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

**Kamil KAYNAK**

Department of Thoracic Surgery, İstanbul University-Cerrahpaşa  
School of Medicine, İstanbul, Turkey

**Mehmet Yaşar KAYNAR**

Department of Neurosurgery, İstanbul University-Cerrahpaşa  
School of Medicine, İstanbul, Turkey

**Esra SAĞLAM KAYTAN**

Department of Radiation Oncology, İstanbul University  
İstanbul School of Medicine, İstanbul, Turkey

**Hayrettin KESMEZACAR**

Department of Orthopedics and Traumatology,  
İstanbul Bilim University School of Medicine, İstanbul, Turkey

**Özgür KILIÇKESMEZ**

Clinic of Radiology, Health Sciences University  
İstanbul Training and Research Hospital, İstanbul, Turkey

**Altan KIR**

Clinic of Thoracic Surgery, Department of Thoracic and  
Cardiovascular Health, Anadolu Health Centre, Kocaeli, Turkey

**Zafer KOÇAK**

Department of Radiation Oncology, Trakya University  
School of Medicine, Edirne, Turkey

**Uğur KORMAN**

Department of Radiodiagnostics, İstanbul University-Cerrahpaşa  
School of Medicine, İstanbul, Turkey

**Kadir KOTİL**

Academy of Medical Science, İstanbul Arel University  
School of Health Sciences, İstanbul, Turkey

**Güniz MEYANCI KÖKSAL**

Department of Anesthesiology and Reanimation, İstanbul  
University-Cerrahpaşa School of Medicine, Turkey

**Cüneyt MÜDERRİSOĞLU**

Department of Internal Medicine, Health Sciences University  
İstanbul Training and Research Hospital, İstanbul, Turkey

**Öner ÖZDEMİR**

Department of Pediatrics, Division of Pediatric Allergy and  
Immunology, Sakarya University Faculty of Medicine, Sakarya,  
Turkey

**Yusuf ÖZTÜRKMEN**

Clinic of Orthopedics, Health Sciences University  
İstanbul Training and Research Hospital, İstanbul, Turkey

**Zuhal PARILDAR**

Department of Biochemistry, Ege University School of Medicine,  
İzmir, Turkey

**Mehmet Emin PIŞKINPAŞA**

Clinic of Internal Medicine, Health Sciences University  
İstanbul Training and Research Hospital, İstanbul, Turkey

**Ziya SALİHOĞLU**

Department of Anesthesiology and Reanimation, Cerrahpaşa  
School of Medicine, İstanbul University, İstanbul, Turkey

**Kaya SARİBEYOĞLU**

Department of General Surgery, İstanbul University-Cerrahpaşa  
School of Medicine, İstanbul, Turkey

**Atakan SEZER**

Department of General Surgery, Trakya University  
School of Medicine, Edirne, Turkey

**Yunus SÖYLET**

Department of Pediatric Surgery, İstanbul University-Cerrahpaşa  
School of Medicine, İstanbul, Turkey

**Ali İhsan TAŞCI**

Clinic of Urology, Bakırköy Dr. Sadi Konuk Training and Research  
Hospital, İstanbul, Turkey

**Mahmut Gökhan TOKTAŞ**

Clinic of Urology, Health Sciences University İstanbul Training and  
Research Hospital, İstanbul, Turkey

**Emine Nur TOZAN**

Department of Algology, İstanbul University İstanbul  
School of Medicine, İstanbul, Turkey

**Volkan TUĞCU**

Clinic of Urology, Bahçelievler Memorial Hospital, İstanbul,  
Turkey

**Yalçın TÜZÜN**

Department of Dermatology, İstanbul University-Cerrahpaşa  
School of Medicine, İstanbul, Turkey

**Ayşe YALIMAN**

Department of Physical Medicine and Rehabilitation,  
İstanbul University İstanbul School of Medicine, İstanbul, Turkey

**Nurhayat YILDIRIM**

Department of Chest Diseases, İstanbul University-Cerrahpaşa  
School of Medicine, İstanbul, Turkey

**Orhan YILMAZ**

Clinic of Otolaryngology, Health Sciences University Dışkapı  
Yıldırım Beyazıt Training and Research Hospital, Ankara, Türkiye

**Özgür YİĞİT**

Clinic of Otorhinolaryngology, Health Sciences University  
İstanbul Training and Research Hospital, İstanbul, Turkey

[istanbulmedicaljournal.org](http://istanbulmedicaljournal.org)





# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

## AIMS AND SCOPE

İstanbul Medical Journal is the scientific, peer reviewed, open access publication of İstanbul Training and Research Hospital. The journal is printed six times in a year; on January, March, May, July, September, November and its publication language is Turkish and English.

The aim of the journal is to publish high level clinical and experimental studies conducted in all fields of medicine. Reviews comprising the latest research findings, reports on rare and educative cases and letters to the editor are also published.

The target population of the journal includes specialists in all fields of medicine, academicians and relevant health care professionals.

The İstanbul Medical Journal is indexed in Web of Science-Emerging Sources Citation Index, TUBITAK ULAKBİM TR Index, EBSCO and GALE.

Processing and publication are free of charge with the journal. No fees are requested from the authors at any point throughout the evaluation and publication process. All manuscripts must be submitted via the online submission system, which is available at [www.istanbulmedicaljournal.org](http://www.istanbulmedicaljournal.org). The journal guidelines, technical information, and the required forms are available on the journal's web page.

All expenses of the journal are covered by the İstanbul Training and Research Hospital. Potential advertisers should contact the Editorial Office. The journal does not publish advertisement.

Statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the opinions of the İstanbul Training and Research Hospital, editors, editorial board, and/or publisher; the editors, editorial board, and publisher disclaim any responsibility or liability for such materials.

All published content is available online, free of charge at [www.istanbulmedicaljournal.org](http://www.istanbulmedicaljournal.org). Printed copies of the journal are distributed to the members of İstanbul Training and Research Hospital as well as the members of the editorial board and the journal's reviewers, free of charge.

İstanbul Training and Research Hospital holds the international copyright of all the content published in the journal.

### Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Open Access Policy is based on the rules of the Budapest Open Access Initiative (BOAI) <http://www.budapestopenaccessinitiative.org/>. By "open access" to peer-reviewed research literature, we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

**Editor: Tevfik Fikret ÇERMİK**

Address: Clinic of Nuclear Medicine, Health Sciences University İstanbul Training and Research Hospital, İstanbul, Turkey

Fax: +90 (212) 530 80 55 E-mail: [tevfik.cermik@sbu.edu.tr](mailto:tevfik.cermik@sbu.edu.tr)

**Publisher : GALENOS PUBLISHING HOUSE**

Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1 Fındıkzade 34093 İstanbul, Turkey

Phone: +90 (212) 621 99 25 Fax: +90 (212) 621 99 27 E-mail: [info@galenos.com.tr](mailto:info@galenos.com.tr)/[yayin@galenos.com.tr](mailto:yayin@galenos.com.tr) Web: [www.galenos.com.tr](http://www.galenos.com.tr)





# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

## INSTRUCTIONS TO AUTHORS

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing ([doaj.org/bestpractice](http://doaj.org/bestpractice)).

Originality, high scientific quality, and citation potential are the most important criteria for a manuscript to be accepted for publication. Manuscripts submitted for evaluation should not have been previously presented or already published in an electronic or printed medium. The journal should be informed of manuscripts that have been submitted to another journal for evaluation and rejected for publication. The submission of previous reviewer reports will expedite the evaluation process. Manuscripts that have been presented in a meeting should be submitted with detailed information on the organization, including the name, date, and location of the organization.

Manuscripts submitted to İstanbul Medical Journal will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in their fields in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions.

An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects," amended in October 2013, [www.wma.net](http://www.wma.net)) is required for experimental, clinical, and drug studies and for some case reports. If required, ethics committee reports or an equivalent official document will be requested from the authors. For manuscripts concerning experimental research on humans, a statement should be included that shows that written informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo. For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. In experimental animal studies, the authors should indicate that the procedures followed were in accordance with animal rights as per the Guide for the Care and Use of Laboratory Animals <http://oacu.od.nih.gov/regs/guide/guide.pdf> and they should obtain animal ethics committee approval. Information on patient consent, the name of the ethics committee, and the ethics committee approval number should also be stated in the Materials and Methods section of the manuscript. It is the authors' responsibility to carefully protect the patients' anonymity. For photographs that may reveal the identity of the patients, signed releases of the patient or of their legal representative should be enclosed.

All submissions are screened by a similarity detection software (iThenticate by CrossCheck).

In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, and data falsification/fabrication, the Editorial Board will follow and act in accordance with COPE guidelines.

Each individual listed as an author should fulfill the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE - [www.icmje.org](http://www.icmje.org)). The ICMJE recommends that authorship be based on the following 4 criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he/she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged in the title page of the manuscript.

İstanbul Medical Journal requires corresponding authors to submit a signed and scanned version of the authorship contribution form (available for download through [www.istanbulmedicaljournal.org](http://www.istanbulmedicaljournal.org)) during the initial submission process in order to act appropriately on authorship rights and to prevent ghost or honorary authorship. If the editorial board suspects a case of "gift authorship," the submission will be rejected without further review. As part of the submission of the manuscript, the corresponding author should also send a short statement declaring that he/she accepts to undertake all the responsibility for authorship during the submission and review stages of the manuscript.

İstanbul Medical Journal requires and encourages the authors and the individuals involved in the evaluation process of submitted manuscripts to disclose any existing or potential conflicts of interests, including financial, consultant, and institutional, that might lead to potential bias or a conflict of interest. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board. To disclose a potential conflict of interest, the ICMJE Potential Conflict of Interest Disclosure Form should be filled in and submitted by all contributing authors. Cases of a potential conflict of interest of the editors, authors, or reviewers are resolved by the journal's Editorial Board within the scope of COPE and ICMJE guidelines.



# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

## INSTRUCTIONS TO AUTHORS

The Editorial Board of the journal handles all appeal and complaint cases within the scope of COPE guidelines. In such cases, authors should get in direct contact with the editorial office regarding their appeals and complaints. When needed, an ombudsperson may be assigned to resolve cases that cannot be resolved internally. The Editor in Chief is the final authority in the decision-making process for all appeals and complaints.

When submitting a manuscript to İstanbul Medical Journal, authors accept to assign the copyright of their manuscript to İstanbul Training and Research Hospital. If rejected for publication, the copyright of the manuscript will be assigned back to the authors. İstanbul Medical Journal requires each submission to be accompanied by a Copyright Transfer Form (available for download at [www.istanbulmedicaljournal.org](http://www.istanbulmedicaljournal.org)). When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Statements or opinions expressed in the manuscripts published in İstanbul Medical Journal reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility in regard to the published content rests with the authors.

### MANUSCRIPT PREPARATION

The manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in December 2016 - <http://www.icmje.org/icmje-recommendations.pdf>). Authors are required to prepare manuscripts in accordance with the CONSORT guidelines for randomized research studies, STROBE guidelines for observational original research studies, STARD guidelines for studies on diagnostic accuracy, PRISMA guidelines for systematic reviews and meta-analysis, ARRIVE guidelines for experimental animal studies, and TREND guidelines for non-randomized public behavior.

Manuscripts can only be submitted through the journal's online manuscript submission and evaluation system, available at [www.istanbulmedicaljournal.org](http://www.istanbulmedicaljournal.org). Manuscripts submitted via any other medium will not be evaluated.

Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal's guidelines. Submissions that do not conform to the journal's guidelines will be returned to the submitting author with technical correction requests.

Authors are required to submit the following:

- Copyright Transfer Form,
- Author Contributions Form, and
- ICMJE Potential Conflict of Interest Disclosure Form (should be filled in by all contributing authors)

during the initial submission. These forms are available for download at [www.istanbulmedicaljournal.org](http://www.istanbulmedicaljournal.org).

### Preparation of the Manuscript

Title page: A separate title page should be submitted with all submissions and this page should include:

- The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
- Name(s), affiliations, and highest academic degree(s) of the author(s),
- Grant information and detailed information on the other sources of support,
- Name, address, telephone (including the mobile phone number) and fax numbers, and email address of the corresponding author,
- Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria.

Abstract: A Turkish and an English abstract should be submitted with all submissions except for Letters to the Editor. Submitting a Turkish abstract is not compulsory for international authors. The abstract of Original Articles should be structured with subheadings (Objective, Methods, Results, and Conclusion). Please check Table 1 below for word count specifications.

Keywords: Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (<https://www.nlm.nih.gov/mesh/MBrowser.html>).

### Manuscript Types

Original Articles: This is the most important type of article since it provides new information based on original research. The main text of original articles should be structured with Introduction, Methods, Results, Discussion, and Conclusion subheadings. Please check Table 1 for the limitations for Original Articles.

Statistical analysis to support conclusions is usually necessary. Statistical analyses must be conducted in accordance with international statistical reporting standards (Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. *Br Med J* 1983; 7; 1489-93). Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.

Units should be prepared in accordance with the International System of Units (SI).

Editorial Comments: Editorial comments aim to provide a brief critical commentary by reviewers with expertise or with high reputation in the topic of the research article published in the journal. Authors are selected and invited by the journal to provide such comments. Abstract, Keywords, and Tables, Figures, Images, and other media are not included.



# İstanbul MEDICAL JOURNAL

İSTANBUL TIP DERGİSİ

## INSTRUCTIONS TO AUTHORS

**Review Articles:** Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed. These authors may even be invited by the journal. Reviews should describe, discuss, and evaluate the current level of knowledge of a topic in clinical practice and should guide future studies. The main text should contain Introduction, Clinical and Research Consequences, and Conclusion sections. Please check Table 1 for the limitations for Review Articles.

**Case Reports:** There is limited space for case reports in the journal and reports on rare cases or conditions that constitute challenges in diagnosis and treatment, those offering new therapies or revealing knowledge not included in the literature, and interesting and educative case reports are accepted for publication. The text should include Introduction, Case Report, Discussion, and Conclusion subheadings. Please check Table 1 for the limitations for Case Reports.

**Letters to the Editor:** This type of manuscript discusses important parts, overlooked aspects, or lacking parts of a previously published article. Articles on subjects within the scope of the journal that might attract the readers' attention, particularly educative cases, may also be submitted in the form of a "Letter to the Editor." Readers can also present their comments on the published manuscripts in the form of a "Letter to the Editor." Abstract, Keywords, and Tables, Figures, Images, and other media should not be included. The text should be unstructured. The manuscript that is being commented on must be properly cited within this manuscript.

Table 1. Limitations for each manuscript type					
Type of manuscript	Word limit	Abstract word limit	Reference limit	Table limit	Figure limit
Original Article	3500	250 (Structured)	30	6	7 or total of 15 images
Review Article	5000	250	50	6	10 or total of 20 images
Case Report	1000	200	15	No tables	10 or total of 20 images
Letter to the Editor	500	No abstract	5	No tables	No media

### Tables

Tables should be included in the main document, presented after the reference list, and they should be numbered consecutively in the order they are referred to within the main text. A descriptive title must be placed above the tables. Abbreviations used in the tables should be defined below the tables by footnotes (even if they are defined within the main text). Tables should be created using the "insert table" command of the word processing software and they should be arranged clearly to provide easy reading. Data presented in the tables should not be a repetition of the data presented within the main text but should be supporting the main text.

### Figures and Figure Legends

Figures, graphics, and photographs should be submitted as separate files (in TIFF or JPEG format) through the submission system. The files should not be embedded in a Word document or the main document. When there are figure subunits, the subunits should not be merged to form a single image. Each subunit should be submitted separately through the submission system. Images should not be labeled (a, b, c, etc.) to indicate figure subunits. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends. Like the rest of the submission, the figures too should be blind. Any information within the images that may indicate an individual or institution should be blinded. The minimum resolution of each submitted figure should be 300 DPI. To prevent delays in the evaluation process, all submitted figures should be clear in resolution and large in size (minimum dimensions: 100 × 100 mm). Figure legends should be listed at the end of the main document.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition.

When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the product, the producer of the product, and city and the country of the company (including the state if in USA), should be provided in parentheses in the following format: "Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)"

All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text.

Limitations, drawbacks, and the shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

### References

While citing publications, preference should be given to the latest, most up-to-date publications. If an ahead-of-print publication is cited, the DOI number should be provided. Authors are responsible for the accuracy of references. Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus/ MEDLINE/PubMed. When there are six or fewer authors, all authors should be listed. If there are seven or more authors, the first six authors should be listed followed by "et al." In the main text of the manuscript, references should be cited using Arabic numbers in parentheses. The reference styles for different types of publications are presented in the following examples.

**Journal Article:** Rankovic A, Rancic N, Jovanovic M, Ivanović M, Gajović O, Lazić Z, et al. Impact of imaging diagnostics on the budget – Are we spending too much? *Vojnosanit Pregl* 2013; 70: 709-11.

**Book Section:** Suh KN, Keystone JS. Malaria and babesiosis. Gorbach SL, Barlett JG, Blacklow NR, editors. *Infectious Diseases*. Philadelphia: Lippincott Williams; 2004.p.2290-308.



# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

## INSTRUCTIONS TO AUTHORS

Books with a Single Author: Sweetman SC. Martindale the Complete Drug Reference. 34th ed. London: Pharmaceutical Press; 2005.

Editor(s) as Author: Huizing EH, de Groot JAM, editors. Functional reconstructive nasal surgery. Stuttgart-New York: Thieme; 2003.

Conference Proceedings: Bengissson S. Sothemin BG. Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, editors. MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics; 1992 Sept 6-10; Geneva, Switzerland. Amsterdam: North-Holland; 1992. pp.1561-5.

Scientific or Technical Report: Cusick M, Chew EY, Hoogwerf B, Agrón E, Wu L, Lindley A, et al. Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Kidney Int: 2004. Report No: 26.

Thesis: Yılmaz B. Ankara Üniversitesindeki Öğrencilerin Beslenme Durumları, Fiziksel Aktiviteleri ve Beden Kitle İndeksleri Kan Lipidleri Arasındaki İlişkiler. H.Ü. Sağlık Bilimleri Enstitüsü, Doktora Tezi. 2007.

Manuscripts Accepted for Publication, Not Published Yet: Slots J. The microflora of black stain on human primary teeth. Scand J Dent Res. 1974.

Epub Ahead of Print Articles: Cai L, Yeh BM, Westphalen AC, Roberts JP, Wang ZJ. Adult living donor liver imaging. Diagn Interv Radiol. 2016 Feb 24. doi: 10.5152/dir.2016.15323. [Epub ahead of print].

Manuscripts Published in Electronic Format: Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis (serial online) 1995 Jan-Mar (cited 1996 June 5): 1(1): (24 screens). Available from: URL: [http:// www.cdc.gov/ncidod/EID/cid.htm](http://www.cdc.gov/ncidod/EID/cid.htm).

## REVISIONS

When submitting a revised version of a paper, the author must submit a detailed "Response to the reviewers" that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer's comment, followed by the author's reply and line numbers where the changes have been made) as well as an annotated copy of the main document. Revised manuscripts must be submitted within 30 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial 30-day period is over.

Accepted manuscripts are copy-edited for grammar, punctuation, and format. Once the publication process of a manuscript is completed, it is published online on the journal's webpage as an ahead-of-print publication before it is included in its scheduled issue. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested within 2 days of their receipt of the proof.

**Editor : Tevfik Fikret ÇERMİK**

Address: University of Medical Sciences, Istanbul Training and Research Hospital, Clinic of Nuclear Medicine, Samatya, Fatih, İstanbul, Türkiye

Phone: +90 212 459 64 53

Fax: +90 212 530 80 55

E-mail: [tevfik.cermik@sbu.edu.tr](mailto:tevfik.cermik@sbu.edu.tr)

**Publisher : GALENOS PUBLISHING HOUSE**

Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1 Fındıkzade 34093 İstanbul, Turkey

Phone: +90 (212) 621 99 25

Fax: +90 (212) 621 99 27

E-mail: [info@galenos.com.tr](mailto:info@galenos.com.tr)/[yayin@galenos.com.tr](mailto:yayin@galenos.com.tr)

Web: [www.galenos.com.tr](http://www.galenos.com.tr)





# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

## CONTENTS

### Original Articles

- 82** Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study  
Süleyman Şahin, Muhammet Bekir Hacıoğlu; Van, Konya, Turkey
- 88** Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer  
Alpaslan Kaban, Samet Topuz, Hamdullah Sözen, Yavuz Salihoğlu; İstanbul, Turkey
- 94** Abdominal Wall Endometriosis: Analysis of 66 Patients at a Tertiary Center  
Besim Haluk Bacanakgil, Hasene Özçam, Mustafa Deveci, Sezgi Güllü Yıldırım; İstanbul, Turkey
- 98** Assessment of Cervical Length by Transvaginal Ultrasound in Pregnant Women Between 24-34 Weeks  
Salim Sezer, Alpaslan Kaban, Baki Erdem; Trabzon, İstanbul, Turkey
- 101** Diaphragm Thickness Measurement in Computed Tomography: Intra- and Inter-Observer Agreement  
Furkan Ufuk, Pınar Çakmak, Ergin Sağtaş, Duygu Herek, Muhammet Arslan, Ahmet Baki Yağcı; Denizli, Turkey
- 107** Vitamin D Deficiency Among Female University Students (18 to 25 years) in Spring  
Filiz Tuna; Edirne, Turkey
- 111** The Relationship of Lumbar Multifidus Muscle Change to Disc Hernia and Low Back Pain: An Magnetic Resonance Imaging Study  
Emrah Sayıt; Samsun, Turkey
- 115** Use of Liquid Phenol for Management of Pilonidal Disease  
Alaattin Öztürk, Yüksel Karaköse; İstanbul, Turkey
- 119** The Effect of Different Hemostatic Systems on the Injury of the External Branch of the Superior Laryngeal Nerve in Thyroidectomy  
Volkan Özben, Recep Özgültekin, Nurten Adatepe, Asım Kaytaz; İstanbul, Turkey
- 125** Effects of Systemic Inflammatory Parameters on Mortality in Elderly Patients Admitted to Emergency Department with Abdominal Pain  
Mehmet Veysel Öncül, Seda Dağar, Emine Emektar, Şeref Kerem Çorbacioğlu, Halit Aytaç, Yunsur Çevik; Ankara, Turkey
- 130** Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-diabetics (Sulfonylurea and Metformin) or Insulin: Bone Tissue Perspective  
Alper Gümüş, Muhammed Emin Düz, Cihan Coşkun, Mustafa Velet, Macit Koldaş; İstanbul, Turkey





# İstanbul MEDICAL JOURNAL

İ S T A N B U L T İ P D E R G İ S İ

## CONTENTS

**137 Obesity Status of University Employees and Associated Factors: Turkey-2015**

Gülcan Demir Özdenk, Lütüye Hilal Özcebe; Kırşehir, Ankara, Turkey

**144 Evaluation of Non-donor Brain-Dead Patients**

İlkay Ceylan, Seda Seven, Sevim Baltalı, Abdurrahman Tünay, Veysel Erden; İstanbul, Turkey

### Case Reports

**148 Cyto-Histopathological Findings of Myofibroblastoma of the Breast: A Case Report**

Büşra Yaprak Bayrak, Ahmet Tuğrul Eruyar, Abdullah Güneş; Kocaeli, Turkey

**152 Radiotherapy in the Treatment of High Volume Chylous Fistula Following Hepatectomy: Case Report and Review of the Literature**

Osman Nuri Dilek, Ayhan Aydın, Turan Acar, Cengiz Tavusbay, Emine Özlem Gür, Salih Can Çelik, Hüseyin Sinan Akay, Mehmet Hacıyanlı; İzmir, Turkey

**156 A Case of Choroid Plexus Papilloma with Rare Location Presenting with Impaired Consciousness**

Nurcan Ünal, Muhammet Mesut Nezir Engin, Önder Kılıçaslan, İbrahim Feyyaz Naldemir, Gülşen Yalçın, Uğur Avcı, Kenan Kocabay; Düzce, Turkey

**159 Neurotoxoplasmosis in a Patient with Acquired Immunodeficiency Syndrome: Magnetic Resonance and Magnetic Resonance Spectroscopy Findings**

Pınar Gülmez Çakmak, Selda Sayın Kutlu; Denizli, Turkey

**163 A Case of Spinal Thoracic Empyema Following Epidural Injection**

Fergane Memmodova, Esengül Liman, Ufuk Emre, Yeşim Karagöz, Veysel Antar, Orhan Yağız; İstanbul, Turkey

**165 Postoperative Fibrin Reaction and Descemet Membrane Detachment: A Case Report**

Mustafa Suat Alıkma, Erkan Ünsal, Tülay Akçetin, Mehmet Özgür Çubuk, Kadir Eltutar; İstanbul, Turkey

**169 Palpable Purpura in a Patient with Uncontrolled Type 2 Diabetes Mellitus: Possible Side Effect of Linagliptin**

Ömercan Topaloğlu, Bahri Evren, İbrahim Şahin; Malatya, Turkey

### History of Medicine

**172 Why is the Medical Symbol a Snake?**

Ekrem Güner, Kamil Gökhan Şeker, Şebnem İzmir Güner; İstanbul, Turkey





## March 14 Feast of Medicine and The Spirit of Medics

University of Health Sciences is both the first health-themed state university in Turkey and the greatest health university of the world. Our university was founded in the facilities built by Sultan Abdülhamit Han II with the vision, "Transitioning from the past into the future" and "Traditionalist but innovative", and with the mission of founding the first modern medical school, Mektebi Tıbbiyye-i Şahane. Our university conducts educational activities in two cities - Istanbul and Ankara - in Turkey in addition to Somalia and Sudan campuses abroad and provides health education on an international level.

While it first served as a military medical school between 1903-1909, Mektebi Tıbbiyye-i Şahane later became a civil medical school. The military Hospital of Haydarpaşa which was located opposite to these facilities, was linked to the school with an underground tunnel and rail system and used as a training hospital for the students.

After the World War I ended and the Mondros Armistice Agreement was signed in 1918, the Allies invaded Istanbul. While the ships of the invading forces were being deployed in the Marmara Sea, the medical students in Haydarpaşa were watching this scene from the windows of the school with sadness. Their instructor, Dr. Tefik Salim Sağlam turned to the students and told them not to worry, as the army of this nation had never been defeated.

However, the English forces had started to place their soldiers in the official institutions in Istanbul immediately, and had also invaded the buildings of the Mektebi Tıbbiyye-i Şahane. The English soldiers emptied the dormitories of the boarding military students and decided to use that part of the building as their headquarters. They even confiscated the bedsteads of the students. The students converted the loft into a dormitory and moved their mattresses there. Later on, this place was called "Hangar Palace" by the students, as a lot of students could only be accommodated in a very cramped area.

The English also forbade the military students to participate to lessons with their uniforms. As the sons of a nation that had just been out of the war, most of the military medics did not have any clothes to put on other than their uniforms. The students had to attend the classes in their pyjamas. This situation hurt the pride of the prospective military doctors of the soldier-nation.

The medics who were on the front line during the First World War, were uncomfortable with the occupation of their nation and being put in a dishonorable situation by the occupiers. Even though they wanted to resist the pressure that was put on them and to rebel, they chose to proceed cautiously due to the fact that people who raised little objections were being arrested and were being sent into exile by the occupation forces.

The medics who were seeking a way to react without making the situation worse, decided to hold a celebration meeting for the 92nd anniversary of the foundation of the Medicine School which started education in 1827.

The anniversary of the foundation of the School of Medicine had never been celebrated until that time. As occupation forces forbade students to be in groups, it could be only possible for students to come together only with the pretext of such a scientific-based program. On March 14, 1919 the students gathered in the conference hall of Ottoman University with their professors. They invited British, American and French Red Cross representatives and a French general who was in charge of Sanitary Inspection Department. The program started with the speech delivered by Mr. Kemal who was a medical student on a brief history of the school. In his speech, Mr. Kemal also stated the services of the Crimean Aziz Bey who started the medical education in Turkish instead of French and talked about the contributions of the other professors. Then, Dr. Memduh Necdet who studied medicine in the United States, stated that 607 Turkish, 240 Greek, 170 Armenian, 79 Jewish and 11 Serbian and Bulgarian students had graduated from the School of Medicine since its foundation. He also reminded the contributions of the School of Medicine to the First World War with figures. After pointing out the depressive situation in Istanbul, he ended his speech by saying "We have been here, and we will be here... Istanbul belongs to us because our independence is here..." After this statement he received a standing ovation. With this meeting, the medics demonstrated that they could come together under any circumstances. Also, they conveyed this very important message that they would not abandon their country to the occupants. The anniversary of the opening of the School of Medicine continued to be celebrated in the following years. Medical students' fight for independence was not only limited to the Medical Feast. They also played a fundamental role in the independence of the country by supporting the initiation and success of the War of Independence.

Since 1919, the Medical Feast has been celebrated and every year on March 14, all medics continue to come together.

Just like our pioneer colleagues who reacted to the occupation on March 14, 1919 by raising the Turkish flag between the two clock towers of Mekteb-i Tıbbiyye-i Şahane, with the same spirit and the same persistence, we raised our flag once again on the night of July 15, 2016 to resist the treacherous coup attempt. We have shown that medics will not surrender to any occupation and betrayal attempt.

Medics who rebelled and fought against the invasion of Istanbul and homeland, continue to be the guarantee of our independence with the same spirit.

**Prof. Dr. Cevdet ERDÖL**  
RECTOR





## 14 Mart Tıp Bayramı ve Tıbbiyyeli Ruhu

Sağlık Bilimleri Üniversitesi, ülkemizin sağlık temalı ilk devlet üniversitesi olduğu gibi dünyanın da en büyük sağlık üniversitesidir. Üniversitemiz, Sultan II.Abdülhamit Han tarafından yaptırılan binada, "Geçmiş ile Geleceğe, Geleneği ancak Yenilikçi" anlayışıyla ülkemizin ilk modern tıp okulu olan Mekteb-i Tıbbiyye-i Şahane'nin devamı olarak kurulmuş olup İstanbul, Ankara, Somali ve Sudan'daki külliyeelerde eğitim faaliyetlerini sürdürmektedir.

Mekteb-i Tıbbiyye-i Şahane, 1903-1909 yılları arasında önce sadece Askeri Tıp Mektebi iken, daha sonra sivil tıp mektebi olarak da hizmet vermiştir. Karşısında bulunan Haydarpaşa Asker Hastanesi, yeraltı tüneli ve raylı sistemle mekteple bağlantı sağlanarak öğrenciler için eğitim hastanesi olarak kullanılmıştır.

1918 yılında biten Birinci Dünya Savaşı'nın ardından Mondros Mütarekesi imzalanmış, itilaf devletleri İstanbul'u işgal etmişti. İşgal kuvvetlerine ait gemiler Marmara Denizi'nde konuşlanırken, o sırada Haydarpaşa'daki Tıbbiyye'de ders gören öğrenciler bu manzarayı okulun pencerelerinden hüğünlü gözlerle izliyorlardı. Dersin hocası Tefik Salim Sağlam öğrencilerine dönerek telaşlanmalarını söyledi. Çünkü bu milletin ordusu asla mağlup olmamıştı.

Ancak işgal kuvvetleri kısa süre içerisinde İstanbul'daki resmî kurumlara asker yerleştirmeye başlamış, Tıbbiye binası da İngilizler tarafından işgal edilmişti. Okula yerleşen İngiliz askerleri, yatılı eğitim alan askeri öğrencilerin yatakhanelerini boşalttıran binanın bu bölümünü karargâh olarak kullanmaya başladılar. Üstelik öğrencilerin karyolarına da el koymuşlardı. Öğrenciler çatı katını yatakhaneye dönüştürerek yer döşeklerini oraya taşıdılar. Çok sayıda öğrencinin ancak sıkışık bir vaziyette konaklayabildiği bu mekân öğrenciler arasında daha sonra Hangar Palas olarak anılacaktı.

İngilizler bununla da yetinmeyerek askeri öğrencilerin derslere üniformalarıyla katılmasını yasaklamıştı. Savaştan yeni çıkmış bir milletin evlatları olarak çoğu askeri tıbbiyelinin üniformadan başka üstüne giyebileceği başka bir kıyafeti yoktu. Öğrenciler çaresizce derslere pijamalarıyla devam etmek zorunda kaldılar. Bu durum asker bir milletin asker tabip adaylarının gururuna dokunuyordu.

Birinci Dünya Savaşı boyunca cephelerde görev alan Tıbbiyyeliler onca emek sonrasında şimdi memleketin işgal edilmiş olmasından, vatanı işgal edenlerin kendilerini düşürdükleri bu onur kırıcı durumdan rahatsızlık duyuyorlardı.

Üzerlerindeki baskıya karşı koymak, baş kaldırmak istiyorlar ancak en ufak bir itirazda bulunanların işgal kuvvetleri tarafından tutuklanıyor, hatta sürgüne gönderiliyor olmasından dolayı temkini de elden bırakamıyorlardı.

İçinde bulundukları durumu daha da kötüleştirmeden tepkilerini göstermek için bir yol arayan Tıbbiyyeliler, eğitime 1827 yılında başlayan Tıbbiyye'nin 92. kuruluş yıldönümünü kutlama toplantısı tertip etmeye karar verdiler.

Tıbbiyye'nin kuruluş yıldönümü o vakte kadar hiç kutlanmış değildi. Ancak işgal kuvvetleri öğrencilerin gruplar halinde bulunmasını yasakladığından, öğrencilerin bir araya gelmesi ancak böylesi bilimsel temelli bir program vesilesi ile mümkün olabilirdi. Öğrenciler 14 Mart 1919 tarihinde hocaları ile birlikte Darülfünun Konferans Salonu'nda toplandılar. Programa İngiliz-Amerikan-Fransız Kızılhaç temsilcileri, Fransız Sıhhiye Müfettiş-i Umumi'si'ni de davet etmişlerdi. Program tıbbiyyeli Kemal Bey'in okulun kısa bir tarihçesini anlatmasıyla başladı. Kemal Bey konuşmasında tıp eğitiminin Fransızca yerine Türkçe yapılmasını sağlayan Kırımlı Ağız Bey ve diğer hocaların hizmetlerinden de bahsetti. Amerika'da tahsil görmüş olan Dr. Memduh Necdet Bey kurulduğu günden itibaren Tıbbiyye'den 607 Türk, 240 Rum, 170 Ermeni, 79 Musevi, 11 Sırp-Bulgar meğun verildiğini ifade edip, Tıbbiyye'nin Birinci Dünya Savaşı'na katkılarını rakamlarla dile getirdi. İstanbul'un içinde bulunduğu buhranlı duruma dikkat çektikten sonra, sözlerini "Buradayız burada kalacağız... İstanbul bizimdir, çünkü istiklal buradadır" diyerek tamamladığında salon alkışlarla inliyordu.

Tıbbiyyeliler bu toplantı ile işgalcilere her koşulda bir araya gelebildiklerini göstermişler, bu vatani düşmana bırakmayacaklarının mesajını vermişlerdi. Tıbbiyye'nin açılış yıldönümü sonraki yıllarda da kutlanmaya devam etti. Tıbbiyyelilerin özgürlük için mücadeleleri sadece Tıp Bayramı ile sınırlı kalmadı. Onlar, Millî Mücadele'nin başlatılmasına ve başarıyla kazanılmasına da destek vererek vatanın bağımsızlığa kavuşmasında önemli görevler üstlendiler.

1919 yılından bu yana Tıbbiyyeliler Bayramı aralıksız olarak kutlanmakta, her yıl 14 Mart'ta tüm tıbbiyyeliler bir araya gelmeyi sürdürmektedirler.

Bu anlayışla bizler de tıpkı 14 Mart 1919'da işgale tepki gösteren öncü meslektaşlarımız gibi, 15 Temmuz hain darbe girişimi gecesinde Mekteb-i Tıbbiyye-i Şahane'nin iki saat kulesi arasına Al Bayrağımızı çekerek aynı ruh ve aynı heyecanla Tıbbiyyelilerin hiçbir işgal ve ihanet girişimine boyun eğmeyeceğini gösterdik.

Tıbbiyye'nin, İstanbul'un ve hatta tüm vatanın işgaline karşı baş kaldıran, birlik olan ve mücadele eden Tıbbiyyeliler, taşıdıkları Tıbbiyyeli ruhu ile bugün de vatanımızın bağımsızlığının teminatı olmaya devam etmektedir.

**Prof. Dr. Cevdet ERDÖL**  
REKTÖR



# Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study

## Üçüncü Basamakta Regorafenib ile Tedavi Edilen Metastatik Kolorektal Kanseri Hastaların Sonuçları-Çok Merkezli Çalışma

İ Süleyman Şahin<sup>1</sup>, İ Muhammet Bekir Hacıoğlu<sup>2</sup>

<sup>1</sup>University of Health Sciences, Van Training and Research Hospital, Clinic of Medical Oncology, Van, Turkey

<sup>2</sup>Konya Training and Research Hospital, Clinic of Medical Oncology, Konya, Turkey

### ABSTRACT

**Introduction:** The clinical benefit of regorafenib therapy in metastatic colorectal cancer (mCRC) patients, who were previously treated with 5-fluorouracil (5-FU), irinotecan, or oxaliplatin based regimens with or without a biologic agent such as vascular endothelial growth factor (anti-VEGF) or anti epidermal growth factor receptor (anti-EGFR), has been shown in several previous phase III studies. In this study, we aimed to analyze the efficacy and toxicity profile of regorafenib in patients with mCRC.

**Methods:** This was a retrospective study of 23 mCRC patients from two different centers in Turkey. All patients were treated with regorafenib as third line setting after failure of two standard consecutive therapies including 5-FU, irinotecan, or oxaliplatin with or without anti-VEGF or anti-EGFR agent. Treatment outcomes along with drug efficacy and safety were analyzed retrospectively.

**Results:** Of the 23 patients, 13 were male (56.5%). Median age was 62 (35-76) years. The rates of RAS wild-type and RAS-mutated tumor were 43.5% and 56.5%, respectively. Eighteen patients (78.2%) received bevacizumab as first-line setting, whereas only five patients (28.8%) were given a prior anti-EGFR agent. Among the 23 patients, only one patient (4.3%) had a partial response. Median progression-free survival was 3.02 (2.6-3.37) months and median overall survival was 6.4 (2.6-10.1) months. There was no prognostic factor associated with survival. Grade 3-4 toxicities were observed in 30.4% of the patients, with hand-foot skin reaction being the most frequent adverse event (42.8%).

**Conclusion:** Although clinical and survival benefits of regorafenib have been demonstrated in previous studies, this advantage seems to be questionable in our study, with a significant toxicity profile making its use challenging. A treatment decision should be made considering the risk of mortality and toxicity profile.

**Keywords:** Metastatic colorectal cancer, overall survival, progression free survival, regorafenib, toxicity

### ÖZ

**Amaç:** Daha önce 5-fluorourasil (5-FU), irinotekan veya oksaliplatin temelli rejimlerle tedavi edilen ve biyolojik ajan olarak vasküler endotelial büyüme faktörü (anti-VEGF) veya anti epidermal büyüme faktörü reseptörü (anti-EGFR) alan veya almayan metastatik kolorektal kanser (mKRC) hastalarında regorafenib tedavisinin klinik yararı daha önceki faz III çalışmalarında gösterilmiştir. Burada mKRC'li hastalarda regorafenibin etkinlik ve toksisite profilini analiz etmeyi amaçladık.

**Yöntemler:** Çalışmamızda Türkiye'deki iki farklı merkezden takip edilen 23 mKRC hastasının retrospektif verileri incelenmiştir. Tüm hastalar anti-VEGF veya anti-EGFR ile kombine olarak veya olmaksızın; 5-FU, irinotekan veya oksaliplatin temelli rejimler ile, iki standart ardışık tedavinin başarısızlığı sonrasında üçüncü basamakta regorafenib ile tedavi edildi. İlaç etkinliği ve güvenliği ile birlikte tedavi sonuçları retrospektif olarak analiz edildi.

**Bulgular:** Yirmi üç hastanın 13'ü erkekti (%56,5) ortalama yaş 62 idi (35-76). RAS wild tip tümör oranı %43,5, RAS mutant tip tümör oranı ise %56,5'ti. On sekiz hasta (%78,2) birinci basamakta bevasizumab tedavisi almıştı (%28,8). Yirmi üç hastanın yalnızca 1'inde (%4,3) kısmi yanıt elde edilmişti. Ortanca progresyonsuz sağkalım 3,02 (2,6-3,37) ay ve ortalama genel sağkalım ise 6,4 (2,6-10,1) aydı. Sağkalımla ilişkili prognostik faktör saptanmadı. En sık yan etki olarak el-ayak sendromu (%42,8) görülmekle birlikte, derece 3-4 yan etki %30,4 hastada saptandı.

**Sonuç:** Önceki çalışmalarda regorafenibin klinik ve sağkalım yararı gösterilmiş olmasına rağmen, bu avantaj, çalışmamızda kullanımını zorlaştıran önemli bir toksisite profili ile şüpheli görünmektedir. Mortalite riski ile toksisite profili göz önünde bulundurularak tedavi kararı verilmelidir.

**Anahtar Kelimeler:** Metastatik kolorektal kanser, genel sağkalım, progresyonsuz sağkalım, regorafenib, yan etki



**Address for Correspondence/Yazışma Adresi:** Süleyman Şahin, University of Health Sciences, Van Training and Research Hospital, Clinic of Medical Oncology, Van, Turkey  
Phone: +90 432 444 99 65 E-mail: drsahins@hotmail.com ORCID ID: orcid.org/0000-0001-9769-2565

**Cite this article as/Atıf:** Şahin S, Hacıoğlu MB. Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study. İstanbul Med J 2019; 20(2): 82-7.

**Received/Geliş Tarihi:** 07.06.2018

**Accepted/Kabul Tarihi:** 28.10.2018

## Introduction

Despite recent advances in the treatment of metastatic colorectal cancer (mCRC), it is still the most frequent gastrointestinal system cancer in the western countries, with being an important cause of cancer mortality, affecting approximately 746.000 men and 614.000 women each year (1). Colorectal cancer is the third most common cancer worldwide and the second most common cause of cancer-related deaths in the United States (US), with 20% to 30% of patients having synchronous metastatic disease at the time of presentation and more than half of the patients eventually developing metastatic disease with unresectable metastases (2). After the introduction of chemotherapeutic agents such as fluoropyrimidines, oxaliplatin, and irinotecan along with monoclonal antibodies targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR), median overall survival (OS) duration of mCRC patients has improved approximately 30 months over the last 20 years (3), with a great extent of this progress being due to molecular targeted therapies, such as anti-angiogenic agents (bevacizumab) or EGFR signaling pathway inhibitors (cetuximab and panitumumab) (4).

Regorafenib, a novel oral multi-kinase inhibitor, has demonstrated antitumor activity in patients with mCRC who were previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy +/- anti-VEGF therapy or anti-EGFR therapy through inhibiting a very diverse range of oncogenic gene products and growth factor receptors including KIT, RET, RAF1, BRAF, BRAFV600E, VEGFR, platelet-derived growth factor receptor PDGFR and fibroblast growth factor receptors (FGFR), hence being approved by FDA 2012 for use as monotherapy as last-line setting (5,6). Anti-tumor activity and survival benefit of regorafenib were previously shown in two large randomized placebo-controlled trials, CORRECT (7) and CONCUR (8), which were performed in mCRC patients progressing on standard therapies. Survival benefit and efficacy of regorafenib were also confirmed by the large European REBECCA (9) cohort study in a real-world setting, with a similar toxicity profile as seen in previous randomized studies mentioned above.

Here, we performed a multicenter retrospective study to evaluate the efficacy and toxicity profile of regorafenib in mCRC patients in Turkey.

## Methods

From October 2015 to December 2017, a total of 23 consecutive Turkish patients from two major centers receiving regorafenib monotherapy for refractory mCRC as third-line setting were analyzed. Patients with histologically confirmed mCRC were included in the study. The study was approved by the Necmettin Erbakan University Local Ethics Committee (Decision No. 2018/1319). This retrospective study was designed in accordance with the World Medical Association Declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects", amended in October 2013. Since it was a retrospective study, no patient consent form could be obtained. We conducted a retrospective multi-center study to assess the efficacy and toxicity profile of regorafenib in mCRC, patients who were previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy +/- anti-VEGF therapy (e.g. bevacizumab, ziv-aflibercept) or anti-EGFR (e.g. panitumumab, cetuximab) when appropriate. Baseline data of all patients, including

disease characteristics, patient demographics, laboratory parameters, performance status (PS), treatments, response to treatments, and toxicities were carefully recorded.

After the failure of standard therapies, regorafenib was initiated as a monotherapy at 160 mg daily dose for 21 days with a 28-day repeating cycle. At the discretion of the physicians, a lower initial dose was allowed depending on the patient's clinical condition, and then the dose was increased by 40 mg per week until the maximum dose of 160 mg, relying on the patient's tolerability.

Evaluation of treatment responses was performed every 3 months by computed tomography (CT) or positron emission tomography (PET)-CT using the Response Evaluation Criteria in Solid Tumor version 1.1. National Cancer Institute Common Terminology Criteria of Adverse events version 4.0 was used to grade the adverse events. Dose reduction was allowed in case of drug intolerance or  $\geq$  grade 3 toxicity. Regorafenib was given until disease progression, unacceptable toxicity or patient's withdrawal.

## Statistical Analysis

All statistical analyzes were performed using Statistical Package for Social Sciences version 21.0 for Windows (SPSS, Inc. Chicago, IL, USA). Descriptive statistics were reported as percentage and median. Survival data were analyzed according to the Kaplan-Meier Method and were compared using Log-rank statistics. P value less than 0.05 was considered as statistically significant. Progression-free survival (PFS) was defined as the period between regorafenib initiation and disease progression or death due to any reason. Overall survival was defined as the period between regorafenib initiation and death due to any cause.

## Results

A total of 23 patients were included in this study. Baseline characteristics are summarized in Table 1. Of the 23 patients, 13 were male (56.5%). Median age was 62 (35-76) years. The rates of RAS wild-type and RAS-mutated tumor were 43.5% and 56.5%, respectively.

Eighteen patients (78.2%) received bevacizumab as first-line setting, whereas only five patients (21.7%) were given a prior anti-EGFR agent. The primary tumor was located on the left side in 17 patients (73.9%). The number of patients who underwent palliative surgery and metastasectomy was nine (39.1%) and five (21.7%), respectively. Most of the patients (91.3%) had a PS of 0-1 at the beginning of regorafenib therapy.

Regarding survival, median PFS was 3.02 (2.6-3.37) months and median OS was 6.4 (2.6-10.1) months for regorafenib therapy during a median follow-up of 5.4 (2.4-23.4) months (Figures 1 and 2). Overall survival was 37 (23.9-50.4) months. The presence of comorbidity was the only prognostic factor in univariate analysis; however, no factors were found to be associated with survival (Table 2).



Approximately 73.92% of patients were commenced on lower doses than standard. Starting dose of 160 mg was administered only in six patients. Dose modification was required in 69.56% of the patients (Table 3). Dose escalation could be performed once in four patients and twice in

**Table 1. Baseline characteristics of patients (n=23)**

Number of patients	23
Median age (years)	62 (35-76)
<b>Sex</b>	
Male	13 (56.5%)
Female	10 (43.5%)
<b>ECOG performance status</b>	
0-1	21 (91.3%)
2	2 (8.7%)
<b>Comorbidity (e.g DM, HT, Atherosclerosis)</b>	
No	16 (69.6%)
Yes	7 (30.4%)
<b>Tumor localization</b>	
Right	6 (26.1 %)
Left	17 (73.9%)
<b>Palliative surgery</b>	
Yes	9 (39.1%)
No	14 (60.9%)
<b>Metastasectomy</b>	
Yes	5 (21.7%)
No	18 (78.3%)
<b>RAS mutation status</b>	
Mutant	13 (56.5%)
Wild-type	10 (43.5%)
<b>First-line therapy</b>	
Folfox/xelox + Beva	9 (39.1%)
Folfox/xelox + Pan/Cet	2 (8.7%)
Folfiri + B	9 (39.1%)
Folfiri + Pan/Cet	3 (13.0%)
<b>Response to first-line therapy</b>	
Partial response	11 (47.8%)
Stable disease	4 (17.4%)
Progression	8 (34.8%)
<b>Second-line therapy</b>	
Folfox	2 (8.7%)
Folfiri	3 (13.0%)
Folfox/B	8 (34.8%)
Folfox + C/P	1 (4.3%)
Folfiri + B	4 (17.4%)
Folfiri + C/P	3 (13.0%)
Other	2 (8.7%)
<b>Response to second-line therapy</b>	
Partial response	8 (34.8%)
Stable disease	8 (34.8%)
Progression	7 (30.4%)
<b>Response to third-line regorafenib</b>	
Partial response	1 (4.3%)
Progression	22 (95.6%)

DM: diabetes mellitus, HT: hypertension

two patients. Dose reduction was required once in seven patients and twice in three patients. Approximately 13.04% of patients discontinued treatment due to toxicity. The median number of treatment cycles was three (1-11). The most common toxicities of any grade were hand-foot skin reaction (HFSR), fatigue, diarrhea, hypertension, mucositis and thrombocytopenia. Grade 3-4 toxicities were observed in seven patients (30.4%) with a descending order as follows, HFSR in 42.8%, fatigue in 28.5%, diarrhea in 14.28% and hypertension in 14.28% (Table 4).

**Figure 1. Overall survival curve****Figure 2. Progression-free survival curve**



**Table 2. Univariate analysis**

Parameters	n (%)	Overall survival (month) univariate analysis	p
Age (years)			
≤60	10 (43.5)	37.1	0.46
>60	13 (56.5)	32.1	
Sex			
Male	13 (56.5)	45.7	0.12
Female	10 (43.5)	25.7	
ECOG performance status			
0-1	21 (91.3)	41.0	0.20
2	2 (8.7)	25.7	
Comorbidity (DM, HT, Atherosclerosis)			
No	16 (69.6)	45.7	<0.001
Yes	7 (30.4)	22.3	
Tumor localization			
Right	6 (26.1)	52.4	0.85
Left	17 (73.9)	37.1	
Palliative surgery			
Yes	9 (39.1)	45.7	0.15
No	14 (60.9)	32.1	
Metastasectomy			
Yes	5 (21.7)	45.7	0.69
No	18 (78.3)	32.1	
RAS mutation status			
Mutant	13 (56.5)	45.7	0.24
Wild-type	10 (43.5)	31.7	
First-line therapy			
Folfox/xelox + Beva	9 (39.1)	37.1	0.17
Folfox/xelox + Pan/Cet	2 (8.7)	31.7	
Folfiri + B	9 (39.1)	57.1	
Folfiri + Pan/Cet	3 (13.0)	26.7	
Response to first-line therapy			
Partial response	11 (47.8)	52.4	0.34
Stable disease	4 (17.4)	32.1	
Progression	8 (34.8)	25.7	
Second-line therapy			
Folfox	2 (8.7)	18.1	0.12
Folfiri	3 (13.0)	26.1	
Folfox/B	8 (34.8)	41.0	
Folfox + C/P	1 (4.3)	25.7	
Folfiri + B	4 (17.4)	NR not reached	
Folfiri + C/P	3 (13.0)	37.1	
Other	2 (8.7)	32.1	
Response to second-line therapy			
Partial response	8 (34.8)	45.7	0.01
Stable disease	8 (34.8)	37.1	
Progression	7 (30.4)	23.0	

**Table 2. Continued**

Parameters	n (%)	Overall survival (month) univariate analysis	p
Response to third-line Regorafenib			
Partial response	1 (4.3)	31.7	0.53
Progression	22 (95.6)	37.1	
DM: diabetes mellitus, HT: hypertension			

**Table 3. Regorafenib administration**

Median number or treatment cycles	3 (1-11)
<b>Starting dose</b>	<b>n (%)</b>
160 mgr.	6 (26.08)
120 mgr. or lower	17 (73.92)
<b>Treatment discontinuation</b>	<b>3 (13.04)</b>
Dose increase	6
Once	4 (66.6)
Twice	2 (33.3)
Dose reduction	10
Once	7 (70)
Twice	3 (30)

**Table 4. Adverse events**

	<b>Any grade, n=18 (78.26%)</b>	<b>Grade 3-4, n=7 (30.4%)</b>
Hand-foot skin reaction	6 (33.3)	3 (42.8)
Fatigue	4 (22.2)	2 (28.5)
Diarrhea	3 (16.6)	1 (14.28)
Hypertension	2 (11.1)	1 (14.28)
Mucositis	2 (11.1)	-
Thrombocytopenia	1 (5.5)	-

## Discussion

In the past 10 years, the availability of many drugs and the advent of new anti-angiogenic agents such as bevacizumab combined in standard regimens as first-line, second-line, or beyond progression setting have offered a considerable survival benefit with improved prognosis in patients with mCRC. Angiogenic regulation consists of a range of pathways and inhibition of a single target, such as VEGF, resulting in up-regulation of a diversity of pro-angiogenic factors (10), suggesting that a salvage treatment setting which includes a multi-kinase inhibitor with anti-angiogenic activity may be a plausible treatment option (11). Regorafenib, a novel agent, is a multi-kinase inhibitor targeting a range of receptors including VEGF 1-3, PDGF, tyrosine receptor kinase-2, FGFR, BRAF, KIT, and RET (12).

Here, we aimed to evaluate the efficacy and safety of this new kinase inhibitor, although not including a representative sample. The median OS and median PFS in our study were 6.4 and 3.02 months, respectively. These findings are comparable to those reported in previous randomized studies. The CORRECT study was an international, randomized, and placebo-controlled phase-III trial including 760 patients who were

randomized 2:1 to receive either regorafenib 160 mg daily or placebo. It demonstrated an improved median OS for regorafenib group compared to the placebo (6.4 months vs 5.0 months,  $p=0.0052$ ) (7), showing similar results to our findings. Another international phase 3 trial, CONCUR, which also confirmed the OS benefit of regorafenib in 204 Asian patients who were randomized 2:1 to receive either regorafenib or placebo (8.8 months vs 6.3 months,  $p=0.00016$ ) (8), had a better median OS than that observed in our study. Median PFS durations for CORRECT and CONCUR trial were 1.9 and 3.2 months in the regorafenib arm, gaining only 0.2 and 1.5 months, respectively, compared to placebo group. The median PFS in our study was similar to that reported in CONCUR trial and higher than in the CORRECT trial. The REBECCA trial, a cohort of 1178 patients with mCRC, was an open-label and single-arm study of 654 patients (in full analyze) treated with regorafenib after a failure on standard therapies. This study demonstrated a median OS of 5.6 months and median PFS of 2.9 months with 12-month survival rate of 22% (9), indicating a similar median PFS but a lower median OS duration compared to those reported in our study, despite the higher number of patients starting with a lower dose of regorafenib in our study (73.9% in our study vs 18% in REBECCA).

The most common toxicities of any grade in our cohort were HFSR, fatigue, diarrhea, hypertension, mucositis and thrombocytopenia. HFSR, fatigue, diarrhea and hypertension were the most common grade 3-4 toxicities. This toxicity profile is substantially consistent with the adverse events reported in the REBECCA real-world cohort (9), CORRECT trial (7), and CONCUR trial (8). Most adverse events were similar in the CONCUR (8) and CORRECT (7) trials, with the only exception of any-grade HFSR (74% vs 47%, respectively) and impaired liver function tests (37% vs 20%, respectively), which were more frequent in CONCUR trial (8). The most common reason leading to drug-discontinuation in our study was the toxicity, similar to REBECCA cohort (9). Most of the patients in our cohort (69.56%) required dose modifications and this was higher than those reported in CORRECT (7) (20% of patients required a dose reduction) and CONCUR trials (8) (40% of patients required a dose reduction). Compared to the REBECCA (9) cohort, a larger proportion in cohort started at a lower dose of regorafenib (18% vs 73.9%, respectively). Patients should be informed about the prophylaxis and management of regorafenib-related adverse events prior to treatment to minimize the incidence of adverse events and to ensure that patients take full advantage of regorafenib treatment, thus optimizing treatment outcomes. Therefore, the most common adverse events should be discussed with the patient before the treatment.

The REBECCA real-world analysis (9) reported that high ECOG PS, a shorter time from the initial diagnosis of metastasis, starting at a lower initial dose of regorafenib, more than 3 metastatic sites, the presence of liver metastasis and KRAS mutation were the factors associated with shorter OS. However, there was no predictive factor associated with survival in our cohort, which might be due to the small sample size of our cohort.

So far, some studies have explored some biomarkers of efficacy for regorafenib, but no useful pretreatment biomarker in clinical practice has yet been determined (13,14). Indeed, there is no predictive biomarker to allow the selection of patients most likely to benefit from regorafenib (11). However, Komori et al. (15) reported that serum CA19-

9 response was an early predictive marker of efficacy of regorafenib in mCRC.

The major limitation in our study was the small sample size, resulting in a suboptimal evaluation of outcome predictors in cox regression analysis. Hence, the results of this study should be interpreted with caution. In addition, selection bias and the absence of independent monitoring were other limitations inherent in retrospective studies, which might affect our results. Furthermore, identifying patients who will tolerate full-dose or a reduced dose of regorafenib is pretty important to optimize the study design. Nevertheless, our findings support the available data in the literature and provide useful information regarding the results of mCRC patients treated with regorafenib.

## Conclusion

Regorafenib, a novel agent, is a multi-kinase inhibitor for use as monotherapy at last-line setting in mCRC. Although regorafenib shows a small but significant survival benefit in patients with mCRC who do not have any further treatment options after the failure over standard therapies, its toxicity profile along with the absence of predictive factors suggest a careful evaluation for the benefit/risk ratio before its use in clinical practice.

**Ethics Committee Approval:** The study was approved by the Necmettin Erbakan University Local Ethics Committee (Decision No. 2018/1319).

**Informed Consent:** Since it was a retrospective study, no patient consent form could be obtained.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - S.Ş.; Design - S.Ş., M.B.H.; Supervision - S.Ş., M.B.H.; Resources - S.Ş.; Data Collection and/or Processing - S.Ş., M.B.H.; Analysis and/or Interpretation - S.Ş., M.B.H.; Literature Search - S.Ş.; Writing Manuscript - S.Ş., M.B.H.; Critical Review - S.Ş., M.B.H.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Mercier J, Voutsadakis IA. a systematic review and meta-analysis of retrospective series of regorafenib for treatment of metastatic colorectal cancer. *Anticancer Res* 2017; 37: 5925-34.
2. Abrahao ABK, Ko YJ, Berry S, Chan KKW. A Comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis. *Clin Colorectal Cancer* 2018; 17: 113-20.
3. Garcia-Alfonso P, Feliu J, Garcia-Carbonero R, Gravalos C, Guillen-Ponce C, Sastre J, et al. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer? *Clin Transl Oncol* 2016; 18: 1072-81.
4. Hofheinz RD, Arnold D, Kubicka S, Prasnikar N, Vogel A. Improving patient outcomes with regorafenib for metastatic colorectal cancer-patient selection, dosing, patient education, prophylaxis, and management of adverse events. *Oncol Res Treat* 2015; 38: 300-8.
5. Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, et al. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. *Cancer Biol Ther* 2015; 16: 1710-9.

6. Kopeckova K, Buchler T, Bortlicek Z, Hejduk K, Chloupkova R, Melichar B, et al. Regorafenib in the real-life clinical practice: data from the czech registry. *Target Oncol* 2017; 12: 89-95.
7. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013; 381: 303-12.
8. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2015; 16: 619-29.
9. Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. *BMC Cancer* 2016; 16: 412.
10. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. *J Clin Oncol* 2010; 28: 453-9.
11. Riechelmann R, Grothey A. The role of regorafenib in metastatic colorectal cancer. *The Lancet Oncology* 2015; 16: 596-7.
12. Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. *Ther Adv Med Oncol* 2017; 9: 551-64.
13. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. *Lancet Oncol* 2015; 16: 937-48.
14. Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, et al. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. *Oncotarget* 2016 7;7: 34811-23.
15. Komori A, Taniguchi H, Hamauchi S, Masuishi T, Kito Y, Narita Y, et al. Serum CA19-9 response is an early predictive marker of efficacy of regorafenib in refractory metastatic colorectal cancer. *Oncology* 2017; 93: 329-35.

# Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer

## Over Kanserinde Neoadjuvan Kemoterapi Sonrası Cerrahi ile Primer Cerrahinin Uzun Dönem Sağkalımların Karşılaştırılması

İD Alpaslan Kaban<sup>1</sup>, İD Samet Topuz<sup>2</sup>, İD Hamdullah Sözen<sup>2</sup>, İD Yavuz Salihoğlu<sup>2</sup>

<sup>1</sup>İstanbul Training and Research Hospital, Clinic of Gynecological Oncology, İstanbul, Turkey

<sup>2</sup>İstanbul University Faculty of Medicine, Department of Gynecological Oncology, İstanbul, Turkey

### ABSTRACT

**Introduction:** To compare long-term survival of primary debulking surgery (PDS) and interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) in patients with advanced ovarian cancer.

**Methods:** Patients who underwent debulking surgery for ovarian cancer between 2001 and 2014 were included in the study.

**Results:** Of 378 patients, 191 (50.5%) underwent PDS and 187 (49.5%) underwent IDS. Compared with PDS group, IDS was associated with higher optimal surgical performance (residual <1 cm) (83% vs 65%,  $p<0.001$ ), lower visible tumor rate in the upper abdomen during surgery (12% vs 46%,  $p<0.001$ ), lower intraabdominal ascites rate (2% vs 64%,  $p<0.001$ ), lower postoperative (within 30 days) mortality (0 vs 5) and lower bowel resection/colostomy rate (3% vs 11%,  $p=0.001$ ). The median follow-up period was 43 (1-161) months. Overall survival (OS) was longer in the PDS group [56.8 months (95% CI: 48.2-65.4) vs 43.5 (95% CI: 38.1-48.8), log-rank test  $p=0.026$ ]. PDS was superior in both residual subgroups, 64.9 vs 44.6 months ( $p=0.008$ ) in  $\leq 1$  cm group and 41.6 vs 25.3 months ( $p=0.044$ ) in  $>1$  cm group. The 8-year OS was higher in the PDS group (31.8% vs 12.7%). According to multivariate Cox analysis, age, suboptimal debulking, IDS and presence of tumor in the upper abdomen were independent factors associated with shorter OS duration (hazard ratio: 1.013; 1.606; 1.456 and 1.495, respectively).

**Conclusion:** NAC in patients with FIGO 2010 stage 3 ovarian cancers is useful in reducing tumor spread, surgical morbidity and suboptimal surgery rates. However, long-term survival rates were shorter than the PDS group.

**Keywords:** Chemotherapy, cytoreduction, FIGO, ovarian carcinoma

### ÖZ

**Amaç:** İleri evre over kanserli hastalarda primer debulking cerrahisi (PDS), neoadjuvan kemoterapi sonrası cerrahisi (NAC), aralıklı debulking cerrahinin (IDS) uzun dönem sağkalım açısından karşılaştırılması amaçlanmıştır.

**Yöntemler:** 2001-2014 yılları arasında yumurtalık kanseri nedeniyle opere edilen hastalardan evre 3 olanlar çalışmaya alındı.

**Bulgular:** Toplam 378 hasta, 191'i (%50,5) PDS, 187'si (%49,5) IDS olarak ayrıldı. PDS grubu ile karşılaştırıldığında, IDS grubunda optimal cerrahi (rezidüel <1 cm) performansı daha yüksek (%83-%65,  $p<0,001$ ), ameliyat sırasında üst batında makroskopik tümör görülen hasta oranı daha az (%12-%46,  $p<0,001$ ), 1 litreden fazla intraabdominal asit daha az (%2-%64,  $p<0,001$ ), postoperatif (30 gün içinde) eksitus daha az (0-5), bağırsak rezeksiyonu/kolostomi oranı daha az (%3-%11,  $p=0,001$ ) izlendi. Ortanca takip süresi 43 (1-161) aydı. Genel sağkalım (GS), PDS grupta daha uzundu [56,8 ay (%95 CI: 48,2-65,4) vs 43,5 (%95 CI: 38,1-48,8), log-rank testi  $p=0,026$ ]. Rezidüel hastalık  $\leq 1$  cm ve  $>1$  cm olan her iki alt grupta PDS üstündü (sırasıyla 64,9 ay 44,6,  $p=0,008$ ; 41,6-25,3,  $p=0,044$ ). 8 yıllık GS oranı, PDS hastalarında daha yüksekti (%31,8'e karşılık %12,7). Çok değişkenli Cox analizine göre, yaş, suboptimal cerrahi, IDS ve üst batin bölgesindeki tümör varlığı, kısa GS süresi ile ilişkili bağımsız faktörlerdi (sırasıyla tehlike oranı: 1,013; 1,606; 1,456 ve 1,495).

**Sonuç:** FIGO evre 3 over kanserli hastalarda neoadjuvant-kemoterapi, tümör yayılımını azaltmada, cerrahi morbiditeyi azaltmada ve optimal storedüksiyonun azaltılmasında yararlıdır. Ancak uzun dönem sağkalım oranları primer cerrahi grubuna göre daha kısa bulundu.

**Anahtar Kelimeler:** Kemoterapi, sitoredüksiyon, FIGO, yumurtalık karsinomu



Address for Correspondence/Yazışma Adresi: Alpaslan Kaban, İstanbul Training and Research Hospital, Clinic of Gynecological Oncology, İstanbul, Turkey  
Phone: +90 532 260 96 84 E-mail: alpaslankaban@gmail.com ORCID ID: orcid.org/0000-0002-3623-7240

Cite this article as/Atıf: Kaban A, Topuz S, Sözen H, Salihoğlu Y. Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer. İstanbul Med J 2019; 20(2): 88-93.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

Received/Geliş Tarihi: 09.01.2019

Accepted/Kabul Tarihi: 14.02.2019

## Introduction

Three-quarters of patients with ovarian cancer are diagnosed with advanced-stage disease (FIGO 2010 stage 3/4) at presentation. Primary debulking surgery (PDS) followed by chemotherapy with paclitaxel and carboplatin, and neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) are two main treatment approaches (1,2). According to randomized controlled trials, survival is similar for both treatment approaches (3-5). These studies showed that postoperative complication rates were lower and the optimal surgery rate was higher in IDS after NAC. Therefore, over the past decade, the use of NAC has increased and PDS rates are showing a negative trend (6).

Recently, several studies have shown poorer survival in IDS compared to PDS (4,7-12).

In this study, we compared the outcomes of patients with advanced stage (FIGO stage 3) ovarian cancer treated with IDS after NAC or PDS.

## Methods

The study included patients who underwent surgery for advanced stage ovarian, tubal, or peritoneal cancer at Istanbul University Istanbul Faculty of Medicine Hospital between 2001 and 2013. A total of 378 patients were evaluated retrospectively. Clinical data were obtained from medical records of the patients. Inclusion criterion was a diagnosis of advanced stage high grade (FIGO stage 3C) epithelial ovarian, tubal, or peritoneal cancer according to postoperative pathology reports. Patients were triaged to undergo PDS followed by adjuvant chemotherapy (PDS group) or to receive neoadjuvant chemotherapy with IDS (IDS group).

## Patients

All patients were evaluated by a multidisciplinary team of gynaecologic oncologists, radiologists, gynaecopathologists, radiation oncologists and medical oncologists. For patient evaluation, we used magnetic resonance imaging and computerized tomography, tumor markers (CA-125, CA19-9, CEA) and computed tomography for lung examination. According to these evaluations, patients planned for primary surgery were directed to preoperative preparation. Patients planned for NAC were referred to the Department of Interventional Radiology for ascites cytology or tru-cut biopsy from tumoral tissue and directed to the NAC protocol after pathological confirmation. NAC consisted of carboplatin (area under the curve 5-6) and paclitaxel (135-175 mg/m<sup>2</sup>) every 3 weeks. The number of planned chemotherapy cycles was 3-4 prior to surgery.

As a standard surgical procedure in both groups (IDS-NAC and PDS), bilateral salpingo-oophorectomy, hysterectomy, appendectomy, and omentectomy were performed, and all visible tumors were removed if possible. Pelvic/para-aortic lymphadenectomy or sampling was performed in some patients. The decision to perform pelvic/para-aortic lymphadenectomy was determined by the surgical team. Other surgical procedures, the most common of which were large/small bowel resection and splenectomy, were performed when necessary. Optimal surgery was defined as the absence of a tumor larger than 1 cm at the end of the surgical procedure. After surgery, all patients

were treated by the same team of medical oncologists and received the same regimen of chemotherapy (paclitaxel plus platinum-based chemotherapy).

## Follow-up

All patients underwent a follow-up protocol after postoperative chemotherapy. The patients were evaluated with a gynecological examination and CA-125 markers every 3-4 months in the first two years. After two years, patients were evaluated every six months. If recurrent disease was suspected, patients were assessed by magnetic resonance imaging and by positron emission tomography, if necessary.

The overall survival (OS) was defined as the time from initial treatment to death or to the last follow-up examination. The primary endpoint of this study was OS.

The Statistical Package for the Social Sciences (SPSS) for Windows version 21 was used to perform all analyzes. Kaplan-Meier method was used for survival distributions and significance for survival duration was determined by the log-rank test. Differences between groups were analyzed using Fisher's exact and chi-square tests. P values less than 0.05 was considered significant.

Since this study is a retrospective review, the permission of the local ethics committee has not been obtained. However, all patients signed an informed consent for the use of their clinical data.

## Results

A total of 378 patients, 191 in the PDS group and 187 in the IDS group, were analyzed. Clinical and survival features are presented in Table 1. During 43 months of median follow-up period, 128 (67%) patients from the PDS group and 137 (73%) patients from the IDS group died ( $p=0.185$ ). The optimal surgery rate was higher in the IDS group (83% vs 65%,  $p<0.001$ ). The mean age was higher in the PDS group ( $56.3\pm13.2$  vs  $59.7\pm10.5$ ). In the PDS group, there was more tumor in the upper abdomen (46% vs 12%,  $p<0.001$ ), intraabdominal ascites more than 1 liter (64% vs 2%,  $p<0.001$ ), higher lymphadenectomy rate (53% vs 13%,  $p<0.001$ ), higher bowel resection/colostomy rate (11% vs 3%,  $p=0.001$ ), and higher postoperative mortality (within 30 days) (5 vs 0) (Table 1).


## Survival Analysis

The PDS group had a higher median OS duration than the IDS group (56.8 vs 43.5 months, log-rank test  $p=0.026$ ). 2-year OS rates were higher in the IDS group (85% vs 77%) and 3-year, 5-year, and 8-year OS rates were higher in the PDS group (64.3% vs 60.6%, 47.1% vs 36.6%, 31.8% vs 12.7%, respectively) (Figures 1-2).

## Subgroup Analysis (Table 2)

Each group was subdivided in terms of optimal surgery. OS times of subgroups based on optimality are presented in Table 2. The best survival was in the PSD group with optimal surgery (64.9 months). The IDS group undergoing suboptimal surgery had the worst survival (25.3 months).





**Figure 1.** Overall survival of patients grouped according to neoadjuvant chemotherapy (log-rank test  $p=0.026$ )

NAC: neoadjuvant chemotherapy

**Table 1. Clinical and survival results of patients based on PDS/IDS**

Feature	Primary debulking surgery (n=191)	Interval debulking surgery (n=187)	p
Age, (years) mean $\pm$ SD	56.3 $\pm$ 13.2	59.7 $\pm$ 10.5	
>60 years	72 (37.7%)	93 (49.7%)	<b>0.007</b>
Performance of optimal surgery	124 (65%)	156 (83%)	<b>&lt;0.001</b>
Presence of visible tumor at upper abdomen during surgery	88 (46%)	23 (12%)	<b>&lt;0.001</b>
Ascites (more than 1 liter)	123 (64%)	5 (2%)	<b>&lt;0.001</b>
Lymphadenectomy	102 (53%)	24 (13%)	<b>&lt;0.001</b>
Bowel resection/colostomy	21 (11%)	6 (3%)	<b>0.001</b>
Total exitus	128 (67%)	137 (73%)	
Postoperative (within 30 days)	5 (2.6%)	-	0.185
Median overall survival (months) 95% CI	56.8 48.2-65.4	43.5 38.1-48.8	<b>0.026</b>
2-year survival rate	77.0%	85.0%	
3-year survival rate	64.3%	60.6%	
5-year overall survival rate	47.1%	36.6%	
8-year overall survival rate	31.8%	12.7%	

SD: standard deviation, CI: confidence interval, PDS: primary debulking surgery, IDS: interval debulking surgery


### Cox regression analysis (Table 3)

Factors related to OS were analyzed by univariate and multivariate analyses (Table 3). The examined factors included age, optimal surgery, presence of tumor in the upper-abdomen, lymphadenectomy and treatment option (PDS or IDS). According to multivariate analysis, suboptimal surgery [hazard ratio (HR), 1.606; (95% CI, 1.184-2.177);  $p=0.002$ ], presence of tumor in the upper-abdomen [HR, 1.495; (95% CI, 1.113-2.006);  $p=0.007$ ], IDS [HR, 1.456; (95% CI, 1.076-1.970);  $p=0.015$ ], and age [HR, 1.013; (95% CI, 1.002-1.024);  $p=0.025$ ] were associated with shorter survival duration. Lymphadenectomy was associated with OS in univariate analysis, but not in multivariate analysis.

### Discussion

The NAC-IDS approach has been undertaken for patients with advanced stage ovarian cancer over the last 25 years, as an alternative option to PDS. This approach is increasingly preferred and the use of PDS is decreasing in clinics (6,13). Comparative survey outcomes for PDS and IDS continue to be published. To date, more than 20 studies comparing survival have been published (Table 4). In some studies, NAC-IDS seems advantageous in terms of survival, whereas others have reported that the PDS approach is preferable (Table 4). However, there is consensus that IDS is superior to PDS in terms of performance of optimal debulking (12-14).

In this study, optimal debulking and absence of upper abdominal metastasis were independent positive prognostic factors according to multivariate analysis (Table 3). These factors were higher in the NAC group. Despite these good results in the NAC group, survival was lower (median OS duration was 43.5 vs 56.8 months,  $p=0.026$ ) (Table 1). The survival advantage of PDS has become more prominent in the long-term survival analysis (Figures 1, 2). In addition, PDS was superior in terms of survival in subgroup analysis based on performance of optimal surgery (Table 2). Interestingly, patients with NAC have a shorter survival rate compared to patients with PDS, even though optimal surgery has been achieved. Similarly, in a recent study, Kessous et al. (15) reported that



**Figure 2.** Comparison of overall survival rates (%) for IDS/PDS groups at 2, 3, 5 and 8th years

IDS: interval debulking surgery, PDS: primary debulking surgery



patients with PDS had better OS than with NAC-IDS (60 months vs 48 months,  $p=0.039$ ). However, complete cytoreduction rates in the PDS group were lower than in the NAC-IDS group (65.9% vs 40.2%,  $p=0.001$ ).

In another study, Rosen et al. (9) reported that optimal surgery rates in patients with PDS were lower than patients with NAC-IDS (64% vs 79%). However, long-term OS rates were significantly higher (seven-year survival rate 8.6% vs 41.1%;  $p<0.0001$ ) in patients with PDS. In our study, 8-year OS rates were higher in the PDS group (31.8% vs 12.7%) (Table 1). In this study, 2-year OS rate in IDS seems to be better (not statistically significant) and 3-year and later survival was higher in PDS. The number of patients who died in the postoperative period was higher in the primary surgery arm (5 vs 0). This result causes the survival of the PDS to be short in the first year.

In a recent comparative study of two groups, May et al. (16) reported that 5-year survival was better for patients undergoing PDS than in patients who received NAC (39% vs 27%;  $p=0.02$ ). However, the gross residual tumor (>1 cm) ratio in the PDS group was higher in their study (28% vs 19%,  $p=0.02$ ).

Many studies comparing the survival of the two groups are presented in Table 4. According to randomized controlled prospective trials, survival rates were similar in patients with advanced stage ovarian cancer who underwent NAC-IDS or PDS. Conversely, in retrospective studies, the survival of patients with PDS appears to be slightly better than that of patients with NAC-IDS (Table 4). However, optimal cytoreduction rates in PDS arms of randomized controlled trials were low. The reported rates were 42% in Vergote and 37.6% in Kehoe. This may be associated with

low survival in the PDS group. Additionally, a patient eligible for PDS may have received NAC due to the randomization procedure. The main limitation in these randomized trials is that the selection process, which significantly biases the results, is usually not known.

In a recent meta-analysis, Qin et al. (17) and colleagues analyzed 22 retrospective observational studies and reported that OS was longer in the PDS group than that in the NAC group, irrespective of the degree of residual disease. Additionally, the authors stated that patients with FIGO stage 3 [HR=1.43, (95% CI: 1.05-1.95)] and 4 [HR=1.14, (95% CI: 1.06-1.23)] diseases had a better survival with PDS.

Regarding the adverse effect of NAC, some authors suggest that chemotherapeutics given may facilitate the emergence of chemotherapy-resistant cancer cell clones in NAC-IDS patients (18,19). Another hypothesis is that the tumor implants, which are shrinking due to chemotherapy, cannot be seen during laparotomy.

There are probably a limited number of patients who are eligible for surgery after NAC, and the criteria for this group need to be clarified. In fact, the main limitation in our study and in other studies comparing NAC and IDS is the uncertainty of patient selection criteria.

## Conclusion

NAC followed by IDS appears to be worse than PDS in patients with stage 3 ovarian cancer. With NAC, tumor spread and surgical morbidity are reduced and optimal cytoreduction rates are increased. However, these positive improvements do not reflect positively on the OS of the patients.

**Table 2. Analysis of overall survival of subgroups according to neoadjuvant chemotherapy and optimal surgery**

Optimality	Surgery	Median overall survival duration (months)				p
		Estimate	Standard error	95% CI		
				Lower bound	Upper bound	
Optimal	Primary surgery (n=124)	64.9	8.1	48.9	80.9	0.008
	Surgery after NAC (n=156)	44.6	3.9	36.9	52.2	
	Overall	56.8	4.4	48.0	65.5	
Suboptimal	Primary surgery (n=67)	41.6	7.6	26.7	56.5	0.044
	Surgery after NAC (n=31)	25.3	1.6	22.0	28.6	
	Overall	34.4	5.0	24.6	44.2	
Overall	Overall	49.7	3.2	43.3	56.0	

CI: confidence interval, NAC: neoadjuvant chemotherapy

**Table 3. Survival related factors according to multivariate and univariate cox regression analysis**

Reference variabl	Univariate analysis				Multivariate analysis			
	HR	95% CI		p	HR	95% CI		p
		Lower	Upper			Lower	Upper	
Age	1.017	1.006	1.027	0.002	1.013	1.002	1.024	0.025
Suboptimal surgery	1.317	1.032	1.681	0.027	1.606	1.184	2.177	0.002
Presence of tumor at upper-abdomen	1.433	1.110	1.849	0.006	1.495	1.113	2.006	0.007
Absance of lymphadenectomy	1.707	1.302	2.237	0.001	1.766	0.938	1.736	0.121
IDS	1.317	1.032	1.681	0.027	1.456	1.076	1.970	0.015

CI: confidence interval, HR: hazard ratio, IDS: interval debulking surgery

**Table 4. Results of studies comparing primary debulking surgery with interval debulking surgery after neoadjuvant chemotherapy in ovarian cancer**

Trials/year	Design	n	Superior	Overall survival (months) IDS vs PDS	p
Vergote et al. (4) (EORTC/NCIC trial)	Randomized controlled	670	-	29.0 vs 30.0	NS
Kehoe et al. (20) (CHORUS)	Randomized controlled	550	IDS	24.1 vs 22.6	NS
Shimizu et al. (21)	Retrospective	165	IDS	31 vs 21	<0.05
Scwartz et al. (22)	Retrospective	265	PDS	12.8 vs 26.1	NS
Kuhn et al. (23)	Prospective, nonrandomized	63	IDS	42 vs 23	0.007
Kayıkcioglu et al. (24)	Retrospective	205	PDS	34.1 vs 37.9	NS
Morice et al. (25)	Retrospective	68	IDS	26 vs 22	NS
Hegazy et al. (26)	Prospective cohort	59	PDS	25 vs 28	NS
Loizzi et al. (27)	Retrospective	60	PDS	32 vs 40	NS
Inciura et al. (28)	Retrospective	574	PDS	23.7 vs 25.4	NS
Steed et al. (29)	Retrospective	116	PDS	29 vs 44	0.03
Hou et al. (30)	Retrospective	172	PDS	46 vs 47	NS
McLean et al. (31)	Retrospective	175	PDS+	29 vs 34	NS
Chi et al. (32)	Retrospective	316	PDS	37 vs 50	-
Rauh-Hain et al. (33)	Retrospective	242	IDS++	33 vs 29	NS
Glasgow et al. (34)	Retrospective	104	PDS€	25 vs 39	NS
Fago-Olsen et al. (8)	Retrospective	1677	PDS	29.4 vs 31.9	0.099
Rosen et al. (9)	Retrospective	326	PDS*	8.6% vs 41.1%	<0.001
Solmaz et al. (35)	Retrospective	292	PDS	48.2 vs 57.7	NS
Bian et al. (36)	Retrospective	339	-	25 vs 25	NS
Luo et al. (19)	Retrospective	341	PDS	41 vs 51	NS
Meyer et al. (13)	Multi-institutional observational	1538	PDS	33 vs 43 (IIIC) 31 vs 36 (IV)	>0.05 (in IIIC)
Kessous et al. (15)	Retrospective	263	PDS	48.8 vs 60.2	0.039
May et al. (16)	Retrospective	303	PDS**	27% vs 39%	0.02
Present study 2018	Retrospective	378	PDS	43 vs 56	0,026

\*The authors reported a 7-year overall survival rate in each group, \*\*5-year survival, +only patients older than 65 years analyzed, ++only stage IV patients analyzed, €only patients older than 70 years analyzed, IDS: interval debulking surgery, PDS: primary debulking surgery

**Ethics Committee Approval:** Since this study is a retrospective review, the permission of the local ethics committee has not been obtained.

**Informed Consent:** All patients signed an informed consent for the use of their clinical data.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - A.K., S.T., H.S., Y.S.; Design - A.K., S.T., H.S., Y.S.; Supervision - A.K., S.T., H.S., Y.S.; Resources - A.K., S.T., H.S., Y.S.; Materials - A.K., S.T., H.S., Y.S.; Data Collection and/or Processing - A.K., S.T., H.S., Y.S.; Analysis and/or Interpretation - A.K., S.T., H.S., Y.S.; Literature Search - A.K., S.T., H.S., Y.S.; Writing Manuscript - A.K., S.T., H.S., Y.S.; Critical Review - A.K., S.T., H.S., Y.S.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

- Du Bois A, Pfistererz J. Future options for first-line therapy of advanced ovarian cancer. *Int J Gynecol Cancer* 2005; 15: 42-50.
- Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. *J Clin Oncol* 2011; 29: 3628-35.
- Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. *Lancet* 2015; 386: 249-57.
- Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med* 2010; 363: 943-53.
- van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. *Obstet Gynecol Surv* 1995; 50: 516-8.

6. Leiserowitz GS, Lin JF, Tergas AI, Cliby WA, Bristow RE. Factors predicting use of neoadjuvant chemotherapy compared with primary debulking surgery in advanced stage ovarian cancer: a national cancer database study. *Int J Gynecol Cancer* 2017; 27: 675-83.
7. Stewart J, Tone A, Jiang H, Bernardini M, Ferguson S, Laframboise S, et al. The optimal time for surgery in women with serous ovarian cancer. *Can J Surg* 2016; 59: 223-32.
8. Fago-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. *Gynecol Oncol* 2014; 132: 292-8.
9. Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. *Gynecol Oncol* 2014; 134: 462-7.
10. Van Meurs HS, Tadjik P, Hof MHP, Vergote I, Kenter GG, Mol BWJ, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. *Eur J Cancer* 2013; 49: 3191-201.
11. Thrall MM, Gray HJ, Symons RG, Noel S, Flum DR, Goff BA. Neoadjuvant chemotherapy in the mdicare cohort with advanced ovarian cancer. *NIH- Natl Instut Heal* 2011; 123: 1-15.
12. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. *Gynecol Oncol* 2006; 103: 1070-6.
13. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. *J Clin Oncol* 2016; JCO681239.
14. Kang S, Nam B-H. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. *Ann Surg Oncol* 2009; 16: 2315-20.
15. Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecol Oncol* 2017; 144: 474-9.
16. May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B GPA. A Comparison of survival outcomes in advanced serous ovarian cancer patients treated with primary debulking surgery versus neoadjuvant chemotherapy. *Int J Gynecol Cancer* 2017; 27: 668-74.
17. Qin M, Jin Y, Ma L, Zhang YY PL. The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. *Oncotarget* 2017; 27: 8614-28.
18. Lim MC, Song YJ, Seo SS, Yoo CW, Kang S, Park SY. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer. *Onkologie* 2010; 33: 324-30.
19. Luo Y, Lee M, Kim HS, Chung HH SY. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. *Med* 2016; 95: e47.
20. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Articles: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. *Lancet* 2015; 386: 249-57.
21. Shimizu Y, Hasumi K. (Treatment of stage III and IV ovarian cancer--is neoadjuvant chemotherapy effective?). *Nihon Sanka Fujinka Gakkai Zasshi* 1993; 45: 1007-14.
22. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. *Gynecol Oncol* 1999; 72: 93-9.
23. Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, Hundelshausen VB, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. *Cancer* 2001; 92: 2585-91.
24. Kayikcioglu F, Köse MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. *Int J Gynecol Cancer* 2001; 11: 466-70.
25. Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhommé C, Pautier P, et al. Results of interval debulking surgery in advanced stage ovarian cancer: An exposed-non-exposed study. *Ann Oncol* 2003; 14: 74-7.
26. Hegazy MAF, Hegazi RAF, Elshafei MA, Setit AE, Elshamy MR, Eltatoongy M, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. *World J Surg Oncol* 2005; 3: 57.
27. Loizzi V, Cormio G, Resta L, Rossi CA, Di Gilio AR, Cuccovillo A, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. *Int J Gynecol Cancer* 2005; 15: 217-23.
28. Inciura A, Simavicius A, Juozaityte E, Kurtinaitis J, Nadisauskiene R, Svedas E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. *BMC Cancer* 2006; 6: 153.
29. Steed H, Oza AM, Murphy J, Laframboise S, Lockwood G, De Petrillo D, et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. *Int J Gynecol Cancer* 2006; 16 Suppl 1: 47-53.
30. Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. *Gynecol Oncol* 2007; 105: 211-7.
31. McLean KA, Shah CA, Thompson SA, Gray HJ, Swensen RE, Goff BA. Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction. *Gynecol Oncol* 2010; 118: 43-6.
32. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leita MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). *Gynecol Oncol* 2012; 124: 10-4.
33. Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman a. K, Boruta DM, Horowitz NS, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. *Ann Surg Oncol* 2012; 19: 959-65.
34. Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). *J Surg Oncol* 2013; 107: 195-200.
35. Solmaz U, Mat E, Levent Dereli M, Turan V, Peker N, Tosun G, et al. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone? *J Buon* 2015; 20: 580-7.
36. Bian C, Yao K, Li L, Yi T ZX. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. *Arch Gynecol Obs* 2016; 293: 163-8.

# Abdominal Wall Endometriosis: Analysis of 66 Patients at a Tertiary Center

## Abdominal Duvar Endometriozis: Tersiyer Merkezde 66 Hastanın Analizi

✉ Besim Haluk Bacanakgil<sup>1</sup>, ✉ Hasene Özçam<sup>2</sup>, ✉ Mustafa Deveci<sup>1</sup>, ✉ Sezgi Güllü Yıldırım<sup>1</sup>

<sup>1</sup>İstanbul Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

<sup>2</sup>İstanbul Haseki Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

### ABSTRACT

**Introduction:** The objective of this study was to review the patients' characteristics and surgical findings of surgically excised abdominal wall endometriosis (AWE) cases.

**Methods:** We retrospectively analyzed the medical records of patients diagnosed with AWE between 2005 and 2015. Descriptive data were collected and analyzed.

**Results:** Sixty-six patients with histopathological diagnosis of AWE were included in our study. The mean age was 32±6.8 years and all cases were multiparous. All patients had a history of previous abdominal surgery and 63 patients had a history of cesarean delivery. The primary symptom was a painful palpable mass. The excised mass was generally on the previous surgical scar. The excised mass location was observed as subcutaneous tissue, fat layer, fascia and muscle tissue. There was no statistical correlation depth of invasion and mass size with the number of previous surgeries.

**Conclusion:** Caesarean incision was considered as the most important predisposing factor for AWE. As caesarean rates are increasing, we believe that the incidence of AWE will increase in the future. For this reason, more prospective studies are needed for prognosis and prophylaxis of the disease.

**Keywords:** Abdominal wall endometriosis, extrapelvic endometriosis, incisional endometriosis, scar endometriosis

### ÖZ

**Amaç:** Çalışmamızın amacı, cerrahi olarak eksize edilmiş abdominal duvar endometriozis (AWE) olgularının hasta karakteristik özelliklerini ve cerrahi bulgularını değerlendirmektir.

**Yöntemler:** 2005-2015 yılları arasında histopatolojik olarak AWE tanısı alan hastaların tıbbi kayıtlarını retrospektif olarak taradık ve tanımlayıcı dataları analiz ettik.

**Bulgular:** Çalışmamıza histopatolojik AWE tanılı 66 hasta dahil edildi. Ortalama yaş 32,0±6,8 idi ve tüm olgular multipar idi. Altmış üç hastanın geçirilmiş abdominal cerrahi öyküsü mevcuttu. Üç olgu hariç, tüm hastaların geçirilmiş sezaryen öyküsü mevcuttu. Hastaların primer semptomu ağrı ve palpe edilen kitle idi. Eksize edilen kitle genellikle önceki cerrahi skar üzerindeydi. Eksize edilen kitle lokasyonu subkutan doku, yağ tabakası, fasya ve kas dokusu olarak izlendi. Abdominal duvara invazyon derinliği ve kitle boyutu ile geçirilmiş cerrahi sayısı arasında bir ilişki izlenmedi.

**Sonuç:** Sezaryen insizyonu, AWE için en önemli predispozan faktör olarak değerlendirildi. Günümüzde sezaryen oranları arttığı için, gelecekte abdominal duvar endometriozis olgularının insidansının artacağına inanıyoruz. Bu nedenle hastalığın prognozu ve profilaksisi için daha çok prospektif çalışmaya gereksinim duyulmaktadır.

**Anahtar Kelimeler:** Abdominal duvar endometriozis, ekstrapelvik endometriozis, insizyonel endometriozis, skar endometriozis

### Introduction

Endometriosis is defined as the presence of endometrial glands and stroma outside the lining of the uterine cavity (1). Endometriosis is often found in intrapelvic areas such as ovaries, posterior cul de sac, ligaments of uterus, pelvic periton, rectovaginal septum, but it may rarely be in extrapelvic regions such as urinary tract, gastrointestinal tract and thorax (2,3). The abdominal wall endometriosis (AWE) is an uncommon

clinical entity with a reported incidence of 0.03-3.5% (4). This condition may develop spontaneously, however, the most important risk factor is previous surgeries (5,6).

The purpose of our study was to investigate the demographic characteristics, surgical history, symptoms, diagnostic methods and intraoperative findings of patients with AWE and to make proposals for implementation.



Address for Correspondence/Yazışma Adresi: Mustafa Deveci, İstanbul Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

Phone: +90 212 459 60 00 E-mail: mustafa.deveci@gmail.com ORCID ID: orcid.org/0000-0003-4061-8414

Cite this article as/Atıf: Bacanakgil BH, Özçam H, Deveci M, Yıldırım SG. Abdominal Wall Endometriosis: Analysis of 66 Patients at a Tertiary Center. İstanbul Med J 2019; 20(2): 94-7.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

Received/Geliş Tarihi: 06.06.2017

Accepted/Kabul Tarihi: 06.06.2018

## Methods

This is a retrospective descriptive case study. We reached the records of patients between November 2005 and March 2015 who had definitive histopathological diagnosis of AWE or scar endometriosis after surgical resection. Age, gravidity, parity, surgical history and characteristics of patients, diagnostic methods, and characteristics of the masses (e.g. number, localization, associated anatomical structures) were recorded. The time interval between the previous surgery and the diagnosis of AWE was defined as the “recognition period”. Patients with intraabdominal organ endometriosis were excluded from study.

This study has been approved by İstanbul Training and Research Hospital Ethics Committee (decision no: 649, date: 15.05.2015). Every patient admitted to our clinic had signed informed consent for admission and we are allowed to investigate clinical data unless we use personal data.

## Statistical Analysis

Statistical analysis was performed using SPSS for Windows version 15.0. Descriptive statistics were reported as number and percentage for categorical data, and mean, standard deviation, minimum and maximum for numerical variables. The trend for rate increase was examined with Mantel-Haenszel linear-by-linear association in chi-square test. Statistical significance level was considered as  $p < 0.05$ .

## Results

Sixty-six patients with histopathological AWE were included in our study (Table 1). The mean age was  $32 \pm 6.8$  years. All cases were multiparous. The recognition period for AWE ranged from 2 to 24 years. Majority of the patients had a history of cesarean delivery. Almost all of the patients had Pfannenstiel incision scar. Major presenting symptoms were palpable mass and pain. Ultrasonography (US) (44%), magnetic resonance imaging (MRI) (12%), computed tomography (CT) (4.5%) and fine-needle aspiration (FNA) (20%) had been performed for preoperative diagnosis. Thirteen of the patients (20%) had no preoperative diagnostic procedure and the masses were detected incidentally. The masses were mostly located at the previous surgery scars. In five patients, the masses were at umbilicus and far from previous scar. Sixty-nine percent of the masses were located at the incision corners. The endometriotic masses were mostly located in the subcutaneous tissue (45.5%). The mean mass size was  $28.7 \pm 10.4$  mm. The masses were completely excised in all patients. Polypropylene mesh graft was used in one patient. There was no statistically significant relationship between mass location and number of cesarean sections ( $p = 0.744$ ) (Table 2). There was no significant relationship between endometriotic mass size and the number of cesarean sections ( $p = 0.197$ ) (Table 3).

## Discussion

Iatrogenic implantation theory is the most widely accepted theory for AWE. According to this theory, it is suggested that endometrial cells are planted directly at the incision (7,8). The development of endometriotic implants/masses mostly in previous gynecologic scars (such as cesarean section, hysterotomy, hysterectomy) supports iatrogenic implantation theory (6,9). Metaplasia and migration theories are other accepted theories in the development of

**Table 1. Characteristics of the patients**

		Range	Mean $\pm$ SD
Age (year)		19-51	$32.0 \pm 6.8$
The recognition period (month)		2-24	$5.6 \pm 4.1$
		n	%
Surgery history	One cesarean section	32	48.5
	Two cesarean sections	23	34.8
	Three cesarean sections	8	12.1
	Ovarian cystectomy	2	3.0
	Hysterectomy	1	1.5
Shape of incision	Transvers (Pfannenstiel)	65	98.5
	Midline	1	1.5
Symptoms and findings	Palpable mass	43	65.2
	Pain	23	34.8
Preoperative imaging	US	29	43.9
	MRI	8	12.1
	CT	3	4.5
	FNA	13	19.7
	None	13	19.7
AWE mass	<b>Region</b>		
	Previous scar	61	92.4
	Umbilicus	5	7.6
	<b>Site (Pfannenstiel)</b>		
	Left corner	26	39.4
	Right corner	20	30.3
	Middle	15	22.7
	<b>Location</b>		
	Subcutaneous tissue	30	45.5
	Muscular	23	34.8
	Fascia	9	13.6
	Fat	4	6.1
		<b>Range</b>	<b>Mean <math>\pm</math> SD</b>
	Number	1-2	$1.0 \pm 0.1$
	Size (mm)	11-55	$28.7 \pm 10.4$

SD: standard deviation, US: ultrasonography, MRI: magnetic resonance imaging, CT: computed tomography, FNA: fine needle aspiration, AWE: abdominal wall endometriosis

**Table 2. The relationship between the number of cesarean sections and the mass localization**

Mass location	Number of cesarean, n (%)		
	One	Two	Three
Subcutaneous tissue	18 (56.3)	9 (39.1)	3 (37.5)
Fat	1 (3.1)	1 (4.3)	1 (12.5)
Fascia	2 (6.3)	3 (13.0)	4 (50.0)
Muscular	11 (34.4)	10 (43.5)	0 (0.0)
$p = 0.744$			



**Table 3. The relationship between the number of cesarean sections and mass size**

Cesarean number	Diameter of mass Mean $\pm$ SD (mm)
One	27.0 $\pm$ 9.9
Two	29.9 $\pm$ 11.6
Three	33.6 $\pm$ 9.1
SD: standard deviation, p=0.197	

extrapelvic endometriosis (9,10). Metaplasia theory claims that the differentiation of primitive mesenchymal cells into endometrial cells in the scar tissue causes endometriosis. The migration theory claims lymphatic or vascular spread of endometrial cells to distant sites. The nodules in previously non-operated patients or nodules in distant locations can be explained by this theory. None of these theories can exactly explain the whole case. Therefore, some researchers claim that genetic and environmental factors together play a role in the etiology of endometriosis (11). Cesarean section is one of the most common causes of AWE (2,6). The incidence of AWE in cesarean scar has been reported to between 0.03-1.08%. In the studies of Khamechian et al. (2) and Ding and Zhu (6), all patients had a history of cesarean section.

AWE usually develops in women of reproductive age (10,12). Predominantly, the patients are multiparous. Palpable mass is seen in 63-100% and pain in 41-92.5% (2,6,9,13). The increase in mass size during menstruation is pathognomonic for scar endometriosis (9,14). In our study, most common finding was palpable mass (65%). In the differential diagnosis, hernia, suture granuloma, primary or metastatic tumors, sarcoma, cysts, nodular and proliferative fasciitis, fat necrosis, lipoma, abscess or hematoma of the abdominal wall should be considered (14,15). US, CT and MRI can be used in the diagnosis and US is the primary imaging method to be preferred. The endometriotic masses are mostly vascularized and hypoechoic sonographically. CT and MRI provide useful information about the anatomic location of the mass in the abdominal wall and its relation with neighboring structures for preoperative evaluation. However, imaging findings are not specific (12,16). Definitive diagnosis is possible only histopathologically (2,17). Some authors recommend FNA cytology before surgical excision. Observation of endometrial gland, stroma and hemosiderin-laden macrophages in cytology are considered diagnostic findings (15,18,19). On the other hand, there is no consensus for FNA, because there is some risk of planting endometrial cells to the puncture site (9,20).

Local wide surgical excision is the primary treatment for AWE. For both treatment and reducing the risk of lesion recurrence, the mass should be widely excised with at least 1 cm margin (6,21). After surgical excision, defect can be repaired by using autologous or synthetic graft according to the width of the defect and its anatomical localization (11,22). Postoperative adjuvant hormone therapy such as danazol, progesterone and GnRH analogs are recommended for patients with concomitant pelvic endometriosis or recurrent AWE (21,23).

### Study Limitations

The major limitations of our study were retrospective nature and failure of post-treatment controls due to inability to reach the majority of patients.

### Conclusion

Endometriosis should be considered in differential diagnosis of a painful mass in anterior abdominal wall, especially in women with a history of pelvic or obstetric surgery. According to our findings and the literature (2,4,6-14,24,25), previous cesarean section is the most well known risk factor in etiology. This suggests that the disease is highly caused by iatrogenic sowing. For this reason, the following recommendations will contribute to non-occurrence of AWE after cesarean sections; intraoperatively, a) rapid removal of the gauze used to clean uterine cavity and ensure no contact to the incision, b) replacement of gloves after uterine incision suturing, c) washing of the abdominal wall tissues with physiological saline after the uterus is closed, d) not using of remaining uterine suture materials elsewhere, e) irrigation of incision with physiological saline after the parietal peritoneum is closed. These recommendations can considerably reduce the incidence of AWE.

**Ethics Committee Approval:** This study has been approved by Istanbul Training and Research Hospital Ethics Committee (decision no: 649, date: 15.05.2015).

**Informed Consent:** Every patient admitted to our clinic had signed informed consent for admission.

**Peer-review:** Externally and internally peer-reviewed.

**Author Contributions:** Concept - B.H.B., H.Ö.; Design - S.G.Y.; Supervision - B.H.B., H.Ö., Resources - M.D., S.G.Y.; Data Collection and/or Processing - B.H.B., M.D.; Analysis and/or Interpretation - H.Ö., S.G.Y.; Literature Search - B.H.B.; Writing Manuscript - M.D.; Critical Review - B.H.B., H.Ö.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

### References

- Accetta I, Accetta P, Accetta AF, Maia FJ, Oliveira AP. Abdominal wall endometrioma. Rev Col Bras Cir 2011; 38: 41-4.
- Khamechian T, Alizargar J, Mazoochi T. 5-Year data analysis of patients following abdominal wall endometrioma surgery. BMC Womens Health 2014; 14: 151-4.
- Jubanjik KJ, Comite F. Extrapelvic endometriosis. Obstet Gynecol Clin North Am 1997; 24: 411-40.
- Nominato NS, Prates LF, Lauer I, Morais J, Maia L, Geber S. Cesarean section greatly increases risk of scar endometriosis. Eur J Obstet Gynecol Reprod Biol 2010; 152: 83-5.
- Ideyi SC, Schein M, Niazi M, Gerst PH. Spontaneous endometriosis of the abdominal wall. Dig Surg 2003; 20: 246-8.
- Ding Y, Zhu J. A retrospective review of abdominal wall endometriosis in Shanghai, China. Int J Gynaecol Obstet 2013; 121: 41-4.



7. Gunes M, Kayikcioglu F, Ozturkoglu E, Haberal A. Incisional endometriosis after cesarean section, episiotomy and other gynecologic procedures. *J Obstet Gynaecol Res* 2005; 31: 471-5.
8. Horton JD, Dezee KJ, Ahnfeldt EP, Wagner M. Abdominal wall endometriosis: a surgeon's perspective and review of 445 cases. *Am J Surg* 2008; 196: 207-12.
9. Vellido-Cotelo R, Muñoz-González JL, Oliver-Pérez MR, de la Hera-Lázaro C, Almansa-González C, Pérez-Sagaseta C, et al. Endometriosis node in gynaecologic scars: a study of 17 patients and the diagnostic considerations in clinical experience in tertiary care center. *BMC Womens Health* 2015; 15: 13.
10. Ecker AM, Donnellan NM, Shepherd JP, Lee TT. Abdominal wall endometriosis: 12 years of experience at a large academic institution. *Am J Obstet Gynecol* 2014; 211: 363.
11. Jamabo RS, Ogu RN. Abdominal scar endometriosis. *Indian J Surg*.2008; 70: 184-7.
12. Solak A, Genç B, Yalaz S, Sahin N, Sezer TÖ, Solak I. Abdominal wall endometrioma: ultrasonographic features and correlation with clinical findings. *Balkan Med J* 2013; 30: 155-60.
13. Ozel L, Sagioglu J, Unal A, Unal E, Gunes P, Baskent E, et al. Abdominal wall endometriosis in the cesarean section surgical scar: a potential diagnostic pitfall. *J Obstet Gynaecol Res* 2012; 38: 526-30.
14. Kaplanoglu M, Kaplanoglu DK, Ata CD, Buyukkurt S. Obstetric scar endometriosis: retrospective study on 19 cases and review of the literature. *International Scholarly Research Notices* 2014; 1-6.
15. Pachori G, Sharma R, Sunaria RK, Bayla T. Scar endometriosis: Diagnosis by fine needle aspiration. *J Cytol* 2015; 32: 65-7.
16. Hensen JH, Van Breda Vriesman AC, Puylaert JB. Abdominal wall endometriosis: clinical presentation and imaging features with emphasis on sonography. *AJR Am J Roentgenol* 2006; 186: 616-20.
17. Cöl C, Yilmaz EE. Cesarean scar endometrioma: Case series. *World J Clin Cases* 2014; 16: 133-6.
18. Medeiros Fd, Cavalcante DI, Medeiros MA, Eleutério J Jr. Fine-needle aspiration cytology of scar endometriosis: study of seven cases and literature review. *Diagn Cytopathol* 2011; 39: 18-21.
19. Veda P, Srinivasaiiah M. Incisional endometriosis: Diagnosed by fine needle aspiration cytology. *J Lab Physicians* 2010; 2: 117-20.
20. Hughes ML, Bartholomew D, Paluzzi M. Abdominal wall endometriosis after amniocentesis. A case report. *J Reprod Med* 1997; 42: 597-9.
21. Chiang DT, Teh WT. Cutaneous endometriosis. Surgical presentations of a gynaecological condition. *Aust Fam Physician* 2006; 35: 887-8.
22. Kokuba EM, Sabino NM, Sato H, Aihara AY, Schor E, Ferreira LM. Reconstruction technique for umbilical endometriosis. *Int J Gynaecol Obstet* 2006; 94: 37-40.
23. Wang PH, Juang CM, Chao HT, Yu KJ, Yuan CC, Ng HT. Wound endometriosis: risk factor evaluation and treatment. *J Chin Med Assoc* 2003; 66: 113-9.
24. Wasfie T, Gomez E, Seon S, Zado B. Abdominal wall endometrioma after cesarean section: a preventable complication. *Int Surg* 2002; 87: 175-7.
25. Teng CC, Yang HM, Chen KF, Yang CJ, Chen LS, Kuo CL. Abdominal wall endometriosis: an overlooked but possibly preventable complication. *Taiwan J Obstet Gynecol* 2008; 47: 42-8.

# Assessment of Cervical Length by Transvaginal Ultrasound in Pregnant Women Between 24-34 Weeks

## Gebelerde Transvajinal Ultrason ile 24-34 Hafta Arasında Servikal Uzunluğun Değerlendirilmesi

Salim Sezer<sup>1</sup>, Alpaslan Kaban<sup>2</sup>, Baki Erdem<sup>1</sup>

<sup>1</sup>University of Health Sciences, Kanuni Training and Research Hospital, Clinic of Gynecology and Obstetrics, Trabzon, Turkey

<sup>2</sup>Istanbul Training and Research Hospital, Clinic of Gynecology and Obstetrics, Istanbul, Turkey

### ABSTRACT

**Introduction:** The purpose of this study was to assess the role of cervical length measurement by transvaginal ultrasound for predicting preterm delivery.

**Methods:** Cervical lengths were measured by transvaginal ultrasound in 73 pregnant women with 24-34 weeks of gestation. Cervical length measurements were analyzed for the predictability of preterm birth.

**Results:** Of the 73 pregnant women, 19 (26%) had preterm labor (<37 weeks) and 54 (74%) had term labor. For predicting preterm birth, cut-off values were determined using the Receiver Operating Characteristic Curve curves and corresponding values. The cut-off value of the cervical length was 31.5 millimeters and sensitivity, specificity, positive predictive value and negative predictive value were 70.3%, 89.4%, 51.5% and 95%, respectively.

**Conclusion:** According to the study, the evaluation of cervical length by transvaginal ultrasound in pregnant women with 24-34 weeks of gestation may be useful as a screening test for preterm birth prediction. The risk of premature birth in pregnant women with a cervical length more than 31 mm is minimal.

**Keywords:** Cervical length, preterm birth, transvaginal ultrasound

### ÖZ

**Amaç:** Bu çalışmanın amacı, erken doğumu öngörmeye transvajinal ultrason ile servikal uzunluk ölçümünün rolünü değerlendirmektir.

**Yöntemler:** Yirmi dört-otuz dört haftalık gebeliği olan 73 kadında, transvajinal ultrasonografi ile servikal uzunluklar ölçüldü. Servikal uzunluk ölçümleri preterm doğum tahmin edilebilirliği açısından analiz edildi.

**Bulgular:** Yetmiş üç gebe kadından 19'u preterm (<37 hafta) (%26) ve 54'ü (%74) miadında doğum yaptı. Erken doğumu kestirmek için, kesme değerleri Receiver Operating Characteristic Curve eğrileri ve karşılık gelen değerler kullanılarak belirlendi. Servikal uzunluğun kesme değeri 31,5 milimetre olarak belirlendi ve duyarlılık, özgüllük, pozitif prediktif değer ve negatif öngörü değeri sırasıyla %70,3, %89,4, %51,5 ve %95 idi.

**Sonuç:** Çalışmaya göre, gebe kadınlarda 24-34. haftalar arasında transvajinal ultrasonografi ile servikal uzunluğun değerlendirilmesi preterm doğum tahmini için tarama testi olarak faydalı olabilir. 31 mm'nin üzerinde servikal uzunluğa sahip gebelerin prematür doğum riski minimaldir.

**Anahtar Kelimeler:** Servikal uzunluk, erken doğum tahmini, transvajinal ultrason

### Introduction

Preterm delivery is the birth that occurred before the completion of 37 weeks of gestation. The rate of preterm birth is different in reports and can be up to 15% (1-4). According to the literature, the incidence of preterm delivery has increased in recent years (5). Preterm delivery is one of the main causes of neonatal morbidity and mortality (5). The risk of mortality and serious acute morbidities such as respiratory distress

syndrome, necrotizing enterocolitis and intraventricular hemorrhage are related with preterm birth (6,7).

In recent years, cervical length measurement by cervical transvaginal ultrasound (US) has been proposed as an effective method for predicting preterm delivery (8-11). However, there is no consensus on the routine use of cervical length measurement for predicting preterm delivery (12-14).



Address for Correspondence/Yazışma Adresi: Alpaslan Kaban, Istanbul Training and Research Hospital, Clinic of Gynecology and Obstetrics, Istanbul, Turkey

Phone: +90 532 260 96 84 E-mail: alpaslankaban@gmail.com ORCID ID: orcid.org/0000-0002-3623-7240

Cite this article as/Atıf: Sezer S, Kaban A, Erdem B. Assessment of Cervical Length by Transvaginal Ultrasound in Pregnant Women Between 24-34 Weeks. Istanbul Med J 2019; 20(2): 98-100.

©Copyright 2019 by the Istanbul Training and Research Hospital/Istanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/Istanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

Received/Geliş Tarihi: 18.05.2018

Accepted/Kabul Tarihi: 06.12.2018

In this study, the relationship between cervical length measurement by transvaginal US and preterm delivery was investigated.

## Methods

This study was performed in pregnant women between 24-34 weeks of pregnancy who applied to the obstetrics clinic for routine antenatal follow-up. Istanbul Gaziosmanpaşa Taksim Training and Research Local Ethics Committee approval was obtained for this study (decision number: 16.01.2009). Informed consent form was obtained from all patients included in the study. Patients with vaginal bleeding, membranous rupture, pregnancies with >3 cm of cervical dilatation, mandatory birth due to fetal or maternal reasons were excluded. Pregnancy history was obtained, the last menstrual period (LMP) was recorded and gestational week was calculated. Gestational weeks were calculated according to the first trimester US of pregnant women who did not know the LMP. The first trimester US was used to determine gestational week if there was a significant difference (more than 7days) between the LMP and first trimester US. The pregnancies that did not have first trimester US and did not know LMP were not included in the study.

The vaginal US probe was prepared by attaching a condom to the tip. The cervix was assessed by transvaginal US. Cervical length measurement was performed visualizing the cervical internal ostium, external ostium and cervical channel on the same line.

A total of 80 pregnant women were included in the study. After the study was completed, seven pregnant women were excluded from the study due to missing data.

Those who gave birth at  $\geq 37$  gestational weeks were accepted as term delivery and  $< 37$  gestational weeks as preterm delivery.

## Statistical Analysis

Statistical analysis was performed by SPSS. Mann-Whitney U test was used in the comparisons between independent groups. The chi-square test was used to compare expected and observed values.

## Results

Of 73 pregnant women, 19 had preterm and 54 had term delivery. The results of these two groups were compared. There was no significant difference between the two groups regarding median gestational age at the time of examination ( $p=0.477$ ). The mean birth age was  $242 \pm 11$  days in preterm delivery and  $275 \pm 7$  days in term delivery. The mean birth weight was  $2371 \pm 292$  grams at preterm delivery and  $3302 \pm 430$  grams at term delivery and the difference was statistically significant ( $p<0.001$ ) (Table 1).

## Cervical Length

The cut-off value of the cervical length was determined using the Receive Operating Characteristic (ROC) curve and the corresponding cervical length values, and the cut-off value was determined as 31.5 mm. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy rate were 70.3%, 89.4%, 51.5%, 95% and 75.3%, respectively (Table 2, Figure 1). Cervical length in 17 of 19 pregnant women who

underwent preterm delivery was below the cut-off value of 31.5 mm (89.4%).

## Discussion

The World Health Organization recognizes births that occur before the completion of 37 gestational weeks as premature births (4). Preterm delivery is a major cause of morbidity and mortality (15). Cervical length measurement by cervical transvaginal US is suggested as an effective screening method for premature birth (8,9,16). However, some studies suggest that it is not useful as a screening method (12,13).

The cervical length can be measured in different ways by US. These are transabdominal, transperineal and transvaginal approaches. Transvaginal approach is considered to be the gold standard (17). In our study, cervical lengths were measured by transvaginal US in 73 women. The cervical length was shorter in women who gave birth before 37 weeks (defined as preterm labor) ( $24 \pm 7$  mm vs  $34 \pm 7$  mm,  $p<0.001$ ).


**Table 1. Characteristics of preterm and term groups**

Features	Preterm (n=19)	Term (n=54)	p
Cervical length, (mm) mean $\pm$ SD	$24 \pm 7$	$34 \pm 7$	$<0.001$
Gestational age during examination, median (95% CI)	32 (30-33)	32 (28-33)	0.477
Age of birth, (days) mean $\pm$ SD	$242 \pm 11$	$275 \pm 7$	$<0.001$
Birth weight, (gr) mean $\pm$ SD	$2371 \pm 292$	$3302 \pm 430$	$<0.001$

CI: confidence interval, SD: standard deviation

**Table 2. Predictive values of cervical length with a cut-off value of 31.5 mm**

	Preterm (n=19)	Term (n=54)	Total
Cervical length ( $\leq 31.5$ mm)	51.5% (17)	48.5% (16)	33
Cervical length ( $> 31.5$ mm)	5.0% (2)	95.0% (38)	40
Total	19	54	73



When the cut-off value was accepted as 31.5 mm, the negative predictive value was 95%. Of the 40 women whose cervical length measurements were above the cut-off value, only 2 had preterm labor (Table 2). The risk of preterm delivery was 51.5% if the cervical length was shorter than 31 mm.

According to Timothy and colleagues, 25 mm cervical length has the best predictive accuracy (8). If the cervical length is shortened and it is detected early in pregnancy, the risk of preterm birth increases.

According to the studies of Kuusela et al. (14), there was no significant association between cervical length (<25 mm) and spontaneous preterm delivery at <37 weeks. The authors reported a significant relationship between cervical length and spontaneous preterm birth at <34 weeks and reported that a larger study is needed to evaluate the prevalence of short cervical length and the possible association with preterm delivery before universal screening is recommended.

There are three main mechanisms associated with the development of a short cervical length (18). Firstly, the most accepted hypothesis is that of an internal weakness of a short cervical length. This cervical insufficiency is usually caused by traumatic or surgical injury or, more rarely, by a congenital disorder or connective tissue disease. Second, another hypothesis is that a short cervical length is due to an inflammatory or infectious process. In the other hypothesis, it is thought that shortening of cervical length is due to uterine contractions. Studies have shown that asymptomatic women with a cervical length less than 25 mm before 24 weeks have higher risk of preterm birth more than controls with a normal cervix (9).

## Conclusion

This study showed that measurement of cervical length by transvaginal US might be useful as a screening test in predicting preterm birth. In this study, the cut-off value was found to be 31.5 mm and the probability of premature birth was lower in women with a cervical length above this value.

**Ethics Committee Approval:** İstanbul Gaziosmanpaşa Taksim Training and Research Local Ethics Committee approval was obtained for this study (decision number:16.01.2009).

**Informed Consent:** Informed consent form was obtained from all patients included in the study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - S.S.; Design - S.S., A.K., B.E.; Supervision - A.K.; Resources - S.S., A.K.; Materials - S.S.; Data Collection and/or Processing - S.S., A.K.; Analysis and/or Interpretation - A.A.; Literature Search - S.S., A.K.; Writing Manuscript - S.S., A.K.; Critical Review - S.S., A.K., B.E.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Vol. 371, The Lancet. 2008. p. 75-84.
2. Slattery MM, Morrison JJ. Preterm delivery. Vol. 360, Lancet. 2002. p. 1489-97.
3. Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med. 2007; 357: 477-87.
4. Spong CY. Defining "term" pregnancy: Recommendations from the defining "term" pregnancy workgroup. Vol. 68, Obstetrical and Gynecological Survey. 2013. p. 611-2.
5. Slattery MM, Morrison JJ. Preterm delivery. Lancet 2015; 360: 1489-97.
6. Iams JD. Care for women with prior preterm birth. In: Preterm birth: Prevention and Management 2010. p. 115-29.
7. Hodgson EJ, Lockwood CJ. Preterm birth: Prevention and Management-Google Books. Preterm Birth Prev 2010.
8. Rafael TJ. Short Cervical Length. In: Preterm birth: Prevention and Management. 2010. p. 130-48.
9. Mella MT, Berghella V. Prediction of Preterm Birth: Cervical Sonography. Vol. 33, Seminars in Perinatology. 2009. p. 317-24.
10. Gynecologists AC of O and. Prediction and prevention of preterm birth. Obstet Gynecol 2012; 120: 964-73.
11. Grimes-Dennis J, Berghella V. Cervical length and prediction of preterm delivery. Vol. 19, Current Opinion in obstetrics and gynecology 2007. p. 191-5.
12. Esplin MS, Elovitz MA, Iams JD, Parker CB, Wapner RJ, Grobman WA, et al. Predictive accuracy of serial transvaginal cervical lengths and quantitative vaginal fetal fibronectin levels for spontaneous preterm birth among nulliparous women. JAMA-J Am Med Assoc 2017; 317: 1047-56.
13. Conde-Agudelo A, Romero R, Hassan SS, Yeo L. Transvaginal sonographic cervical length for the prediction of spontaneous preterm birth in twin pregnancies: A systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203: 128.e1-12.
14. Kuusela P, Jacobsson B, Söderlund M, Bejlm C, Almström E, Ladfors L, et al. Transvaginal sonographic evaluation of cervical length in the second trimester of asymptomatic singleton pregnancies, and the risk of preterm delivery. Acta Obstet Gynecol Scand 2015; 94: 598-607.
15. Ananth CV, Joseph KS, Oyelese Y, Vintzileos AM. Trends in preterm birth and perinatal mortality among singletons: united states, 1989 through 2000. Obstet Gynecol 2005; 105: 1084-91.
16. Ginsberg Y, Goldstein I, Khatib N, Farago N, Weiner Z. Lower uterine segment thickness and cervical length. Volume 212, Issue 1, Supplement, Page S134. DOI: <https://doi.org/10.1016/j.ajog.2014.10.290>
17. O'Hara S, Zelesco M, Sun Z. Cervical length for predicting preterm birth and a comparison of ultrasonic measurement techniques. Australas J Ultrasound Med 2013; 16: 124-34.
18. Callen P. Ultrasonography in obstetrics and gynaecology. 5<sup>th</sup> ed. Philadelphia: Saunders Elsevier; 2008.

# Diaphragm Thickness Measurement in Computed Tomography: Intra- and Inter-Observer Agreement

## Bilgisayarlı Tomografide Diyafram Kalınlık Ölçümü: Gözlemci İçi ve Gözlemciler Arası Güvenilirlik

İ Furkan Ufuk, İ Pınar Çakmak, İ Ergin Sağtaş, İ Duygu Herek, İ Muhammet Arslan, İ Ahmet Baki Yağcı

Pamukkale University Faculty of Medicine, Department of Radiology, Denizli, Turkey

### ABSTRACT

**Introduction:** Diaphragm thickness (DT) measurement in computed tomography (CT) has become popular in recent years. Our aim was to assess the intra- and inter-observer agreement of DT measurement and to investigate the best points for DT assessment in CT based on the most reliable measurement.

**Methods:** Thoraco-abdominal CT angiography scans of 44 patients (23 males, mean age:  $49.9 \pm 17.8$  years) were retrospectively evaluated. All of the CT images were evaluated independently by four radiologists. Each observer evaluated images twice to assess intra-observer reproducibility. On both axial and coronal reconstructed CT images, the crura of 88 hemidiaphragms were measured at five different points. A p value less than 0.05 was considered to indicate statistical significance. Intra- and inter-observer agreement was evaluated by using intraclass correlation coefficient (ICC) scores with a 95% confidence interval.

**Results:** In intra-observer analysis, ICC scores demonstrated substantial to almost perfect agreement for all measurements (ICC score range: 0.758-1). When we analyzed the inter-observer agreement, there was a moderate to almost perfect agreement for each measurement point (ICC score range: 0.523-0.895). All axial measurements showed the highest inter-observer agreement (ICC scores were 0.926 and 0.886 for first and second measurements, respectively). The maximum inter- and intra-observer agreement for single point DT measurements were found in maximum DT at the level of the origin of the celiac artery and in anterior DT at the level of the upper part of the L1 vertebral body.

**Conclusion:** CT is a reliable tool DT measurement with excellent intra- and inter-observer agreement.

**Keywords:** Computed tomography, diaphragm thickness, measurement, reliability

### ÖZ

**Amaç:** Çeşitli hastalıklarda bilgisayarlı tomografide (BT) diyafram kalınlığı (DK) ölçümü son yıllarda popüler hale gelmiştir. Amacımız, DK ölçümünün gözlemci içi ve gözlemciler arası anlaşmasını değerlendirmek ve en güvenilir ölçümlere dayanarak BT'de en iyi DK ölçümü yerini araştırmaktır.

**Yöntemler:** DK ölçümünde 44 hastanın (23 erkek, ortalama yaş;  $49,9 \pm 17,8$ ) torako-abdominal BT anjiyografisi retrospektif olarak değerlendirildi. Tüm BT görüntüleri dört radyolog tarafından bağımsız olarak değerlendirildi. Her gözlemci, gözlemciler arası tekrarlanabilirliği değerlendirmek için görüntüleri iki kez değerlendirdi. Hem aksiyal hem de koronal rekonstrüksiyon yapılmış BT görüntülerinde, 88 hemidiyaframın krusları beş farklı noktada ölçülmüştür. İstatistiksel anlamlılığı göstermek için 0,05'ten küçük bir p değeri göz önüne alınmıştır. Gözlemci içi ve gözlemciler arası anlaşma, %95 güven aralığında sınıf içi korelasyon katsayısı (ICC) skorları kullanılarak değerlendirildi.

**Bulgular:** Gözlemci içi arası analizde, ICC skorları, tüm ölçümler için iyi - neredeyse mükemmel bir anlaşma göstermiştir (ICC skorları aralığı; 0,758-1). Gözlemciler arası anlaşmayı incelediğimizde, her bir ölçüm noktası için orta - neredeyse mükemmel bir anlaşma vardı (ICC skoru aralığı, 0,523-0,895). Tüm aksiyal ölçüm değerleri en yüksek gözlemciler arası anlaşmayı gösterdi (ICC skorları sırasıyla birinci ve ikinci ölçümler için 0,926 ve 0,886 idi). Tek nokta DK ölçümleri için en iyi gözlemci içi ve gözlemciler arası anlaşma, çölyak arter çıkımı düzeyinde maksimum DK ve L1 vertebra gövdesinin üst kısmı seviyesinde anterior DK ölçülmesinde bulundu.

**Sonuç:** Bilgisayarlı tomografi, yüksek gözlemci içi ve gözlemciler arası uyum nedeniyle DK ölçümü için güvenilir bir araçtır.

**Anahtar Kelimeler:** Bilgisayarlı tomografi, diyafram kalınlığı, ölçüm, güvenilirlik



Address for Correspondence/Yazışma Adresi: Furkan Ufuk, Pamukkale University Faculty of Medicine, Department of Radiology, Denizli, Turkey

Phone: +90 554 511 50 88 E-mail: furkan.ufuk@hotmail.com ORCID ID: orcid.org/0000-0002-8614-5387

Cite this article as/Atıf: Ufuk F, Çakmak P, Sağtaş E, Herek D, Arslan M, Yağcı AB. Diaphragm Thickness Measurement in Computed Tomography: Intra- and Inter-Observer Agreement. İstanbul Med J 2019; 20(2): 101-6.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

Received/Geliş Tarihi: 03.08.2018

Accepted/Kabul Tarihi: 03.09.2018



## Introduction

The diaphragm is the major inspiratory muscle with a dome-like shape and measurement of diaphragm thickness (DT) in various disorders has become popular in recent years. Decreased DT on ultrasound was shown to correlate with reduced myocyte cross-sectional area in a porcine model (1). Measurement of DT in computed tomography (CT) has been shown to be successful in the assessment of the success of diaphragm pacing system in amyotrophic lateral sclerosis (ALS) patients (2), detection of diaphragmatic thinning due to mechanical ventilator therapy and sepsis (3,4), and the diagnosis of unilateral diaphragm paralysis (5). In previous studies (2-5), DT measurement in CT was performed by single observers. The main limitation of CT in DT measurement is the absence of a consensus on reliable measurement locations (points). This may lead to variability in the performance of CT in DT measurements, which may weaken the reliability of CT measurements. To the best of our knowledge, no study has investigated the best points for DT measurement and agreement between observers.

Our aim was to assess the intra- and inter-observer agreement of DT measurement and to investigate the best points for DT assessment in CT based on the most reliable measurement.

## Methods

This retrospective study started after our institutional Pamukkale University Local Ethics Committee approved letter of application (decision no: 60116787-20/85543). Informed consent was not obtained from the patients because of retrospective nature of the study.

## Patients

Patients who underwent thoraco-abdominal CT angiography for suspected acute aortic syndrome between January 2016 and July 2017 were included the study. The exclusion criteria were as follows: pulmonary pathology that can affect DT measurement (such as lower lob atelectasis, mass or pleural effusion), focal or diffuse diaphragmatic crus defect and CT examinations with inadequate diagnostic quality due to motion artifacts. A total of 44 patients (23 males, mean age: 49.9±17.8 years, range: 18-85 years) were included in the study.

## Computed Tomography Scanning Protocol


All thoraco-abdominal CT angiography scans were obtained in the supine position with maximum inspiration using a multi-detector CT scanner (Brilliance 16; Philips Healthcare, Best, Netherlands). The area between the thoracic inlet and the deep costophrenic sulcus was scanned. The scanning parameters were as follows: tube voltage, 120 kV; tube current, 100 mAs; collimation, 16x0.75 mm; field of view, 300 mm; matrix, 512x512; rotation time, 0.75 s; table speed, 15 mm/s and beam pitch, 0.94. All CT images were reconstructed in transverse and coronal planes at 1.5 mm slice thickness.

## Radiological Evaluation

All CT images were evaluated independently by four radiologists with various experience (3, 9, 12 and 20 years) on the same workstation (Extended Brilliance Workspace, Philips Healthcare). Observers were blinded to measurements of each other. Each observer evaluated


the images twice to assess intra-observer reproducibility. The second assessment was done at least three months after the first to prevent recall.

Five measurements were performed on both axial and coronal images for each hemidiaphragm (88 hemidiaphragms) thickness. CT images were evaluated in the mediastinal window (window center, 90 HU; window width, 350 HU) and magnification was freely modifiable. Measurements were performed as described by Sukkasem et al. (5). On both axial and coronal reconstructed CT images, the crura of the hemidiaphragms were measured at the level of the origin of the celiac artery, and minimum and maximum DT were recorded. In addition, measurements were recorded for each crura at the level of the upper part of the L1 vertebral body along the anterior, middle and posterior aspects of the vertebral body on axial images and upper, middle and lower aspects of the vertebral body on coronal images (Figure 1).



**Figure 1.** Points of diaphragm thickness measurements. a) Axial computed tomography scan at the celiac artery origin level (arrow) shows maximum and minimum diaphragm thickness measurements

Max: maximum diaphragm thickness at the level of the origin of the celiac artery, Min: minimum diaphragm thickness at the level of the origin of the celiac artery



**Figure 1.** b) Axial computed tomography scan at the L1 vertebra corpus level shows anterior, mid and posterior diaphragm thickness measurements

Ant:anterior diaphragm thickness at the level of the upper part of the L1 vertebral body on axial images, Mid:mid diaphragm thickness at the level of the upper part of the L1 vertebral body, Post: posterior diaphragm thickness at the level of the upper part of the L1 vertebral body on axial images

**Table 1. The diaphragm thickness measurement results of patients and intra-observer agreement scores for each measurement**

	First evaluation Mean $\pm$ SD (mm)	Second evaluation Mean $\pm$ SD (mm)	Intraclass correlation coefficient	Lower bound (95% CI)	Upper bound (95% CI)
<b>Axial (observer 1)</b>					
Max	7.3 $\pm$ 1.9	7.7 $\pm$ 1.8	0.951	0.911	0.995
Min	2.9 $\pm$ 0.6	3 $\pm$ 0.4	0.915	0.845	0.951
Ant	5.3 $\pm$ 1.5	5.1 $\pm$ 1.3	0.94	0.891	0.992
Mid	3.6 $\pm$ 0.8	3.5 $\pm$ 0.6	0.937	0.885	0.966
Post	3.1 $\pm$ 0.8	3.2 $\pm$ 0.5	0.895	0.808	0.943
<b>Coronal (observer 1)</b>					
Max	6.2 $\pm$ 1.8	6.9 $\pm$ 1.9	0.912	0.866	0.986
Min	2.2 $\pm$ 0.6	2.4 $\pm$ 0.5	0.905	0.868	0.961
Low	2.5 $\pm$ 0.6	2.9 $\pm$ 1.1	0.88	0.872	0.905
Mid	2.9 $\pm$ 1	3 $\pm$ 0.7	0.924	0.860	0.958
Upp	4.6 $\pm$ 1.7	4.1 $\pm$ 1.4	0.774	0.659	0.899
<b>Axial (observer 2)</b>					
Max	6.5 $\pm$ 2.1	6.8 $\pm$ 1.8	0.962	0.926	0.991
Min	2.8 $\pm$ 0.6	3 $\pm$ 0.4	0.948	0.904	0.972
Ant	5.1 $\pm$ 1.3	5.1 $\pm$ 1.3	1	1	1
Mid	3.7 $\pm$ 1	3.5 $\pm$ 0.8	0.966	0.937	0.981
Post	3.3 $\pm$ 0.7	3 $\pm$ 0.5	0.95	0.909	0.973
<b>Coronal (observer 2)</b>					
Max	7.2 $\pm$ 2.4	6.6 $\pm$ 1.4	0.795	0.773	0.832
Min	2.2 $\pm$ 0.5	2.3 $\pm$ 0.4	0.885	0.813	0.951
Low	3 $\pm$ 1.5	3.3 $\pm$ 1.2	0.825	0.763	0.879
Mid	3.4 $\pm$ 0.8	2.9 $\pm$ 0.4	0.785	0.718	0.834
Upp	4.9 $\pm$ 0.5	4.5 $\pm$ 0.4	0.812	0.782	0.935
<b>Axial (observer 3)</b>					
Max	7.3 $\pm$ 2.4	7.1 $\pm$ 2	0.972	0.947	0.990
Min	2.9 $\pm$ 0.7	2.9 $\pm$ 0.5	0.904	0.882	0.972
Ant	5.2 $\pm$ 1.6	5.2 $\pm$ 1.3	0.975	0.955	0.986
Mid	4 $\pm$ 1.3	4.1 $\pm$ 1.2	0.923	0.869	0.952
Post	3.6 $\pm$ 0.9	3.7 $\pm$ 0.6	0.913	0.840	0.952
<b>Coronal (observer 3)</b>					
Max	7.2 $\pm$ 2.4	7.1 $\pm$ 1.8	0.947	0.903	0.971
Min	2.3 $\pm$ 0.5	2.7 $\pm$ 0.4	0.822	0.767	0.856
Low	3.2 $\pm$ 1.4	4.1 $\pm$ 1.2	0.758	0.659	0.888
Mid	3.5 $\pm$ 1.1	3.5 $\pm$ 0.9	0.949	0.913	0.963
Upp	4.7 $\pm$ 0.8	4.2 $\pm$ 0.7	0.767	0.712	0.835
<b>Axial (observer 4)</b>					
Max	6.8 $\pm$ 1.9	6.7 $\pm$ 1.6	0.974	0.953	0.986
Min	2.6 $\pm$ 0.5	2.6 $\pm$ 0.3	0.951	0.910	0.973
Ant	4.9 $\pm$ 1.5	4.5 $\pm$ 1.1	0.952	0.912	0.974
Mid	3.8 $\pm$ 1.1	3.7 $\pm$ 0.7	0.939	0.888	0.967
Post	3.3 $\pm$ 1.1	3.2 $\pm$ 0.8	0.95	0.928	0.978
<b>Coronal plane (observer 4)</b>					
Max	6.3 $\pm$ 2.3	6.9 $\pm$ 1.7	0.867	0.820	0.882
Min	2.2 $\pm$ 0.6	2.5 $\pm$ 0.4	0.882	0.817	0.936
Low	3.6 $\pm$ 1.8	4.1 $\pm$ 1.6	0.788	0.712	0.893

**Table 1. Continued**

	First evaluation Mean $\pm$ SD (mm)	Second evaluation Mean $\pm$ SD (mm)	Intraclass correlation coefficient	Lower bound (95% CI)	Upper bound (95% CI)
<b>Coronal plane (observer 4)</b>					
Mid	3.3 $\pm$ 0.9	3.7 $\pm$ 0.7	0.83	0.782	0.874
Upp	4.1 $\pm$ 0.8	4.8 $\pm$ 0.6	0.768	0.638	0.826

Max: maximum diaphragm thickness at the level of the origin of the celiac artery, Min: minimum diaphragm thickness at the level of the origin of the celiac artery, Ant: anterior diaphragm thickness at the level of the upper part of the L1 vertebral body on axial images, Mid: mid diaphragm thickness at the level of the upper part of the L1 vertebral body, Post: posterior diaphragm thickness at the level of the upper part of the L1 vertebral body on axial images, Upp: diaphragm thickness at the upper aspects of the L1 vertebral body on coronal images, Low: diaphragm thickness at the lower aspects of the L1 vertebral body on coronal images, CI: confidence interval, SD: standard deviation

**Table 2. The inter-observer agreement for the first and second measurements**

	Intraclass correlation coefficient	Lower bound (95% CI)	Upper bound (95% CI)
<b>First measurements</b>			
<b>Axial</b>			
Max	0.895	0.773	0.947
Min	0.564	0.349	0.660
Ant	0.823	0.727	0.900
Mid	0.753	0.649	0.873
Post	0.722	0.533	0.887
All	0.926	0.873	0.958
<b>Coronal</b>			
Max	0.753	0.610	0.853
Min	0.625	0.439	0.789
Low	0.742	0.607	0.854
Mid	0.614	0.453	0.792
Upp	0.705	0.523	0.822
All	0.790	0.684	0.870
<b>Second measurements</b>			
<b>Axial</b>			
Max	0.817	0.765	0.909
Min	0.782	0.723	0.904
Ant	0.860	0.773	0.918
Mid	0.721	0.558	0.851
Post	0.736	0.591	0.860
All	0.886	0.832	0.926
<b>Coronal</b>			
Max	0.613	0.383	0.772
Min	0.523	0.252	0.707
Low	0.640	0.479	0.804
Mid	0.762	0.669	0.876
Upp	0.585	0.294	0.734
All	0.776	0.662	0.838

Max: maximum diaphragm thickness at the level of the origin of the celiac artery, Min: minimum diaphragm thickness at the level of the origin of the celiac artery, Ant: anterior diaphragm thickness at the level of the upper part of the L1 vertebral body on axial images, Mid: mid diaphragm thickness at the level of the upper part of the L1 vertebral body, Post: posterior diaphragm thickness at the level of the upper part of the L1 vertebral body on axial images, Upp: diaphragm thickness at the upper aspects of the L1 vertebral body on coronal images, Low: diaphragm thickness at the lower aspects of the L1 vertebral body on coronal images, CI: confidence interval

### Statistical Analysis

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) for Windows (Version 24.0, SPSS Inc. IBM Corp, Chicago, IL). The distribution of normality for each continuous variable group was calculated by Kolmogorov-Smirnov Z-test. Student's t-test was used for comparisons of paired samples. A p value less than 0.05 was considered to indicate statistical significance. Intra- and inter-observer agreement was evaluated by using intraclass correlation coefficient (ICC) scores with a 95% confidence interval (CI). Intra- and inter-observer agreement was categorized as follows: 0.01-0.20 as poor, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial and 0.81-1.00 as almost perfect.

### Results

In all groups, DT values showed normal distribution. The results of DT measurements of 44 patients and intra-observer agreement scores for each measurement are shown in Table 1. The inter-observer agreement



**Figure 1.** c) Coronal reformatted computed tomography images at the celiac artery level shows maximum and minimum diaphragm thickness measurements

Max: maximum diaphragm thickness at the level of the origin of the celiac artery

**Table 3. Comparison of first and second measurements by different observers for all measurements**

Second measurement	First measurement p value			
p value	OBS-1	OBS-2	OBS-3	OBS-4
OBS-1	0.465	0.212	0.589	0.674
OBS-2	0.355	0.273	0.740	0.688
OBS-3	0.289	0.068	0.688	0.723
OBS-4	0.448	0.045*	0.759	0.812


OBS: indicates observer

\*Statistically significant value

for the first and second measurements is given in Table 2. There was a statistically significant difference between the measurements of observer 2 and observer 4 when all DT measurements were compared in the axial and coronal plane ( $p=0.045$ ) (Table 3).


In intra-observer analysis, ICC scores demonstrated substantial to almost perfect agreement for all measurements (ICC scores range=0.758-1) (Table 1). When we analyzed the inter-observer agreement, there was a moderate to almost perfect agreement for each measurement points (ICC score range=0.523-0.895). All axial measurement values showed the highest inter-observer agreement (ICC scores were 0.926 and 0.886 for first and second measurements, respectively). There was a substantial agreement between observers for all coronal measurement values with ICC scores of 0.790 (95% CI, 0.684 - 0.870) and 0.776 (95% CI, 0.662 - 0.838) for the first and second measurements, respectively (Table 2).

The maximum inter- and intra-observer agreement for single point DT measurements were found in maximum DT at the level of the origin of the celiac artery and in anterior DT at the level of the upper part of the L1 vertebral body. In the coronal plane, the intra- and inter-observer agreement for DT measurements varied widely for each measurement point (Tables 1 and 2).



**Figure 1. d)** Coronal reformatted computed tomography images at the celiac artery level shows maximum and minimum diaphragm thickness measurements

Min: minimum diaphragm thickness at the level of the origin of the celiac artery



**Figure 1. e)** Coronal reformatted computed tomography image at the L1 vertebra corpus level shows upper, mid and lower diaphragm thickness measurements

Mid: mid diaphragm thickness at the level of the upper part of the L1 vertebral body, Upp: diaphragm thickness at the upper aspects of the L1 vertebral body on coronal images, Low: diaphragm thickness at the lower aspects of the L1 vertebral body on coronal images

## Discussion

This study showed that the assessment of DT by CT has high intra and inter-observer reliability. All DT measurements showed the highest inter-observer agreement at five points (maximum, minimum thickness at the level of celiac artery origin, anterior, middle and posterior thickness at the level of L1 vertebral body) on axial CT images. There was substantial agreement between observers for all measurements on coronal CT images. The maximum inter- and intra-observer agreement for single point DT measurements were found in maximum DT at the level of the origin of the celiac artery and in anterior DT at the level of the upper part of the L1 vertebral body. In the coronal plane, the intra- and inter-observer agreement for DT measurements varied widely for each measurement point. Therefore, we suggest that if DT will be evaluated in the coronal plane, it would be appropriate to evaluate by measuring from all described 5 points.

Despite the increased use of CT for diaphragm evaluation, there is a lack of reference locations for DT measurement in CT. To the best of our knowledge, this is the first study that assessed the intra- and inter-observer agreement for DT measurement in CT and that investigated the best points for measurement in CT. The inter-observer variability in our study varied from moderate to almost perfect according to the measurement points and image plane. Therefore, we can say that the image plane (axial or coronal) and location is very important for DT measurement in CT. In our study, DT measurements were performed from the upper part L1 vertebra corpus level due to blurring of the diaphragm crus by psoas muscle in the middle and lower parts of the L1 vertebra corpus level. Unlike Sukkasem et al. (5), we did not measure DT at the level of Smooth Muscle Actin (SMA) origin, due to blurring of the diaphragm crus by psoas muscle at SMA origin level in many patients.

In mechanically ventilated patients and patients with paralyzed hemidiaphragm, diaphragmatic dysfunction is an important cause of complications, such as pulmonary atelectasis, infection and hypoxemia. These complications have been shown to correlate with mortality, poor prognosis and significantly higher health costs (6-9). In addition, weakness of the diaphragm is a major cause of difficult weaning from mechanical ventilation (10). Therefore, evaluation of DT and functions is very important. It has been shown that ultrasound (US) measurements of DT have a high degree of reproducibility and decreased DT on ultrasound has been shown to correlate with reduced myocyte volume (1,9-14). Experience is important when performing DT measurement by US. For an inexperienced observer, it may be difficult to accurately measure the DT by UA in incompatible patients (14). Compared to US, CT better depicts the anatomy of the diaphragm and also demonstrates associated lung and mediastinal pathologies (15-18). However, CT is not a suitable method for only assessing DT due to radiation exposure. Therefore, it is more appropriate to assess DT on CT images which were obtained to evaluate lung or mediastinal pathology.

There are only a few studies on DT evaluation in CT (2-5). Sanli et al. (2) found that DT is an important feature in patients with ALS in whom diaphragm pacing system implantation is planned. In their study, a single observer measured DT at the level of thoracic 11-12 vertebra corpus on coronal images. The location specified for DT measurement



is not a specific point and represents a very large area for DT measurement. In addition, they did not specify the CT slice thickness used in the study (2). Lee et al. (3) demonstrated that DT decreased in patients who underwent mechanical-ventilation therapy in CT. In that study, a radiologist measured the DT at the level of the celiac artery by using software on axial and coronal images. However, the number of patients included in the study was thirteen, which is quite small. Also, they did not specify the thickness of the CT slice used in the study (3). Jung et al. (4) found that diaphragm volume was decreased in patients with sepsis in CT. In their study, the diaphragm volumes were calculated semi-automatically by a single radiologist. However, in this study, it was not specified in which phase (inspiration-expiration) the CT images were obtained (4). Sukkasem et al. (5) found a high sensitivity and specificity in the differentiation of paralyzed and non-paralyzed hemidiaphragms when they assumed 2.5 mm as the threshold value of a minimum DT on axial images at the level of celiac artery in CT. In their study, all measurements were performed by one observer and the slice thickness of the CT was variable (range: 0.625 to 5 mm) (5). We used a standard 1.5 mm slice thickness in our study. Our results demonstrated a better inter-observer agreement for axial CT images than coronal CT images. This may be due to relatively thick CT slices or due to the natural shape of the diaphragm (the shape of the dome).

Our study also has some limitations. The relatively small sample size is the first one. However, this study was not intended to determine DT values in the population. The aim of this study was to determine the best DT measurement points in CT and the reliability of DT measurement in CT. The retrospective design of the study is the second one. However, these are acceptable limitations due to the lack of similar CT studies.

## Conclusion

CT is a reliable tool for DT measurement with excellent intra and inter-observer reliability. This is the first study that reveals the best and reproducible measurement points and plane for DT measurements in CT. All DT measurement values at five identified points on axial CT images showed the highest inter-observer reliability. The most reliable single measurement point in the axial plane was maximum DT at the level of the celiac artery or anterior DT at the level of the upper part of the L1 vertebral body.

**Ethics Committee Approval:** This retrospective study started after our institutional Pamukkale University Local Ethics Committee approved letter of application (decision no: 60116787-20/85543).

**Informed Consent:** Informed consent was not obtained from the patients because of retrospective nature of the study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - F.U., P.Ç.; Design - F.U., P.Ç., D.H., E.S.; Supervision - F.U., A.B.Y.; Data Collection and/or Processing - F.U., P.Ç., D.H.; Analysis and/or Interpretation - F.U., D.H., A.B.Y.; Literature Search - F.U., M.A., E.S.; Writing Manuscript - F.U., D.H., M.A.; Critical Review - D.H., A.B.Y.

**Conflict of Interest:** Authors have no conflicts of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

1. Reynolds SC, Meyyappan R, Thakkar V, Tran BD, Nolette MA, Sadarangani G, et al. Mitigation of ventilator-induced diaphragm atrophy by transvenous phrenic nerve stimulation. *Am J Respir Crit Care Med* 2017; 195: 339-48.
2. Sanli A, Sengun IS, Tertemiz KC, Alpaydin AO, Karacam V, Sanli BA, et al. Importance of diaphragm thickness in amyotrophic lateral sclerosis patients with diaphragm pacing system implantation. *Surg Endosc* 2016; 30: 154-8.
3. Lee GD, Kim HC, Yoo JW, Lee SJ, Cho YJ, Bae K, et al. Computed tomography confirms a reduction in diaphragm thickness in mechanically ventilated patients. *J Crit Care* 2016; 33: 47-50.
4. Jung B, Nougaret S, Conseil M, Coisel Y, Futier E, Chanques G, et al. Sepsis is associated with a preferential diaphragmatic atrophy: a critically ill patient study using tridimensional computed tomography. *Anesthesiology* 2014; 120: 1182-91.
5. Sukkasem W, Moftah SG, Kicska G, Godwin JD, Pipavath S, Stern E. Crus atrophy: Accuracy of computed tomography in diagnosis of diaphragmatic paralysis. *J Thorac Imaging* 2017; 32: 383-90.
6. Vassilakopoulos T, Petrof BJ. A Stimulating Approach to Ventilator induced Diaphragmatic Dysfunction. *Am J Respir Crit Care Med* 2017; 195: 281-2.
7. Kim WY, Suh HJ, Hong SB, Koh Y, Lim CM. Diaphragm dysfunction assessed by ultrasonography: influence on weaning from mechanical ventilation. *Crit Care Med* 2011; 39: 2627-30.
8. Damuth E, Mitchell JA, Bartock JL, Roberts BW, Trzeciak S. Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis. *Lancet Respir Med* 2015; 3: 544-53.
9. Dhungana A, Khilnani G, Hadda V, Guleria R. Reproducibility of diaphragm thickness measurements by ultrasonography in patients on mechanical ventilation. *World J Crit Care Med* 2017; 6: 185-9.
10. Dres M, Dubé B-P, Mayaux J, Delemazure J, Reuter D, Brochard L, et al. Coexistence and Impact of Limb Muscle and Diaphragm Weakness at Time of Liberation from Mechanical Ventilation in Medical Intensive Care Unit Patients. *Am J Respir Crit Care Med* 2017; 195: 57-66.
11. Vivier E, Mekontso Dessap A, Dimassi S, Vargas F, Lyazidi A, Thille AW, et al. Diaphragm ultrasonography to estimate the work of breathing during non-invasive ventilation. *Intensive Care Med* 2012; 38: 796-803.
12. Boussuges A, Gole Y, Blanc P. Diaphragmatic motion studied by m-mode ultrasonography: methods, reproducibility, and normal values. *Chest* 2009; 135: 391-400.
13. Goligher EC, Laghi F, Detsky ME, Farias P, Murray A, Brace D, et al. Measuring diaphragm thickness with ultrasound in mechanically ventilated patients: feasibility, reproducibility and validity. *Intensive Care Med* 2015; 41: 642-9.
14. Sarwal A, Walker FO, Cartwright MS. Neuromuscular ultrasound for evaluation of the diaphragm. *Muscle Nerve* 2013; 47: 319-29.
15. Caskey CI, Zerhouni EA, Fishman EK, Rahmouni AD. Aging of the diaphragm: a CT study. *Radiology* 1989; 171: 385-9.
16. Dovgan DJ, Lenchik L, Kaye AD. Computed tomographic evaluation of maximal diaphragmatic crural thickness. *Conn Med* 1994; 58: 203-6.
17. Harlaar L, Ciet P, van der Ploeg AT, Brussee E, van der Beek NAME, Wielopolski PA, et al. Imaging of respiratory muscles in neuromuscular disease: A review. *Neuromuscul Disord* 2018; 28: 246-56.
18. Goo HW. Four-Dimensional CT of the diaphragm in children: initial experience. *Korean J Radiol* 2018; 19: 111-8.



# Vitamin D Deficiency Among Female University Students (18 to 25 years) in Spring

## Kadın Üniversite Öğrencilerinde Hastalık Riski Düzeyinde Vitamin D Eksikliği

● Filiz Tuna

Trakya University Faculty of Health Sciences, Department of Physical Therapy and Rehabilitation, Edirne, Turkey

### ABSTRACT

**Introduction:** In this study, the laboratory results of female university students whose vitamin D levels were requested were reviewed. Thus, it was aimed to determine the levels of vitamin D, as well as to classify it as deficiency, insufficiency, normal and preferred.

**Methods:** The vitamin D levels of 92 female university students between the ages of 18 and 25 years who admitted to an outpatient clinic between April and May 2017 were retrospectively evaluated. Vitamin D levels were classified according to the criteria of the Endocrine Society. Vitamin D deficiency was accepted in individuals with vitamin D levels below 20 ng/mL. Spearman's correlation test was used for statistical analysis.  $P < 0.05$  was considered significant.

**Results:** The mean 25-hydroxyvitamin D [25(OH)D] level was  $17.32 \pm 7.18$  ng/mL. The frequency of deficiency, insufficiency, normal and desired 25(OH)D levels were 78.3% (72), 14.1% (13), 6.5% (6) and 1.1% (1), respectively.

**Conclusion:** In this retrospective study in female university students, vitamin D deficiency was found to be frequent. In addition to other trainings, awareness raising and education are compulsory to exclude possible risks of vitamin D deficiency. Additionally, the development of health policies for vitamin D supplementation without laboratory examination in this population would prevent possible skeletal and extra-skeletal problems.

**Keywords:** 25(OH)D vitamin, insufficiency, adolescents

### ÖZ

**Amaç:** Bu çalışmada, vitamin D düzeyi istenen kadın üniversite öğrencilerinin laboratuvar sonuçları gözden geçirilmiştir. Böylece vitamin D düzeylerini belirlemek, ayrıca eksiklik, yetersizlik, normal ve tercih edilen düzey olarak sınıflandırmak amaçlanmıştır.

**Yöntemler:** Bu çalışmaya Nisan ve Mayıs 2017 tarihleri arasında polikliniğe başvuran 18-25 yaş arası 92 kadın üniversite öğrencilerinin vitamin D düzeyleri üzerinde retrospektif olarak yapıldı. Vitamin D düzeyleri Endokrin Topluluğu'nun önerilerine göre sınıflandırıldı. Vitamin D düzeyi 20 ng/mL'nin altında olan bireylerde vitamin D eksikliği varlığı kabul edildi. İstatistiksel analiz için Spearman korelasyon testi kullanıldı.  $P < 0,05$  anlamlı olarak kabul edildi.

**Bulgular:** 25-hidroksivitamin D [25(OH)D] seviyesi ortalama  $17.32 \pm 7.18$  ng/mL idi. Eksik, yetersiz, normal ve arzu edilen 25(OH)D düzeyi oranları sırasıyla %78,3 (72), %14,1 (13), %6,5 (6) ve %1,1 (1) saptandı.

**Sonuç:** Kadın üniversite öğrencilerinde yürüttüğümüz bu retrospektif çalışmada; hastalık oluşturma riski düzeyinde olan vitamin D eksikliğinin sık olduğu görüldü. Diğer eğitimlerin yanı sıra D vitamini eksikliğinin olası risklerini dışlamak için bilinçlendirme ve eğitim zorunludur. Ayrıca, bu popülasyonda laboratuvar incelemesi olmaksızın gerekli D vitamini takviyesi için sağlık politikalarının geliştirilmesi olası iskelet ve iskelet dışı problemleri önleyecektir.

**Anahtar Kelimeler:** 25(OH)D vitamini, yetersizlik, gençler

### Introduction

Vitamin D, a hormone called "Pro-survival Molecule" due to its role in the immune system and cell life, is also necessary for the prevention of type 2 diabetes and obesity, which are important problems of current era (1,2). Optimal levels of vitamin D are indispensable for substantial effects on many systems in sensitive populations such as pregnant women, nursing women, children, adolescents, and elder individuals as

well as in all stages of human life (3,4). It contributes to the prevention of depression in adolescents and increase in cardiovascular capacity in young adults (5,6).

Vitamin D level below 20 ng/mL is defined as deficiency by Endocrine Society (ES). Its deficiency is associated with increased risk of cancer, especially colorectal (7,8). Hereditary or acquired diseases (e.g., tumor-induced osteomalacia, hyperparathyroidism, granulomatous diseases



**Address for Correspondence/Yazışma Adresi:** Filiz Tuna, Trakya University Faculty of Health Sciences, Department of Physical Therapy and Rehabilitation, Edirne, Turkey  
Phone: +90 505 791 27 27 E-mail: drftuna@gmail.com ORCID ID: orcid.org/0000-0002-9563-8028

**Cite this article as/Atıf:** Tuna F. Vitamin D Deficiency Among Female University Students (18 to 25 years) in Spring. İstanbul Med J 2019; 20(2): 107-10.

**Received/Geliş Tarihi:** 04.04.2018  
**Accepted/Kabul Tarihi:** 20.12.2018

and lymphoma) and insufficiency in organs (e.g., liver, kidney and skin) may decrease vitamin D levels. In addition, using sun cream, pigmentation or aging on the skin affects the synthesis of vitamin D. Also, gastrointestinal diseases adversely effect vitamin D absorption and obesity leads to an increase in its deposition (9). The use of certain drugs such as immunosuppressants, steroids and anticonvulsants also leads to the destruction of vitamin D (10,11). However, there is no enough data on vitamin D status and recommendations for asymptomatic, adolescent female university students who do not have any disease or use drugs that affect vitamin D metabolism (12). While vitamin D deficiency is mainly considered to be a predisposing factor to many diseases, neither adolescent female nor male students are included in the risk group in terms of low vitamin D status and are evaluated in daily practice (12).

In this study, we aimed to determine and classify vitamin D levels as deficiency, insufficiency, normal and preferred in female university students.

## Methods

This cross-sectional, retrospective and descriptive study was carried out with the approval of the Local Ethics Committee of the Faculty of Health Sciences of Trakya University (TÜTF-BAEK 2017/335). Vitamin D levels of female university students between the ages of 18 and 25 years who admitted to Physical Medicine and Rehabilitation Department of Trakya University Hospital between April and May 2017 were examined. Data of students with no systemic or chronic disease, no drug use, and no history of disease that would affect vitamin D metabolism were included. Exclusion criteria were as follows: male gender, drug use, serum 25-hydroxyvitamin D [25(OH)D] level obtained by a method other than electrochemiluminescence method (Beckman Coulter UniCel Dxl 600), and the presence of a known disease. Each student was contacted by phone and interviewed about the style of clothing. Written consent was obtained from each participant. The clothing style was recorded as veiled or unveiled. Serum 25(OH)D levels were classified as deficiency (below 20 ng/mL), insufficiency (21-29 ng/mL), normal (30-39 ng/mL) and preferred (40-60 ng/mL) levels according to most frequently used method by ES (13).

## Statistical Analysis

Statistical evaluations were performed using IBM SPSS version 20.0 (IBM Corporation, Armonk, NY, USA). Descriptive statistical methods (frequency, percentage, mean, standard deviation) were used to assess the study data. The relationships between variables were assessed using Spearman's rho correlation test. The significance limit for all statistics was selected as  $p < 0.05$ . Kolmogorov Smirnov test was used to check whether the data were normally distributed. Mann-Whitney U test was used to compare the mean 25(OH)D levels between groups when the data were abnormally distributed. Two-sample Kolmogorov Smirnov Z test was used to make inter-group (unveiled vs veiled) comparisons of 25(OH)D classifications.

## Power Analysis

The post-hoc power of this study was calculated as 100% based on 25(OH)D levels between unveiled and veiled groups (18.25 vs 13.19) with a standard deviation of 1.67, and with an alpha level of 5%.

## Results

Data of 92 female university students were reached. Mean age, height, weight, and body mass index (BMI) of the students were shown in Table 1. The mean 25(OH)D level was  $17.32 \pm 7.18$  ng/mL. According to ES, 25(OH)D levels were below the normal range in 92.4% (85) participants. The frequency of (all participants with) deficiency, insufficiency, normal and preferred 25(OH)D levels were 78.3% (72), 14.1% (13), 6.5% (6) and 1.1% (1), respectively. The distribution of participants according to clothing style (unveiled and veiled) were 81.5% (75) and 18.5% (17), respectively. There was no statistically significant difference in the distribution of the 25(OH)D Classification groups among the clothing style groups (Table 2). The mean 25(OH)D levels among unveiled and veiled participants were  $18.25 \pm 0.80$  and  $13.19 \pm 1.67$  ng/mL, respectively. There were a statistically significant difference between the groups in terms of mean 25(OH)D levels and negative correlation between 25(OH)D concentrations and veiled dressing style ( $r = -0.275$ ,  $p = 0.008$ ) (Table 3).

## Discussion

Although veiling is largely accepted as a predisposing factor for vitamin D insufficiency, both the unveiled females in our study and in countries with sufficient sunlight in previous studies did not have desired vitamin D levels (14,15).

**Table 1. The descriptive statistics and 25(OH)D levels of participants**

	n	Minimum	Maximum	Mean	Standard deviation
Age (years)	92	18	24	20.28	1.65
Weight (kg)	92	42.00	77.00	56.83	6.37
Height (m)	92	1.50	1.78	1.64	0.05
BMI (kg/m <sup>2</sup> )	92	16.85	27.64	21.02	2.00
25(OH)D (ng/mL)	92	6.77	48.74	17.32	7.18

BMI: body mass index, 25(OH)D: 25-hydroxyvitamin D

**Table 2. Distribution of 25(OH)D classifications among groups**

Groups		n (% within groups)			
		Unveiled n=75	Veiled n=17	p value	Total n=92
25 (OH) D classification	Deficiency	57 (76.0)	15 (88.2)	0.986	72 (78.3)
	Insufficiency	12 (16.0)	1 (5.9)		13 (14.1)
	Normal	5 (6.7)	1 (5.9)		6 (6.5)
	Preferred	1 (1.3)	0 (0)		1 (1.1)

Two-sample Kolmogorov Smirnov Z test, 25(OH)D: 25-hydroxyvitamin D

**Table 3. 25(OH)D levels (ng/mL) of participants according to clothing style**

Clothing style	n	Minimum-maximum	Mean	Standard deviation	95% CI	p value
Unveiled	75	7.96-48.74	18.25	0.80	16.65-19.85	<0.001
Veiled	17	6.77-34.60	13.19	1.67	9.66-16.72	

CI: confidence interval, Mann-Whitney U test, 25(OH)D: 25-hydroxyvitamin D

The adverse effect of veiling on vitamin D status has led some researchers to assume the possibility of musculoskeletal complaints and low bone mineral density in veiled female with traditional Islamic type of dressing (16). Guzel et al. (16) reported significantly lower serum 25(OH)D levels with a mean of  $33.1 \pm 16$  ng/mL in the veiled women compared with the unveiled, but none of the veiled women had vitamin D insufficiency. Budak et al. (17) reported that there was a statistically significant difference between two groups of female students with different clothing style and the veiled group had vitamin D deficiency with a mean of  $6.09 \pm 4.7$  ng/mL. Tsur et al. (18) reported vitamin D deficiency in 50-100% of ultra-Orthodox young males who wore clothing which covers more than 90% of body. They also found that vitamin D deficiency was strongly associated with the degree of sun exposure. However, some researchers indicates that healthy females, even in countries with enough sunlight, are at risk for osteomalacia due to vitamin D deficiency (14,15). For all these reasons, the female gender in combination with veiling does not suffice for the possibility of vitamin D deficiency. Risks should be assessed comprehensively. In this study, 18.5% of females (17) had veiling, but 92.4% of all females (85) had low vitamin D. Faghih et al. (19) showed “alarmingly prevalent” vitamin D insufficiency and deficiency in Iranian students in a cross-sectional study including 126 female (51.2% and 44%) and 128 male (49.5% and 48%) university students. In our female population, we found that vitamin D deficiency was as high as 78.3%. The frequency of participants with normal and preferred vitamin D were 6.5% and 1.1%, respectively. Consistent with the literature, 25(OH)D levels were below 20 ng/mL in the majority of our participants. Data on vitamin D levels of young adults in our country are limited. The mean 25(OH)D level of 94 young individuals who applied to the hospital was  $21.57 \pm 11.41$  ng/mL by Uçar et al. (20). Hekimsoy et al. (21) reported that 74.9% of adults, especially females (78.7%), living in an urban, off-shore region have 25(OH)D deficiency. In this study, the reasons for mean 25 (OH) D levels below the normal are probably due to (a) in young adults, the lowest vitamin D levels are before summer onset. The data of our study group was obtained between April and May, when vitamin D levels are considered to be lowest. More significant differences between the veiled and unveiled female could possibly be shown if we had assessed data of these variables at a time of highest expected seasonal levels, but we have shown significant negative correlation between 25(OH)D concentrations and veiling even before the start of summer. (b) Edirne where our study was conducted is in the Marmara region of Turkey, latitudes  $40^{\circ}30' - 42^{\circ}00'$  North and  $26^{\circ}00' - 27^{\circ}00'$  East. The average maximum temperatures range between  $6.5^{\circ}\text{C}$  in winter to  $31.7^{\circ}\text{C}$  in summer, with annual average of  $19.6^{\circ}\text{C}$  (22). (c) In our study, the data were assessed in a group of students with approximately 9-month training period, during which they resided in Edirne, which is a non-coastal living area. Therefore, we support the view that university students should be considered as a risky group for vitamin D deficiency regardless of their clothing style and gender.

The mean 25(OH)D level was  $17.32 \pm 7.18$  ng/mL in our study. Serum vitamin D levels below 20 ng/mL affect skeletal health (8). Although the histopathological findings of osteomalacia in stage 1 are missing, intestinal calcium absorption decreases and loss of bone mineral density develops in this stage, named as subclinical osteomalacia. Indeed, the

findings are observed when stage 2 is reached. Thus, no new bone loss occurs in stage 3, but instead histological and clinical findings are clearly identified. For all these reasons, the treatment in the stage with apparent findings does not prevent bone loss. The precautions should be focused in the asymptomatic first stage (23). However, many individuals with subclinical osteomalacia still remain without a laboratory confirmation and the lack of this knowledge leads to delay in taking precautions.

Vitamin D deficiency can contribute to patient burden caused by psychological reasons (depression, schizophrenia), and autoimmune disorders (type 1 diabetes, multiple sclerosis, rheumatoid arthritis), infections, asthma, type 2 diabetes, osteoporosis, osteomalacia and cancer (1,10). On the other hand, vitamin D supplementation is easy, safe and inexpensive (24). Unless vitamin D deficiency is eliminated, individuals are candidates for all these risks independent of deficiency, defined or undefined. However, supplementation is made only in the defined deficiencies. The missing aspect of our study is that we did not investigate parathyroid hormone levels, skin type and eating habits. However, our results are important to create awareness for optimal vitamin D requirements in this population.

## Conclusion

Our results indicate that vitamin D deficiency is frequently observed in female students. Awareness and training aimed at excluding the possible risks of vitamin D deficiency as well as other trainings are mandatory. Additionally, the development of health policies to provide the necessary vitamin D support in this population without laboratory examination would prevent possible skeletal and extra-skeletal problems.

## Acknowledgements

We are particularly grateful to Prof. Dr. Necdet Süt, who performed the statistical analysis of the study.

**Ethics Committee Approval:** Trakya University Faculty of Health Sciences Local Ethics Committee (TÜFT-BAEK 2017/335).

**Informed Consent:** Written consent was obtained from each participant.

**Peer-review:** Externally and internally peer-reviewed.

**Financial Disclosure:** The author declared that this study has received no financial support.

## References

1. Chirumbolo S, Björklund G, Sboarina A, Vella A. The role of vitamin D in the immune system as a pro-survival molecule. *Clin Ther* 2017; 39: 894-916.
2. Sergeev IN. Vitamin D-Cellular  $\text{Ca}^{2+}$  link to obesity and diabetes. *J Steroid Biochem Mol Biol* 2016; 164: 326-30.
3. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. *The Lancet* 2014; 383: 146-55.
4. Wintermeyer E, Ihle C, Ehnert S, Stöckle U, Ochs G, de Zwart P, et al. Crucial role of vitamin D in the musculoskeletal system. *Nutrients* 2016; 8: 319.
5. Al Asoom LI. Assessment of plasma level of 25 (OH) D and its correlation with cardiorespiratory fitness in young females of Dammam City, KSA. *Journal of Taibah University Medical Sciences* 2016; 11: 456-63.

6. Karabel M, Şimşek Ş, Kenan Haspolat Y, Kelekçi S, Karabel D, Tuncel T, et al. The association between depression and vitamin d and parathyroid hormone levels in adolescents. *International Journal of Pediatrics* 2016; 4: 1365-72.
7. Mondul AM, Weinstein SJ, Layne TM, Albanes D. Vitamin D and cancer risk and mortality: state of the science, gaps, and challenges. *Epidemiol Rev* 2017; 39: 28-48.
8. Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. *J Clin Endocrinol Metab* 2013; 98: E1283-304.
9. Vimalaswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. *PLoS Med* 2013; 10: e1001383.
10. Schwalfenberg G. Not enough vitamin D. *Canadian Family Physician* 2007; 53: 841-54.
11. Yıldız EP, Poyrazoglu Ş, Bektas G, Kardelen AD, Aydınli N. Potential risk factors for vitamin D levels in medium-and long-term use of antiepileptic drugs in childhood. *Acta Neurol Belg* 2017; 117: 447-53.
12. Souberbielle J-C, Courbebaisse M, Cormier C, Pierrot-Deseilligny C, Viard J-P, Jean G, et al. When should we measure vitamin D concentration in clinical practice? *Scand J Clin Lab Invest Suppl* 2012; 243: 129-35.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011; 96: 1911-30.
14. Güllü S, Erdoğan MF, Uysal AR, Başkal N, Kamel AN, Erdoğan G. A Potential Risk for Osteomalacia due to Sociocultural Lyfestyle in Turkish Women. *Endocr J* 1998; 45: 675-8.
15. Alagöl F, Shihadeh Y, Boztepe H, Tanakol R, Yarman S, Azizlerli H, et al. Sunlight exposure and vitamin D deficiency in Turkish women. *J Endocrinol Invest* 2000; 23: 173-7.
16. Guzel R, Kozanoglu E, Guler-Uysal F, Soyupak S, Sarpel T. Vitamin D status and bone mineral density of veiled and unveiled Turkish women. *J Womens Health Gend Based Med* 2001; 10: 765-70.
17. Budak N, Çiçek B, Sahin H, Tutus A. Bone mineral density and serum 25-hydroxyvitamin D level: is there any difference according to the dressing style of the female university students. *Int J Food Sci Nutr* 2004; 55: 569-75.
18. Tsur A, Metzger M, Dresner-Pollak R. Effect of different dress style on vitamin D level in healthy young Orthodox and ultra-Orthodox students in Israel. *Osteoporos Int* 2011; 22: 2895-8.
19. Faghih S, Abdolazadeh M, Mohammadi M, Hasanzadeh J. Prevalence of vitamin d deficiency and its related factors among university students in shiraz, iran. *Int J Prev Med* 2014; 5: 796-9.
20. Uçar F, Taşlıpınar MY, Soydaş AÖ, Özcan N. Ankara etlik ihtisas eğitim ve araştırma hastanesine başvuran hastalarda 25-OH Vitamin D düzeyleri. *Eur J Basic Med Sci* 2012; 2: 12-5.
21. Hekimsoy Z, Dinç G, Kafesçiler S, Onur E, Güvenç Y, Pala T, et al. Vitamin D status among adults in the Aegean region of Turkey. *BMC Public Health* 2010; 10: 782.
22. (cited 2018 20/03/2018). Available from: <https://mgm.gov.tr/veridegerlendirme/il-ve-ilceler-istatistik.aspx?m=EDIRNE>.
23. Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. *J Bone Miner Res* 2010; 25: 305-12.
24. Kennel KA, Drake MT, Hurley DL, editors. Vitamin D deficiency in adults: when to test and how to treat. *Mayo Clinic Proceedings*; 2010: Elsevier.

# The Relationship of Lumbar Multifidus Muscle Change to Disc Hernia and Low Back Pain: An Magnetic Resonance Imaging Study

## Lomber Multifidus Kas Değişimiyle Disk Hernisi ve Bel Ağrısı Arasındaki İlişki: Bir Manyetik Rezonans Görüntüleme Çalışması

Emrah Sayıt

University of Health Sciences, Samsun Training and Research Hospital, Clinic of Orthopaedics and Traumatology, Samsun, Turkey

### ABSTRACT

**Introduction:** Our aim was to evaluate the relationship between lumbar multifidus (LM) muscle atrophy and lumbar disc herniation by magnetic resonance imaging (MRI) findings in patients with low back pain.

**Methods:** Lumbar MRI of 264 patients aged between 18 and 80 years who had a history of back pain for at least 6 months were evaluated retrospectively for LM muscle atrophy. LM muscle atrophy was evaluated at L4-5 and L5-S1 levels in axial T2-weighted images. The lumbar MRI of the patients were evaluated for LM muscle atrophy and lumbar intervertebral disc herniation. The relationship of LM muscle atrophy to lumbar intervertebral disc herniation and back pain was investigated statistically.

**Results:** Of 264 (147 female, 117 male) patients, 88 patients (33.3%) had grade 0 atrophy, 135 (51.1%) had grade 1 atrophy and 41 (15.5%) had grade 2 atrophy. The prevalence of LM muscle atrophy was 73.5% in females and 49.8% in males. In 210 of 264 patients, intervertebral disc herniation was detected at any level in the lumbar spine. Of these 210 patients, 150 (71%) had grade 1 and 2 LM muscle atrophy. Spinal canal stenosis, intervertebral disc herniation and nerve root compression were not detected in 54 of 264 patients. Of these 54 patients, 28 had grade 0 atrophy, 23 had grade 1 atrophy and 3 had grade 2 atrophy.

**Conclusion:** In our study, 9.8% of patients with low back pain had grade 1 and 2 LM muscle atrophy without accompanying spinal canal stenosis, intervertebral disc herniation or nerve root compression. LM muscle atrophy alone may be the cause of low back pain in patients with normal MRI.

**Keywords:** Low back pain, lumbar disc herniation, magnetic resonance imaging, multifidus muscle

### ÖZ

**Amaç:** Bizim buradaki amacımız kronik bel ağrısı ile lomber multifidus (LM) kas atrofisi arasındaki ilişkiyi manyetik rezonans görüntüleme (MRG) bulguları ile birlikte değerlendirmektir.

**Yöntemler:** En az 6 aydır sırt ağrısı şikayeti bulunan yaşları 18 ile 80 arasında değişen 264 hastanın lomber MRG'si retrospektif olarak LM kas atrofisi açısından değerlendirildi. LM kas atrofisi aksiyal T2 görüntülemelerde L4-5 ve L5-S1 düzeylerinden değerlendirildi. Hastaların lomber MRG'si LM kas atrofisi ve lomber intervertebral disk herniasyonu açısından değerlendirildi. LM atrofisinin lomber intervertebral disk herniasyonunu ve bel ağrısı ile olan ilişkisi istatistiksel olarak araştırıldı.

**Bulgular:** İki yüz altmış dört (147 kadın, 117 erkek) hastanın lomber MRG'sinde 88 hastada (%33,3) evre 0 atrofi, 135 hastada (%51,1) evre 1 atrofi ve 41 hastada (%15,5) evre 2 atrofi saptandı. Kadınlarda LM atrofisinin sıklığı %73,5 olup erkeklerde %49,8'dir. İki yüz altmış dört hastanın 210'unda lomber vertebralarda herhangi bir seviyede intervertebral disk hernisi saptandı. İki yüz on hastanın 150'sinde (%71) LM kasında evre 1 ve 2 atrofi saptandı. İki yüz altmış dört hastanın 54'ünde herhangi bir seviyede intervertebral disk herniasyonu, spinal kanal darlığı ve sinir kökü basısı saptanmadı. Bu 54 hastanın 28'inde evre 0, 23'ünde evre 1 ve 3'ünde evre 2 atrofi saptandı.

**Sonuç:** Bizim yapmış olduğumuz çalışmada lomber intervertebral disk herniasyonu, spinal kanal stenozu ve sinir kökü basısı mevcut olmayan tek şikayeti bel ağrısı olan %9,8 olguda LM kasında evre 1 ve 2 atrofi saptanmıştır. Tamamen normal MRG'si olan olgularda LM kas atrofisi tek başına bel ağrısının nedeni olabilir.

**Anahtar Kelimeler:** Bel ağrısı, lomber disk hernisi, manyetik rezonans görüntüleme, multifidus kası



Address for Correspondence/Yazışma Adresi: Emrah Sayıt, University of Health Sciences, Samsun Training and Research Hospital, Clinic of Orthopaedics and Traumatology, Samsun, Turkey  
Phone: +90 505 670 86 62 E-mail: dremrahsayit@gmail.com ORCID ID: orcid.org/0000-0003-0733-8621

Cite this article as/Atıf: Sayıt E. The Relationship of Lumbar Multifidus Muscle Change to Disc Hernia and Low Back Pain: An Magnetic Resonance Imaging Study. İstanbul Med J 2019; 20(2): 111-4.

Received/Geliş Tarihi: 21.11.2017  
Accepted/Kabul Tarihi: 16.07.2018



## Introduction

Low back pain (LBP) is a common and often recurrent health problem. Approximately 80% of people have at least one case of LBP during their lifetime. Paraspinal muscles play a significant role in the stability and functional movements of the lumbar spine (1). The lumbar multifidus (LM) muscle is the main stabilizer of the lumbar spine, and is important for spinal motion and stability (2,3). Dysfunction of the LM muscle has been found to be important in chronic and recurrent LBP (4). Chronic diseases and long-term neurological inhibition after trauma may cause muscle atrophy and may lead to the replacement of healthy LM muscle fibrils with adipose tissue (5). Morphological changes of LM muscles in patients with lumbosacral disc herniation have been reported in literature (6-9). Kim et al. (7) demonstrated that the cross-sectional areas of the LM muscle were reduced when the symptom duration was 6 months or longer in case of lumbar disc herniation. In addition, studies in the literature have shown that LBP and paraspinal muscle atrophy have a relationship (3-5). In this study, we evaluated the relationship between lumbar disc herniation and LM muscle atrophy in patients with LBP by using magnetic resonance imaging (MRI).

## Methods

The University of Health Sciences, Samsun Training and Research Hospital Ethics Committee approval was received for this study (decision no: 2017/24). In total, 264 patients (range: 18-80 years) who suffered from LBP for six months or longer were retrospectively evaluated. Patients with spinal fractures, malignancy, intraspinal mass, spondylitis, previous surgery or structural deformity were not included the study.

## Radiological Protocol and Imaging

The MRI images were obtained with a 1.5 Tesla MAGNETOM Aera® MRI device (Siemens Healthcare, Erlangen, Germany) with a body surface coil. The sequences included sagittal T1-weighted fast spin-echo (FSE) (TR/TE: 475/9.3), T2-weighted FSE (TR/TE: 3790/97) and axial T2-weighted FSE (TR/TE: 4271/108), 280 mm field of view, 180×256 matrix, and 4 mm section thickness, NEX 2.

LM muscle atrophy was assessed at L4-L5 and L5-S1 levels in all patients. LM muscle was evaluated in three grades according to fatty atrophic changes, as grade 0 (fatty atrophy less than 10%), grade 1 (fatty atrophy between 10% and 50%) and grade 2 (fatty atrophy greater than 50%) (Figure 1) (10,11). Evaluation of the fatty atrophic changes in the LM muscle was performed visually and it was conducted by a single researcher. The fatty infiltration percentages were bilaterally identical in all study groups.

## Statistical Analysis

Statistical analysis was performed with SPSS software version 21 (IBM Corporation, Armonk, USA). Kolmogorov-Smirnov test was used to test the normal distribution of data. The results were presented as mean, standard deviation, minimum, maximum, frequency and percentage according to characteristics.

Independent Samples t test or univariate analysis of variance were used for intergroup comparisons. Chi-square test was used for the comparison of nominal variables.  $P < 0.05$  was considered significant.

## Results

### Patients

One hundred and forty-seven women (62.3%) and 117 men (37.7%) with LBP were included in the study. The mean age was  $47.6 \pm 14.0$  years (range=18-80 years). The mean age of the patients with and without lumbar intervertebral disc herniation at any level is shown Table 1.

### Imaging Results

Two hundred and ten (115 female, 95 male) (79.5%) patients were diagnosed as having lumbar intervertebral disc herniation at any level by MRI. Intervertebral disc herniation was not detected in 54 (32 female, 22 male) of 264 patients. The mean age of the patients with and without lumbar intervertebral disc herniation is shown in Table 1. Of 264 patients, 88 (33.3%) had grade 0 atrophy, 135 (51.1%) had grade 1 atrophy and 41 (15.5%) had grade 2 atrophy. LM muscle atrophy was 73.5% in women and 49.8% in men ( $p=0.01$ ). In addition, LM muscle atrophy was more common in both male and female patients older than 40 years of age (Table 2). All LM muscles were bilaterally atrophic.

**Table 1. The mean age of the patients with and without lumbar intervertebral disc herniation**

Intervertebral disc herniation at any level	Grade	Female	Male	p
With herniation (n=210)	0 (n=60)	$39.7 \pm 9.2$ (n=26)	$37.8 \pm 12.1$ (n=34)	0.12
	1 (n=112)	$50.1 \pm 9.3$ (n=62)	$49.8 \pm 10.6$ (n=50)	0.70
	2 (n=38)	$64.7 \pm 6.6$ (n=27)	$64 \pm 15.7$ (n=11)	0.83
Without herniation (n=54)	0 (n=28)	$34.1 \pm 10.1$ (n=13)	$32.8 \pm 11.1$ (n=15)	0.75
	1 (n=23)	$43.6 \pm 13.3$ (n=16)	$53.7 \pm 14.5$ (n=7)	0.19
	2 (n=3)	(n=3)	(n=0)	*

Grade 0 atrophy: fatty infiltration <10%, Grade 1 atrophy: fatty infiltration 10%-50%, Grade 2 atrophy: fatty infiltration >50%

\*Comparison cannot be made because there were no male patients in this group

**Table 2. Assessment of lumbar multifidus muscle atrophy according to age and sex**

LM muscle atrophy					
	<40 years		>40 years		p
Male	Grade 0	31 (75.6%)	Grade 0	18 (23.6%)	<0.001
	Grade 1+2	10 (24.4%)	Grade 1+2	58 (76.4%)	
Female	Grade 0	25 (60.9%)	Grade 0	14 (13.2%)	<0.001
	Grade 1+2	16 (39.1%)	Grade 1+2	92 (86.8%)	

LM: lumbar multifidus, grade 0: fatty infiltration <10%, Grade 1: fatty infiltration 10%-50%, Grade 2: fatty infiltration >50%

Disc herniation and LM muscle atrophy at L4-L5 level was significantly associated with age ( $p=0.001$  and  $p<0.001$ , respectively), and disc herniation at L5-S1 level was not significantly associated with age ( $p=0.49$ ). The coexistence of LM muscle atrophy and disc hernia at both levels (LM muscle atrophy and disc herniation at L4-L5 level,  $p=0.58$ , LM muscle atrophy and disc herniation at L5-S1 level,  $p=0.87$ ) and disc herniation at L4-L5 and L5-S1 levels ( $p=0.36$ ) were not associated with age.

The mean age of patients according to the grade of LM muscle atrophy is given in Table 3. There was a significant difference in the mean age of the patients with respect to different grades of LM muscle atrophy ( $p<0.01$ ). LM muscle atrophy was found to increase with age.

Of 54 patients without lumbar intervertebral disc herniation, 28 had grade 0 atrophy, 23 had grade 1 atrophy (Figures 2a, b), and 3 had

grade 2 atrophy. In addition, there was no spinal stenosis or nerve root compression in MRI of 25 patients with grade 1 or 2 LM muscle atrophy to explain the LBP. Moreover, 9.8% of our patients with LBP had normal MRI except for those with LM muscle atrophy.

## Discussion

The LM muscle is an important local stabilizer of the lumbar spine. It can be divided into superficial and deep fibers, each with different functions. Because the superficial and deep parts of the muscle are near the center of lumbar joint rotation, the deep fibers can control intervertebral movement and the superficial fibers are well-suited to control spine orientation (4). Increased fat infiltration of the LM muscle may lead to lumbar dysfunction and this may cause LBP (9,12). Eating


**Table 3. The mean age of patients according to the grade of LM muscle atrophy, excluding the patients with disc herniation**

LM muscle atrophy	Number of patients	Age (years)	p
Grade 0	28	19.6±10.5	<0.001
Grade 1	23	33.9±14.1	
Grade 2	3	52.6±3.6	

LM: lumbar multifidus, Grade 0: fatty atrophy <10%, Grade 1: fatty infiltration 10%-50%, Grade 2: fatty infiltration >50%



**Figure 1.** Axial T2-weighted images showing examples of lumbar multifidus muscle atrophy. Panel (a) shows grade 0 atrophy: fatty infiltration <10%; panel (b) shows grade 1 atrophy: fatty infiltration 10%-50%; and panel (c) shows grade 2 atrophy: fatty infiltration >50%



**Figure 2.** A 53-year-old female patient with grade 1 lumbar multifidus (LM) muscle atrophy without disc herniation. Mid-sagittal image (a) showing normal L4-L5 and L5-S1 discs, no significant loss of height or disc herniation. Axial T2-WI (b) showing grade 1 LM muscle atrophy at L4-L5 level



**Figure 3.** A 63-year-old female patient with intervertebral disc herniation. Mid-sagittal T2-WI (a) showing dehydration and bulging in the discs. Axial T2-WI (b) at L4-L5 level showing left paracentral herniation. Grade 2 atrophy is seen in lumbar multifidus muscle

disorders, inactivity, and chronic diseases can cause muscle atrophy. LM muscle atrophy is more frequent in women. In our study, LM muscle atrophy was also found to be more common in women (73.5%). There is decline in muscle mass (approximately 8% for every ten years) after 40 years of age (5). In this study, LM muscle atrophy was found to be more common in females and males older than 40 years ( $p<0.001$ ).

Morphological changes of the LM muscle can be detected by ultrasonography (US), computed tomography (CT) and MRI (4). US is not preferred for LM muscle assessment due to low tissue contrast and limited field of vision. CT can be used to assess LM muscle changes. However, it requires moderate to high radiation and provides less tissue contrast than MRI. MRI is quite successful in showing changes in LM muscle and additional pathologies in patients with LBP. In addition, MRI provides better soft tissue contrast than CT. MRI does not use ionizing radiation or any other type of radiation (4). LM muscle fatty atrophy is visualized as high intensity areas on T2-weighted sequences. Most of the mobility in the lumbar region emerges from L5-S1 and L4-L5 levels (11). Hence, we evaluated these levels to associate LM muscle with LBP.

Patients with LM muscle atrophy have more lumbar disc herniation than patients without atrophy. In our study, we found grade 1 (53.3%) LM muscle atrophy in 112 of the 210 patients and grade 2 (18%) atrophy in 38 patients with lumbar intervertebral disc herniation at any level (Figures 3). We also found that coexistence of disc herniation and LM muscle atrophy at L4-5 levels was associated with age ( $p<0.05$ ). However, coexistence of disc herniation and LM muscle atrophy at L5-S1 level was not associated with age.

Ekin et al. (5) reported that 13% of patients with LBP had LM muscle atrophy without disc herniation. In our study, 23 (42.5%) of 54 patients had grade 1 LM muscle atrophy and 3 patients (5.5%) had grade 2 atrophy with LBP without lumbar intervertebral disc herniation. In 26 patients (9.8%) with grade 1 and grade 2 LM muscle atrophy, lumbar MRI was normal. We could not find any explanation of the causes for LBP radiologically, except for LM muscle atrophy. We thought that LM muscle atrophy may be the only finding in patients with LBP.

Woodham et al. (4) reported that spinal manipulative therapy in combination with LM muscle stabilization exercises could reduce LM muscle atrophy. In addition, there is evidence that specific exercise protocols, including multifidus activation, reverse the atrophy of the LM muscle and that these exercises can reduce LBP (13).

MRI is a useful imaging method for the detection of LBP etiology. Malignancy, inflammatory diseases, and infectious processes should be considered in patients with LBP (5). It should be noted that LM muscle atrophy could cause LBP in patients, even those with normal lumbar MRI findings. In our study, 9.8% of patients with LBP had grade 1 or 2 LM muscle atrophy without lumbar intervertebral disc herniation, spinal stenosis, or nerve root compression.

## Conclusion

The LM muscle is the main stabilizer of the lumbar spine and LM muscle atrophy is closely associated with LBP. In our study, 9.8% of patients

with LBP had grade 1 or 2 LM muscle atrophy without intervertebral disc pathologies or nerve root compression. We believe that LM muscle atrophy can be the only finding in patients with LBP.

**Ethics Committee Approval:** The University of Health Sciences, Samsun Training and Research Hospital Ethics Committee approval was received for this study (decision no: 2017/24).

**Informed Consent:** Retrospective study.

**Peer-review:** Externally and internally peer-reviewed.

**Financial Disclosure:** The author declared that this study has received no financial support.

## References

- Altinkaya N, Cekinmez M. Lumbar multifidus muscle changes in unilateral lumbar disc herniation using magnetic resonance imaging. *Skeletal Radiol* 2016; 45: 73-7.
- Freeman MD, Woodham MA, Woodham AW. The role of the lumbar multifidus in chronic low back pain: a review. *PM R* 2010; 2: 142-6; quiz 1 p following 167.
- Kjaer P, Bendix T, Sorensen JS, Korsholm L, Leboeuf- Yde C. Are MRI-defined fat infiltrations in the multifidus muscles associated with low back pain? *BMC Med* 2007; 5: 2.
- Woodham M, Woodham A, Skeate JG, Freeman M. Long-term lumbar multifidus muscle atrophy changes documented with magnetic resonance imaging: a case series. *J Radiol Case Rep* 2014; 8: 27-34.
- Ekin EE, Kurtul Yildiz H, Mutlu H. Age and sex-based distribution of lumbar multifidus muscle atrophy and coexistence of disc hernia: an MRI study of 2028 patients. *Diagn Interv Radiol* 2016; 22: 273-6.
- Hyun JK, Lee JY, Lee SJ, Jeon JY. Asymmetric atrophy of multifidus muscle in patients with unilateral lumbosacral radiculopathy. *Spine* 2007; 32: 598-602.
- Kim WH, Lee SH, Lee DY. Changes in the cross-sectional area of multifidus and psoas in unilateral sciatica caused by lumbar disc herniation. *J Korean Neurosurg Soc* 2011; 50: 201-4.
- Farshad M, Gerber C, Farshad-Amacker NA, Dietrich TJ, Laufer-Molnar V, Min K. Asymmetry of the multifidus muscle in lumbar radicular nerve compression. *Skelet Radiol* 2014; 4: 49-53.
- Battié MC, Niemelainen R, Gibbons LE, Dhillon S. Is level- and side-specific multifidus asymmetry a marker for lumbar disc pathology? *Spine J* 2012; 12: 932-9.
- Parkkola R, Rytokoski U, Kormanen M. Magnetic resonance imaging of the discs and trunk muscles in patients with chronic low back pain and healthy control subjects. *Spine* 1993; 18: 830-6.
- Kader DF, Wardlaw D, Smith FW. Correlation between the MRI changes in the lumbar multifidus muscles and leg pain. *Clin Radiol* 2000; 55: 145-9.
- Wu WW, Hu ZJ, Fan SW, Xu WB, Fang XQ, Zhao FD. Influencing of chronic low back pain on multifidus muscle atrophy. *Zhongguo Gu Shang* 2014; 27: 207-12.
- Hides JA, Stanton WR, McMahon S, Sims K, Richardson CA. Effect of stabilization training on multifidus muscle cross-sectional area among young elite cricketers with low back pain. *J Orthop Sports Phys Ther* 2008; 38: 101-8.

# Use of Liquid Phenol for Management of Pilonidal Disease

## Pilonidal Hastalığın Tedavisinde Sıvı Fenol Kullanımı

● Alaattin Öztürk<sup>1</sup>, ● Yüksel Karaköse<sup>2</sup>

<sup>1</sup>İstanbul Adatıp Hospital, Clinic of Surgery, İstanbul, Turkey

<sup>2</sup>İbni Sina Hospital, Clinic of Surgery, İstanbul, Turkey

### ABSTRACT

**Introduction:** This study describes the treatment of pilonidal sinus with liquid phenol and reports its short-term results.

**Methods:** Patients with pilonidal disease were operated under local anesthesia. Primary and secondary pits were excised. Pilonidal cyst cavity was cleaned with brushing, curettage and irrigation. Wounds were left open. Chemical destruction of sinus wall was performed by liquid phenol.

**Results:** A total of 67 patients with pilonidal sinus were enrolled in this study. The mean duration of surgery was 14.7 minutes. The mean follow-up period was 27.3 months. There were no systemic complications. Two patients had hemorrhage and three patients had wound infection. The wound healing time was 3-6 weeks. Three cases of recurrence were observed in the follow-up period (4.47 %).

**Conclusion:** Minimally-invasive surgical technique with liquid phenol is a safe and effective outpatient procedure that can be performed under local anesthesia. It has low recurrence and postoperative morbidity rates.

**Keywords:** Phenol, pilonidal sinus, wound healing

### ÖZ

**Amaç:** Bu çalışma, pilonidal sinüsün sıvı fenol ile tedavisini tanımlayıp kısa dönemdeki sonuçlarını bildirmektedir.

**Yöntemler:** Pilonidal sinüslü hastalar lokal anestezi altında ameliyat edildiler. Primer ve sekonder delikler eksize edildi. Pilonidal sinüs kavitesi fırça ile temizlendi, kürete edildi ve yıkandı. Yaralar açık bırakıldı. Sinüs duvarı sıvı fenol kullanılarak kimyasal olarak tahrip edildi.

**Bulgular:** Bu çalışmaya pilonidal sinüsü olan toplam 67 hasta alındı. Ortalama ameliyat süresi 14,7 dakika idi. Ortalama takip süresi 27,3 ay idi. Sistemik komplikasyon görülmedi. İki hastada kanama ve üç hastada yara enfeksiyonu gelişti. Yara iyileşme süresi 3-6 hafta idi. Takip süresinde üç hastada (%4,47) nüks görüldü.

**Sonuç:** Sıvı fenol ile minimal invaziv cerrahi yöntem, lokal anestezi ile uygulanabilen güvenli ve etkili bir işlemdir. Bu işlemin nüks ve morbidite oranları düşüktür.

**Anahtar Kelimeler:** Fenol, pilonidal sinüs, yara iyileşmesi

### Introduction

Pilonidal disease lesions are usually located beneath the skin in the sacrococcygeal region. Since its first definition, there are discussions about the treatment of pilonidal disease. Surgeons prefer to operate pilonidal diseases with wide excision extending to sacral tissue. Some surgeons leave the wound to secondary healing, some suture midline wounds for primary closure, and others use more complicated procedures, such as different kind of skin flaps designed to protect the incision away from the midline or flatten the natal cleft. Most commonly, such a complicated procedure requires general anesthesia and hospitalization. In addition, antibiotic treatment, drainage and variable use of sutures are also needed. Pilonidal sinus surgeries are notorious for their associated morbidity, recurrence rates, poor cosmetic results and costs (1). This

study describes outpatient liquid phenol treatment of pilonidal disease with local anesthesia and reports short-term results of the technique.

### Methods

#### Study Design

From February 2011 to March 2014, a total of 67 patients with symptomatic pilonidal disease were treated in our hospital. The surgeries included acute/ chronic or primary/recurrent pilonidal diseases. Patients did not receive any premedication or antibiotics, with the exception of medical management in five patients with infected pilonidal disease. Clinical, operative and follow-up data were recorded prospectively. No patients were excluded. The patients were followed-up on a monthly basis and disease recurrence was assessed by office interview and



Address for Correspondence/Yazışma Adresi: Alaattin Öztürk, İstanbul Adatıp Hospital, Clinic of Surgery, İstanbul, Turkey

Phone: +90 532 415 63 01 E-mail: aloz1969@yahoo.com ORCID ID: orcid.org/0000-0002-4729-7716

Cite this article as/Atıf: Öztürk A, Karaköse Y. Use of Liquid Phenol for Management of Pilonidal Disease. İstanbul Med J 2019; 20(2):115-8.

Received/Geliş Tarihi: 26.07.2018

Accepted/Kabul Tarihi: 10.11.2018



physical examination. The interviews were held between September 2012 and December 2014. Recurrence was defined as the return of the symptoms after a recovery period. All patients signed a written informed consent form. The study was performed with the approval of the Fatih University Sema Practice and Research Hospital Ethics Committee of the Hospital (date: 22.11.2010, decision no: 204).

### Surgical Technique

We performed the same surgical technique in all patients regardless of the forms of the disease. Except for three patients, all participants had many primary and secondary pits and had advanced stage pilonidal disease (pit is the tissue including the external orifice and the intradermal part of pilonidal disease). Local infiltrative anesthesia with 2 to 6 mL of bupivacaine (Marcaine 0.5%; AstraZeneca Turkey, İstanbul, Turkey) was usually sufficient for pain control regardless of the extent of disease or coexistence of infection. Local anesthesia was performed in all patients who underwent surgery, except six patients who asked for spinal anesthesia. Four of these six patients had an infected pilonidal disease.

Patients were placed in a prone or proctologic position. The buttocks were retracted with adhesive tape. The sacral region was completely

shaved and disinfected with povidone iodine solution. The sinus was explored with a metal probe and marked with a marker pen. No blue dye or similar substance was used for demonstration of sinus tracts.

We made a minimum of two holes by excision of primary or secondary pits. If there were more than two pits, we performed deconstruction with a round cautery blade. Using surgical forceps, aspirator, curette or brush, we cleaned the entire contents of each sinus with debridement. We injected or dripped 3 to 5 mL of 80% liquid phenol into the sinus cavity, waited for 3 to 5 minutes and aspirated and irrigated the cavity with saline solution. The sinus wall was destroyed with this application (Figure 1). The phenol application was repeated if necessary. After careful hemostatic control, we packed the sinus cavity with a thin rolled wet gauze (Figure 2).

### Postoperative Care and Follow-up

There was a relatively short period of postoperative follow-up (15 minutes to 2 hours for local anesthesia) before discharge. While antibiotics and analgesics were prescribed for patients with infected pilonidal disease, only analgesics were given to patients with non-infected pilonidal disease. There was no activity restriction such as driving, sitting or walking.

On the first or second postoperative day, we checked the patients for bleeding and other morbidities and instructed relatives of the patients about wound care. Patients were followed weekly until complete wound healing and then re-checked at 6 months (Figure 3).

### Statistical Analysis

We evaluated our results in Excel program as percentage and ratio. We did not use any statistical program.

### Results

A total of 67 patients with pilonidal sinus were treated by two surgeons between February 2011 and March 2014. Forty-eight patients (71.6%) were male and 19 (28.4%) were female. Male to female ratio was 2.5. The mean age of the patients was 26.8 years (range=16-52). The mean duration of symptoms was 3.8 years (range=2 months-10 years). Forty-six



Figure 1. Destruction of sinus wall by liquid phenol



Figure 2. Packing sinus cavity



Figure 3. Complete wound healing

patients had a primary pit in the midline. Of these, 28 had a single pit and 18 had multiple pits. Twenty-one patients had one or more pits extending in the midline. Eight of 67 patients were recurrent pilonidal disease. In our series, 11 patients had acute (infection or abscess) pilonidal disease.

The mean duration of surgery was 14.7 minutes (range=10-22 min), excluding the waiting time of the local anesthesia effect. Local anesthesia prevented pain for 3 to 4 hours after surgery. Three patients required parenteral analgesia in the postoperative period. The time required for wound healing was 3 to 6 weeks (mean 38 days). The mean follow-up was 27.3 months (range=6-37 months). The characteristics and operative findings of patients are shown in Table 1.

There were no systemic complications. Local complications included hemorrhage in two patients (one on the first postoperative day and one on the fourth postoperative day) that were both treated with blood stopper solution (Ankaferd, Immun Pharmaceutical Cosmetics, Ankara, Turkey) and infectious, foul-smelling, yellow-green discharge in three patients which were treated locally with antibiotic solution (Rifocin 125 mg/1.5 mL ampoule, Sanofi Turkey, İstanbul, Turkey). In 22 patients, we used a silver nitrate stick to permanently destroy unwanted granulation tissue.

There were three recurrences (4.4%) during follow-up. All three patients were treated with the same technique. Patient outcomes with liquid phenol treatment are summarized in Table 2.

**Table 1. Characteristics and operative findings of patients (n=67)**

Age	16-52 years (mean=26.8)
Gender	
Male	48 (71.6%)
Female	19 (28.4%)
Duration of symptoms	2 month-10 years (mean=3.8 years)
Presentation of disease	
Acute	11 (16.4%)
Chronic	56 (85.6%)
Previous surgery	8 (11.9%)
Location of pits	
Only midline	46
Midline and lateral	21
Anesthesia	
Local	62
Spinal	5
Mean operative time	14.7 minutes (range=10-27)

**Table 2. Outcome of the patients**

Follow-up	27.3 months
Additional parenteral analgesic requirement	3
Complication	
Infection	3
Bleeding	2
Recurrence	3 (4.4%)
Mean recovery time	38 days

## Discussion

Many treatment methods have been reported for pilonidal sinus, but few treatments provide perfect long-term results. There are many stages and clinical presentations of pilonidal disease. Therefore, surgeons should know all available techniques and select the proper treatment according to the extent and severity of the disease and patient preference. Scientific data demonstrate that both open and closed surgical approaches have similar complication rates (2). In addition, both extensive and conservative surgical approaches in pilonidal sinus treatment are associated with similar recurrence rates (3).

Commonly, approximate hospital stay is between 5 and 14 days, and recovery period is between 6 and 10 weeks after total excision and open healing of pilonidal sinuses. In addition, the recurrence rate after surgery is 8% to 21%. Following years, instead of traditional methods, different types of primary closure procedures reduced the recovery time by less than 2 weeks, but hospital stay remained between 7 and 10 days and the recurrence rates ranged from 8% to 30%. These results dominate the use of primary closure procedures. However, one report demonstrated that this group had a recurrence rate of 23% compared to 12% in patients treated with excision and packing procedures (4).

There are still many therapeutic challenges in the treatment of pilonidal disease. Many surgical and non-surgical (conservative) modalities have been proposed. The vast majority of cases are treated surgically. However, there is no consensus on the "ideal" surgical technique. In order to determine an ideal surgical technique, we must first define the ideal management principles. According to accepted principles, some authors have suggested minimally invasive surgery (or non-excisional surgery) for pilonidal disease treatment. Support is growing for this treatment modality.

Phenol-based treatment of pilonidal disease is one of the minimally invasive or non-excisional surgery methods. Khanna and Rombeau (5) classified various treatment strategies for pilonidal disease and described phenol application as an "experimental treatment". However, according to us and based on other studies, this method is suitable following conservative (non-surgical) treatment (6). Some authors stated that non-excisional therapies, such as phenol application, could result in a high rate of recurrence, especially when patients were not followed up closely (7). Crystalline phenol has been shown to be a successful treatment modality for pilonidal sinus disease, with similar results to other surgical treatments (8). Simple treatment methods for pilonidal disease such as minimally invasive surgery or non-excisional treatments have been associated with less morbidity and low recurrence rates (9-13).

Based on the pathogenesis of acquired foreign body, we described a novel surgical treatment for pilonidal disease that integrates the principles of a minimally invasive operative approach. Our method consists of easy excision of primary and secondary pilonidal pits only, with debridement, sinus cavity cleaning, and chemical cauterization of the sinus cavity and sinus wall with liquid phenol.

The results of surgical treatment for pilonidal disease differ substantially between studies, even among those describing similar techniques.

Postoperative infection and recurrence rates vary between nil and 40% or higher (14,15). In general, the recurrence time for pilonidal disease after surgery is 5 years, but recurrence can be seen in ten years after surgery (16).

Because of the small number of patients in this study and the short follow-up period, definitive conclusions cannot be made. However, our study describes a method of minimally invasive pilonidal disease surgery that resulted in no systemic complications. Three patients had recurrence during the follow-up period. We believe that the cause of recurrence was secondary infection.

## Conclusion

Liquid phenol application is a simple, safe, and effective outpatient procedure for treating pilonidal sinus disease. It is performed by local anesthesia and can achieve good aesthetic outcomes for both chronic and acute infectious pilonidal disease. In case of recurrence, the same treatment can be repeated without hesitation.

**Ethics Committee Approval:** The study was performed with the approval of the Fatih University Sema Practice and Research Hospital Ethics Committee of the Hospital (date: 22.11.2010, decision no: 204).

**Informed Consent:** All patients signed a written informed consent form.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - A.Ö., Y.K.; Design - A.Ö., Y.K.; Supervision - A.Ö., Y.K.; Resources - A.Ö., Y.K.; Data Collection and/or Processing - A.Ö., Y.K.; Analysis and/or Interpretation - A.Ö., Y.K.; Literature Search - A.Ö., Y.K.; Writing Manuscript - A.Ö., Y.K.; Critical Review - A.Ö.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

- Gips M, Melki Y, Salem L, Weil R, Sulkes J. Minimal surgery for pilonidal disease using trephines: Description of a new technique and long-term outcomes in 1,358 patients. *Dis Colon Rectum* 2008; 51: 1656-62.
- de Parades V, Bouchard D, Janier M, Berger A. Pilonidal sinus disease. *J Visc Surg* 2013; 150: 237-47.
- Aslam MN, Shoaib S, Choudhry AM. Use of Limberg flap for pilonidal sinus-a viable option. *J Ayub Med Coll Abbottabad* 2009; 21: 31-3.
- Oueidat D, Rizkallah A, Dirani M, Assi T, Shams A, Jurjus A. 25 years' experience in the management of pilonidal sinus disease. *Open Journal of Gastroenterology* 2014; 4: 1-5.
- Khanna A, Rombeau JL. Pilonidal disease. *Clin Colon Rectal Surg* 2011; 24: 46-53.
- Girgin M, Kanat BH, Ayten R, Cetinkaya Z, Kanat Z, Bozdağ A, et al. Minimally invasive treatment of pilonidal disease: crystallized phenol and laser depilation. *Int Surg* 2012; 97: 288-92.
- Bissett IP, Isbister WH. The management of patients with pilonidal disease-a comparative study. *Aust NZ J Surg* 1987; 57: 939-42.
- Attaallah W, Coşkun Ş, Coşkun M, Solmaz A, Yeğen C, Gençosmanoğlu R. Sakrokoksigeal yerleşimli pilonidal sinus hastalığının tedavisinde kristalize fenol uygulaması: Gerçekten başarılı mı? *Kolon Rektum Hast Derg* 2015; 25: 28-33.
- da Silva JH. Pilonidal cyst: cause and treatment. *Dis Colon Rectum* 2000; 43: 1146-56.
- Dag A, Colak T, Turkmenoglu O, Sozutek A, Gundogdu R. Phenol procedure for pilonidal sinus disease and risk factors for treatment failure. *Surgery* 2012; 151: 113-7.
- Akan K, Tihan D, Duman U, Özgün Y, Erol F, Polat M. Pilonidal sinus tedavisinde cerrahi Limberg flep yöntemi ile kristalize fenol uygulamasının retrospektif karşılaştırılması. *Ulusal Cer Derg* 2013; 29: 162-166.
- Işık A, Fırat D, İdiz UO. Approaches to recurrent/complicated and acute cases. *Türkiye Klinikleri J Gen Surg-Special Topics* 2018; 11: 112-4.
- Isik A, Idiz O, Fırat D. Novel approaches in pilonidal sinus treatment. *Prague Medical Report* 2016; 117: 145-52.
- Allen-Mersh TG. Pilonidal sinus: finding the right track for treatment. *Br J Surg* 1990; 77: 123-32.
- Petersen S, Koch R, Stelzner S, Wendlandt TP, Ludwig K. Primary closure techniques in chronic pilonidal sinus: a survey of the results of different surgical approaches. *Dis Colon Rectum* 2002; 45: 1458-67.
- Doll D, Krueger CM, Schrank S, Dettmann H, Petersen S, Duesel W. Timeline of recurrence after primary and secondary pilonidal sinus surgery. *Dis Colon Rectum* 2007; 50: 1928-34.

# The Effect of Different Hemostatic Systems on the Injury of the External Branch of the Superior Laryngeal Nerve in Thyroidectomy

## Tiroidektomi Ameliyatında Kullanılan Farklı Damar Kapama Sistemlerinin Süperior Laringeal Sinirin Eksternal Dalı Yaralanması Üzerine Etkisi

İD Volkan Özben<sup>1</sup>, İD Recep Özgültekin<sup>1</sup>, İD Nurten Adatepe<sup>2</sup>, İD Asım Kayta<sup>3</sup>

<sup>1</sup>İstanbul University-Cerrahpaşa Faculty of Medicine, Department of General Surgery, İstanbul, Turkey

<sup>2</sup>İstanbul University-Cerrahpaşa Faculty of Medicine, Department of Neurology, İstanbul, Turkey

<sup>3</sup>İstanbul University-Cerrahpaşa Faculty of Medicine, Department of Otorhinolaryngology, İstanbul, Turkey

### ABSTRACT

**Introduction:** Vessel-sealing and ultrasonic coagulation systems that provide rapid and effective hemostasis are widely used in thyroid surgery. An important disadvantage of these systems is injury to the neighboring anatomical structures by thermal damage. However, data on injury to the external branch of the superior laryngeal nerve is limited. The aim of this study was to evaluate the effect of different vascular closure systems on this nerve injury in thyroidectomy.

**Methods:** A total of 45 patients who underwent thyroidectomy for benign thyroid disease between October 2008 and February 2009 were included in the study. Patients were randomized and divided into three groups, each consisting of 15 patients. Systems used were vessel-sealer in the first group, harmonic scalpel in the second group and conventional suture ligation technique in the third group. Laryngeal electromyography findings and voice complaints were compared.

**Results:** There were 37 female (82%) and 8 male patients. The mean age was 47.9±11.1 years. Demographic features and surgical procedures were statistically similar in all groups (p>0.05). The control electromyography of 84 nerves with preoperatively confirmed normal findings showed that three (10.7%) of the 28 nerves in the vessel sealer group, two (7.1%) of the 28 nerves in the harmonic scalpel group, and two (7.1%) of the 28 nerves in the suture ligation group had complete or partial nerve injury (p>0.05). No significant difference was found between the groups in terms of voice complaints (p>0.05).

**Conclusion:** Compared to the conventional suture ligation technique, the use of vascular closure devices does not increase the risk of injury to the external branch of the superior laryngeal nerve.

**Keywords:** Electromyography, external branch of the superior laryngeal nerve, nerve injury, thyroidectomy, vascular closure systems

### ÖZ

**Amaç:** Hızlı ve etkin bir şekilde hemostaz sağlayan damar mühürleyici ve ultrasonik koagülasyon sistemleri tiroid cerrahisinde yaygın bir şekilde kullanılmaktadır. Bu sistemlerin bir dezavantajı termal hasar yolu ile komşu anatomik yapılara zarar verebilmesidir. Ancak süperior laringeal sinirin eksternal dalının yaralanması ile ilgili veriler sınırlıdır. Bu çalışmanın amacı tiroidektomi ameliyatında kullanılan farklı damar kapama sistemlerinin bu sinir yaralanması üzerine olan etkisini değerlendirmektir.

**Yöntemler:** Çalışmaya Ekim 2008 ile Şubat 2009 tarihleri arasında selim tiroid hastalığı nedeni ile tiroidektomi ameliyatı yapılan toplam 45 hasta dahil edildi. Hastalar randomize edilerek her biri 15'er hastadan oluşan toplam üç gruba ayrıldı. Ameliyatta ilk grupta damar mühürleyici, ikinci grupta harmonik kesici ve üçüncü grupta klasik sütür ile bağlama tekniği kullanıldı. Hastaların laringeal elektromiyografi bulguları ve ses şikayetleri karşılaştırıldı.

**Bulgular:** Hastaların 37'si kadın (%82), 8'i erkek ve yaş ortalaması 47,9±11,1 yıl idi. Demografik özellikler ve cerrahi işlemler tüm gruplarda istatistiksel olarak benzer bulundu (p>0,05). Ameliyat öncesi elektromiyografi bulguları normal olan 84 adet sinirin kontrol incelemesinde damar mühürleyici grubunda 28 sinirin 3'ünde (%10,7), harmonik kesici grubunda 28 sinirin 2'sinde (%7,1) ve klasik sütür ile bağlama grubunda 28 sinirin 2'sinde (%7,1) tam veya parsiyel sinir yaralanması mevcuttu (p>0,05). Ses şikayetleri açısından gruplar arasında anlamlı fark saptanmadı (p>0,05).

**Sonuç:** Damar kapama cihazlarının kullanımı klasik sütür bağlama tekniği ile karşılaştırıldığında, süperior laringeal sinirin eksternal dalı yaralanması riskini artırmadığı görülmektedir.

**Anahtar Kelimeler:** Elektromiyografi, süperior laringeal sinirin eksternal dalı, sinir yaralanması, tiroidektomi, damar kapama sistemleri



Address for Correspondence/Yazışma Adresi: Volkan Özben, İstanbul University-Cerrahpaşa Faculty of Medicine, Department of General Surgery, İstanbul, Turkey

Phone: +90 534 648 46 78 E-mail: volkanozben@yahoo.co.uk ORCID ID: orcid.org/0000-0002-9620-5080

Cite this article as/Atıf: Özben V, Özgültekin R, Adatepe N, Kayta A. The Effect of Different Hemostatic Systems on the Injury of the External Branch of the Superior Laryngeal Nerve in Thyroidectomy. İstanbul Med J 2019; 20(2):119-24.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

Received/Geliş Tarihi: 31.01.2018

Accepted/Kabul Tarihi: 16.10.2018



## Introduction

Thyroidectomy requires good anatomic exposure, careful dissection and adequate hemostasis. The principles of safe and effective thyroid surgery were standardized by Emil Theodor Kocher and Theodor Billroth between 1873-1883, and the mortality rate decreased to less than 5% thanks to this technique that reduces bleeding with the ligation of the arteries of the thyroid gland (1). Although this principle is still valid, morbidity rates have decreased with the increase in experience and the use of modern techniques.

In recent years, alternatives to electrocoagulation have been developed and been widely used in thyroid surgery, such as bipolar vessel sealer and ultrasonic cutter, which provide rapid and effective hemostasis (2-4). However, a disadvantage of these systems is that they can damage adjacent anatomical structures by direct or lateral thermal spread (5-7). These adjacent structures include the external branch of the superior laryngeal nerve (EBSLN), and in particular, injury to the nerve occurs during the dissection of the upper pole of the thyroid gland (8,9). EBSLN is the only nerve that innervates the cricothyroid muscle, which is the tensor of the vocal cords, and its injury may lead to hoarseness, loss of strength of the voice, vocal fatigue and inability to achieve high pitch tasks (10,11).

Although there are many studies in the literature on the effect of vascular closure systems on postoperative complications in thyroid surgery, there is little data on EBSLN injury (12). Therefore, in this study, we aimed to evaluate the effect of different vascular closure systems on iatrogenic EBSLN injury in patients undergoing thyroidectomy.


## Methods

For the study, approval was obtained from İstanbul University, Cerrahpaşa Faculty of Medicine, Ethics Committee of Medical, Surgical and Pharmaceutical Research (decision no: 35792). A total of 45 patients who underwent thyroidectomy at the Endocrine Surgery Service of İstanbul University, Cerrahpaşa Faculty of Medicine between October 2008 and February 2009 were included in the study. Patients who had undergone previous thyroid surgery, patients with recurrent disease or thyroid cancer, and patients with voice complaints prior to surgery were excluded from the study. All patients were informed about the procedures and written informed consent was obtained.


The patients were randomized by computer program and divided into three equal groups, each consisting of 15 patients. All patients underwent thyroid function tests, thyroid ultrasonography, scintigraphy or fine needle aspiration biopsy for preoperative diagnosis. Standard bilateral thyroidectomy (total, near-total or subtotal) was performed. All patients were operated by the same surgical team. LigaSure Precise® (Valleylab Corp., Tyco Healthcare Group LP, Colorado, US) was used for vascular ligation in the first group (LigaSure group) (Figure 1), Ultracision® harmonic scalpel (Ethicon Endo-Surgery, Ohio, US) in the second group (Ultracision group) (Figure 2), and conventional suture ligation technique in the third group (suture group) (Figure 3).

Under general anesthesia, the patient was placed in a supine position with the neck extended. After proper skin cleansing, Kocher's collar incision was made, and upper and lower skin flaps were developed.


Thyrohyoid and sternohyoid muscles were divided vertically in the midline, and surgical field was entered. The right lobe of the thyroid was dissected free from the middle thyroid vein. The superior parathyroid gland was identified and preserved. The superior thyroid artery and vein were dissected and ligated from the level close to the thyroid capsule. In the meantime, no dissection was performed to



**Figure 1.** Release of the upper pole of the right thyroid gland with LigaSure Precise®



**Figure 2.** Release of the upper pole of the left thyroid gland with Ultracision®



**Figure 3.** Release of the upper pole of the left thyroid gland with conventional suture ligation technique

reveal the EBSLN. The right recurrent laryngeal nerve was preserved in the anterolateral tracheal area. Subsequently, the inferior pole vessels were ligated by preserving inferior parathyroid gland. The contralateral thyroid lobe was removed in a similar manner. Thyroidectomy procedure was completed with removal of the specimen along with the isthmus. Following hemostasis, a drain was placed. The midline muscles and skin were closed and the operation was terminated.

The function of EBSLN was evaluated by laryngeal electromyography (EMG). Recordings were performed before and after surgery in all patients, and bilateral cricothyroid muscles were examined. Preoperative muscular pathologies were investigated and repeated after one month because of abnormal spontaneous discharges. Before the control EMG, the patients were questioned in terms of phonation disorders (hoarseness, loss of strength of the voice, vocal fatigue and inability to achieve high pitch tasks). Neuropack MEB-9102K (Nihon Kohden, Tokyo, Japan) device was used for laryngeal EMG. Recordings were performed

with concentric bipolar needle electrodes (size: 50x45 mm) (Myoline, Spes Medica, Italy). The ground electrode was placed in the neck area far from the needle entrance site and the patient was placed in the supine position. Local anesthetic agent or premedication was not performed because the procedure was relatively painless and anesthetic agents could cause artifact in action potentials in the cricothyroid muscle. A needle electrode was inserted into the cricothyroid muscle to evaluate the function of EBSLN. For this purpose, the neck of the patient was extended and the needle electrode was inserted into the cricothyroid membrane in the midline and directed 30-45 degrees laterally (Figure 4). After making sure that the tip of the electrode was in the muscle by phonation, the input activity of the needle, the presence of spontaneous activity at rest, the shape, duration and amplitudes of the motor unit action potentials during active contraction of the muscle were recorded via an audiometer and oscilloscope. Wave morphology was evaluated by the same neurologist in terms of EBSLN injury.

Demographic data, pathological diagnoses, surgical procedure, EMG findings and vocal complaints that occurred within one month after surgery were recorded in the follow up forms prepared for each patient.

#### Statistical Analysis

Data were analyzed by using SPSS 11 (SPSS Inc., Chicago, IL, USA), and comparisons between groups were performed using ANOVA post hoc Tukey and chi-square tests. Values were given as mean  $\pm$  standard deviation.  $P < 0.05$  was considered statistically significant.

#### Results


Of the 45 patients included in the study, 37 were female (82%) and 8 were male (18%). The mean age of the patients was  $47.9 \pm 11$  (range: 21-68) years. Demographic data and clinical findings of the patients are presented in Table 1. The rate of female patients was 87% in the LigaSure group and 80% in the Ultracision and suture groups. Histopathological examination revealed no malignancy. There was no statistically significant difference between the demographic data and the surgeries performed ( $p > 0.05$ ).

The distribution of preoperative and postoperative EMG findings of groups is given in Table 2. When all groups were taken into account, a total of five EBSLN had pathologic EMG findings in the preoperative period. These were unilateral weak activity in one patient and unilateral activity loss in one patient in the LigaSure group, unilateral activity loss in one patient and unilateral neurogenic involvement in one patient in the Ultracision group, and unilateral weak activity in one patient in the suture group. In addition, unilateral EBSLN function could not be evaluated in one patient in the suture group because of postoperative technical failure. As a result, a total of 84 nerves were included in the statistical analysis, except for one nerve that could not be evaluated due to technical failure and five nerves with preoperative pathology in the EMG.

While EMG findings were normal in the preoperative period, one patient (6.7%) in the LigaSure group and one patient (6.7%) in the suture group had a unilateral cricothyroid muscle denervation pattern in the postoperative period (Figure 5). In addition, two patients (13.3%) in the LigaSure group, two patients (13.3%) in the Ultracision group



**Figure 4.** Insertion of the needle electrode into the cricothyroid muscle for the evaluation of superior laryngeal nerve function in a patient who underwent postoperative electromyography



**Figure 5.** (a) Normal motor unit action potential pattern and (b) denervation pattern in laryngeal cricothyroid muscle electromyography

and one patient (6.7%) in the suture group developed unilateral weak action potential patterns in the postoperative period despite normal preoperative EMG findings. Denervation and weak action potential patterns were consistent with EBSLN injury (Table 2).

In the postoperative control EMG of 84 EBSLNs with preoperative normal EMG findings, pathology was detected in three of the 28 EBSLN in the LigaSure group, two of the 28 EBSLN in the Ultracision group, and two of the 28 EBSLN in the suture group. There was no statistical difference between the groups ( $p=0.61$ ) (Table 3).

Postoperative vocal complaints were present in three patients in the LigaSure group, three patients in the Ultracision group and two patients in the suture group. No significant difference was found between groups in terms of vocal complaints ( $p=0.60$ ) (Table 3).

## Discussion

Thyroidectomy is one of the common surgeries in general surgery clinics. Although the principles of surgery have not changed much, new devices

have been put into use with developing technology in order to make hemostasis faster and safer. LigaSure®, also known as electrothermal vessel sealing system, is a dissection and coagulation device developed in recent years. Ultracision® provides simultaneous coagulation and cutting with ultrasonic energy, and also has achieved a place in thyroid surgery in a short time (2-4). However, a significant disadvantage of these systems is that they may cause nerve injuries in thyroid surgery depending on the energy used (5-7). The results obtained in this study that specifically analyzed EBSLN injury showed that the use of these vascular closure systems in thyroidectomy surgery did not increase this complication compared to the classical suture ligation technique.

In the studies comparing vascular closure systems and conventional suture technique in the literature, complications such as postoperative hemorrhage, recurrence laryngeal nerve injury and hypoparathyroidism were evaluated in the morbidity parameters (3,4,6,7), and data on EBSLN injury were insufficient. The only study in this regard is a prospective randomized study by Arslan et al. (12) that compares the harmonic scalpel with conventional suture ligation technique in thyroidectomy.

**Table 1. The distribution of demographic characteristics and surgical procedures according to groups**

	LigaSure group	Ultracision group	Suture group	p
Age, years $\pm$ SD	44.4 $\pm$ 11	46.6 $\pm$ 12	50.8 $\pm$ 11	0.4
Female/male, n (%)	13/2 (87)	12/3 (80)	12/3 (80)	0.6
Surgery, n (%)				0.3
Total thyroidectomy	10 (67)	7 (47)	10 (67)	-
Near-total/subtotal thyroidectomy	5 (33)	8 (53)	5 (33)	-

SD: standard deviation

**Table 2. Distribution of electromyography findings according to groups**

	LigaSure group		Ultracision group		Suture group	
	Preoperative	Postoperative	Preoperative	Postoperative	Preoperative	Postoperative
<b>EMG findings, n (%)*</b>						
Bilaterally normal	13 (87)	11 (73)	13 (87)	12 (80)	14 (93)	11 (73)
Unilateral weak activity	1 (7)	3 (20)	0 (0)	2 (13)	1 (7)	2 (13)
Unilateral activity loss	1 (7)	0 (0)	1 (7)	0 (0)	0 (0)	0 (0)
Unilateral neurogenic involvement	0 (0)	0 (0)	1 (7)	1 (7)	0 (0)	0 (0)
Unilateral denervation	0 (0)	1 (7)	0 (0)	0 (0)	0 (0)	1 (7)
Technical failure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)
<b>EMG findings, n (%)**</b>						
Normal	28 (93)	26 (87)	28 (93)	27 (90)	29 (97)	26 (87)***
Pathologic	2 (7)	4 (13)	2 (7)	3 (10)	1 (3)	3 (10)

EMG: electromyography, \*numbers and percentages refer to the number of patients, \*\*numbers and percentages refer to the number of nerves, \*\*\*since the nerve could not be found on one side due to technical failure, it was not taken into consideration

**Table 3. Comparison of superior laryngeal nerve injury and postoperative phonation disorders among groups**

	LigaSure group	Ultracision group	Suture group	p
Surgical SLN injury, SLN number (%)	3/28 (10.7)	2/28 (7.1)	2/28 (7.1)	0.6
Phonation disorder, number of patients	2	2	2	0.6

SLN: superior laryngeal nerve, SD: standard deviation



A total of 206 patients were included in this study, and temporary and permanent EBSLN injuries were detected in four (4%) and three (%) patients in the harmonic scalpel group and in two (1.9%) and two patients (1.9%) in the other group, respectively. No significant difference was found between the groups. The authors concluded that the use of a harmonic scalpel was safe for EBSLN injury.

The superior laryngeal nerve is separated from the vagus around the skull base; it descends from the medial of the carotid vessels and is divided into two branches as internal and external at the level of hyoid bone. The internal branch provides the sensation of epiglottis and larynx. EBSLN runs with superior thyroid vessels, and provides motor innervation of the cricothyroid muscle and determines the style of the voice by tensing the vocal cords (8,10,11). As a result of trauma to the nerve, the vocal cord in that side becomes flaccid and this creates difficulty in phonation. This is especially important for those who practice their profession using their voice continuously (teacher, announcer, singer, etc.) (8,11).

Vocal changes related to EBSLN injury were first described by Moran and Castro (13) in 1951, and later Cernea et al. (14) reported the anatomical classification of the different localizations of the nerve and reported high-risk location for surgical injury. According to this classification, EBSLN has a high-risk of injury during the release of thyroid upper pole. Later, Selvan et al. (15) described a new classification system on the anatomical localization of the nerve accompanied by EMG findings by performing EBSLN monitoring. According to this classification, the area with the highest risk of injury is defined as the area 1 cm superior-posterior of the artery before entering the thyroid gland. In the light of this anatomical information, some authors stated that the EBSLN should be explored directly or by intraoperative nerve monitoring before ligation of the artery (16-18), while others stated that even careful dissection in this area could damage the nerve (15,19). In our study, EBSLN was not visualized in none of the patients as it was thought to increase the risk of nerve injury and dissection was performed close to the capsule of the thyroid gland.

The fact that the vocal change due to EBSLN injury in thyroid surgery is not noticed by both the patient and the surgeon, or the requirement of detailed analyzes in order to reveal the pathology even if it is noticed shows why less attention is given to this nerve than the recurrent laryngeal nerve. Recurrent laryngeal nerve injury can be detected by simple diagnostic methods such as indirect laryngoscopy or fiberoptic examination, EBSLN injury requires the use of more advanced techniques such as laryngeal videostroboscopy, spectrographic analysis and laryngeal EMG. Among these techniques, the more invasive and time-consuming cricothyroid muscle EMG is the most accurate diagnostic method (9,20). The risk of iatrogenic partial or complete EBSLN injury varies between 0% and 6% after thyroidectomy and this rate increases up to 60% when EMG is performed (12,14,18,21).

In our study, the muscle denervation pattern detected in one patient in the LigaSure group and one patient in the suture group in the postoperative period is the most objective finding indicating complete nerve injury. This finding was not observed in any patient in the Ultracision group. In addition, weak action potentials detected in two

patients in the LigaSure and Ultracision groups and one patient in the suture group indicate a mild axonal injury, namely partial nerve injury. There was no difference in EBSLN injury when all groups were compared.

Although surgical iatrogenic injuries are the most frequent, viral infectious diseases, trauma, peripheral neuropathies and some motor neuron diseases may cause loss of function in EBSLN and clinical symptoms may be subclinical (22). In our study, preoperative EMG was performed in all patients in order to determine if the postoperative nerve damage was iatrogenic or was an already existing pathological condition. When all study groups were considered, five patients had pathologic EMG findings in the preoperative period. If EMG is not performed in the preoperative period in such patients, the pathological EMG findings that may develop after surgery may lead to misinterpretations in terms of nerve damage. Similarly, the phonation disorders that can occur in patients with no obtained cricothyroid muscle activity in preoperative EMG, but with normal postoperative findings cannot be attributed to EBSLN injury. This suggests that the anatomical localization of the muscle may have changed due to the enlarged thyroid tissue. In our study, the right cricothyroid muscle could not be localized in one patient in the suture group. An additional interpretation could not be made for this muscle, which suggests that anatomical localization is impaired due to the displacement secondary to surgery.

### Study Limitations

Lack of EMG control in the long term after surgery is an important limitation of our study. In laryngeal nerve paralysis, EMG findings may vary according to the severity and duration of nerve damage. In neuropraxia, neurogenic involvement that improves in a few weeks and decreased activity are observed in cricothyroid muscle. While denervation and reinnervation are seen in axonotmesis, denervation and loss of motor unit as well as inability to reinnervate are observed in neurotmesis (23). For this reason, EMG should be repeated after 6 or 12 months in order to monitor the course of axon damage in the nerve and to follow up the reinnervation in cases with mild nerve damage and denervation. In addition, the lack of evaluation of the vocal cords by laryngoscopic examination in order to reveal whether the cause of vocal complaints is EBSLN injury or any recurrent laryngeal nerve injury is another limitation of the study.

### Conclusion

In this study, it was found that hemostatic vascular closure systems did not increase the risk of EBSLN injury in thyroid surgery compared to the conventional suture ligation technique. The choice of the device to be used should be made by considering factors such as experience and cost.

**Ethics Committee Approval:** For the study, approval was obtained from Istanbul University-Cerrahpaşa Faculty of Medicine Ethics Committee of Medical, Surgical and Pharmaceutical Research (decision no: 35792).

**Informed Consent:** All patients were informed about the procedures and written informed consent was obtained.

**Peer-review:** Internally peer-reviewed.



**Author Contributions:** Concept - V.Ö., R.Ö.; Design - V.Ö., R.Ö., N.A.; Supervision - R.Ö., N.A., A.K.; Resources - V.Ö., N.A., A.K.; Data Collection and/or Processing - V.Ö.; Analysis and/or Interpretation - V.Ö., R.Ö.; Literature Search - V.Ö., R.Ö.; Writing Manuscript - V.Ö., R.Ö., N.A., A.K.; Critical Review - N.A., R.Ö., A.K.

**Conflict of Interest:** The authors have no conflict of interest.

**Financial Disclosure:** The authors did not receive financial support for this study.

## References

1. Becker WF. Presidential address: pioneers in thyroid surgery. *Ann Surg* 1977; 185: 493-504.
2. Erbil Y, Sümer A, Sari S, Ercetin C, Issever H, Ozarmagan S. Novel hemostatic devices in thyroid surgery: are they necessary in every patient performing thyroidectomy? *Surg Technol Int* 2010; 19: 85-90.
3. Saint Marc O, Cogliandolo A, Piquard A, Famà F, Pidoto RR. LigaSure vs clamp-and-tie technique to achieve hemostasis in total thyroidectomy for benign multinodular goiter: a prospective randomized study. *Arch Surg* 2007; 142: 150-6.
4. Yildirim O, Umit T, Ebru M, Bulent U, Belma K, Betül B, et al. Ultrasonic harmonic scalpel in total thyroidectomies. *Adv Ther* 2008; 25: 260-5.
5. Adamczewski Z, Król A, Kałużna-Markowska K, Brzeziński J, Lewiński A, Dedecjus M. Lateral spread of heat during thyroidectomy using different haemostatic devices. *Ann Agric Environ Med* 2015; 22: 491-4.
6. Yao HS, Wang Q, Wang WJ, Ruan CP. Prospective clinical trials of thyroidectomy with LigaSure vs conventional vessel ligation: a systematic review and meta-analysis. *Arch Surg* 2009; 144: 1167-74.
7. Zanghi A, Cavallaro A, Di Vita M, Cardì F, Di Mattia P, Piccolo G, et al. The safety of the Harmonic® FOCUS in open thyroidectomy: a prospective, randomized study comparing the Harmonic® FOCUS and traditional suture ligation (knot and tie) technique. *Int J Surg* 2014; 12 Suppl: S132-5.
8. Kochilas X, Bibas A, Xenellis J, Anagnostopoulou S. Surgical anatomy of the external branch of the superior laryngeal nerve and its clinical significance in head and neck surgery. *Clin Anat* 2008; 21: 99-105.
9. Potenza AS, Araujo Filho VJF, Cernea CR. Injury of the external branch of the superior laryngeal nerve in thyroid surgery. *Gland Surg* 2017; 6: 552-62.
10. Furlan JC, Brandão LG, Ferraz AR, Rodrigues AJ. Surgical anatomy of the extralaryngeal aspect of the superior laryngeal nerve. *Arch Otolaryngol Head Neck Surg* 2003; 129: 79-82.
11. Seven H, Alkan Z, Cakir BO, Sam B, Uslu B, Turgut S. The topographical anatomy of the external branch of the superior laryngeal nerve and its importance in thyroid surgery: A cadaver study. *Kulak Burun Bogaz İhtis Derg* 2003; 11: 161-5.
12. Arslan K, Erenoglu B, Dogru O, Ovet G, Turan E, Atay A, et al. Is the superior laryngeal nerve really safe when using harmonic focus in total thyroidectomy? A prospective randomized study. *Asian J Surg* 2018; 41: 222-8.
13. Moran RE, Castro AF. The superior laryngeal nerve in thyroid surgery. *Ann Surg* 1951; 134: 1018-21.
14. Cernea CR, Ferraz AR, Nishio S, Dutra A Jr, Hojaij FC, Santos LRM. Surgical anatomy of the external branch of the superior laryngeal nerve. *Head and Neck* 1992; 164: 634-9.
15. Selvan B, Babu S, Paul MJ, Abraham D, Samuel P, Nair A. Mapping the compound muscle action potentials of cricothyroid muscle using electromyography in thyroid operations: a novel method to clinically type the external branch of the superior laryngeal nerve. *Ann Surg* 2009; 250: 293-300.
16. Barczyński M, Randolph GW, Cernea C; International Neural Monitoring Study Group in Thyroid and Parathyroid Surgery. International survey on the identification and neural monitoring of the EBSLN during thyroidectomy. *Laryngoscope* 2016; 126: 285-91.
17. Masuoka H, Miyauchi A, Higashiyama T, Yabuta T, Fukushima M, Ito Y, et al. Prospective randomized study on injury of the external branch of the superior laryngeal nerve during thyroidectomy comparing intraoperative nerve monitoring and a conventional technique. *Head Neck* 2015; 37: 1456-60.
18. Uludag M, Aygun N, Kartal K, Citgez B, Besler E, Yetkin G, et al. Contribution of intraoperative neural monitoring to preservation of the external branch of the superior laryngeal nerve: a randomized prospective clinical trial. *Langenbecks Arch Surg* 2017; 402: 965-76.
19. Bellantone R, Boscherini M, Lombardi CP, Bossola M, Rubino F, De Crea C, et al. Is the identification of the external branch of the superior laryngeal nerve mandatory in thyroid operation? Results of a prospective randomized study. *Surgery* 2001; 130: 1055-9.
20. Sulica L. The superior laryngeal nerve: function and dysfunction. *Otolaryngol Clin North Am* 2004; 37: 183-201.
21. Jansson S, Tisell LE, Hagge I, Sanner E, Stenborg R, Svensson P. Partial superior laryngeal nerve (SLN) lesions before and after thyroid surgery. *World J Surg* 1988; 12: 522-7.
22. Dursun G, Demireller A, Koçak I, Selçuki D, Acar A, Demirci S. Laryngeal elektromiyografi. *Baş ve Boyun Damar Cerrahisi Dergisi* 1995; 3: 253-61.
23. Ertekin C. Sentral ve Periferik EMG. *Anatomi-Fizyoloji-Klinik. META Basım, İzmir* 2006; 571-9.

# Effects of Systemic Inflammatory Parameters on Mortality in Elderly Patients Admitted to Emergency Department with Abdominal Pain

## Acil Servise Karın Ağrısı ile Başvuran Yaşlı Hastalarda Sistemik Enflamatuvar Parametrelerin Mortalite Üzerine Etkisi

İD Mehmet Veysel Öncül, İD Seda Dağar, İD Emine Emektar, İD Şeref Kerem Çorbacıoğlu, İD Halit Aytar, İD Yunsur Çevik  
University of Health Sciences, Ankara Keçiören Training and Research Hospital, Clinic of Emergency, Ankara, Turkey

### ABSTRACT

**Introduction:** The aim of this study was to evaluate the prognostic value of systemic inflammatory markers, especially neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in geriatric patients presenting to the emergency department with abdominal pain.

**Methods:** This retrospective study was conducted in the Emergency Department of University of Health Sciences Ankara Keçiören Training and Research Hospital between 01.08.2016 and 31.12.2016. All patients over 65 years who presented with abdominal pain were included in the study. The demographic data, complete blood count parameters, diagnosis, surgical procedures, [American Society of anesthesiologists (ASA)] scores, length of hospital stay and hospital outcomes were evaluated.

**Results:** Six hundred and eighty-eight patients were included in the study. Surgery was performed in 77 patients (12%). The most frequent diagnosis was bowel obstruction (n=57, 8.3%). There were statistically significant differences between non-survivors (n=91) and survivors according to 30-day mortality in terms of age, ASA score, lymphocyte count, NLR and PLR (p<0.001, p=0.03, p<0.001, p<0.001, 40 p>0.001, respectively). There were also statistically significant differences between non-survivors (n=189) and survivors according to 365-day mortality in terms of age, surgery type, lymphocyte count, NLR and PLR (p<0.001, p<0.001, p=0.009, p=0.01, p<0.001, p<0.001 respectively). In the multivariate regression analysis, the clinical feasibility of the laboratory parameters was not significant for both 30 day and 365-day mortality (p>0.05).

**Conclusion:** According to the results of our study, we believe that NLR and PLR values do not have clinical utility as prognostic markers in determining 30-day and 365-day mortality in geriatric patients presenting with abdominal pain.

**Keywords:** Abdominal pain, elderly, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio

### ÖZ

**Amaç:** Bu çalışmada acil servise karın ağrısı ile başvuran geriyatrik hastalarda sistemik enflamatuvar parametrelerin, özellikle nötrofil-lenfosit oranı (NLO) ve platelet-lenfosit oranlarının (PLO) prognostik değerlerinin değerlendirilmesi amaçlanmıştır.

**Yöntemler:** Çalışma retrospektif bir çalışma olup, 01.08.2016-31.12.2016 tarihleri arasında bir eğitim ve araştırma hastanesi acil tıp kliniğinde yapıldı. Karın ağrısı şikayeti ile başvuran 65 yaş ve üzeri tüm hastalar çalışmaya dahil edildi. Hastaların demografik verileri, başvuru anında alınan tam kan sayımı parametreleri beyaz kan hücresi sayımı, tanıları, uygulanan cerrahi yöntemler, American Society of Anaesthesiologists (ASA) skorları, hastanede kalış süreleri ve hastane sonlanımları değerlendirildi.

**Bulgular:** Çalışmaya 688 hasta alındı. Hastaların 77'sine (%12) cerrahi operasyon yapılmıştı. Barsak obstrüksiyonu en sık konulan tanıydı (n=57, %8,3). Yaş, ASA skoru, lenfosit, NLO ve PLO arasında ölen (n=91) ve yaşayan hastalar arasında 30 günlük mortaliteye göre istatistiksel olarak anlamlı fark vardı (sırasıyla p<0,001, p=0,03, p<0,001, p<0,001, p>0,001). Ayrıca yaş, lenfosit, platelet, ASA skoru, NLO ve PLO arasında ölen (n=189) ve yaşayan hastalar arasında 365 günlük mortaliteye göre istatistiksel olarak anlamlı farklılıklar vardı (sırasıyla p<0,001, p<0,001, p=0,009, p=0,01, p<0,001, p<0,001). Çok değişkenli regresyon analizinde ise, incelenen laboratuvar parametrelerinin klinik uygulanabilirliği, hem 30 günlük hem de 365 günlük mortalite için anlamlı bulunmadı (p>0,05).

**Sonuç:** Çalışmamızın sonuçlarına göre, karın ağrısı ile başvuran geriyatrik hastalarda 30 günlük ve 365 günlük mortaliteyi belirlemede, NLO ve PLO değerlerinin prognostik belirteçler olarak klinik faydası olmadığını düşünüyoruz.

**Anahtar Kelimeler:** Abdominal ağrı, yaşlılık, nötrofil-lenfosit oranı, platelet-lenfosit oranı



Address for Correspondence/Yazışma Adresi: Emine Emektar, University of Health Sciences, Ankara Keçiören Training and Research Hospital, Clinic of Emergency, Ankara, Turkey

Phone: +90 312 355 22 19 E-mail: emineakinci@yahoo.com ORCID ID: orcid.org/0000-0002-6056-4401

**Cite this article as/Atıf:** Öncül MV, Dağar S, Emektar E, Çorbacıoğlu ŞK, Aytar H, Çevik Y. Effects of Systemic Inflammatory Parameters on Mortality in Elderly Patients Admitted to Emergency Department with Abdominal Pain. İstanbul Med J 2019; 20(2):125-9.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

Received/Geliş Tarihi: 06.06.2018

Accepted/Kabul Tarihi: 14.11.2018

## Introduction

Abdominal pain is one of the first most common causes emergency department admissions for the elderly. In emergency cases, the frequency of abdominal pain in the elderly population was found to be between 3% and 13% (1). While two-thirds of elderly patients with abdominal pain are admitted to the hospital, one-fifth of the patients in this group are surgically treated (2). Surgical intervention was found to be twice as high in geriatric patients with abdominal pain compared to younger patients. In addition, in geriatric patients with abdominal pain, the mortality rate is 6 to 8 times higher than other age groups (1). Physical examination findings in patients over 65 years of age who presented to the emergency department with abdominal pain differ from the findings of the young patients. Loss of neural functions in the feeling and assessment of pain, additional diseases, regular or multiple drug use, muscle atrophy are among the causes of this condition (3).

White blood cells (WBC) are regarded as a well-defined inflammatory marker and/or stress indicator. Furthermore, the neutrophil-lymphocyte ratio (NLR) calculated by dividing the absolute neutrophil count by absolute lymphocyte count was introduced as a new indicator for inflammatory response. In terms of mortality, a significant relation is observed between NLR and acute coronary syndrome, non-ST myocardial infarction, ischemic or hemorrhagic strokes, pulmonary embolism, various cancer types. On the other hand, it has been suggested that platelet-lymphocyte ratio (PLR) can be used as a potential indicator for the detection of thrombotic activity or inflammation in various oncological and cardiac diseases (4,5).

There are a limited number of publications in the literature showing the relationship between subtypes of WBC count (especially NLR) and mortality under severe clinical conditions and major surgical interventions. All these parameters can be examined by a complete blood count, which is common, easy and cost-effective.

In our study, we aimed to investigate the prognostic value of these parameters in the abdominal pain of the geriatric age group with high early and late mortality rates.

## Methods

The study was conducted retrospectively between 01.08.2016 and 31.12.2016 following the approval from Ethics Committee of University of Health Sciences Ankara Keçiören Training and Research Hospital (dated 27.07.2016 and numbered 1193). The study was conducted in accordance with World Medical Association Declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects", (amended in October 2013). The study was a retrospective study and the consent was not obtained from the patients.

## Patient Selection

The International Classification of Disease-10 codes R10.4 (other and unspecified abdominal pain), K35.9 (acute appendicitis, unspecified), K81.0 (acute cholecystitis), R10.0 (acute abdomen), K56.7 (Ileus, unspecified), K52.8 (other specified non-infective gastroenteritis and colitis) were screened from the hospital automation system (Akgün

Health Information Systems®) and the study population consisted of patients who met the inclusion criteria.

The demographic data, the complete blood count parameters such as hemoglobin, platelet count, WBC, NLR, Red Cell Distribution Width, PLR on admission, diagnosis, surgical methods, American Society of anesthesiologists (ASA) score, length of hospital stay, comorbidities, clinical outcomes (discharge or death) were obtained from automation system and patient files. In addition to these data, information about the survival status of the patients were obtained from Mortality Notification System of the Institute of Public Health, the Ministry of Health and recorded. Patients with trauma, history of hematologic disease, myocardial infarction within 30-days, liver failure, immunosuppressive status, and patients under the age of 65 and patients with missing data were excluded from the study.

## Laboratory Parameters

Complete blood count is carried out with Abbott Cell-Dyn 3700 (Abbott Laboratories, Illinois, US). NLR was calculated as the ratio of neutrophil count to lymphocyte count, whereas, PLR was calculated as the ratio of platelet count to lymphocyte count.

## Statistical Analysis

Data were analyzed using SPSS for Windows 16 package program. Kolmogorov-Smirnov test was performed to examine whether the distribution of discrete or continuous numerical variables complies with normal distribution. Descriptive statistics were shown as median IQR (25-75) for discrete and continuous numeric variables and as number of observations and percentages (%) for quantitative data. Categorical variables were assessed with chi-square test and continuous variables were assessed with Mann-Whitney U test. Multivariate Binary Logistic Regression analysis was used to determine adjusted odds ratio (OR) for 30-day and 1-year mortalities. The OR was presented at the confidence interval of 95% [95% confidence intervals (CI)].  $P < 0.05$  was accepted as statistically significant.

## Results

Eight hundred and seventy-six patients were included in this study. After excluding 188 patients who met the exclusion criteria or with missing data, 688 patients were included in the study. Of the included patients, 381 (55.4%) were female and 307 (44.6%) were male. The median age was 76 (IQR 70-82) years. The demographic data of the patients are given in Table 1.

Statistical analyzes comparing the demographic and clinical characteristics of non-survivors and survivors according to 30-day mortality are shown in Table 2. There was a statistically significant difference in terms of age, ASA score, lymphocyte count, NLR and PLR. Statistical analyzes comparing the demographic and clinical characteristics of non-survivors and survivors according to 365-day mortality are shown in Table 3. There was a statistically significant difference in terms of age, lymphocyte count, platelet count, ASA score, NLR and PLR.

The multivariate logistic regression analysis was performed with various variables to determine 30-day mortality. Age, NLR, PLR and lymphocyte

count were included into the established multivariate model that was found acceptable by Hosmer-Lemeshow test, it was noted that it would not be clinically feasible to determine 30-day mortality in consideration of these parameters. It was also considered that the age variable had

<b>Table 1. Demographic and clinical characteristics of patients</b>	
<b>Gender, n (%)</b>	
Female	381 (55.4)
Age, years (IQR 25-75%)	76 (70-82)
<b>Comorbid diseases, n (%)</b>	
Diabetes mellitus	198 (28.8)
Hypertension	168 (24.4)
Coronary artery disease	204 (29.7)
Congestive heart failure	81 (11.8)
Chronic renal failure	28 (4.1)
Malignancy	35 (5.1)
Surgically treated patients, n (%)	77 (12)
<b>Type of surgery, n (%)</b>	
Midline laparotomy	35 (45)
Appendectomy	13 (17.3)
Hernia repair	6 (8)
Cholecystectomy	10 (12)
Perforation repair	8 (11)
Colectomy	5 (6.7)
<b>ASA score</b>	
ASA-2	53 (7.7)
ASA-3	609 (88.5)
ASA-4	26 (3.8)
ASA-5	0 (0)
<b>Diagnosis n (%)</b>	
Ileus	57 (8.3)
Acute cholecystitis	39 (5.7)
Acute appendicitis	19 (2.8)
Perforation	9 (1.3)
Hernia	4 (0.6)
Acute pancreatitis	45 (6.5)
Mesenteric ischemia	7 (1)
Other	508 (73.8)
<b>Laboratory results (IQR%25-75)</b>	
WBC (/μL)	11100 (8400-14875)
Hemoglobin (g/dL)	13.1 (11.8-14.3)
Platelet count (x10 <sup>3</sup> )	232 (188-295)
Neutrophil (/μL)	8450 (5800-12100)
Lymphocyte (/μL)	1400 (900-2100)
NLR	5.73 (3.22-11.0)
PLR	161.4 (104.95-255.41)
30-day mortality, n (%)	91 (13.7)
365-day mortality, n (%)	189 (27.5)
Length of hospital stay (IQR 25-75%)	6 (4-10)
ASA: American Society of Anesthesiologists, WBC: white blood cells, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio	

no effect when the width of CI was evaluated independently from the significance on the table ( $p < 0.001$ , OR=1.1 95% CI: 1.06-1.14) (Table 4).

The multivariate logistic regression analysis was performed with various variables to determine 365-day mortality. Age, NLR, PLR, lymphocyte count, platelet count and hemoglobin level were included into the established multivariate model that was found acceptable by Hosmer-Lemeshow test, it was deemed clinically inapplicable to determine 365-day mortality in consideration of these parameters. Similar to 30-day mortality, though the age variable was statistically feasible, it did not have any effect when the width of CI was considered independently from the significance on the table ( $p < 0.001$ , OR=1.081 95% CI: 1.053-1.11) (Table 5).

## Discussion

Regarding the values of routine complete blood count parameters (especially NLR and PLR values) in predicting 30-day and 365-day mortality in elderly patients admitted to emergency department with abdominal pain, we underline two significant results considering the results obtained by our study. First of all, in terms of NLR and PLR values standing as the primary research subjects in our study in accordance with 30-day and 365-day mortality estimates, the NLR and PLR values of non-survivors according to 30-day and 365-day mortality were statistically

**Table 2. Clinical characteristics of patients according to 30-day mortality**

	Non-survivor	Survivor	p
Gender, n (%)			
Female	51 (56)	330 (55.3)	0.8
Male	40 (44)	267 (44.7)	
Age, years (IQR 25-75%)	82 (76-85)	75 (69-81)	<0.001
Surgically treated patients, n (%)	13(14.3)	64 (10.7)	0.3
ASA score			
ASA 2	1 (1.1)	52 (8.7)	0.03
ASA 3	86 (94.5)	523 (87.6)	
ASA 4	4 (4.4)	22	
*Laboratory (IQR%25-75)			
WBC (/μL)	11400 (8500-14300)	11100 (8500-14300)	0.3
Hemoglobin (g/dL)	13 (11.7-13.9)	13.2 (11.8-14.3)	0.1
Platelet count (x103)	242 (187-318)	231 (188-292)	0.5
Neutrophil (/μL)	9100 (5800-14200)	8400 (5800-11700)	0.1
Lymphocyte (/μL)	1000 (700-1700)	1500 (1000-2200)	<0.001
NLR	9.2 (4.4-16.1)	5.5 (3.1-10.1)	<0.001
PLR	234.2 (139-349.5)	154.1 (101.7-238)	<0.001

ASA: American Society of Anesthesiologists, WBC: white blood cells, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio \*Mann-Whitney U test



**Table 3. Clinical characteristics of patients according to 365-day mortality**

	Non-survivor	Survivor	p
Gender, n (%)			
Female	97 (25.5)	284 (74.5)	0.1
Male	92 (30)	215 (70)	
Age, years (IQR 25-75%)	80 (74-85)	75 (69-81)	<0.001
Surgically treated patients, n (%)	26(33.8)	51 (66.2)	0.1
ASA score			
ASA 2	6 (11.3)	47 (88.7)	0.01
ASA 3	178 (29.2)	431 (70.8)	
ASA 4	5 (19.2)	21 (80.8)	
*Laboratory (IQR%25-75)			
WBC (/μL)	11200 (8500-15000)	11000 (8400-14300)	0.3
Hemoglobin (g/dL)	12.5 (11.4-13.9)	13.3 (12-14.3)	<0.001
Platelet count (x103)	249 (188-338)	229 (188-282)	0.009
Neutrophil (/μL)	8900 (6200- 13250)	8300 (5600-11700)	0.081
Lymphocyte (/μL)	1100 (725-1675)	1500 (1100-2200)	<0.001
NLR	7.6 (3.7-13.8)	5.4 (3.0-10)	<0.001
PLR	230 (133-330)	148 (101-222)	<0.001
ASA: American Society of Anesthesiologists, WBC: white blood cells, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio *Mann-Whitney U test			
RDW: Red Cell Distribution Width, MPV: Mean Platelet Volume			

**Table 4. Multivariate logistic regression analysis to predict 30-day mortality**

	Wald	p	OR (95% CI)
Age	30.7	<0.001	1.1 (1.06-1.14)
NLR	7.6	0.006	1.004 (1.001-1.074)
PLR	1.1	0.2	1.001 (0.9-1.003)
Lymphocyte	1.9	0.1	1.0 (1.0-1.0)

OR: odds ratio, CI: confidence intervals, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio

**Table 5. Multivariate logistic regression to predict 365-day mortality**

	Wald	p	OR (95% CI)
Age	34.087	<0.001	1.081 (1.053-1.11)
NLR	1.562	0.2	1.018 (0.99-1.04)
PLR	2.506	0.1	1.002 (1.00-1.004)
Lymphocyte	0.88	0.3	1.0 (1.00-1.00)
Hemoglobin	3.457	0.06	0.92 (0.84-1.004)
Platelet count	1.427	0.2	1.00 (1.00-1.00)

OR: odds ratio, CI: confidence intervals, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio

significantly higher compared to survivors ( $p<0.001$ ). Although the OR values for mortality estimation were statistically significant with multivariate logistic regression analysis, we believe that the use of OR in clinical practice is not feasible since the OR values are very close to 1. In addition, the secondary important outcome is that hemoglobin levels were lower in non-survivors according to 365-day mortality compared to survivors, however, platelet counts were higher. However,

both statistically and clinically significant results were not achieved in multivariate logistic regression analyzes in terms of determining clinical utility in a similar way. In conclusion, we found that these parameters were not useful in predicting mortality in abdominal pain in the elderly patients.

Physiological changes occur in many systems in the elderly. In addition to these, additional age-related diseases, changes due to previous operations, multidrug use, weakening of the immune system lead to the detection of diseases at a more advanced stage, thus causing an increase in mortality rate (6,7). Abdominal pain in the geriatric age group is one of the most complicated and time-consuming causes of emergency department admissions. Due to obscure findings of physical examinations and low sensitivity of laboratory results in geriatric patients, new indicators are still needed for the diagnosis of acute abdomen in elderly. In the literature, NLR and PLR values, which are regarded as the indicators of diagnosis and predictors of mortality, were higher in certain diseases in all age groups in comparison to the control group (8). Furthermore, this rate was found to be higher in geriatric patient groups (9). Yavuz et al. (10) suggested that preoperative NLR value is a significant data that is easily performed and used for the diagnosis of appendicitis. However, there are numerous studies expressing that these parameters are insufficient as mortality predictor. In the study of Emektar et al. (11) regarding the importance of NLR and PLR values to predict mortality in patients over 65 years of age with femoral fractures, they found that NLR and PLR values were higher in survivors compared to non-survivors. However, the authors noted that the relevant values were not reliable for clinical use when both sensitivity and specificity were considered. In the study conducted by Vaughan-Shaw et al. (12), the relationship between mortality rates and NLR values of patients who underwent abdominal surgery were

examined, and 30-day and 365-day mortality rates were calculated as 31% and 50%, respectively. In our study, 30-day and 365-day mortality rates were 13.7% and 27.5%, respectively. Contrary to Vaughan-Shaw et al. (12), our study population included both patients with and without surgery, therefore this could be one of the reasons of lower mortality rates in our study.

Although our results are not consistent with the current literature, NLR and PLR values were insufficient to predict mortality in patients over 65 years of age with abdominal pain. Therefore, the clinical use of NLR and PLR are poor indicators as a prognostic marker. However, we would encounter these ratios as subtitle in the scoring systems to be developed in accordance with future researches.

### Study Limitations

The retrospective and single-centered structure of this study is the main limitation. The postoperative hematological parameters of the patients were not analyzed. The inflammatory process is a complex process, therefore, other inflammatory parameters were excluded from the scope of this study.

### Conclusion

It is important to identify new risk factors in predicting mortality in geriatric patients with abdominal pain. NLR and PLR are cost-effective, universally accessible and routine parameters that can be easily and rapidly measured without additional cost. According to our study results, we believe that NLR and PLR values are not clinically applicable as a prognostic value in predicting 30-day and 365-day mortality rates in the elderly patients with abdominal pain.

**Ethics Committee Approval:** The study was conducted retrospectively between 01.08.2016 and 31.12.2016 following the approval from Ethics Committee of University of Health Sciences Ankara Keçiören Training and Research Hospital (dated 27.07.2016 and decision no: 1193).

**Informed Consent:** The study was a retrospective study and the consent was not obtained from the patients.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - M.V.Ö.; Design - M.V.Ö., S.D., E.E.; Supervision - E.E., Ş.K.Ç., Y.Ç.; Resources - M.V.Ö., S.D., H.A.; Materials - M.V.Ö., S.D., H.A.; Data Collection and/or Processing - M.V.Ö., H.A.; Analysis and/or Interpretation - E.E., Ş.K.Ç., Y.Ç.; Literature Search

- M.V.Ö., S.D., H.A.; Writing Manuscript - M.V.Ö., E.E.; Critical Review - Ş.K.Ç., Y.Ç.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support

### References

1. Birnbaumer DM. The Elder Patient. In: Marx J, Hockberger R, Walls R, (eds). Rosen's Emergency Medicine: Concepts and clinical practice. Philadelphia: Mosby Elsevier; 2010: 2348-52.
2. Lewis LM, Banet GA, Blanda M, Hustey FM, Meldon SW, Gerson LW. Etiology and clinical course of abdominal pain in senior patients: A prospective, multicenter study. *J Gerontol A Biol Sci Med Sci* 2005; 60: 1071-6.
3. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. *J Surg Oncol* 2005; 91: 181-4.
4. Huang J, Chen Y, Cai Z, Chen P. Diagnostic value of platelet indexes for pulmonary embolism. *Am J Emerg Med* 2015; 33: 760-63.
5. Kundi H, Balun A, Cicekcioglu H, Cetin M, Kiziltunc E, Cetin Z, et al. The relation between platelet-to-lymphocyte ratio and Pulmonary Embolism, Severity Index in acute pulmonary embolism. *Heart & Lung: The Journal of Acute and Critical Care* 2015; 44: 340-43.
6. Lyon C, Clark D. Diagnostic of acute abdominal pain in older patients. *Am Fam Physician* 2006; 74: 1537-44.
7. Bugliosi TF, Meloy TD, Vukov LF. Acute abdominal pain in the elderly. *Ann Emerg Med* 1990; 19: 1383-6.
8. Sun X, Luo L, Zhao X, Ye P, Du R. The neutrophil-to-lymphocyte ratio on admission is a good predictor for all-cause mortality in hypertensive patients over 80 years of age. *BMC Cardiovasc Disord* 2017; 17: 167.
9. Yan W, Li JZ, He KL. The relationship between neutrophil-to-lymphocyte ratio and major cardiovascular events in elderly patients with chronic heart failure. *J Geriatr Cardiol* 2017; 14: 780.
10. Yavuz E, Ercetin C, Uysal E, Solak S, Biricik A, Yigitbas H. Diagnostic value of neutrophil/lymphocyte ratio in geriatric cases with appendicitis. *Turk Geriatri Derg* 2014; 17 345-9.
11. Emektar E, Corbacioglu, SK, Dagar S, Uzunozmanoglu H, Safak T, Cevik Y. Prognostic value of the neutrophil-lymphocyte and platelet-hip fracture, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, one-year mortality lymphocyte ratios in predicting one-year mortality in patients with hip fractures and aged over 60 years. *Eurasian J Med* 2017; 16: 165-70.
12. Vaughan-Shaw PG, Rees JR, King AT. Neutrophil lymphocyte ratio in outcome prediction after emergency abdominal surgery in the elderly. *Int J Surg* 2012; 10: 157-62.

# Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-diabetics (Sulfonylurea and Metformin) or Insulin: Bone Tissue Perspective

Oral Anti-diyabetik (Sülfonilüre, Metformin) ya da İnsülin ile Tedavi Edilen Tip 2 Diabetes Mellituslu Hastalarda Reseptör Aktivatör Nükleer Kappa-B Ligandı, Osteoprotegerin Düzeylerinin Kemik Dokusu Yönünden İncelenmesi

Alper Gümüş<sup>1</sup>, Muhammed Emin Düz<sup>1</sup>, Cihan Coşkun<sup>1</sup>, Mustafa Velet<sup>2</sup>, Macit Koldaş<sup>1</sup>

<sup>1</sup>İstanbul Haseki Training and Research Hospital, Clinic of Medical Biochemistry Laboratory, İstanbul, Turkey

<sup>2</sup>İstanbul Haseki Training and Research Hospital, Clinic of Internal Medicine, İstanbul, Turkey

## ABSTRACT

**Introduction:** We aimed to investigate the levels of receptor activator of nuclear factor kappa-b ligand (RANKL) and osteoprotegerin (OPG) in order to evaluate the negative effects of type 2 diabetes mellitus on bone health and their relationship to the severity of disease based on the treatment. We also evaluated the relationship between hemoglobin A1c (HbA1c), parathyroid hormone (PTH) and bone specific alkaline phosphatase (BAP) levels and RANKL and OPG levels.

**Methods:** The study group consisted of 19 volunteers (15 females and 4 males) and 65 patients with type 2 diabetes mellitus (49 females and 16 males). In order to evaluate the relationship between the treatment and the disease severity, the patient group was divided into two subgroups: patients treated with oral anti-diabetics (OAD) (sulfonylurea and metformin) or insulin. The levels of glucose, calcium, phosphorus, HbA1c, BAP, PTH, RANKL and OPG were compared.

**Results:** The RANKL and OPG levels of patients treated with insulin were significantly higher than the control group (p=0.008, p=0.033, respectively). However, there was no significant difference in the OAD group for both parameters (p=0.1, p=0.46, respectively). There was no significant difference between the groups in terms of PTH and BAP levels (p=0.97, p=0.66, respectively).

**Conclusion:** We believe that RANKL and OPG levels are higher in patients with poor glycemic control and that they may be indicators of disease severity.

**Keywords:** Insulin, metformin, osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, sulfonylurea, type 2 diabetes mellitus

## ÖZ

**Amaç:** Tip 2 diabetes mellitusun kemik sağlığı üzerindeki olumsuz etkilerini, tedaviye bağlı olarak hastalığın ağırlığı ile olan ilişkisini değerlendirmek için reseptör aktivatör nükleer kappa-B ligandı (RANKL) ile birlikte osteoprotegerin (OPG) düzeylerini araştırdık. Ayrıca hemoglobin A1c (HbA1c), paratiroid hormon (PTH), kemik spesifik alkalen fosfataz (BAP) düzeylerinin hem RANKL hem de OPG düzeyleri ile ilişkisini değerlendirmektir.

**Yöntemler:** Çalışma grubunu 19 gönüllüden (15 kadın, 4 erkek), hasta grubunu ise 65 tip 2 diabetes mellituslu (49 kadın, 16 erkek) hasta oluşturdu. Uygulanan tedavi ile hastalık ağırlığı arasındaki ilişkiyi değerlendirebilmek için hasta grubu oral anti diyabetik alan (sülfonilüre, metformin) ya da insülin kullananlar olmak üzere iki alt gruba ayrılarak glikoz, kalsiyum, fosfor, HbA1c, BAP, PTH, RANKL, OPG düzeyleri karşılaştırıldı.

**Bulgular:** Kan glikozun insülinle düzenlenen tip 2 diabetes mellituslu hastaların hem RANKL hem de OPG düzeyleri kontrol grubuna göre anlamlı derecede yüksekti (sırasıyla; p=0,008, p=0,033). Ancak OAD grubu her iki parametre için de farklı değildi (sırasıyla; p=0,1, p=0,46). Gruplar arasında PTH ve BAP değerleri açısından anlamlı fark yoktu (sırasıyla; p=0,97, p=0,66).

**Sonuç:** RANKL ile OPG düzeylerinin, glisemik kontrol bozukluğu olan hastalarda daha yüksek olduğunu, hastalık şiddetinin birer göstergesi olabileceğini düşünüyoruz.

**Anahtar Kelimeler:** İnsülin, metformin, osteorrotegerin, reseptör kapa-B faktörü reseptör etkinleştirici bağlayıcı, sülfonilüre, tip 2 diabetes mellitus



**Address for Correspondence/Yazışma Adresi:** Alper Gümüş, İstanbul Haseki Training and Research Hospital, Clinic of Medical Biochemistry Laboratory, İstanbul, Turkey  
Phone: +90 533 437 76 69 E-mail: dralpergumus@gmail.com ORCID ID: orcid.org/0000-0002-4453-6339

**Cite this article as/Atıf:** Gümüş A, Düz ME, Coşkun C, Velet M, Koldaş M. Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-diabetics (Sulfonylurea and Metformin) or Insulin: Bone Tissue Perspective. İstanbul Med J 2019; 20(2): 130-5.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

**Received/Geliş Tarihi:** 23.07.2018

**Accepted/Kabul Tarihi:** 07.11.2018

## Introduction

The World Health Organization reported that the number of patients with diabetes mellitus (DM) reached 422 million in 2014 (1). The prevalence of DM is reported to be between 4.75% and 11.3% in Turkey (2). The vast majority of DM patients (90-95%) suffer from type 2 DM (DM2) (3). DM2 is a disease characterized by hyperinsulinemia and hyperglycemia due to insulin resistance. Hyperglycemia has an important role in the pathogenesis of diabetic complications, because it increases protein glycation and allows gradual accumulation of advanced glycation end products (AGEs) in body tissues. Recent studies suggest that the interaction of AGEs with receptor for AGEs alter intracellular signaling, gene expression, and release pro-inflammatory molecules and free radicals that contribute to the pathology of DM complications (4). These factors lead to a condition characterized by low-level chronic inflammation. By observing immune responses, changes can be observed in many parameters that affect the skeletal system, such as osteocalcin, vitamin-D, adiponectin, leptin, receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) (5). More commonly recognized DM complications, such as macrovascular disease, retinopathy, nephropathy and neuropathy, DM-related bone disease, have gained growing attention (6). DM2-related bone disease is a latent, progressive pathological process and is difficult to diagnose using routine clinical, radiological and biochemical methods. Although DM2 patients have normal or increased bone density, their bone turnover is reduced and bone quality is altered. Consequently, DM2 patients experience increased bone fragility and fracture risk (7,8). The relationship between DM and bone disease has been known for more than 50 years, and both diseases share similar socio-economic characteristics (9). To clarify this relationship, many different parameters have been evaluated. RANKL and OPG are parameters that are currently being studied to reveal the mechanisms of this relationship.

Bone tissue is constantly renewed due to mechanical stress and hormonal changes. This regeneration depends on the balance between osteoclastic bone resorption and osteoblastic bone formation. RANKL is expressed by osteoblasts and other bone marrow stromal cells, whereas RANK is expressed by other members of pre-osteoclast and osteoclast cells (10). RANKL-RANK interactions activate transcription factors that regulate osteoclastogenesis, resulting in osteoclast assembly and differentiation. OPG, synthesized by osteoblasts, inhibits this interaction by acting as a trap receptor for RANKL and prevents proliferation, differentiation and bone resorption activity of osteoclasts (11,12). OPG is a glycoprotein synthesized by the *TNFRSF11B* gene located on chromosome 8 and is a cytokine receptor from the tumor necrosis factor receptor superfamily (13). Recent studies suggest that RANKL and OPG have a central role in DM-related bone pathologies (14-17).

Parathyroid hormone (PTH) is a calciotropic hormone that promotes bone resorption and inhibits calcium extraction to maintain adequate levels of plasma calcium. PTH exerts its effects on bone density thorough osteoclasts. Interestingly, PTH receptors are located on osteoblasts. Communication between osteoblasts and osteoclasts is thought to be mediated by RANKL (18). Therefore, if the relationships between RANKL, RANK, OPG and DM-related bone diseases are to be examined, then PTH is an important parameter to be considered. Bone specific alkaline

phosphatase (BAP) (EC 3.1.3.1) is considered to be a highly specific marker of bone-forming activity of osteoblasts (19). Previous studies have suggested that serum BAP is useful in predicting bone mineral density (20,21). Therefore, PTH and BAP are useful tools to evaluate the bone turnover process.

Several factors such as hemoglobin A1c (HbA1c), duration of disease, presence of certain complications and treatment method used, have been used to determine the severity of DM. Some of these variables can be used together to calculate the disease severity index (22). We determined the severity of the disease based on whether patients use insulin treatment because it is a simpler and easier method to determine poor glycemic control. We divided the patient group into two subgroups, as patients receiving oral anti-diabetic (OAD) treatment and patients receiving insulin treatment. If glycemic control could not be achieved with OAD treatments, it was replaced with insulin treatments. Therefore, insulin therapy is an indicator of poor glycemic control and can be used as a marker for assessing the severity of the disease.

In this study, we aimed to investigate the levels of RANKL and OPG in patients and healthy subjects to evaluate the negative effects of DM on bone health, as well as their relationship with the severity of disease, which is determined by the treatment method. In addition, we assessed the relationship between HbA1c, PTH, and BAP levels and RANKL and OPG levels.

## Methods

### Patient Characteristics

This study was conducted at the Medical Biochemistry Laboratory and Internal Medicine Clinic of İstanbul Haseki Training and Research Hospital in İstanbul. Sixty-five (49 female, 16 male) DM2 patients volunteered for this study and the control group (15 female, 4 male) was selected from healthy volunteers. Consent was obtained from all participants. All the patients were surveyed regarding age, gender, time of diagnosis, smoking history and the presence of other systemic diseases. Patients who suffered from cardiac problems, advanced nephropathy, neurologic symptoms, smoking history and other osteoporotic problems, were excluded from the study. The patients were grouped based on the clinical evaluations by internal medicine specialists. The patient group was divided into two subgroups: patients receiving OAD treatment (OAD group) (n=25) and patients receiving insulin treatment (insulin group) (n=40).

Patients in the OAD group were treated with metformin (biguanide group OAD) or gliclazide (sulfonyleurea group OAD) or a combination of two drugs. The insulin group used only insulin preparations and did not receive any additional OAD as part of the treatment protocol. The treatment protocols were unchanged for the participants in the patient groups in the last six months. After the patients fasted for 12-16 hours, venous blood samples were collected in gel-separated tubes without anticoagulants to determine levels of RANKL, OPG and other routine parameters. Serum samples were stored at -20 °C for approximately 10-90 days after incubating for 30 minutes, and centrifugation at 1500 × g for 10 minutes. Additionally, whole blood samples were collected in EDTA tubes for HbA1c analysis.



## Analytical Methods

A solid-phase sandwich immunoassay ELISA kit with a reported linearity range of 31-4000 pg/mL, within-run CV of 2.7% and within-day CV of 4.5% (Assaybiotech Omnikine S-RANKL ok-0161, Assaybiotech, California, USA) was used to analyze RANKL levels. Also, another solid-phase sandwich immunoassay ELISA kit with a reported linearity range of 93.7-6000 pg/mL, within-run CV of 2.2% and within-day CV of 4.3% (Immunoleader Boster Technology OPG ek0480, Boster, California, USA) was used to analyze OPG levels.

RANKL and OPG units: RANKL and OPG are not routinely measured, and therefore, there is currently no consensus on units of measurement. Currently, studies report their levels in ng/mL for convenience. Therefore, we reported our results using ng/mL.

HbA1c levels were measured using an HPLC technique via Arkray Adams A1c analyzer (Arkray, Kyoto, Japan). Glucose, calcium, and phosphorus levels were measured via AU2700 (Beckman Coulter, California, USA) biochemistry auto-analyzer. PTH and BAP levels were measured via DXI-800 auto-analyzer (Beckman Coulter, California, USA).

## Statistical Analysis

The results were analyzed using the SPSS version 17 (Statistical Package for Social Sciences) software package (IBM, New York, USA). Mean, standard deviation (SD), minimum and maximum values were calculated. Quantitative data were conformed to normal distribution characteristics and groups were treated independently. ANOVA was applied to determine the differences in the measured parameters between the groups with 95% confidence interval. The probability value (p) was set at <0.05. The post-hoc Tukey HSD test was applied for pairwise group comparisons. The power was calculated using the PASS 12 package program (NCSS, Utah, USA).

## Ethical Approval

The authors declare that all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of İstanbul Haseki Training and Research Hospital (decision no: 24.09.2014/181).

## Results

### Descriptive Analysis

Age, gender, duration of disease and duration of insulin use for each group are shown in Table 1. In all groups, gender and age had no significant effect on the parameters measured ( $p=0.256$ ,  $p=0.313$ , respectively). The duration of diabetes was significantly different between OAD and insulin groups ( $p<0.05$ ).

The power of this study was calculated as 0.9017 using the ANOVA test procedure for all pairs with the current design containing three groups (one control group and two patient groups). The type 1 error ( $\alpha$  value or p-value) was set to 0.05. The power of present study was calculated from the results after the study was completed.

Descriptive statistics of the measured parameters are shown in Table 2.

The bar graphs illustrate the distribution of RANKL and OPG levels between the groups (Figures 1, 2).

The power of this study with the current design, which contains three groups (one control group and two patient groups) was calculated to be 0.88 using ANOVA for all pairs. The type 1 error ( $\alpha$  value or p value) was set at 0.05. The power of the present study was computed from the results after the study was completed.

### Group Comparisons

The three groups (control, OAD and insulin) were compared using ANOVA and differences in RANKL and OPG levels were observed between the groups ( $p=0.004$ ,  $p=0.031$ , respectively). In order to understand the causes of these differences, we performed a post-hoc Tukey test and observed significant differences between the control group and the insulin group both in RANKL and OPG levels ( $p=0.008$ ,  $p=0.033$ , respectively). However, OAD group did not differ significantly for both parameters ( $p=0.1$ , and  $p=0.46$ , respectively). As expected, HbA1c levels were significantly different between all groups ( $p<0.001$ ). There was no significant difference between the groups in terms of PTH and BAP levels ( $p=0.97$ ,  $p=0.66$ , respectively).

### Correlation of the Evaluated Parameters

A weak but significantly positive correlation was detected between RANKL and OPG levels by Pearson correlation analysis ( $r=0.264$ ,  $p<0.05$ ). Moreover, OPG levels had weak but significantly positive relationships

**Table 1. The mean age, duration of diabetes mellitus and insulin use for each group**

	Control group (n=19)		OAD group (n=25)		Insulin group (n=40)		p
Age, years	52±6.75		54.6±6.38		54.7±5.81		0.256
Duration of diabetes mellitus, years	-		7.4±5.08		11.2±5.7		-
Duration of insulin use, years	-		-		5.1±3.9		-
Gender	n	%	n	%	n	%	0.313
Female	15	78	19	76	30	75	-
Male	4	22	6	24	10	25	-


OAD: oral anti-diabetics

with HbA1c levels and DM2 duration ( $r=0.230$ ,  $p<0.05$  and  $r=0.242$ ,  $p<0.05$ ).

## Discussion


DM2 is a multi-systemic disease that affects bone tissue by impairing the quality of bone structure and thus increasing bone fragility. The bone is traditionally considered a rigid organ that protects visceral organs and supports the body. However, we now know that bone is a complex and highly active, metabolic and endocrine organ. Energy hemostasis affects bone metabolism and osteocalcin has been reported to mediate this interaction (23). Insulin induces the production of under-carboxylated osteocalcin through post-translational modification in osteoblasts. Increased under-carboxylated osteocalcin stimulates pancreatic insulin

synthesis and secretion, while increasing adiponectin production in fat tissues, thereby altering energy expenditure by increasing tissue sensitivity to insulin production (24). Adiponectin is a major cytokine secreted from adipocytes during glucose metabolism (25). Adiponectin, which is known to increase insulin sensitivity, has been reported to decrease in patients with DM. Previous studies have shown that adiponectin negatively affects bone formation (26). Increased RANKL and OPG levels have been reported in DM2 (14-17,27). Adiponectin is reported to be the main regulator of OPG levels. There is a negative correlation between adiponectin and OPG levels. In previous studies on OPG and RANKL, experiments have been frequently performed in patients with advanced-stage DM with microvascular pathology or in patients with cardiovascular system problems (28,29).



**Figure 1.** The average Receptor Activator of Nuclear Factor Kappa-B Ligand concentration in each group. The error bars represent the standard errors of the respective groups (control group: 0.19, OAD group: 0.23, insulin group: 0.16).

OAD: oral anti-diabetics, RANKL: receptor activator of nuclear factor kappa-b ligand



**Figure 2.** The average Osteoprotegerin concentration in each group. The error bars represent the standard errors of the respective groups (control group: 0.049, OAD group: 0.065, insulin group: 0.040).

OAD: oral anti-diabetics, OPG: osteoprotegerin

**Table 2.** The mean, standard deviation, minimum and maximum levels of glucose, hemoglobin A1c, calcium, phosphorus, parathyroid hormone, bone specific alkaline phosphatase, receptor activator of nuclear factor kappa-B ligand and osteoprotegerin and the number of subjects (n) in each group. P values obtained from group comparison statistics for each parameter are given in the table

		Glucose (mg/dL)	HbA1c (%)	Ca (mg/dL)	P (mg/dL)	PTH (pg/mL)	BAP (µg/L)	RANKL (ng/mL)	OPG (ng/mL)
Control group (n=19)	Mean	95	5.3	10	3.9	31.1	12.5	2.97	0.43
	Min	76	4.7	9	2.5	6.3	6.3	1.67	0.09
	Max	125	5.7	11.4	5.1	59.2	30.6	5	0.79
	SD	11.4	0.26	0.54	0.63	13.1	5.9	0.83	0.21
OAD group (n=25)	Mean	135	7.2	10.1	4.4	29.7	13.5	3.64	0.54
	Min	82	5.9	9.4	3.5	15	5.6	2.06	0.01
	Max	251	10.2	11.3	5.7	53	30.6	6.78	1.31
	SD	43.5	1.05	0.46	0.54	11.1	5.17	1.18	0.32
Insulin group (n=40)	Mean	181	8.9	10.2	4.1	31.8	12.7	3.87	0.64
	Min	95	6.5	9.5	3.2	10.6	6	2.06	0.18
	Max	360	13	11.4	5	80.7	27.8	7.42	1.4
	SD	67.5	1.64	0.46	0.43	15.6	4.44	1.06	0.29
p		<0.001	<0.001	0.091	0.07	0.975	0.66	0.031	0.004

Min: minimum, Max: maximum, SD: standard deviation, HbA1c: hemoglobin A1c, OAD: oral anti-diabetics, Ca: calcium, P: phosphorus, PTH: parathyroid hormone, BAP: bone specific alkaline phosphatase, RANKL: receptor activator of nuclear factor kappa-b ligand, OPG: osteoprotegerin

The unique aspect of our study was the investigation of RANKL and OPG levels in patients with DM2 using either OAD or insulin and in healthy volunteers (control group). In addition, we aimed to investigate the effects of disease severity on these parameters.

The RANKL and OPG levels in patients with DM2 using insulin were significantly higher than the control group. Previous studies have reported a higher risk of fracture in DM2 patients treated with insulin (30,31). Yaturu et al. (32) reported increased OPG levels in DM2 patients. The same study indicated a significant relationship between OPG levels and insulin resistance indicators, such as fasting glucose. In our study, the RANKL and OPG levels of patients with DM2 who regulated blood glucose with insulin were significantly higher than the control group and the relationship between OPG levels and HbA1c levels as well as DM2 duration was another finding suggesting that OPG levels were affected by disease severity. Gaudio et al. (33) reported that plasma OPG levels in DM2 patients were significantly higher in the patient groups than in the control group, but the RANKL levels were significantly lower. Additionally, we found that both OPG and RANKL levels were significantly higher in DM2 patients in our study. However, Gaudio et al. (33) performed their study in postmenopausal women and did not conduct treatment-related evaluation of the data between the groups. In support of this information, Jung et al. (34) reported that RANKL levels may be related to the gender of patients.

One of the limitations of our study was the dominance of female gender in all three groups. In such a case, the effect of menopause must be taken into consideration. However, the groups did not differ in terms of age.

Insulin is a metabolic hormone with strong effects on glucose and lipid metabolism. Insulin for DM2 treatment, in addition to its glycemic effects, also acts as an anabolic agent in bone and induces anti-inflammatory effects (35). It has been reported that C-reactive protein levels are lowered in DM2 patients who are being treated with insulin, although the glucose levels remain unchanged (36). On the other hand, previous observations indicate that fracture risk is higher in DM2 patients treated with insulin (31,37). The anti-inflammatory properties of insulin are insufficient to limit the chronic, low-grade inflammation, which is the underlying pathology of DM2. However, insulin treatments are derived from synthetic preparations, and although they treat hyperglycemia, they may not adequately prevent the negative effects due to low levels of chronic inflammation caused by DM2. On the other hand, the adverse effects of DM2 on bone health may cumulatively increase over time. The duration of DM2 was longer in insulin group than in OAD group. Therefore, the adverse effects that are not observed in the early stages may become more pronounced in the advanced stages. Significant differences between the control group and the insulin group may be indicative of this phenomenon.

There were no significant differences between the control group and the OAD group in terms of OPG and RANKL levels. OADs are agents that induce endogenous insulin production. Sulfonylureas are the most common prescribed drug for DM2 treatment. There are studies reporting that sulfonylureas reduce fracture risk in DM2

patients (37,38). Except for enhancing pancreatic insulin secretion, sulfonylureas have no known, direct effect on bone tissue. However, the effects of metformin are not limited to insulin release alone. Metformin improves glucose metabolism via activation of adenosine monophosphate (AMP)-activated protein kinases (AMPK), which is also expressed in bone tissue (39). AMPK is a potential stimulator of bone marrow progenitor cells. Stimulation of AMPK results in the activation of osteoblasts in cell culture experiments (40). Shao et al. (41) reported that high serum glucose levels could suppress osteoblast proliferation, but the use of metformin ameliorated this suppression. In addition, metformin is also effective in correcting the pathology underlying diabetes. Zhen et al. (42) reported that treatment with metformin significantly decreases reactive oxygen species production. Experimental studies have implicated that metformin limits osteoclast activity through RANKL (43). Zinman et al. (44) concluded that a combination of metformin and sulfonylurea reduces levels of carboxy-terminal collagen crosslinks that serve as a marker for bone resorption in DM2 patients. Therefore, the OADs evaluated in our study may act as bone preservatives (45). It has been reported that the risk of osteoporotic bone fracture is higher in patients with DM2 who received insulin monotherapy than those receiving combined therapy (46). In our study, the absence of significant differences in RANKL and OPG levels between the OAD group and the control group may be related to the protective effects of OADs.

## Conclusion

We did not observe significant differences between the groups in terms of Ca, P, PTH and BAP levels. In their meta-analysis, Starup-Linde et al. (47) reported that PTH and BAP levels did not significantly differ between diabetic and control groups. Our findings were consistent with their data. We have demonstrated that there are no differences between OAD and insulin groups.

Although impairment of bone quality could not be conclusively demonstrated with routine assay parameters in terms of Ca, P, PTH and BAP levels, and was not related to disease severity in this study, OPG presented correlation with HbA1c and DM duration. So, OPG may confer benefits in determining and monitoring the DM2-dependent bone quality deterioration, and risk stratification of fractures in diabetics. Additional larger (blood pressure and anthropometric measurements, questioning life-style conditions, other routine laboratory parameters) and long-term (monitoring the individuals) studies are needed to accumulate sufficient data on this subject.

**Ethics Committee Approval:** This study was approved by the Ethics Committee of Istanbul Haseki Training and Research Hospital (decision number: 24.09.2014/181).

**Informed Consent:** Consent was obtained from all participants.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - A.G., M.E.D., C.C., M.V., M.K.; Design - A.G., M.E.D., C.C., M.V., M.K.; Supervision - A.G., M.E.D., C.C., M.V., M.K.; Resources - A.G., M.E.D., C.C., M.V., M.K.; Data Collection and/or Processing - A.G., M.E.D., C.C., M.V., M.K.; Analysis and/or Interpretation - A.G., M.E.D., C.C., M.V., M.K.; Literature Search - A.G., M.E.D., C.C., M.V.,

M.K.; Writing Manuscript - A.G., M.E.D., C.C., M.V., M.K.; Critical Review - A.G., M.E.D., C.C., M.V., M.K.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

- Global report on diabetes. World Health Organization, Geneva, 2016 [http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf). Received 12.03.2016.
- Onat A, Karakoyun S, Akbaş T, Karadeniz FÖ, Karadeniz Y, Çakır H, et al. Turkish adult risk factor survey 2014: Overall mortality and coronary disease incidence in Turkey's geographic regions. *Turk Kardiyol Dern Ars* 2015; 43: 326-32.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2009; 32(Suppl 1): 62-7.
- Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. *Diabetes Res Clin Pract* 2005; 67: 3-21.
- Ginaldi L, Martinis DM. Osteoimmunology and beyond. *Curr Med Chem* 2016; 23: 3754-74.
- Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. *Phys Ther* 2008; 88: 1322-35.
- Motyła KJ, Laura R, McCabe AB, Schwartz AV. Bone and glucose metabolism: A two-way street. *Arch Biochem Biophys* 2010; 503: 2-10.
- Schwetz V, Pieber T, Obermayer-Pietsch B. The endocrine role of the skeleton: Background and clinical evidence. *Eur J Endocrinol* 2012; 166: 959-67.
- Hough, SF. Diabetic osteopenia. *Diabetes Res Clin Pract* 1989; 7: 161-2.
- Qiu S, Rao DS, Palnitkar S, Parfitt AM. Differences in osteocyte and lacunar density between black and white American women. *Bone* 2006; 38: 130-5.
- Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998; 93: 165-76.
- Bell NH. RANK ligand and the regulation of skeletal remodeling. *J Clin Invest* 2003; 111: 1120-2.
- Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. *Cell* 1997; 89: 309-19.
- Tirosh A. High RANKs for diabetes and osteoporosis. *science translational medicine*. 2013; 177: 177-49.
- Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. *Genes and Development* 1998; 12: 1260-8.
- Galluzzi F, Stagi S, Salti R, Toni S, Piscitelli E, Simonini G, et al. Osteoprotegerin serum levels in children with type 1 diabetes: A potential modulating role in bone status. *Eur J Endocrinol* 2005; 153: 879-85.
- García-Hernández A, Arzate H, Gil-Chavarría I, Rojo R, Moreno-Fierros L. High glucose concentrations alter the biomineralization process in human osteoblastic cells. *Bone* 2012; 50: 276-88.
- Huang JC, Sakata T, Pfeleger LL, Bencsik M, Halloran BP, Bikle DD, et al. PTH Differentially regulates expression of RANKL and OPG. *J Bone Miner Res* 2003; 19: 235-44.
- Masrouf, R J, Mahjoub, S. Quantification and comparison of bone-specific alkaline phosphatase with two methods in normal and paget's specimens. *Caspian J Intern Med* 2012; 3: 478-83.
- Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, et al. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. *Life Sci* 2005; 77: 1130-9.
- Lumachi F, Camozzi V, Tombolan V, Luisetto G. Bone mineral density, osteocalcin, and bone-specific alkaline phosphatase in patients with insulin-dependent diabetes mellitus. *Ann N Y Acad Sci* 2009; 1173: Suppl 1: E64-7.
- Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. *Am J Manag Care* 2008; 14: 15-23.
- Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. *Cell* 2007; 130: 456-69.
- Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. *Proc Natl Acad Sci U S A* 2008; 105: 5266-70.
- Yamamoto S, Matsushita Y, Nakagawa T, Hayashi T, Noda M, Mizoue T. Circulating adiponectin levels and risk of type 2 diabetes in the Japanese. *Nutr Diabetes* 2014; 4: e130.
- Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. *Eur J Endocrinol* 2008; 160: 265-73.
- Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, Lubberink M, et al. Association of plasma osteoprotegerin and adiponectin with arterial function cardiac function and metabolism in asymptomatic type 2 diabetic men. *Cardiovasc Diabetol* 2011; 10: 67.
- Gordin D, Soro-Paavonen A, Thomas MC, Harjutsalo V, Saraheimo M. Osteoprotegerin Is an independent predictor of vascular events in finnish adults with type 1 diabetes. *Diabetes Care* 2013; 36: 1827-33.
- Bjerre M. Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. *Springer Plus* 2013; 2: 658.
- Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: The Nurses' Health Study. *Diabetes Care* 2006; 29: 1573-8.
- Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Andrew R, Hoffman AR, et al. Fracture risk in diabetic elderly men: the MrOS study. *Diabetologia* 2014; 57: 2057-65.
- Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. *Cytokine* 2008; 44: 168-71.
- Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE. Relationships between osteoprotegerin, receptor activator of the nuclear factor kappa ligand and serum levels and carotid intima-media thickness in patients with type 2 diabetes mellitus. *Panminerva Med* 2014; 56: 221-5.
- Jung K, Lein M, Hösslin Kv, Grosse A, Roth S, Possinger K, Lüftner D. Osteoprotegerin and receptor activator of nuclearfactor-kappa Bligand (RANKL) in the serum of healthy adults. *Int J Biol Markers* 2002; 17: 177-81.
- Thrallkill KM, Lumpkin CK, Jr Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. *Am J Physiol Endocrinol Metab* 2005; 289: E735-45.
- Kothari VI, Galdo JA, Mathews ST. Hypoglycemic agents and potential anti-inflammatory activity. *J Inflamm Res* 2016; 9: 27-38.
- Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, Chiasserini V, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. *Diabetes Care* 2008; 31: 199-203.
- Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. *Diabetologia* 2005; 48: 1292-9.



39. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. *Diabetes* 2002; 51 :2074-81.
40. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. *BMC Cell Biol* 2007; 8: 51.
41. Shao X, Cao X, Song G, Zhao Y, Shi B. Metformin Rescues the MG63 Osteoblasts against the Effect of High Glucose on Proliferation. *J Diabetes Res* 2014; 453940.
42. Zhen D, Chen Y, Tang X. Metformin reverses the deleterious effects of high glucose on osteoblast function. *J Diabetes Complications* 2010; 24: 334-44.
43. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. *J Cell Biochem* 2011; 112: 2902-9.
44. Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2010; 95: 134-42.
45. Gilbert MP, Pratley RE. The impact of diabetes treatments on bone health in patients with type 2 diabetes mellitus. *Endocr Rev* 2015; 36: 194-213.
46. Losada E, Soldevila B, Ali MS, Martínez-Laguna D, Nogués X, Puig-Domingo M. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study. *Osteoporos Int* 2018; 29: 2079-86.
47. Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients-a meta-analysis, and a methodological study on the effects of glucose on bone markers. *J Osteoporos Int* 2014; 25: 1697-708.

# Obesity Status of University Employees and Associated Factors: Turkey-2015

## Bir Üniversite Çalışanlarının Obezite Durumu ve İlişkili Etmenler: Türkiye-2015

✉ Gülcan Demir Özdenk<sup>1</sup>, ✉ Lütfiye Hilal Özcebe<sup>2</sup>

<sup>1</sup>Sinop University Vocational School of Health Services, Department of Medical Services and Techniques, Sinop, Turkey

<sup>2</sup>Hacettepe University Faculty of Medicine, Department of Public Health, Ankara, Turkey

### ABSTRACT

**Introduction:** Obesity is a growing public health concern with increasing prevalence in the world. It is aimed to investigate the relationship between socio-demographic features, dietary habits, physical activity level and body mass index (BMI) of the officers and contracted staff between the ages of 18-64 working in administrative units of a university and some factors affecting these relationships.

**Methods:** The population of this cross-sectional study consists of officers and contracted staff working at a university campus. The data were evaluated by using SPSS 20.0 program. Descriptive statistics, chi-square test and three different binary logistic regressions were conducted in the study.

**Results:** The mean age of the employees was 36.4±8.23 years and 67.4% of the participants were male. Half of the participants had bad dietary habits, 15.8% of the participants were physically "active" and 68.2% were overweight and obese. Being male and the importance given to health (good and above) were found to be protective factors against the bad dietary habits. Low educational level (1.88) and being married (2.32) were the risk factors for bad dietary habits. Males (2.78), married participants (1.94), participants with good and above importance given to health (1.62) and participants working as a contracted staff (2.68) were found to be physically more active. Being male (2.16), having children (2.32) and being physically active (1.78) were found to be risk factors for overweight and obesity.

**Conclusion:** It was found that there were differences in nutrition, physical activity and obesity among university staff with different social structures. Awareness of BMI values, healthy nutrition and physical activity levels should be increased in the intervention programs aimed at changing the lifestyle of individuals working in different statuses in the society.

**Keywords:** Adult, body mass index, dietary habits, obesity, physical activity

### ÖZ

**Amaç:** Dünyada giderek artış gösteren obezite büyüyen bir halk sağlığı endişesidir. Bir üniversitede, 18-64 yaş arasında idari teşkilatta görev yapan memurların ve sözleşmeli olarak çalışan personelin sosyo-demografik özellikleri, beslenme alışkanlıkları, fiziksel aktivite düzeyi ve vücut kitle indeksi (VKİ) ile aralarındaki ilişkiyi etkileyen bazı faktörlerin incelenmesi amaçlanmıştır.

**Yöntemler:** Kesitsel araştırmanın evrenini, bir üniversiteye bağlı yerleşkelerde memur ve sözleşmeli personel olarak çalışan katılımcılar oluşturmaktadır. Verilerin değerlendirilmesi SPSS 20.0 programı kullanılarak yapılmıştır. Çalışmada tanımlayıcı istatistikler, ki-kare testi ve üç farklı ikili lojistik yapılmıştır.

**Bulgular:** Çalışanların yaş ortalaması 36,4±8,23 yıl olup %67,4'ü erkektir. Katılımcıların yarısı kötü beslenme alışkanlıklarına sahiptir ve katılımcıların %15,8'i fiziksel olarak "aktif" ve %68,2'si kilolu ve şişman olarak bulunmuştur. Erkek olmak ve sağlığa verilen önem (iyi ve üzeri) kötü beslenme alışkanlıklarına karşı koruyucu faktör olarak bulunmuştur. Düşük eğitim düzeyi (1,88) ve evli olma (2,32) durumu kötü beslenme alışkanlıkları için risk faktörleridir. Erkekler (2,78), evliler (1,94), sağlığa verilen önem (iyi ve üzeri-1,62) ve sözleşmeli işçi (2,68) olarak çalışanlar fiziksel olarak daha aktif olduğu bulunmuştur. Erkek cinsiyet (2,16), çocuk sahibi olma (2,32) ve fiziksel aktif olma (1,78) durumu aşırı kiloluluk ve obezite için risk faktörleri olarak bulunmuştur.

**Sonuç:** Aynı üniversitede çalışan farklı sosyal yapıya sahip olan kesimler arasında beslenme, fiziksel aktivite ve şişmanlık düzeylerinin farklılıkları olduğu bulunmuştur. Toplum içindeki farklı statülerde çalışan bireylerin yaşam tarzının değiştirilmesine yönelik müdahale programlarında, VKİ değerleri konusunda bilinçlendirilmesi, sağlıklı beslenme ve fiziksel aktivite düzeylerinin artırılması gerekmektedir.

**Anahtar Kelimeler:** Yetişkin, beden kitle indeksi, beslenme alışkanlıkları, şişmanlık, fiziksel aktivite



**Address for Correspondence/Yazışma Adresi:** Gülcan Demir Özdenk, Sinop University Vocational School of Health Services, Department of Medical Services and Techniques, Sinop, Turkey  
Phone: +90 530 696 99 01 E-mail: gdozdenk@ahievran.edu.tr ORCID ID: orcid.org/0000-0003-4639-399X

**Cite this article as/Atf:** Demir Özdenk G, Özcebe LH. Obesity Status of University Employees and Associated Factors: Turkey-2015. İstanbul Med J 2019; 20(2): 137-43.

**Received/Geliş Tarihi:** 07.06.2018

**Accepted/Kabul Tarihi:** 07.11.2018

## Introduction

In recent years, being overweight and obesity have been emphasized as global public health problems with dramatic increase, Unhealthy nutrition and physical inactivity are among the leading causes of obesity. One of the main causes of obesity is the energy imbalance between calorie intake from foods and calories consumed. Globally, the food choice of people is becoming more unhealthy and there is an increase in physical inactivity due to increased consumption of high-fat foods, widespread consumption of fast-food products, rapid urbanization, changes in transport and working styles depending on the developments in technological areas, increase in the sedentary lifestyle arisen from the increase in the level of welfare, and lack of supportive environments. These changes provide a basis for various health problems, especially obesity (1).

According to the World Health Organization (WHO), obesity is a health problem defined as “abnormal or excessive fat accumulation that may impair health” (1). Overweight and obesity are among the important risk factors for most of the Non-Communicable Diseases (NCD) such as diabetes, cardiovascular diseases and cancer (2). According to the report of Turkey Nutrition and Health Survey (TNHS) in 2010, it was stated that prevalence of mild obesity among adults in Turkey was 34.6% and prevalence rate of obesity was 30.3% (3).

WHO states that physical inactivity is the fourth most important cause for mortality at the global level and that it has caused the death of approximately 3.2 million people worldwide. According to WHO, one out of every four adults are not active enough and this situation is similar in Turkey (4). In the TNHS report, it was stated that the percentage of people who did not exercise was 71.9%. There are approximately seven out of every ten men and eight out of every ten women who do not exercise throughout the country (3). Several studies have found a positive correlation between regular physical activity and prevention, treatment and management of NCD. In addition, the role of regular physical activity in improving health and preventing diseases has been inclusively described (5,6). Regular physical activity facilitates body weight management by providing energy expenditure (2). It is possible to reduce the incidence of NCD by modifying and managing behavioral risk factors that cause obesity and physical inactivity (7,8). In physically active adults, the risk of premature death can be reduced by 20-30%, and the risk of NCD development can be reduced by up to 50% (9,10).

In Turkey, as in the world, an unhealthy diet and physical inactivity are among the preventable, serious risk factors for obesity and associated NCDs (1). Based on the fact that working style is an important factor in the development of obesity, it is necessary to determine the dietary habits, physical activity levels and body mass index (BMI) values of the employees working at desk jobs and contracted staff, and to provide evidences based on the situation determination researches for these interventions. Conducting studies on obesity status of people from different segments of society and examining these studies especially in terms of the relationship between dietary habits and physical activity level are important for the evaluation of the obesity prevention and control program.

## Methods

The necessary institutional permission was obtained from the Ahi Evran University Ethics Committee rectorate and ethical approval (number: 78968926-051/1076-5326) was received from the university ethics committee within the scope of ethical conduct in human research number 20696. Employees have been informed about the content and purpose of the research and it was stated that participation in the survey was based on voluntariness, and verbal consent of the employees were taken.

This cross-sectional study was conducted with a total of 554 employees working at the administrative units of a university as officer and contracted staff. The working statuses used in the study were defined as “officer is a person who performs fundamental and continuous public services by the state” and contracted staff was defined as “a person working in temporary jobs in the required areas in case of a vacant position” (11).

The data of the study were collected by visiting 9 different campuses in November-December 2015. The sample was not selected. The university employee or contracted personnel between 18-64 years of age who were at least primary school graduates were tried to be reached and the rate of participation was 85.9%. Some of the employees did not participate in the study due to reasons such as being on leave, attending meetings, being on maternity leave and working hard due to supervision. The data obtained from the participants were collected by observation-based survey technique.

The dependent variables of the study were the dietary habits questionnaire scoring form, the International Physical Activity Questionnaire-Short Form (IPAQ-Short Form) and WHO adult BMI classification. The independent variables of the study were age, gender, educational status, employment type, marital status, parental status, family type, dietitian application status and level of importance given to health. Physical activity level and dietary habits were also evaluated as independent variables.

**Dietary Habits Questionnaire:** A questionnaire on dietary habits scoring developed by Arslan et al. (12) was used in the evaluation of dietary habits. When the person gets a healthy, adequate and balanced nutrition, she/he gets full score from the questionnaire. The total number of questions in the questionnaire is nine and the maximum score is 62. Dietary habits were evaluated as poor (<35 points), moderate (35-48 points) and good (>48 points) in accordance with the scores obtained from the questionnaire (12).

**IPAQ-Short Form:** The validity and reliability of the IPAQ Short Form has been validated in Turkish. The questionnaire used in this study includes questions about the types (walking, moderate-intensity and vigorous-intensity physical activities and sitting duration), duration and frequency of physical activity performed at least 10 minutes in the “last seven days”. In order to determine the level of physical activity, the total score is calculated by converting the data of walking, moderate-intensity and vigorous-intensity physical activities into metabolic equivalent of task (MET) values. According to the total score obtained, the physical activity levels of the participants were determined and classified as MET-min/week. Physical activity levels were evaluated in three categories:

inactive (<600 MET-min/week), minimally active (600-3000 MET-min/week) and active (>3000 MET-min/week (13).

**Anthropometric Measurements:** Body weights and statuses of the employees participated in the study were measured by visiting the relevant department in the first hours of morning shift. The anthropometric measurements were made in the Frankfurt plane through the SECA 813 electronic scale (Seca, Hamburg, Germany) and the SECA 213 stadiometer (Seca, Hamburg, Germany), with their underwear, by taking off their clothes and shoes. All measurements were made by the same researcher in an appropriate room, preferably with an empty stomach. The BMIs of the employees were calculated from the equation [body weight/stature (m<sup>2</sup>)] (14). BMI results were evaluated according to the WHO classification of adult BMI. Participants were classified as underweight (<18.5), normal (18.5-24.9), overweight (25.0-29.9) and obese (≥30.0) according to the values obtained from the BMI equation (15).

### Statistical Analysis

Statistical analyzes were assessed by using the SPSS 20 (SPSS 20.0 for Windows, Chicago, Ill. USA) package program. Descriptive statistics (percent distribution, mean and standard deviation, median, distribution interval) were used in the summary of the data and chi-square test was used for comparing the groups. For multivariate analysis, the possible factors identified with univariate analyses were further entered into

the logistic regression (Forward Stepwise-Likelihood Ratio) analysis to determine independent predictors of dependent variables. Hosmer-Lemeshow goodness of fit statistics were used to assess model fit. Odds ratio (Odds Ratio) and 95% confidence interval (CI) were calculated. A 5% type 1 error level was used to infer statistical significance.

In the further analysis, dependent variables were categorized and analyzed as [poor (reference), moderate and good] for dietary habits, [inactive (reference), minimal active and active] for physical activity level and BMI [normal and below (reference), overweight and above] for BMI values.

### Results

The mean age of the 471 university employees participated in the study was 36.4±8.23 years, median age was 35, and the youngest and oldest participants were 20 and 62 years old (not given in the Table).

Sixty-seven point four percent of the employees were male, 59.2% were graduated from “associate degree and above” and 63.2% were employed as officers. Seventy-seven point seven percent of the employees stated that they were married, 70.8% stated that they had children and 55.6% stated that they gave importance to their health at the level of “good and above” (Table 1).

Forty-eight point five percent of the employees had moderate and good dietary habits. Males had better dietary habits than females ( $p=0.017$ ) (Table 2).

The physical activity level of 58.9% of the employees was found to be “minimally active and above”. Physical activity level of males (65.1%) was higher than the females (45.8%) ( $p<0.001$ ). The percentage of physical activity of employees graduated from “high school and below” was higher than the employees graduated from “associate degree and above” ( $p=0.017$ ). The physical activity level of 55.9% of married employees and 68.9% of single employees was “minimally active and above” ( $p=0.017$ ). Seventy-two percent of contracted staff and 51.2% of officers were physically “active” ( $p<0.001$ ). Sixty-three point eight percent of the employees who declared the level of importance given to health as “good and above” and 52.9% of the employees who declared the level as “poor and below” were found to be physically active ( $p=0.017$ ) (Table 2).

Sixty-eight point two percent of the employees were overweight and obese, and males (74.2%) were more overweight and obese than the females (55.8%) ( $p<0.001$ ). The ratio of “overweight and obese” was higher in the age group “40 years and older” than other age groups ( $p<0.001$ ). Seventy-three point five percent of married individuals and 49.0% of single individuals were “overweight and obese” ( $p<0.001$ ). The percentage of being “overweight” and “obese” was higher in the employees who had children ( $p<0.001$ ) (Table 2).

Odds Ratio and 95% CI were calculated through logistic regression analysis by correcting the factors such as gender, marital status and level of importance given to health through dietary habits. The constant coefficient of the model for the dietary habits was found to be -0.523. Males have 1.68 (1.13-2.50) times better dietary habits than females ( $p=0.010$ ). Single individuals have 1.61 (1.03-2.51) times better dietary habits than the married individuals ( $p=0.033$ ) (Table 3).

**Table 1. Distribution of sociodemographic characteristics of employees**

	Total	
	Number	Percentage
<b>Gender (n=476)</b>		
Male	321	67.4
Female	155	32.6
<b>Education Status (n=476)</b>		
Primary school and below	67	14.1
High school	127	26.7
Associate degree and above	282	59.2
<b>Type of employment (n=476)</b>		
Officer	301	63.2
Contracted staff	175	36.8
<b>Marital status (n=476)</b>		
Married	370	77.7
Single	106	22.3
<b>Parental status * (n=475)</b>		
Yes	337	70.8
No	139	29.2
<b>Level of importance given to health* (n=468)</b>		
Very poor	11	2.3
Poor	25	5.3
Average	172	36.8
Good	216	46.2
Excellent	44	9.4

\*Eight people did not specify the level of importance given to health



Table 2. Distribution of body mass index values, physical activity levels and dietary habits according to sociodemographic characteristics of employees

	Dietary Habits				Physical Activity Levels				Body Mass Index Values			
	Poor	Moderate and Good	Total	p	Inactive	Minimally active and active	Total	p	Underweight and normal	Overweight and Obese	Total	p
Gender	n	%	n	%	n	%	n	%	n	%	n	%
Male	153	47.7	168	52.3	321		321		78	25.8	224	74.2
Female	92	59.4	63	40.6	155	0.017	155		65	44.2	82	55.8
Age groups <sup>‡</sup>												<0.001
20-29 years	49	48.0	53	52.0	102		102		45	48.9	47	51.1
30-39 years	120	52.2	110	47.8	230		230		74	34.3	142	65.7
40-49 years	50	54.3	42	45.7	92	0.649	92	0.643	18	19.8	73	80.2
≥50 years	21	44.7	26	55.3	47		47		4	8.9	41	91.1
Education status												<0.001
Primary school and below	30	44.8	37	55.2	67		67		13	19.7	53	80.3
High school	64	50.4	63	49.6	127	0.417	127	0.017	39	32.2	82	67.8
Associate degree and above	151	53.5	131	46.5	282		282		91	34.7	171	65.3
Marital status												<0.001
Married	199	53.8	171	46.2	370	0.059	370	0.017	93	26.5	258	73.5
Single	46	43.4	60	56.6	106		106		50	51.0	48	49.0
Parental status												<0.001
Yes	174	51.6	163	48.4	337	0.913	337	0.138	80	24.9	241	75.1
No	71	51.1	68	48.9	139		139		63	49.2	65	50.8
Family types												<0.001
Core family	200	51.7	187	48.3	387		387		113	31.2	249	68.8
Extended family	29	50.0	29	50.0	58	0.972	58	0.141	16	28.1	41	71.9
I live alone	16	51.6	15	48.4	31		31		14	46.7	16	53.3
Type of employment												0.695
Officer	154	51.2	147	48.8	301	0.860	301	<0.001	92	32.5	191	67.5
Contracted staff	91	52.0	84	48.0	175		175		51	30.7	115	69.3
Importance given to health <sup>†</sup>												0.838
Poor and below	117	56.2	91	43.8	208	0.066	208	0.017	64	32.5	133	67.5
Good and above	124	47.7	136	52.3	260		260		78	31.6	169	68.4
Total	245	51.5	231	48.5	476		476		143	31.8	306	68.2 <sup>‡</sup>

<sup>†</sup> Five people did not specify the age and eight people did not respond to the question of giving importance to their health.

<sup>‡</sup> Figures in table may not add up to totals due to rounding

**Table 3. Relationship between variables with dietary habits, physical activity level and body mass index values**

		Dietary Habits <sup>1</sup>		Physical Activity <sup>2</sup>		Body Mass Index <sup>3</sup>	
		OR (%95 CI)	p	OR (%95 CI)	p		
Age						1.636(1.214-2.205)	0.001
Gender	Female	Reference	0.010	Reference	<0.001	Reference	0.002
	Male	1.688 (1.136-2.508)		2.728(1.779-4.184)		2.045(1.307-3.202)	
Marital Status	Married	Reference	0.033	Reference	0.005		
	Single	1.618 (1.039-2.519)		2.021(1.231-3.318)			
Parental status	Yes	-	-	-	-	2.048(1.235-3.398)	0.006
	No	-		-		Reference	
Importance given to health	Poor and below	-	-	Reference	0.020	-	-
	Good and above	-		1.596 (1.077-2.364)		-	-
Type of employment	Officer	-	-	Reference	<0.001	-	-
	Contracted staff	-		2.984(1.937-4.599)		-	-
Level of physical activity	Inactive	-	-	-	-	Reference	0.015
	Minimally active and active	-	-	-	-	1.724(1.113-2.670)	

<sup>1</sup>Model 1: Correct classification rate (CCR)=54.7% / Hosmer-Lemeshow p=0.908, <sup>2</sup>Model 2: CCR=64.3% / Hosmer-Lemeshow p=0.940, <sup>3</sup>Model 3: CCR=71.8% / Hosmer-Lemeshow p=0.66

Odds Ratio and 95% CI were calculated through logistic regression analysis by correcting the factors such as gender, education status, marital status, parental status and family types through physical activity levels. The constant coefficient of the model for the level of physical activity was found to be -1.081. Males were 2.72 (1.77-4.18) times, single individuals were 2.02 (1.23-3.31) times, those who gave importance to their health at the level “good and above” were 1.59 (1.07-2.36) times and contracted staff was 2.98 (1.93-4.59) times more physically active than the others ( $p<0.001$ ,  $p=0.005$ ,  $p=0.020$ ,  $p<0.001$ ) (Table 3).

Odds Ratio and 95% CI were calculated through logistic regression analysis by correcting the factors such as age, gender, education status, family types, marital status, parental status and level of physical activity through BMI. The constant coefficient of the model for BMI was found to be -1.536. The advancing age increased the risk of being overweight and obese by 1.63 (1.21-2.20) times ( $p=0.001$ ). When the effect of gender on body mass index was examined, significant results were obtained. The risk of being “overweight and obese” was 2.04 (1.30-3.20) times higher in males and 2.04 (1.23-3.39) times higher in those who had children ( $p=0.002$ ,  $p=0.006$ ). Individuals with “minimally active and active” physical activity level were 1.72 (1.11-2.67) times more likely to be “overweight and obese” than those who are inactive ( $p=0.015$ ) (Table 3).

## Discussion

Unhealthy dietary habits and inadequate physical activity cause obesity problems. In this study, it was aimed to determine dietary habits, physical activity levels and obesity status of employees working in a university and some socio-demographic characteristics affecting them. Nutrition is one of the major determinants of health and many important NCDs can be prevented or delayed. Almost half of the employees (48.5%) had better dietary habits, which means about 5 out of 10 people ate

healthy. This shows that approximately half of the surveyed group was fed healthy.

In this study, it was found that men’s dietary habits were 1.68 times better. Unlike these findings, different studies have shown that women’s dietary habits are better than men (16,17). The reason why our results are different is that male participants are outnumbered in administrative staff and that the working status has revealed more regular nutritional behaviors.

Single individuals have 1.61 times better dietary habits. In this study, it can be said that men have regular nutritional habits because they mostly work in office services and professional occupational groups. In this study, employees working at different campuses of the university were contacted. Healthy nutrition environment may not be provided in every campus. The characteristics of the nutritional environment are likely to affect the sociodemographic characteristics of the people (18). For this reason, it is also an important and controversial issue that it is necessary to investigate the obstacles for adequate and balanced nutrition of people, as well as their knowledge, and to provide solutions for these, and to establish nutrition friendly circles.

In the TNHS-2010 report, the percentage of individuals aged 12 years and over who exercise 1-2 times a week in the last 7 days is reported to be 9.7% in total (3). In this study, physical activity level of 9.3% of the employees working at desk jobs was found to be “active”. In studies conducted with people working at desk jobs in Turkey, the percentage of physically “active” participants is 5.8%-25.9% (19-21). In this study, it was seen that the officers working at desk jobs were living more sedentarily than the other groups.

In the study, men were physically 2.72 times more active than women. A systematic review of the different studies conducted in our country

(14,22-24) and in other countries suggests that men have higher level of physical activity than women. When we compared our study with the other studies in which the level of physical activity of men was higher than that of women, the study was consistent with the literature.

Single employees were 2.02 times more physically active. Trost et al. (23) have stated in the systematic study that there are studies that show a positive relationship between marital status and physical activity and that there are also conflicting studies (23). Similar results have been found in the study of the Bulut (22) and Deniz (25). In our study, the reason why physical activity levels of single individuals were higher was that married individuals spend their free time with their families and they are older.

Individuals who give importance to their health at the level of “good” and “above” were 1.59 times more physically active than those with “poor and below” level. Trost et al. (23) reported that there was a positive correlation between perceived health status and physical activity, and that it was repeated in all study findings. Likewise, in the study of Yetim (24), it was stated that the average IPAQ scores was highest among those evaluating general health status as very good. Unlike the findings of this study, Bulut (22) stated that there was no significant difference in the physical activity levels of those who assessed their health status through their statements as “very good/good” “not bad” or “bad/very bad” (22). In order to obtain a better health level, individuals need to have a healthy life style. It is expected that those who give importance to their health should avoid the risky behaviors and apply healthy living principles that will protect and improve their health. It is essential to quit using tobacco and tobacco products, to avoid excessive alcohol consumption, to get healthy nutrition and to do regular physical activities for living a healthy life.

Contracted staff was 2.98 times more physically active than officers. Similarly, in the study of Bulut (22), it was stated that the level of physical activity of private company personnel was higher than the administrative personnel and it was found to be statistically significant (22). Contracted personnel, who has high levels of activity, are working in jobs that require to exert more power and energy and that sometimes require working overtime (security, cafeterias, cleaning etc.).

In parallel with the increase in BMI values in the world, it is observed that the percentage of obesity is also increasing. In TNHS-2010 report, it was stated that the prevalence of mild obesity was 34.6% and the prevalence of obesity was 30.3% in Turkey (3). In TURDEP-II study, the prevalence overweight and obesity in Turkey was reported to be 37.0% and 36.0%, respectively (26). In this study, the percentage of overweight was 47.4% and percentage of obesity was 20.7%. Various studies conducted in Turkey have shown different results in terms of the prevalence of overweight (25.0%-47.4%) and obesity (19.4%-32.0%) (27-29). The results of this study have similar values. The results suggest that obesity is a primary health problem in this group.

The increase in age also increases the risk of being overweight and obese by 1.63 times. According to the Turkey Nutrition and Health Survey (TNHS) 2010 report, which supports the finding of this study, it is stated that BMI increases with age and the percentage of being overweight and obese in the 51-64 age group is higher than other age groups (3).

In TNHS-2010 report, the prevalence of obesity (BMI  $\geq 30$  kg/m<sup>2</sup>) in male individuals was 20.5%, while it was 41.0% in female individuals and prevalence of overweight was higher in male individuals (M: 39.1%, F: 29.7%) (3). According to the findings of TURDEP II study, BMI values were higher in women compared to the mean of both genders (26). When the effect of gender on BMI was examined, significant results were obtained, and it was found that the risk of being overweight and obese for men was 2.04 times higher than women. According to our research, the prevalence of obesity in women was clearly lower than that of men, which might be because the age groups of the employees participating in the study are lower than the compared studies.

The risk of being “overweight and obese” in individuals with children was 2.04 higher than the others. According to the BMI evaluation in the study by Çayır et al. (30), the percentage of obesity also increases as the number of children increases. In the study of Erem et al. (28), it was stated that there was a linear relationship between the number of parity and the prevalence of obesity and BMI in women and that the prevalence of obesity and BMI level increases as the number of parity increases. The results are consistent with the results obtained in this study. In other words, the main demographic factors remain at the forefront in obesity. As the number of children increases with age, the age factor should not be ignored in these differentiations.

Population-based cross-sectional studies conducted to determine the relationship between physical activity and weight gain show an inverse relationship between physical activity level and weight gain, body fat increase, overweight or obesity prevalence (31). In our study, it was determined that the risk of being overweight and obese increased in individuals who are minimally active and active (1.72 times). In some studies, an inverse relationship between physical activity and BMI was reported (28). With these findings, which are inconsistent with the literature, it can be considered that individuals are trying to be physically active because of obesity.

Since participants are a group of people working as administrative and contracted staff at a university, they represent only a specific sub-group of the society, not the entire society. It should also be assessed in the interpretation of the findings that the dietary habits and physical activity level of the participants were determined by their own statements. The most important limitation of this study was that environmental conditions were not evaluated in terms of healthy nutrition and physical activity.

## Conclusion

All these results suggest that interventions are needed to increase physical activity to prevent obesity. Interventions are needed to enable people to perform physical activities appropriate to their working and living conditions.

In conclusion, prominence of gender, which is a sociodemographic characteristic, in the formation of nutritional habits, physical activity and obesity is noteworthy. Marital status, the level of giving importance to health and employment type are important in eating habits and physical activity behaviors. The increase in age, having a child and the level of physical activity are important variables in obesity. All these

results suggest that interventions are needed to increase physical activity to prevent obesity. Interventions are needed to enable people to perform physical activities appropriate to their working and living conditions. In this respect, age and gender-specific nutrition, obesity and physical activity policies that address all employees and programs on promoting and improving health are required to be developed. It is also thought that it is necessary to learn the social and cultural lifestyle as well as the environmental conditions that may affect healthy nutrition and physical activity.

**Ethics Committee Approval:** The necessary institutional permission was obtained from the Ahi Evran University rectorate and ethical approval (number: 78968926-051/1076-5326).

**Informed Consent:** Verbal consent of the employees were taken.

**Peer-review:** Externally and internally peer-reviewed.

**Author Contributions:** Concept - G.D.Ö., L.H.Ö.; Design - G.D.Ö., L.H.Ö.; Supervision - G.D.Ö.; Resources - G.D.Ö.; Data Collection and/or Processing - G.D.Ö., L.H.Ö.; Analysis and/or Interpretation - G.D.Ö., L.H.Ö.; Literature Search - G.D.Ö.; Writing Manuscript - G.D.Ö., L.H.Ö.; Critical Review - G.D.Ö., L.H.Ö.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

- WHO. Obesity and overweight (serial online). 2018 Mar (cited 2018 March 4). Available from: URL: <http://www.who.int/mediacentre/factsheets/fs311/en/>
- Bowman SA. Dietary and lifestyle practices of normal weight and overweight US adults. *Body Mass Index: New Research* 2005; 118-33.
- Bakanlık TS. Türkiye beslenme ve sağlık araştırması 2010: Beslenme durumu ve alışkanlıklarının değerlendirilmesi sonuç raporu. Ankara, Sağlık Bakanlığı Sağlık Araştırmaları Genel Müdürlüğü. 2014.
- WHO. Physical activity (serial online). 2017 Apr (cited 2017 April 27). Available from: URL: <http://www.who.int/mediacentre/factsheets/fs385/en/>
- Baptista F, Kathleen FJ. Physical activity in growth and development. In: Ainsworth BE, Macera CA, editors. *Physical activity and public health practice*. Boca Raton: CRC Press; 2012.p.114-18.
- Bell JA, Hamer M, van Hees VT, Singh-Manoux A, Kivimäki M, Sabia S. Healthy obesity and objective physical activity. *Am J Clin Nutr* 2015; 102: 268-75.
- Bueno-de-Mesquita HB. Noncommunicable diseases of major public health interest and prevention. *Asia Pac J Public Health* 2015; 27: 110-5.
- Riley L, Guthold R, Cowan M, Savin S, Bhatti L, Armstrong T, et al. The World Health Organization STEP wise approach to noncommunicable disease risk-factor surveillance: methods, challenges, and opportunities. *Am J Public Health* 2016; 106: 74-8.
- Murphy R, Dugdill L, Crone D. *Physical activity and health promotion: evidence-based approaches to practice*. United States: John Wiley & Sons; 2009.
- Loitz CC, Potter RJ, Walker JL, McLeod NC, Johnston NJ. The effectiveness of workplace interventions to increase physical activity and decrease sedentary behaviour in adults: protocol for a systematic review. *Syst Rev* 2015; 4: 178.
- Kanunu SHT, Tazminat SP. Devlet memurları kanunu ve tababet ve şuaatı sanatlarının tarzi icrasına dair kanun ile sağlık bakanlığının teşkilat ve görevleri hakkında kanun hükmünde kararnamede değişiklik yapılmasına dair kanun: Kanun; 2016.
- Arslan P, Karaağaoğlu N, Duyar İ, Güleç E. Yükseköğrenim gençlerinin beslenme alışkanlıklarının puanlandırma yöntemi ile değerlendirilmesi. *Besl Diyet Derg* 1994; 22: 195-208.
- Bozkuş T, Türkmen M, Kul M, Özkan A, Öz Ü, Cengiz C. Beden eğitimi ve spor yüksekokulu'nda öğrenim gören öğrencilerin fiziksel aktivite düzeyleri ile sağlıklı yaşam biçimi davranışlarının belirlenmesi ve ilişkilendirilmesi. *Int JSCS* 2014; 1: 49-65.
- Savcı S, Öztürk M, Arkan H, İnal İnce D, Tokgözoğlu L. Physical activity levels of university students. *Türk Kardiyo Derg* 2006; 34: 166-72.
- Bakanlık TCS. Obezite. Halk Sağlığı Genel Müdürlüğü (serial online). 2017 May (cited 2017 May 27). Available from: URL: <http://beslenmehareket.saglik.gov.tr/>
- Erçim RE, Pekcan G. Genç yetişkinlerin beslenme durumunun sağlıklı yeme indeksi-2005 ile değerlendirilmesi. *Besl Diyet Derg* 2015; 42: 91-8.
- Yurtseven E, Eren F, Vehid S, Koksall S, Ergin Oz E, Erdogan M. Beyaz yakalı çalışanların beslenme alışkanlıklarının değerlendirilmesi. *Kocatepe Tıp Derg* 2014; 15: 20-6.
- Demir Özdenk G. Bir üniversitenin çalışanlarının beslenme okuryazarlığı ve ilişkili etmenlerin incelenmesi (dissertation). Ankara: Hacettepe Univ. 2016.
- Erdoğan M, Certel Z, Güvenç A. Masa başı çalışanlarda fiziksel aktivite düzeyi: Obezite ve diğer özelliklere göre incelenmesi (Akdeniz Üniversitesi Tıp Fakültesi Hastanesi Örneği). *Spor Hekim Derg* 2011; 46: 97-107.
- Uyanık GE. Ofis çalışanlarında fiziksel aktivite düzeyinin yaşam kalitesine etkisi (dissertation). İstanbul: Beykent Univ. 2016.
- Vural Ö, Eler S, Atalay Güzel N. Masa başı çalışanlarda fiziksel aktivite düzeyi ve yaşam kalitesi ilişkisi. *Spormetre beden eğitimi ve spor bilimleri dergisi* 2010; 8: 69-75.
- Bulut S. Bir fizik tedavi ve rehabilitasyon eğitim ve araştırma hastanesinde görev yapan personelin fiziksel aktivite düzeyi ve ilgili faktörlerin belirlenmesi (dissertation). Ankara: Hacettepe Univ. 2010.
- Trost SG, Owen N, Bauman AE, Sallis JF, Brown W. Correlates of adults' participation in physical activity: review and update. *Med Sci Sports Exerc* 2002; 34: 1996-2001.
- Yetim M. Sağlık çalışanlarının genel sağlık durumu, fiziksel aktivite düzeyleri ve etkileyen faktörler (dissertation). İstanbul: Marmara Univ. 2017.
- Deniz M. Yetişkinlerde fiziksel aktivite düzeyi ile sosyo-ekonomik durum arasındaki ilişkinin araştırılması (dissertation). Bursa: Uludağ Univ. 2011.
- Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dincag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. *Eur J Epidemiol* 2013; 28: 169-80.
- Akova İ. Yirmi yaş üstü erişkinlerde uyku süresi, kalitesi, fiziksel aktivite düzeyi ve bazı antropometrik ölçümler arasındaki ilişkiler (dissertation). Sivas: Cumhuriyet Univ.2016.
- Erem C, Arslan C, Hacıhasanoglu A, Deger O, Topbaş M, Ukinç K, et al. Prevalence of obesity and associated risk factors in a Turkish population (Trabzon city, Turkey). *Obes Res* 2004; 12: 1117-27.
- Hatemi H, Yumuk VD, Turan N, Arik N. Prevalence of overweight and obesity in Turkey. *Metab Syndr Relat Disord* 2003; 1: 285-90.
- Çayır A, Atak N, Köse S. Beslenme ve Diyet kliniğine başvuranlarda obezite sıklığı ve etkili faktörlerin belirlenmesi. *Ankara Univ Tıp Fak Mecm* 2009; 64: 13-9.
- Eriksen D, Rosthøj S, Burr H, Holtermann A. Sedentary work-Associations between five-year changes in occupational sitting time and body mass index. *Prev Med* 2015; 73: 1-5.



# Evaluation of Non-donor Brain-Dead Patients

## Donör Olmayan Beyin Ölümü Olgularının Değerlendirilmesi

İlkay Ceylan, Seda Seven, Sevim Baltalı, Abdurrahman Tünay, Veyssel Erden

İstanbul Training and Research Hospital, Clinic of Anesthesiology, İstanbul, Turkey

### ABSTRACT

**Introduction:** Patients with chronic organ failure receive organs from living donors or brain-dead donors. In our country, brain death and organ transplantation procedures are carried out with Turkish Laws #2238 on the Harvesting, Storage, Grafting, and Transplantation of Organs and Tissues (June 3, 1979). Improvements in legislation have been made on the criteria of diagnosis of brain death and how diagnosis will be made. The recommendation for termination of life support of non-donor brain-dead patients was removed. Due to this uncertainty, hesitancy arises in terms of the discontinuation of life support among healthcare workers. In our study, we aimed to draw attention to the issue about the fate of non-donor brain-dead patients.

**Methods:** In our study, we retrospectively evaluated data of brain-dead patients between January 1, 2011 and June 1, 2017 in our hospital.

**Results:** Of the 122 patients with brain death, 102 were not donors. The mean lifetime of non-donor patients was 29±56 hours. It was observed that cardiac death occurred in the longest surviving patient after 116 hours following declaration. Thirty-five patients were given new vasopressor or inotropic drugs after brain death.

**Conclusion:** The brain-dead person is considered medically and legally dead despite heartbeats. It is not reasonable to maintain the life support of the individual who is considered dead. Considering the insufficient number of intensive care units and the high cost of medical support, it is of great importance to establish legal arrangements that will allow the discontinuation of medical support that is useless in non-donor brain-dead patients and enable the use of life-supporting devices for the patients in the waiting list.

**Keywords:** Brain death, organ donation, discontinuation of life support

### ÖZ

**Amaç:** Kronik organ yetmezlikli hastalar için organlar canlı vericilerden ya da beyin ölümü gerçekleşmiş kişilerden alınmaktadır. Ülkemizde beyin ölümü ve organ nakli işlemleri 1979 yılında çıkartılan 2238 sayılı “Organ ve Doku Alınması, Saklanması ve Nakli Hakkında Kanun” ile yürütülmektedir. Mevzuatta yapılan değişiklikler ile beyin ölümü tanısının kriterleri ve tanının nasıl konulacağı konusunda iyileştirmeler yapılmıştır. Beyin ölümü tanısı almış, ancak donör olmayan olguların yaşam desteğinin sonlandırılması önerisi kaldırılmıştır. Bu belirsizlik nedeni ile sağlık çalışanları içinde yaşam desteğinin kesilmesi konusunda tereddüt oluşmaktadır. Çalışmamızda organ nakli yapılamayan donörlerin akıbeti ile ilgili açıkta kalan konuya dikkat çekmeyi amaçladık.

**Yöntemler:** Çalışmamızda hastanemizde 1 Ocak 2011 ile 1 Haziran 2017 tarihleri arasında görülen beyin ölümü olguları retrospektif olarak incelendi.

**Bulgular:** Beyin ölümü tanısı konulmuş 122 hastanın 102’sinin donör olmadığı görüldü. Donör olmayan hastaların ortalama yaşam süresi 29±56 saattir. En uzun yaşayan hastamızın deklarasyon sonrasında 116 saat kardiyak ölümün gerçekleşmediği görülmüştür. Otuz beş hastaya beyin ölümü bildirimi sonrasında yeni vazopressör veya inotrop ilaç başlanmıştır.

**Sonuç:** Beyin ölümü gerçekleşmişse kalp atışı sürüyor olsa dahi kişi tıbben ve hukuken ölü kabul edilir. Ölü kabul edilen bireyin yaşam desteklerinin devam ettirilmesi makul değildir. Yoğun bakım yatak sayısının yetersizliği ve tıbbi destek maliyetinin yüksek olması dikkate alındığında, donör olmayan beyin ölümlü olgularda faydasız olan tıbbi desteğin kesilmesi ve yaşamı destekleyen cihazların öncelikle bekleyen hastaların kullanımına olanak sağlayacak yasal düzenlemelerin oluşturulması büyük önem taşımaktadır.

**Anahtar Kelimeler:** Beyin ölümü, organ nakli, yaşam desteğinin kesilmesi



Address for Correspondence/Yazışma Adresi: İlkay Ceylan, İstanbul Training and Research Hospital, Clinic of Anesthesiology, İstanbul, Turkey  
Phone: +90 533 631 31 13 E-mail: ceylanilkay@yahoo.com ORCID ID: orcid.org/0000-0003-3306-3107

Cite this article as/Atıf: Ceylan İ, Seven S, Baltalı S, Tünay A, Erden V. Evaluation of Non-donor Brain-Dead Patients. İstanbul Med J 2019; 20(2): 144-7.

Received/Geliş Tarihi: 17.09.2018

Accepted/Kabul Tarihi: 14.11.2018

## Introduction

Organ transplantation is a surgical operation in which an irreversibly damaged organ is removed and replaced with a functioning organ harvested from a donor. Organs are received from living donors or brain-dead donors. Brain death was first described in 1959 by Mollaret and Goulon as “coma dépassé”. The milestone for the definition of brain death was the publication of the Harvard criteria. Following this definition, brain death and organ transplantation issues have united and progressed on common ground (1). In our country, brain death and organ transplantation procedures are carried out with Turkish Laws #2238 on the Harvesting, Storage, Grafting, and Transplantation of Organs and Tissues (June 3, 1979). Improvements in legislation have been made over time on the criteria of diagnosis of brain death and how diagnosis will be made, however, there is no clarity about non-donor cases. Although brain-dead patients are considered legally dead (2), health workers may hesitate to terminate life support due to uncertainty in legislation.

In this study, a retrospective analysis of brain-dead patients in a training and research hospital between 2011 and 2017 was conducted, and it was aimed to draw attention to unclear points in the management of non-donor cases in the light of the data obtained.

## Methods

Brain-dead patients between January 1, 2011 and June 1, 2017 were reviewed retrospectively after receiving approval from the Istanbul Training and Research Hospital Ethics Committee of our hospital (decision no: 23/06/2017-1018). According to the decision taken by the organ transplantation commission of our hospital, single-photon emission computed tomography is performed as a supportive test for the patients who are thought to be clinically brain-dead after the apnea test and then declaration is done. Demographic data, reasons for admission, “acute physiology and chronic health evaluation (APACHE 2)” scores, time to diagnosis, additional test rates, transplantation rates, time to transplantation, time to cardiac death of non-donor patients, and procedures performed during this period were recorded.

## Statistical Analysis

Statistical analysis was performed using Minitab 17 (Minitab Statistical Software, Pennsylvania, USA). Descriptive statistics were expressed as mean, minimum-maximum, standard deviation, numbers and percentage.

Data with non-normal distribution were compared using Mann-Whitney U test and chi-square test was used to compare categorical variables.

## Results

In our study, 122 patients were examined. The mean time from the intensive care unit admission to the suspicion of brain death was found to be  $3.79 \pm 3.1$  days. The distribution of the patients diagnosed with brain death according to years and diagnosis are shown in Figure 1 and Figure 2, respectively. It has been observed that the hemorrhagic cerebrovascular events take the first place among the causes of brain death. This is followed by ischemic cerebrovascular events, trauma,

malignancy, successful resuscitation after cardiac arrest, infections and intoxications. Although four out of 122 patients were diagnosed with brain death after apnea test, declaration could not be made because no supportive test could be performed. Brain death declaration was made in 118 patients and 20 of these 118 patients became donors. Apnea test could not be performed due to hypoxia or hemodynamic instability in three donors and five non-donors. Demographic data of donors and non-donors are shown in Table 1. There was no significant difference between two groups in terms of age, APACHE 2 scores and time to declaration ( $p > 0.05$ ). Two of 15 patients who were non-citizens of the Republic of Turkey became donors. The mean organ harvesting duration was  $18.15 \pm 15$  hours. The mean cardiac death of the non-donor patients was  $29 \pm 56$  hours, and the longest period between brain death and cardiac death was 116 hours (Table 2). Thirty-five non-donor patients were given new vasopressor or inotropic drugs after brain death notification. Twelve of these patients had cardiopulmonary resuscitation (CPR) after cardiac arrest.

## Discussion

Organ transplantation has been used as a salvage treatment in patients with end-stage organ failure. The organs required for these patients are harvested from living or brain-dead donors.

While death is a medical condition, it has psychological, economic, legal, ethical, religious and social consequences. Somatic death, which means cessation of heartbeats and breathing, is accepted and understood as death (3). Brain death is now accepted as the irreversible loss of brain and brain stem reflexes. For this reason, brain death is not sufficiently recognized and causes anxiety among relatives of patients and health workers. Furthermore, coma, persistent vegetative status and brain death cannot be clearly differentiated by society. Therefore, the improvements seen after these clinical conditions, although very rarely, are misunderstood by the society and cause them to move away from the idea of organ transplantation and discontinuation of life support after brain death (4,5).

**Table 1. Demographic data of cases**

	Donors (n=20)	Non-donors (n=102)
Age (years)	44.05±14.06	51.49±17.38
Gender, male/female	13/7	63/39
Nationality (RoT)	18 (90%)	89 (87.2%)
APACHE 2	26.85±7.9	26.34±6.23
RoT: republic of Turkey, APACHE 2: acute physiology and chronic health evaluation score Data were expressed as n, n (%) and mean ± standard deviation		

**Table 2. Declaration data**

	Donors (n=20)	Non-donors (n=102)
Apnea test	17 (85%)	87 (85.2%)
Supportive test	20 (100%)	98 (96%)
Declaration (day)	3.8±2.46 (1-9)	3.79±3.1 (1-20)
Cardiac death (hours)	18.15±7.79 (12-36)	29.56±22.52 (1-116)
Declaration: the time until the diagnosis of brain death (day); Cardiac death: time to cardiac death and/or organ donation (hours), Data were given as n (%), mean ± SD and minimum-maximum value		




Figure 1. Patients diagnosed with brain death by years




Figure 2. Diagnosis of patients with brain death

Another reason for rejecting discontinuation of life support is religious concerns. According to Islam, life is sacred and protected. However, according to the results of fiqh studies, it is accepted that brain death is also true death. In the published fatwa, it is stated that brain-dead people should be accepted as dead (6).

With the entry into force of the Law No. 2238 on 29 May 1979, it is decided that the organs can be taken from brain-dead people. Although there is no definition of brain death in the law, this situation did not create problems in practice. On 16 August 1990, the brain death criteria approved by the General Directorate of Therapy Services of the Ministry of Health have been notified. Brain death criteria were published in the Official Gazette on August 20, 1993, and the concept of brain death was given a legal dimension. Although there was a statement indicating that “If the organ donation permit cannot be obtained after the brain death is declared to the relative of the patient, the medical support applied to the patient will be discontinued” in the 1993 criteria, this approach was amended in the Regulation on Organ and Tissue Transplantation dated June 1, 2000, and was rephrased as “the medical support can be

discontinued if the relatives of the patient permit”. In the Regulation on Organ and Tissue Transplantation, dated February 1, 2012, the rules for the diagnosis of brain death have been re-published, but there was no statement on the decision to discontinue medical support in non-donor cases made by relatives of the patient and/or by the health team (1). This has led to hesitations in discontinuing medical support by making the issue of authority questionable. For Turkish law, as in Universal Medicine Law, death also occurs when a person’s brain and brainstem functions are lost to an irreversible degree. The brain-dead person is considered medically and legally dead despite heartbeats. It is not reasonable to maintain the life support of a dead individual. Although this condition is not included in the new regulation, it should be noted that there is no need to wait for approval or request of the relatives of the patient for discontinuation of life support if there is no consent for organ transplantation in a person whose brain death has been realized and duly certified. In addition, in the presence of another patient in need of a life support device such as a mechanical ventilator, resources should be allocated to patients in need due to the fair use principle; otherwise, continuation of medical support with such a device could lead to the responsibility of the physician (7).

In our retrospective evaluation, it was seen that four patients were expected to undergo an additional test after apnea test; however, cardiac death was observed in these patients. Due to this delay, declaration could not be made to the family and potential organ donors were lost. In our evaluation, organ transplantation was not accepted by the relatives of 98 cases. In non-donors, the period between brain death and cardiac death was determined to be at least 1 hour, maximum 116 hours and mean 29.56 hours. Although the financial burden of 98 brain-dead patients with a mean of 29.56 hours of care could not be calculated, it can be regarded as futile. Karasu et al. (8) reported that 43 non-donor patients had lived for a mean of 2.5 days and continued life support in case their relatives change their minds. In addition, they stated that they had continued life support since relatives of patients did not allow life support to be discontinued before 2012. In our study, we identified 11 cases before 2012 and we found that five of them were started vasopressors.

In our study, we determined that 35 non-donor patients were started vasopressor agent after the family interview. Although the reason for the failure to discontinue life support could not be reached from our records, we have seen that one patient in 2011 and 11 patients in 2012 underwent CPR. A study showed that physicians and nurses who believe that life support should be maintained in these cases is 13.4% and 20.1%, respectively. In the same study, it was revealed that 11.2% of physicians did not believe that the brain-dead cases had died legally (9). The main reason for the continuation of life support by health care workers may be that medical law is not included in medical education and health workers cannot get enough support from the institutions. When this is the case, it will be reasonable to apply to the organ transplant management of the hospital. Health workers should be encouraged to participate in the trainings provided by the Ministry of Health and the lack of information should be avoided. It should also be kept in mind that healthcare professionals

are individuals and may have concerns about discontinuing life support due to their religious, conscientious, and social presence as well as their professional personality. Therefore, all health care workers responsible for patient care should also be supported in this direction.

Relatives of patients who cannot comprehend the definition of brain death hope that their patients can return to life and therefore they are reluctant to decide to discontinue medical support. Intimate early communication with the relatives of the patients can overcome this, however, relatives of patients who are difficult to communicate and who are in a state of denial in addition to the unwillingness of health workers to discontinue life support lead to occupation of beds by non-donor cases. This situation prevents the intensive care conditions from being used by intensive care patients. The lack of confidence in the existing legislation and the decision to interrupt the medical support in non-donor cases and the decision on who to make this decision is not being explicitly stated increases the doubts about this issue (10).

## Conclusion

Considering the necessity of rational use of intensive care beds in our country and the high cost of medical support, we think that the legal arrangements that will allow us to discontinue medical support that is useless in non-donor cases and to direct the life supporting devices to the waiting patients should be implemented rapidly.

**Ethics Committee Approval:** The study was approved by the Ethics Committee of Istanbul Training and Research Hospital with the decision number 23/06/2017-1018.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - İ.C.; Design - İ.C., S.S.; Supervision - V.E.; Data Collection and/or Processing - S.S., S.B.; Analysis and/or Interpretation - İ.C.; Literature Search A.T.; Writing Manuscript - İ.C., S.S.; Critical Review - V.E.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

1. Çil O, Görkey Ş. Beyin ölümü kriterlerinin tarihsel gelişimi ve kadavradan organ nakline etkisi. *Marmara Tıp Dergisi* 2014; 7: 69-74.
2. Hakeri H. Organ ve doku nakli ve hukuki sorunlar. Tıp, etik, din, sosyoloji ve hukuk bağlamında organ nakli, sorunlar ve çözüm önerileri sempozyumu; 2014 Mayıs 9; Malatya, Türkiye.
3. Süren Ö. Organ ve doku naklinin etik açıdan incelenmesi. *TBB Dergisi* 2007; 73: 174-95.
4. Can F. Organ bağışında aile onayı üzerine bir gözden geçirme. *Nesne Psikoloji Dergisi* 2017; 5: 131-49.
5. Kıraklı C, Uçar ZZ, Anıl AB, Özbek İ. Yoğun bakımda beyin ölümü kesin tanı süresinin kılalmasını organ bağış oranlarına etkisi. *Yoğun Bakım Dergisi* 2011; 1: 8-11.
6. Görgülü Ü. İslam hukuku açısından yaşam desteğinin sonlandırılması. tıp, etik, din, sosyoloji ve hukuk bağlamında organ nakli, sorunlar ve çözüm önerileri sempozyumu; 2014 Mayıs 9; Malatya, Türkiye.
7. Hakeri H. Tıp Hukuku. 10. Baskı. Ankara: Seçkin Yayıncılık; 2015.
8. Karasu D, Yılmaz C, Karaduman I, Çınar YS, Büyükkoyuncu N. Beyin ölümü olgularının retrospektif analizi. *Yoğun Bakım Dergisi* 2015; 6: 23-6.
9. Tepehan S, Elmas İ. Beyin ölümü tanısı almış hastalarda tıbbi desteği kesme kararı ve bu konudaki yetki sorunu. *Bakırköy Tıp Dergisi* 2016; 12: 207-12.
10. Tepehan S, Elmas İ. Türkiye’de beyin ölümü tanısına güven sorunu ve organ bağışına yansımaları. *Yoğun Bakım Hemşireliği Dergisi* 2014; 18: 8-14.



# Cyto-Histopathological Findings of Myofibroblastoma of the Breast: A Case Report

## Meme Myofibroblastomunun Sito-Histopatolojik Bulguları: Olgu Sunumu

● Büşra Yaprak Bayrak<sup>1</sup>, ● Ahmet Tuğrul Erucar<sup>1</sup>, ● Abdullah Güneş<sup>2</sup>

<sup>1</sup>Kocaeli University Faculty of Medicine, Department of Pathology, Kocaeli, Turkey

<sup>2</sup>University of Health Sciences, Derince Training and Research Hospital, Department of General Surgery, Kocaeli, Turkey

### ABSTRACT

Myofibroblastoma of the breast is a rare mesenchymal tumor, probably originating from stromal fibroblasts. In this case report, cyto-histopathological findings of myofibroblastoma of the breast are discussed.

A 68-years-old male patient was admitted to our clinic with a rapidly growing, painless mass in the breast. Radiological examination revealed a mobile, solid mass resembling to fibroadenoma. Fine needle aspiration revealed spindle cell clusters with fibrous stroma and a clear background. Hypocellular aspirates demonstrated neoplastic cells with cyanophilic cytoplasm and mild/moderate pleomorphism, and naked elongated nuclei including fine granular chromatin, nuclear groove and inclusion. The lesion was reported as "benign spindle cell neoplasm". Tru-cut biopsy revealed short fascicles composed of uniform benign spindle cells with hyalinized collagen bands accompanied by mast cells and patchy lymphoid infiltration. Immunoreactivity was positive with CD34, smooth muscle actin (SMA), desmin and vimentin, but negative with CD117, CD10, Epithelial Membrane Antigen, S-100, pan-cytokeratin and p53. This case was reported as "classic variant of myofibroblastoma", and the patient was operated in another clinic. There was no recurrence during follow-up.

Myofibroblastoma is a rare, benign mesenchymal tumor, usually seen in the breast parenchyma. While the tumor is diagnosed based on the fibro-myofibroblastic differentiation characteristics, other tumors and tumor-like spindle cell lesions should also be kept in mind. The cytological features of 22 cases in the literature were similar. Aspirates are generally hypercellular with mild-moderate pleomorphism, nuclear groove and inclusions. Histopathology shows positivity for CD34, vimentin, desmin and SMA. Clinical/radiological characteristics and atypia, growth pattern, mitosis and immunohistochemistry should all be evaluated together. Cytomorphology may be the first step in diagnosis; however, immunohistochemical studies should not be ignored in differential diagnosis.

**Keywords:** Fine needle aspiration cytology, breast, histopathology, myofibroblastoma

### ÖZ

Memenin myofibroblastomu sık rastlanmayan, olasılıkla stromal fibroblastlardan kaynaklanan mezenkimal bir tümördür. Bu olguda myofibroblastomun sito-histopatolojik bulguları tartışılmaktadır.

Altmış sekiz yaşında erkek hasta memede hızla büyüyen ağrısız kitle nedeniyle kliniğimize başvurdu. Muayenede tespit edilen mobil, sert kitlenin radyolojik olarak fibroadenoma'ya benzediği düşünüldü. İnce iğne aspirasyonunda temiz arka planlı, fibröz stromalı iğsi hücre kümeleri görüldü. Hiposellüler aspiratlarda hafif-orta pleomorfizm gösteren, siyanofilik sitoplazmalı, çıplak elonge nükleuslu, nükleer çentik, inklüzyon içeren, ince granüler kromatinli neoplastik hücreler dikkati çekti. Lezyon "benign iğsi hücreli neoplazm" olarak raporlandı. Tru-cut biyopside hyalinize kollajen bantlar arasında uniform, benign iğsi hücrelerden oluşan, mast hücreleri ve yama tarzı lenfoid infiltrasyonun eşlik ettiği kısa fasiküller izlendi. CD34, smooth muscle aktin (SMA), desmin, vimentin ile pozitif, CD117, CD10, epitelyal membran antijen, S-100, pansitokeratin, p53 ile negatif reaksiyon gösterdi. Bu bulgularla "myofibroblastom" olarak raporlandı. Hastanın isteğiyle dış merkezde eksizyon yapıldı. Takiplerinde rekürrens izlenmedi.

Myofibroblastom genelde meme parankiminde görülen, nadir, benign mezenkimal tümördür. Tümörün fibro-myofibroblastik differansiasyon özelliğine bağlı olarak tanı konulurken, diğer tümör ve benzeri iğsi hücreli lezyonlar akıldan bulundurulmalıdır. Literatürdeki 22 olgunun sitolojik özellikleri benzerdir. Aspiratlarda nükleer çentik/inklüzyonlar bulundurabilen hafif-orta pleomorfik iğsi hücreler görülür. Histopatolojisinde CD34, vimentin, desmin ve SMA pozitifdir. Klinik/radyolojik özellikler ve atipi, büyüme paterni, mitoz, immünohistokimyanın hepsi beraber değerlendirilmelidir. Tanıda ilk aşama sitomorfoloji olabilir ancak immünohistokimyasal çalışmalar ayrımsal tanıda göz ardı edilmemelidir.

**Anahtar Kelimeler:** İnce iğne aspirasyon sitolojisi, meme, histopatoloji, myofibroblastoma



Address for Correspondence/Yazışma Adresi: Büşra Yaprak Bayrak, Kocaeli University Faculty of Medicine, Department of Pathology, Kocaeli, Turkey

Phone: +90 262 303 84 55 E-mail: busra.yaprakbayrak@kocaeli.edu.tr ORCID ID: orcid.org/0000-0002-0537-3127

Cite this article as/Atf: Bayrak BY, Erucar AT, Güneş A. Cyto-Histopathological Findings of Myofibroblastoma of the Breast: A Case Report. İstanbul Med J 2019; 20(2): 148-51.

Received/Geliş Tarihi: 24.10.2017

Accepted/Kabul Tarihi: 08.06.2018

## Introduction


Myofibroblastoma of the breast is a rare mesenchymal tumor, probably originating from stromal fibroblasts. Although it is actually defined in males, it can affect both sexes (1,2). In recent years, the morphological spectrum of myofibroblastoma of the breast has widened considerably and has been seen in different unusual variants such as epithelioid, cellular, fibrous, deciduoid-like, lipomatous, myxoid and infiltrating (2,3). Myofibroblastoma has similar morphological, immunohistochemical and cytogenetic findings with spindle cell lipoma and cellular angiofibroma (4). Although there are rare cytological definitions of many isolated patients, the role of cytopathology and histopathology in the preoperative diagnosis of myofibroblastoma has not been established yet (3).

In this case report, we aimed to reveal the cyto-histopathological findings of myofibroblastoma of the breast in a 68-year-old male patient and to discuss special cytological definitions with immunohistochemical criteria in preoperative differential diagnosis.

## Case Report

A 68-year-old male patient with multinodular goiter was admitted to our clinic for a rapidly growing, painless mass in the last month. Physical examination showed a mobile, hard mass in the right breast parenchyma.

There were no nipple and skin changes, and axillary lymph nodes. Ultrasonography revealed a 4x5 cm, well-circumscribed, hypoechoic solid nodule located in the retro-areolar area of the right breast, radiologically resembling a fibroadenoma. Fine needle aspiration (FNA) was performed by a radiologist. Alcohol-fixed smears were prepared and rapidly stained with Papanicolaou stain. Breast specimen obtained by was examined by a pathologist. Cytopathological smears showed loosely structured fibrous stromal spindle cell clusters with a clean background without necrosis or inflammation (Figure 1a). Hypocellular aspirates demonstrated neoplastic cells with cyanophilic cytoplasm and mild/moderate pleomorphism, and naked elongated nuclei including fine granular chromatin, nuclear groove and inclusion (Figure 1b and 1c). No mitosis was observed. In light of these findings, the lesion was reported as “benign spindle cell neoplasm” and Tru-cut biopsy or excision was recommended for histopathological evaluation. Ultrasonography-guided Tru-cut biopsy was performed and short fascicles composed of uniform benign spindle cells with hyalinized collagen bands accompanied by mast cells and patchy lymphoid infiltration were observed (Figure 2). Tumor cells showed positive reaction with CD34 (Figure 3), smooth muscle actin (SMA) (Figure 4), desmin (Figure 5), vimentin (Figure 6), and negative reaction with CD117 (Figure 7), CD10, epithelial membrane antigen EMA, S-100, pan-cytokeratin (Figure 8) and p53.




**Figure 1.** Cytopathological smears of breast sample (Papanicolaou, a: x200, b and c: x400)


1a. Spindle cells with narrow eosinophilic cytoplasm intermingled with extracellular matrix material

1b. Individually dispersed spindle cells with pseudo-inclusion and oval nuclei

1c. Cohesive cell cluster with fine granular chromatin and without nuclear pleomorphism




**Figure 2.** Histopathological appearance of myofibroblastoma (hematoxylin&eosin, x200). Uniform, large spindle cells without mitotic activity and necrosis that were arranged in fascicles and separated by hyalinized collagen bands without ducts or lobules




**Figure 3.** Positive immunohistochemical profile of myofibroblastoma case for CD34 (x200)






**Figure 4.** Positive immunohistochemical profile of myofibroblastoma case for Smooth Muscle Actin (x200)




**Figure 5.** Positive immunohistochemical profile of myofibroblastoma case for desmin (x200)




**Figure 6.** Positive immunohistochemical profile of myofibroblastoma case for vimentin (x200)

All antibodies used in the immunohistochemistry device (Leica bond-mix; Leica Biosystems, Newcastle, United Kingdom) were obtained from Leica Biosystems (Newcastle, United Kingdom). Accompanied by morphological and immunohistochemical findings, this breast tumor was reported as “myofibroblastoma, classical variant”. The mass excision was performed at an external center upon request of the patient. No recurrence was observed in the patient for three months.

Verbal and written informed consent was obtained from the patient who participated in this study.



**Figure 7.** Negative immunohistochemical profile of myofibroblastoma case for CD117 (x200)



**Figure 8.** Negative immunohistochemical profile of myofibroblastoma case for pan-cytokeratin (x200)

## Discussion

Myofibroblastoma is a rare, typically slow-growing, well-circumscribed, mobile, benign mesenchymal spindle cell tumor, which is usually seen in breast parenchyma, and therefore may be confused with fibroadenoma in physical examination and mammography. Clinicopathological discrimination was first made by Wargotz et al. (5). It is most commonly seen in postmenopausal women and elderly men. Seventy cases have been reported in the literature since 2008 (6). However, since wide morphologic and immunohistochemical spectrum due to the fibro-myofibroblastic differentiation of this unusual prototypic tumor, pathologists should be aware of the differential diagnosis.

When any spindle cell lesion was detected cytologically or histopathologically in the breast, spindle cell metaplastic carcinoma, malignant phyllodes tumor as well as fibromatosis, spindle cell lipoma, which may contain similar genetic abnormalities and histological features, scar, postoperative spindle cell nodule, myofibroblastoma, pseudoangiomatous stromal hyperplasia (fascicular type), leiomyoma, adenomyoepithelioma, nodular fasciitis, solitary fibrous tumor, inflammatory myofibroblastic tumor, peripheral nerve sheath tumor, smooth muscle tumors, primary sarcoma, metastatic sarcoma, metastatic spindle cell carcinoma and metastatic malignant melanoma should be kept in mind in the differential diagnosis (7).

Spindle cell carcinoma in a spindle cell cluster containing a small number of epithelial components (glandular, squamous) with chondroid, osseous heterologous elements and obvious ductal carcinoma in situ may be confused with long and broad fascicular fibromatosis, which is clinically and radiologically mixed with carcinoma, consisting of benign spindle cells that extend into the surrounding fat and glandular parenchyma and invade breast ducts and lobules, and express nuclear  $\beta$ -catenin. Nodular fasciitis is a hypercellular, “spindle cell tissue culture” like, fast growing, well-circumscribed, superficial mass consisting of short fascicles and whorls with high mitotic index, stromal myxoid appearance, extravasated erythrocyte, lymphoid clusters and cells with variable collagen accumulation. Postoperative spindle cell nodule is a benign mesenchymal lesion composed of myofibroblastic spindle cells with mild/medium nuclear pleomorphism, small vessel proliferation, hemosiderin-laden macrophages, foamy cells and lymphocytes. There is no surgical history in inflammatory myofibroblastic tumor and marked inflammatory infiltration is observed (7).

Various patterns can be observed histologically (2). The classic type is seen as a well-limited tumor with no real capsule and it has various variants. They can be referred as cellular variant (cell stroma ratio is higher than classic), collagenous variant (containing marked stromal collagen in less cellularity), infiltrative variant (tumor infiltrating normal breast duct, lobules and fat tissue, and having irregular margin), myxoid variant (with myxoid stroma), lipomatous variant (with primary fat tissue component), decidual variant (solid/trabecular nests of cells with large wide cytoplasm), and epithelioid variant (consisting of cells with epithelioid appearance (forming clusters, cords, alveolar groups and linear sequences) that can be confused microscopically with invasive lobular carcinoma).

Cytology, histopathology and immunohistochemistry are very helpful for accurate diagnosis in myofibroblastoma (8). In this study, we also demonstrated the cyto-histopathological findings of a breast myofibroblastoma with morphological findings. As in all cases in the literature, immunohistochemical findings of this tumor were positive for CD34 and vimentin (9). Desmin and SMA markers were also positive, as was the case in most cases. Pan-cytokeratin EMA, S-100 and CD117 markers, which were generally negative, were also negative in our case. CD10, which was positive in very few cases, was negative in this case (9). Due to the rarity of myofibroblastoma, preoperative diagnosis of cytology has still not been established. The FNA cytological features of the 22 cases in the literature are basically similar and consist of single and cluster benign spindle cells (9). Although most of the aspirates were hypercellular, aspiration of our case was hypocellular. There was no significant nuclear atypia in our case, there was mild to moderate pleomorphism and nuclear grooves and inclusions as seen in some cases (9,10). As a result of FNA, we diagnosed “benign spindle cell neoplasm” as in most cases. The differential diagnosis of classical type myofibroblastoma involves spindle cell tumors and tumor-like lesions. They originate primarily from the breast parenchyma (9). Spindle and epithelial cells should be considered together in the evaluation of spindle cell lesions. Clinical and radiological features, as well as the presence and degree of atypia, growth pattern, mitotic activity and immunohistochemical examination should all be evaluated together (11). Spindle cell/mesenchymal lesions should not be diagnosed as

malignant unless there are large number of mitotic figures and atypical and prominent pleomorphism (9). In the absence of these features, histopathological evaluation can eliminate the suspicions in cytology. In our case, benign spindle cells forming hyalinized collagen bands in the stroma were helpful in the diagnosis.

## Conclusion

The first step in the approach to spindle cell lesions can be cytomorphology, however, immunohistochemical studies should not be ignored in the differential diagnosis of myofibroblastoma.

**Informed Consent:** Verbal and written informed consent was obtained from the patient who participated in this study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - B.Y.B., A.T.E.; Design - B.Y.B.; Supervision - B.Y.B., A.T.E.; Resources - B.Y.B., A.T.E.; Materials - B.Y.B., A.T.E.; Data Collection and/or Processing - B.Y.B., A.T.E.; Analysis and/or Interpretation - B.Y.B.; Literature Search - B.Y.B.; Writing Manuscript - B.Y.B., A.T.E.; Critical Review - B.Y.B., A.T.E.

**Conflict of Interest:** There is no conflict of interest with any institution or company.

**Financial Support:** The authors declared that they did not receive financial support for this study.

## References

- Wargotz ES, Weiss SW, Norris HJ. Myofibroblastoma of the breast: sixteen cases of a distinctive benign mesenchymal tumor. *Am J Surg Pathol* 1987; 11: 493-502.
- Magro G. Mammary myofibroblastoma: a tumor with a wide spectrum. *Arch Pathol Lab Med* 2008; 132: 1813-20.
- Álvarez-Rodríguez F, Gimeno-Arangué M, López-Varela C, González-Peramato P, Tortoledo-Bruni A, Rodríguez-Costa J, et al. Fine-needle aspiration cytology of mammary myofibroblastoma: a report of six cases. *Acta Cytol* 2012; 56: 501-5.
- Flucke U, van Krieken JH, Mentzel T. Cellular angiofibroma: analysis of 25 cases emphasizing its relationship to spindle cell lipoma and mammary-type myofibroblastoma. *Mod Pathol* 2011; 24: 82-9.
- Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. *Hum Pathol* 1989; 20: 732-40.
- Magro G, Flecher C, Eusebi V. Myofibroblastoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver NJ, eds. *WHO classification of tumours of the breast*. Lyon: IARC Press 2012; 130-1.
- Schnitt SJ. Spindle cell lesions of the breast. In: Collins LC, ed. *Current concepts in breast pathology*. Philadelphia, PA: W.B. Saunders; 2009: 375-90.
- Salemis NS, Nakos G, Tsiambas E, Tsantilis V, Seretis C. Rapidly growing myofibroblastoma of the breast diagnosed in a premenopausal woman: Management and review of the literature. *Breast Dis* 2012; 34: 29-34.
- Fügen A, Elif S, Gülistan G, Meryem D, Günay G. Fine-needle aspiration cytology of a mammary myofibroblastoma: A case report on the role of immunohistochemistry and cell block preparations and a review of the literature. *Diagn Cytopathol* 2016; 44: 1064-9.
- Yang CS, Chang MC, Jan YJ, Wang J. Fine needle aspiration of breast myofibroblastoma. *Acta Cytol* 2010; 54: 356-8.
- Mac DeMay R. The art & science of cytopathology. Superficial aspiration cytology. In: *Breast*. 2<sup>nd</sup> edition, Chicago: ASCP Press; 2012. p. 1052-118.



# Radiotherapy in the Treatment of High Volume Chylous Fistula Following Hepatectomy: Case Report and Review of the Literature

## Hepatektomi Sonrasında Gelişen Yüksek Debili Şilöz Fistül Tedavisinde Radyoterapi: Olgu ve Literatür Sunumu

Osman Nuri Dilek<sup>1</sup>, Ayhan Aydın<sup>2</sup>, Turan Acar<sup>1</sup>, Cengiz Tavusbay<sup>1</sup>, Emine Özlem Gür<sup>1</sup>, Salih Can Çelik<sup>1</sup>, Hüseyin Sinan Akay<sup>3</sup>, Mehmet Hacıyanlı<sup>1</sup>

<sup>1</sup>Katip Çelebi University, Atatürk Training and Research Hospital, Clinic of General Surgery, İzmir, Turkey

<sup>2</sup>Katip Çelebi University, Atatürk Training and Research Hospital, Clinic of Radiation Oncology, İzmir, Turkey

<sup>3</sup>Katip Çelebi University, Atatürk Training and Research Hospital, Clinic of Gastroenterology, İzmir, Turkey

### ABSTRACT

Lymphatic injury is common in surgical procedures, but only 1-11% of cases present with chylous fistula. Although high volume chylous fistula is a rare condition after liver resection, serious life-threatening complications such as empyema and peritonitis secondary to severe mechanical, nutritional and immunological disorders due to protein loss may accompany this condition. Here, we report a 58-year-old male patient with Klatskin tumor (Bismuth-Corlette, 3A) who had high volume chylous fistula after right hepatectomy. In spite of medical treatment (fat-free diet, somatostatin) and tube drainage for 4 weeks, daily chylous fistula ranged between 600-1800 cc/day. Due to the prolonged drainage, low-dose radiotherapy was applied to the patient. The patient underwent fractionated radiotherapy protocol at a daily dose of 150 cGy (total 1200 cGy) for 8 days. The drainage decreased to 150 cc on day 1, than to 50 cc on day 3 and the drain was removed on day 5. The patient has been under follow up without any problem for 18 months. Several interventional and surgical multimodal procedures have been described in the literature for the treatment of refractory chylous fistulas. There are very few studies on radiotherapy in the literature. We believe that low-dose fractionated radiotherapy may be an alternative treatment modality for refractory cases.

**Keywords:** Chylous fistula, complication, hepatectomy, liver, radiotherapy

### ÖZ

Lenfatik yaralanma cerrahi girişimler sırasında sıklıkla olmakla birlikte, olguların %1-11'inde şilöz fistül olarak karşımıza çıkmaktadır. Karaciğer rezeksiyonları sonrasında yüksek debili şilöz fistül nadiren görülen bir durum olmakla beraber, protein kaybına bağlı olarak ortaya çıkan ciddi mekanik, nütrisyonel ve immünolojik bozukluklar sonucunda ampiyem ve peritonit gibi yaşamı tehdit eden ciddi komplikasyonlar tabloya eşlik edebilir.

Burada, 58 yaşındaki Klatskin tümörlü (Bismuth-Corlette, 3A) bir erkek hastamızda yaptığımız sağ hepatektomi sonrasında ortaya çıkan yüksek debili bir şilöz fistül olgusu sunulmuştur. Yapılan 4 haftalık tıbbi (yağdan fakir diyet, somatostatin) tedaviye ve tüp drenaja rağmen günlük şilöz fistülün 600-1800 cc/gün arasında değişerek devam ettiği gözlemlendi. Sürecin uzaması nedeniyle, hastaya düşük doz radyoterapi uygulamasının yapılmasına karar verildi. Hastaya günlük 150 cGy fraksiyone dozda 8 günlük radyoterapi protokolü (toplam 1200 cGy) uygulandı. Uygulama sonrası 1. günde drenaj miktarı 150 cc'ye ve sonraki 3 günde toplam 50 cc'ye indi ve dren çekildi. Hasta post-operatif 18 aydır problemsiz izlenmektedir.

Literatürde medikal tedaviye dirençli şilöz fistüllerin tedavisi amacıyla girişimsel ve cerrahi pek çok multimodal prosedür tanımlanmıştır. Tedavide radyoterapi uygulaması ile ilgili çalışmalar ise çok azdır. Olgumuzda uyguladığımız düşük doz fraksiyone radyoterapi uygulamasının tedaviye dirençli olgularda alternatif bir tedavi yöntemi olabileceğine inanıyoruz.

**Anahtar Kelimeler:** Şilöz fistül, komplikasyon, hepatektomi, karaciğer, radyoterapi



**Address for Correspondence/Yazışma Adresi:** Osman Nuri Dilek, Katip Çelebi University, Atatürk Training and Research Hospital, Clinic of General Surgery, İzmir, Turkey  
Phone: +90 232 243 43 43 E-mail: osmannuridilek@gmail.com ORCID ID: orcid.org/0000-0002-6313-3818

**Cite this article as/Atıf:** Dilek ON, Aydın A, Acar T, Tavusbay C, Gür EÖ, Çelik SC, Akay HS, Hacıyanlı M. Radiotherapy in the Treatment of High Volume Chylous Fistula Following Hepatectomy: Case Report and Review of the Literature. İstanbul Med J 2019; 20(2): 152-5.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

**Received/Geliş Tarihi:** 05.09.2017

**Accepted/Kabul Tarihi:** 05.06.2018

## Introduction

Approximately 2.4 liters of lymphatic fluid rich in fat (0.4-6 g/dL) is absorbed from the intestines and is introduced into the circulation by lymphatic channels. Sixty to seventy percent of this transport occurs through thoracic duct. There are immunoglobulins, enzymes, digested products and leukocytes (400-6800 white blood cell/mL), mostly lymphocytes, in lymphatic fluid (1).

Chylous fistula was first described in the 17<sup>th</sup> century after trauma (1). Lymphatic injury is seen in the neck, thoracic and intraabdominal surgery, however, only 1-11% of cases present with chylous fistula (2). Nowadays, it is seen more due to increased number of extended radical surgeries. In order to be able to call a fistula, the triglyceride value should be more than 110 mg/dL in the biochemical analysis of the collected fluid (1,3). Depending on the volume in cases with fistula, serious complications such as fluid-electrolyte-protein imbalance, malnutrition, acidosis, impaired immune functions, prolonged hospital stay and infection may occur (2).

The classical approach in patients with chylous fistulas includes diet control (high protein, low fat, medium-chain triglyceride diet), fasting, somatostatin administration, parenteral fluid supplementation and total parenteral nutrition (1,2,4,5). In case of increased volume of chylous fistula and prolonged drainage, the risk of morbidity increases and the stabilization of the patient becomes more difficult. Several interventional and surgical treatment methods have been described in the literature for patients refractory to medical treatment (Table 1) (1,2). Despite all interventions, the surgical approach may also fail in the treatment of refractory cases with high volume. There are some studies reporting that approximately half of the patients can die due to complications (1,2,6).

There are several studies on the development of chylous acid or chylothorax after radiotherapy or exposure to radiation. However, there are few studies on the use of radiotherapy in the treatment of chylous fistula (1,2,5,6).

Here, we present a refractory high volume chylous fistula case that was successfully treated by radiotherapy, and discuss the topic in the light of the literature.

## Case Report

The serous drainage started on post-operative day 5 in a 58-year-old male patient who underwent right hepatectomy for Klatskin tumor (Bismuth-Corlette, 3A) and increased from 300-700 cc to 1100 cc on day 7 with becoming a milky-white fluid rich in fats. Biochemical analysis of drain fluid confirmed chylous fistula (triglycerides >110 mg/dL). In spite of medical treatment (fasting, diet, somatostatin and parenteral fluid therapy) for 4 weeks, daily chylous fistula ranged between 600-1800 cc/day (Figure 1). There was no improvement despite all the classical medical treatment modalities. Due to the prolonged drainage, the radiotherapy treatment protocol was decided to be applied earlier. Informed consent was obtained from the patient and radiotherapy was initiated. The patient underwent an 8-day low-dose fractionated radiotherapy protocol at a daily dose of 150 cGy (total 1200 cGy) starting from post-operative day 28 (Figure 2). The drainage decreased to 150 cc

on day 1, than to 50 cc on day 3 and the drain was removed. Therapeutic radiotherapy was completed and liver functions of the patient were normal. He was discharged without any problems and the patient has been under follow up without any problem for 18 months.

## Discussion

Chylous ascites may develop due to traumatic and atraumatic causes. Intraabdominal tumors (17-57%), anomalies (32%), cirrhosis (11%) and mycobacterial infections (10%) are the most common atraumatic medical causes (2,5). Studies have shown that lymph node dissection and the number of lymph nodes, tumors fed from the superior mesenteric artery, retroperitoneal tumor invasion, paraaortic region dissection, surgeon's experience, radical surgical procedures, chronic pancreatitis, hypoalbuminemia, neoadjuvant chemotherapy and early enteral nutrition may play a role in the development of chylous acid (1,2,7).

It is common for the lymphatic structures to be traumatized during surgical procedures and they recover spontaneously in most cases. There are very few cases reported after liver surgery. It can be seen especially after transplantation and major liver surgery. In their study including 516 liver transplantation cases, Yilmaz et al. (3) stated that 24 cases (4.6%) had chylous acid. In the same study, hypoalbuminemia, presence of acid, hilar zone dissection and using vessel sealing system have been reported to increase the risk (3). In a systematic analysis performed by Weniger et al. (2), chylous acid was observed in 4.7% of liver surgeries, 1-11% of pancreatic surgeries, 1-6.6% of colorectal surgeries and 11.5% of gastric tumor surgeries with D3 lymph node dissection. The location of the pathology can be detected by lymphangiography in 75% of cases (2,8,9). In our case, it was thought that chylous fistula developed after extensive hilar and lymphatic dissections performed for right hepatectomy for hilar cholangiocarcinoma. However, no localization study was performed in our case.

The clinical case series related to the treatment of chylous acid or fistula are limited and there are no treatment guidelines and algorithms (2). Most of the chylous fistula cases (77%-100%) recover with the classic medical approach (1,2,5). We applied the classical approach modalities in our patient for four weeks, but we failed. Various and more aggressive modalities are applied in cases with inadequate response to treatment (Table 1). In addition to the aforementioned treatments for chylous acid in cases without drain, there are also case series with intermittent paracentesis. Diuretics have no place in treatment. Although there were literature data on the use of orlistat, we did not use it (1,5).


Application of local chemical sclerosing agents and embolization with lymphangiography are the treatment options that should be considered before surgery for the refractory cases. Matsumoto et al. (10) treated 8 of 9 cases with lymphangiography. Shunt surgery (Le Vein or Denver) or ligation of open lymphatic ducts are the other recommended treatment methods (1,11). In a series of 163 cases with complex oncologic surgical procedures, Kaas et al. (12) reported that 12 cases (7.4%) had chylous acid and nine of them recovered with conservative treatment, and that they applied peritoneovenous shunting in three cases. However, there are also studies reporting that shunts should be revised frequently and that 20% of the cases have died (13).

Table 1. Treatment modalities applied in chylous fistulas	
Medical	- Enteral nutrition/TPN (Total parenteral nutrition)
	- Fat restriction on diet
	- Octreotide, 300 µg/day
	- Orlistat (Reversible lipaz inhibitor)
	- Etilefrine (Sympathomimetic), 120 mg/day
Interventional	- Paracentesis
	- Pleurodesis/Peritoneodesis (Talc, tetracyclin, fibrin glue, concentrated glucose solution, streptokinase, OK-432...)
	- Percutaneous drainage
	- TIPS (Transjugular intrahepatic portosystemic shunts)
	- Lymphangiography
	- Embolization of lymph ducts (Cysterna chyle embolization)
Surgical	- Low-dose radiotherapy application
	-Abdominal drainage
	-Pleuroperitoneal shunt
	-Peritoneovenous shunt
	-Ligation of Cysterna chyle (Open/Laparoscopic)



**Figure 1.** The chylous fistula volume from the subhepatic drainage varies between 600-1800 cc per day

Sensitivity of the lymphatic tissue to radiation is known. It is known that chylous acid may develop due to radiotherapy. On the other hand, it is also known that edema occurs in the lymphatic tissue primarily, followed by narrowing of the canals and decrease in lymphatic tissue size. There are very few publications in the literature on this subject (1,6,14-18). Dietl et al. (14) achieved successful results with low-dose radiotherapy in refractory lymphorrhea after vascular interventions in the inguinal region. Habermehl et al. (15) reported similar results. In the literature, there are studies reporting that chylous acids due to celiac lymphoma is treated by radiotherapy (14). It was reported that chylous fistula developed after gastric cancer surgery with D2 dissection was successfully treated with low-dose radiation (15). The largest series



**Figure 2.** Radiotherapy protocol: The patient underwent an 8-day low-dose fractionated radiotherapy protocol at a daily dose of 150 cGy (total 1200 cGy) starting from post-operative day 28

of chylous fistulas treated with a radiotherapeutic approach was by Sziklavari et al. (6) from Germany with 7 cases. The cases in this series included patients undergoing thoracotomy and lobectomy or wedge resection. Regarding the operated organ, our case is the first case treated with radiotherapy in the literature. As a result, we achieved a successful outcome in our patient with low-dose radiotherapy (Figure 1). On the 5<sup>th</sup> day of low-dose radiotherapy, the drainage stopped and the patient has been under follow up without any problem for 18 months.

**Conclusion**

High volume chylous fistula is a serious complication with high morbidity and mortality. In the literature, several interventional and surgical multimodal procedures have been described for the treatment of the refractory chylous fistulas. However, there is few data about radiotherapy in the treatment. We believe that low-dose fractionated radiotherapy may be an alternative treatment modality for refractory cases.

**Informed Consent:** Informed consent was obtained from the patient and radiotherapy was initiated.

**Peer-review:** Externally and internally peer-reviewed.

**Author Contributions:** Concept - O.N.D., A.A.; Design - O.N.D., A.A.; Supervision - O.N.D.; Resources - T.A., E.Ö.G.; Materials - H.S.A.; Data Collection and/or Processing - C.T., T.A.; Analysis and/ or Interpretation - O.N.D., M.H.; Literature Search - T.A., S.C.Ç.; Writing Manuscript - O.N.D., M.H.; Critical Review - O.N.D., A.A.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

**References**

1. Tessier DJ, Geibel J. Chyle fistula. In: <http://emedicine.medscape.com/article/190025-overview>, 2015

2. Weniger M, D'Haese JG, Angele MK, Kleespies A, Werner J, Hartwig W. Treatment options for chylous ascites after major abdominal surgery: A systematic review. *Am J Surg* 2016; 211: 206-13.
3. Yılmaz M, Akbulut S, Işık B, Ara C, Özdemir F, Aydın C, et al. Chylous ascites after liver transplantation: Incidence and risk factors. *Liver Transplantation* 2012; 18: 1046-52.
4. Baran M, Cakir M, Yükksekaya HA, Arikan C, Aydın U, Aydogdu S, et al. Chylous ascites after living related liver transplantation treated with somatostatin analog and parenteral nutrition. *Transplant Proc* 2008; 40: 320-1.
5. Steinemann DC, Dindo D, Clavien PA, Nocito A. Atraumatic chylous ascites: Systematic review on symptoms and causes. *J Am Coll Surg* 2011; 212: 899-905.e1-4.
6. Sziklavari Z, Allgäuer M, Hübner G, Neu R, Ried M, Grosser C, et al. Radiotherapy in the treatment of postoperative chylothorax. *J Cardiothoracic Surgery* 2013; 8: 72.
7. Shiba H, Wakiyama S, Gocho T, Ishida Y, Misawa T, Yanaga K. A case of successful conservative treatment for chylous ascites after living-donor liver transplantation. *Int Surg* 2012; 97: 360-2.
8. Haberal M, Karakayali H, Moray G, Bilgin N. Surgical treatment of chylous ascites following partial living-related liver transplantation. *Transpl Int* 1998; 11: 327-8.
9. Kuboki S, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, et al. Chylous ascites after hepatopancreatobiliary surgery. *Br J Surg* 2013; 100: 522-7.
10. Matsumoto T, Yamagami T, Kato T, Hirota T, Yoshimatsu R, Masunami T, et al. The effectiveness of lymphangiography as a treatment method for various chyle leakages. *Br J Radiol* 2009; 82: 286-90.
11. Aalami OO, Allen DB, Organ CH Jr. Chylous ascites: a collective review. *Surgery* 2000; 128: 761-78.
12. Kaas R, Rustman LD, Zoetmulder FA. Chylous ascites after oncological abdominal surgery: incidence and treatment. *Eur J Surg Oncol* 2001; 27: 187-9.
13. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, et al. Chylous ascites after postchemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. *J Urol* 2006; 176: 1463-7.
14. Dietl B, Pfister K, Aufschläger C, Kasprzak PM. Radiotherapy of inguinal lymphorrhea after vascular surgery. A retrospective analysis. *Strahlenther Onkol* 2005; 181: 396-400.
15. Habermehl D, Hahl G, Eckstein HH, Meisner F, Combs SE. Radiotherapeutic management of lymphatic fistulas: An effective but disregarded therapy option. *Chirurg* 2017; 88: 311-6.
16. Gerstein J, Kofahl-Krause D, Fruhauf J, Bremer M. Complete remission of a lymphoma-associated chylothorax by radiotherapy of the celiac trunk and thoracic duct. *Strahlenther Onkol* 2008; 184: 484-7.
17. Kim SW, Kim JH. Low-dose radiation therapy for massive chylous leakage after subtotal gastrectomy. *Radiat Oncol J* 2017; 35: 380-4.
18. Corradini S, Liebig S, Niemoeller OM, Zwicker F, Lamade W. Successful radiation treatment of chylous ascites following pancreatoduodenectomy. *Strahlenther Onkol* 2015; 191: 448-52.



# A Case of Choroid Plexus Papilloma with Rare Location Presenting with Impaired Consciousness

## Bilinç Bulanıklığı ile Başvuran Nadir Yerleşimli Koroid Pleksus Papillom Olgusu

● Nurcan Ünal<sup>1</sup>, ● Muhammet Mesut Nezir Engin<sup>1</sup>, ● Önder Kılıçaslan<sup>1</sup>, ● İbrahim Feyyaz Naldemir<sup>2</sup>,  
● Gülşen Yalçın<sup>1</sup>, ● Uğur Avcı<sup>1</sup>, ● Kenan Kocabay<sup>1</sup>

<sup>1</sup>Düzce University Faculty of Medicine, Department of Pediatrics, Düzce, Turkey

<sup>2</sup>Düzce University Faculty of Medicine, Department of Radiology, Düzce, Turkey

### ABSTRACT

Intraventricular papillary neoplasms originating from the choroid plexus epithelium are called choroid plexus tumors (CPT). In pediatric patients. The most common findings in CPT are seizures, subarachnoid hemorrhage, focal neurological deficits, hydrocephalus and symptoms of increased intracranial pressure. A 4.5-month-old, previously healthy girl was admitted to our Pediatric Emergency Department with complaints of inadequate nutrition, vomiting and drowsiness in the last 2 days. The patient was admitted to the pediatric intensive care unit and saline loading treatment was initiated due to presumed dehydration caused by inadequate nutrition. As dehydration-related pathology was not detected, brain tomography scan was performed for possible cranial pathology and it revealed increased bilateral lateral ventricular diameters. As a result of magnetic resonance imaging results, the patient was diagnosed as having choroid plexus papilloma. After the shunt was inserted, the patient regained consciousness and an elective surgery was planned. Inadequate nutrition and drowsiness are the most common causes of admissions to pediatric emergency department, and these symptoms are usually due to dehydration. Cranial pathologies should be considered in patients who do not respond to fluid loading treatments and whose laboratory findings and vital signs are stable. As in our patient, the patients with choroid plexus papilloma should be evaluated clinically and shunt surgery should be performed firstly. Timing of surgery should be decided according to the effect and clinical status.

**Keywords:** Choroid plexus papilloma, hydrocephalus, impaired consciousness

### ÖZ

Koroid pleksus epitelinden gelişen intraventriküler papiller neoplazilere koroid pleksus tümörleri (KPT) denir. Çocuk hastalarda KPT'de en sık görülen bulgular nöbetler, subarahnoid kanama, fokal nörolojik defisit ve hidrosefali ile artan kafa içi basıncın belirtileridir. Öncesinde sağlıklı olduğu öğrenilen 4,5 aylık kız hasta, son 2 gündür olan beslenme azlığı, bir kez kusma ve sonrasında gelişen uykuya meyil şikayeti ile çocuk acil servisimize başvurdu. Hasta pediatri yoğun bakım ünitesine yatırılıp ön planda beslenememeye bağlı dehidratasyon düşünülerek serum fizyolojik yükleme tedavisi başlandı. Yapılan tetkiklerde dehidratasyona ait patoloji gözlenmemesi üzerine olası kraniyal patolojiler açısından çekilen bilgisayarlı beyin tomografisinde bilateral lateral ventriküler çaplarının normale göre artmış olduğu görüldü. Bunun üzerine çekilen manyetik rezonans görüntüleme sonuçları neticesinde hastaya koroid pleksus papillomu tanısı konuldu. Şant takıldıktan sonra hastanın bilinci açıldı, ileri dönemde elektif şartlarda operasyon planlandı. Beslenme azlığı ve uykuya meyil şikayetinin çocuk acil servisine en sık başvurulardandır ve bu semptomlar genellikle dehidratasyona bağlıdır. Sıvı yükleme tedavilerine yanıt vermeyen, laboratuvar ve vital bulguları stabil olan hastalarda mutlaka kraniyal patolojiler düşünülmelidir. Bizim hastamızda olduğu gibi koroid pleksus papillomu tanısı konulan hastaların klinik durumu değerlendirilerek öncelikle hastalara şant takılması gereklidir. Sonrasında etki ve klinik duruma göre cerrahi tedavinin ne zaman yapılacağına karar verilmelidir.

**Anahtar Kelimeler:** Koroid pleksus papillomu, hidrosefali, bilinç bulanıklığı



**Address for Correspondence/Yazışma Adresi:** Muhammet Mesut Nezir Engin, Düzce University Faculty of Medicine, Department of Pediatrics, Düzce, Turkey  
Phone: +90 542 637 88 10 E-mail: doktormesut@hotmail.com ORCID ID: orcid.org/0000-0002-0874-6857

**Cite this article as/Atıf:** Ünal N, Engin MMN, Kılıçaslan Ö, Naldemir İF, Yalçın G, Avcı U, Kocabay K. A Case of Choroid Plexus Papilloma with Rare Location Presenting with Impaired Consciousness. İstanbul Med J 2019; 20(2): 156-8.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.

©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

**Received/Geliş Tarihi:** 01.11.2017

**Accepted/Kabul Tarihi:** 16.05.2018

## Introduction


Choroid plexus is an epithelial tissue localized in the ventricles and secretes cerebrospinal fluid (CSF). Intraventricular papillary neoplasms originating from this epithelium are called choroid plexus tumors (CPT) (1). The most common symptoms of CPT in pediatric patients are hydrocephalus, signs of increased intracranial pressure (IICP), seizures, subarachnoid hemorrhage or focal neurological deficits (2). These tumors constitute 0.4-0.6% of all brain tumors. Fifty percent of the CPTs are localized in the lateral ventricle, 40% in the fourth ventricle and 5% in the third ventricle (1). As a result of meta-analyses of cases published until 1998, it was seen that 45% of the papillomas were diagnosed in the first year and 74% were diagnosed in the first 10 years (3). In this case report, it was aimed to draw attention to choroid plexus papilloma (CPP) by presenting a rare CPP located in the third ventricle that was detected in a 4.5-month-old girl following admission for impaired consciousness.

## Case Report

A 4.5-month-old, previously healthy girl was admitted to our Pediatric Emergency Department with complaints of inadequate nutrition, vomiting and drowsiness in the last 2 days. Her body temperature was 36.7 °C, and heart and respiratory rates were within normal limits according to age. There was no abnormality in blood pressure. On physical examination, her general condition was poor and she was stuporous. The patient did not respond to the verbal stimulus and had a response to painful stimuli. Her skin was pale and mucous membranes were dry with decreased turgor. Other system examinations were normal. The patient was immediately hospitalized in pediatric intensive care unit and saline loading therapy was initiated due to presumed dehydration caused by inadequate nutrition. Blood gas analysis, complete blood count and biochemical tests were within normal ranges according to age. As there was no change in consciousness after fluid treatment, the blood pressure was within normal limits and there was no dehydration-related pathology. Imaging was planned for possible cranial pathologies. Because the anterior fontanel diameter was not appropriate for ultrasonography (USG), brain computed tomography (CT) was performed and it was seen that bilateral lateral ventricular diameters were increased compared to normal. In the magnetic resonance imaging (MRI) of the brain, an isointense, multilobulated mass lesion that was located in the third ventricular floor and was extending inferiorly along the cerebral aqueduct on unenhanced sagittal T1-weighted image (Figure 1a). There was a homogenous contrast enhancement on enhanced sagittal T1-weighted image (Figure 1b). At the same time, the third ventricle and lateral ventricles were enlarged on the coronal T2-weighted image (Figure 2). The diagnosis of CPP was made by MRI results. The patient underwent a shunt surgery for hydrocephalus at an external healthcare center and the patient regained consciousness. Follow-up was planned for the patient and future elective surgery was decided. Informed consent was obtained from relatives of the patient.

## Discussion

CPP is a rare congenital tumor of neuroectodermal origin in children and adults (4). Choroidal plexus tumor was classified as grade 1, 2 and 3 by World Health Organization, and they were named as CPP, atypical



**Figure 1.** a) At Sagittal T1WI, isointens multilobulated mass, located at the base of third ventricle and extending down along the aqueductus cerebri b) After administration of contrast medium, heterogeneous enhancement was noted



**Figure 2.** At coronal T2WI; marked dilatation 3. and lateral ventricles

CPP, and choroid plexus carcinoma, respectively (5). Due to mechanical obstruction, hydrocephalus in CPTs is frequently caused by the spread of the mass and excessive secretion of CSF. As in our case, clinical findings in CPTs, especially in papillomas, are always associated with accompanying hydrocephalus. The symptoms of these tumors include head enlargement, bulging fontanelle, papilledema, diplopia due to paralysis of 6<sup>th</sup> cranial nerve, seizures, ataxia, nausea/vomiting, motor and sensory disorders, restlessness and disturbances of consciousness (1). Our patient had inadequate nutrition, impaired consciousness, vomiting and drowsiness. As the fontanel does not close in children under one year of age, symptoms due to IICP are slower and it may present as inadequate nutrition as in our patient.

Differential diagnosis is very important for follow-up and appropriate treatment. The diagnosis of brain tumors can be made by CT, but MRI is the gold standard for treatment planning and follow-up. In CT, CPPs appear iso- to hyperdense in the intraventricular area and sometimes include microcalcifications (6). Bilateral lateral ventricular diameters were larger than normal in CT scan of our patient. The lesion shows

homogeneous isointensity on T1-weighted images and hyperintensity on T2-weighted images in MRI, as in our patient (5).

The first treatment option is surgery. Postoperative radiotherapy is recommended if the patient has undergone subtotal excision and the patient is over 3 years of age. Radiotherapy is not recommended in patients younger than 3 years of age because it may cause neurological complications in the developing brain (1). The patient had undergone shunt operation because of hydrocephalus detected in her CT scan. Because of the small size of the tumor and good prognosis of the patient, no additional surgical intervention was performed and radiotherapy was not applied since our patient was under 3 years of age.

The factors associated with prognosis in CPP are symptoms, the size and the location of the tumor (5). In CPP, 1,5-year survival rates were reported as 90%, 81% and 71%, respectively (7).

## Conclusion

Inadequate nutrition and drowsiness are the most common causes of admissions to Pediatric Emergency Department and are usually due to problems, such as dehydration, which can be solved by rapid treatment in the emergency department. Etiologic evaluation must be performed before initiating fluid therapy in patients without signs of dehydration. Cranial pathologies should be considered in the differential diagnosis in patients who do not respond to fluid loading treatments and who has persistent impaired consciousness despite stable laboratory findings and vital signs. Transfontanelle USG or cranial CT should be performed according to the fontanel diameter in these patients and MRI should be performed to clarify the diagnosis and follow-up the patient if a pathology is detected.

**Informed Consent:** Informed consent was obtained from relatives of the patient.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - Ö.K.; Design - N.Ü., İ.F.N.; Supervision - M.M.N.E.; Data Collection and/or Processing - M.M.N.E.; Analysis and/or Interpretation - N.Ü., U.A.; Literature Search - M.M.N.E.; Writing Manuscript - M.M.N.E.; Critical Review - K.K.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Karabağlı H, Karabağlı P. Koroid pleksus tümörleri. *Türk Nöroşir Derg* 2014; 24: 68-7.
2. Laarakker AS, Nakhla J, Kobets A, Abbott R. Incidental choroid plexus papilloma in a child: A difficult decision. *Surg Neurol Int* 2017; 8: 86.
3. Waldron JS, Tihan T. Epidemiology and pathology of intraventricular tumors. *Neurosurg Clin N Am* 2003; 14: 469-82.
4. Kapoor A, Aggarwal A, Ahuja CK, Salunke P. Primary choroid plexus papilloma of cerebellopontine angle: An unusual entity in infancy. *J Pediatr Neurosci* 2016; 11: 287-8.
5. Sethi D, Arora R, Garg K, Tanwar P. Choroid plexus papilloma. *Asian J Neurosurg* 2017; 12: 139-41.
6. Jaiswal AK, Jaiswal S, Sahu RN, Das KB, Jain VK, Behari S. Choroid plexus papilloma in children: Diagnostic and surgical considerations. *J Pediatr Neurosci* 2009; 4: 10-6.
7. Wolff JE, Sajedi M, Brant R, Coppes MJ, Egeler RM. Choroid plexus tumours. *Br J Cancer* 2002; 87: 1086-91.

# Neurotoxoplasmosis in a Patient with Acquired Immunodeficiency Syndrome: Magnetic Resonance and Magnetic Resonance Spectroscopy Findings

## Edinsel İmmün Yetersizlik Sendromlu Hastada Nörotoksoplazmozis: Manyetik Rezonans ve Manyetik Rezonans Spektroskopisi Bulguları

✉ Pınar Gülmez Çakmak<sup>1</sup>, ✉ Selda Sayın Kutlu<sup>2</sup>

<sup>1</sup>Pamukkale University Faculty of Medicine, Department of Radiology, Denizli, Turkey

<sup>2</sup>Pamukkale University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Denizli, Turkey

### ABSTRACT

Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) is an important public health problem. In recent years, opportunistic infections that can develop in patients with AIDS are rapidly diagnosed by imaging modalities. A 31-year-old HIV-positive male patient presented with fever, headache and progressive bilateral muscle weakness. Magnetic resonance imaging (MRI) revealed multiple mass lesions with peripheral edema. In MR spectroscopy (S), lactate-lipid peak was detected. Hemorrhagic transformation was observed in some lesions in control brain MRI. Here, we aimed to present MRI and MRS findings of a patient with neurotoxoplasmosis and to demonstrate that hemorrhagic transformation may develop during follow-up and treatment.

**Keywords:** AIDS, cerebral toxoplasmosis, HIV, magnetic resonance spectroscopy

### ÖZ

İnsan immün yetmezlik virüsü (HIV) enfeksiyonu ve edinsel immün yetmezlik sendromu (AIDS) önemli bir halk sağlığı sorunudur. Son yıllarda, edinsel immün yetersizlik sendromlu hastalarda gelişebilen fırsatçı enfeksiyonlar, görüntüleme ile hızlı bir şekilde tanı almaktadır. Otuz bir yaşında bir HIV-pozitif hasta; ateş, baş ağrısı ve ilerleyen iki taraflı kas güçsüzlüğü ile başvurdu. Manyetik rezonans görüntüleme (MRG) ödemi de bulunan çok sayıda kitle lezyonu izlendi. Lezyonların MR spektroskopisinde (S), laktat ve lipid piki tespit edildi. Kontrol beyin MRG'de bazı lezyonlarda hemorajik transformasyon gözlemlendi. Bu yazıda, bir nörotoksoplazmozis hastasının MR ve MRS görüntüleme bulgularını sunmak ve takip-tedavi sırasında hemorajik transformasyonun gelişebileceğini göstermek istedik.

**Anahtar Kelimeler:** AİDS, serebral toksoplazmozis, HIV, manyetik rezonans spektroskopisi

### Introduction

*Toxoplasma gondii* is an intracellular protozoan that causes central nervous system involvement in patients with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS). *Toxoplasma* is transmitted by oral or transplacental route (1). Acute infection is usually asymptomatic. Neurotoxoplasmosis is caused by the reactivation of latent infection in the brains of immunocompromised patients with a CD4+ T lymphocyte count of less than 200 cells/ $\mu$ L (2,3). The clinical presentation most commonly includes headache, fever, hemiparesis, intracranial mass, and cranial nerve palsy (4). In addition to the brain, lung, heart and skeletal muscle involvement can be seen. Today, early diagnosis of HIV infection and opportunistic infection prophylaxis in patients with AIDS has reduced the frequency of neurotoxoplasmosis.

We present magnetic resonance imaging (MRI) and MR spectroscopy (S) findings of a patient with neurotoxoplasmosis.

### Case Report

A 31-year-old male patient admitted to emergency department of our hospital in December 2017 with complaints of fever, headache, vomiting, blurred vision and progressive bilateral weakness. Regarding medical history and laboratory findings of the patient, AIDS was diagnosed in the emergency department. Laboratory data showed reactive HIV antibodies and HIV-RNA was 1.109.000 copies/mL. An absolute CD4 count was 8 cells/ $\text{mm}^3$ . Brain MRI was performed at 1.5 Tesla (Signa Excite HD; GE Medical Systems, Milwaukee, WI, USA) with an 8-channel head coil due to fever and neurological symptoms. MRI showed T2-FLAIR hyperintense lesions



**Address for Correspondence/Yazışma Adresi:** Pınar Gülmez Çakmak, Pamukkale University Faculty of Medicine, Department of Radiology, Denizli, Turkey  
Phone: +90 505 258 98 49 E-mail: pinarcakmak20@gmail.com ORCID ID: orcid.org/0000-0003-4652-6748

**Cite this article as/Atıf:** Gülmez Çakmak P, Sayın Kutlu S. Neurotoxoplasmosis in a Patient with Acquired Immunodeficiency Syndrome: Magnetic Resonance and Magnetic Resonance Spectroscopy Findings. İstanbul Med J 2019; 20(2): 159-62.

©Copyright 2019 by the İstanbul Training and Research Hospital/İstanbul Medical Journal published by Galenos Publishing House.


©Telif Hakkı 2019 İstanbul Eğitim ve Araştırma Hastanesi/İstanbul Tıp Dergisi, Galenos Yayınevi tarafından basılmıştır.

**Received/Geliş Tarihi:** 12.03.2018


**Accepted/Kabul Tarihi:** 15.05.2018




with edema in the centrum semiovale, basal ganglia, corticomedullary junction and cerebellum (Figure 1). In addition, a ring-enhancing lesion in the cerebellum was also observed in contrast-enhanced MRI (Figure 2). MRS (single voxel, short TE) was performed for the cerebellar



**Figure 1a.** Axial T2-FLAIR images showing hyperintense lesions with edema in the cerebellum




**Figure 1b.** Axial T2-FLAIR images showing hyperintense lesions with edema in the basal ganglia




**Figure 1c.** Axial T2-FLAIR images showing hyperintense lesions with edema at the corticomedullary junction and in the centrum semiovale


lesion. Point resolved spectroscopy sequence (PRESS) with short echo time was used. PRESS parameters were TR/TE=2000/32 ms; NEX=128 and voxel volume=1 mL. MRS revealed Choline (Cho) reduction at 3.19 ppm, creatinine reduction at 3.04 ppm and N-acetylaspartate (NAA) reduction at 2.00 ppm, and increased lipid-lactate (Lip/Lac) at 1.33 ppm.




**Figure 2.** Axial contrast-enhanced T1W images showing a ring-enhancing lesion in the cerebellum




**Figure 3.** Magnetic Resonance Spectroscopy (single voxel, PRESS; TR/TE/ NEX=2000 ms/32 ms/128); reduced choline (3.19 ppm), creatinine (3.04 ppm) and N-acetyl aspartate (2.00 ppm), increased lipid-lactate peak (1.33 ppm)




**Figure 4a.** Axial T1W image showing hemorrhagic transformation developed in the cerebellum



**Figure 4b.** Axial T1W image showing hemorrhagic transformation developed in the basal ganglia



**Figure 5a,b.** Axial T2-FLAIR image of the patient on admission



**Figure 5c,d.** Axial T2-FLAIR image of the patient during treatment period

In our patient, MRS demonstrated Lip/Lac peaks compared to healthy brain parenchyma (Figure 3). Brain biopsy could not be performed. Neurotoxoplasmosis was suspected with clinical and MRI findings. Antiviral, antiparasitic and anti-edema treatment was initiated. In control MRI, T1W hyperintense, T2W hypointense areas compatible with early subacute hemorrhage developed in some lesions (Figure 4). The patient had no history of thrombocytopenia, hemorrhagic diathesis and trauma. In the second control brain MRI, the number and size of the lesions decreased and the clinical improvement was observed during this period (Figure 5). In this case report, consent was obtained from the patient to present the case.

## Discussion

Neurotoxoplasmosis is an important diagnosis in HIV-positive patients. Neurotoxoplasmosis in patients with AIDS is due to the reactivation of acquired infection as immunity decreases when CD4 count is less than 200/ $\mu$ L (5). In patients with suspected neurotoxoplasmosis, it is necessary to define bradyzoites in brain tissue and to determine toxoplasma gondii DNA in the cerebrospinal fluid with polymerase chain reaction

test to confirm the diagnosis. However, in patients with suspected neurotoxoplasmosis, treatment precedes the diagnosis and brain MRI and MRS provide valuable information for toxoplasma encephalitis (6). In brain MRI, multiple ring enhancing lesions with edema and mass effect at the corticomedullary junction of frontal and parietal lobe, centrum semiovale and basal ganglia in patients with AIDS are diagnostic for neurotoxoplasmosis. Ring enhancing lesions in brain MRI can be seen in abscess, glioblastoma, tuberculoma, metastasis and radiation necrosis (7,8). The eccentric target sign is considered pathognomonic for neurotoxoplasmosis (9). In MRS, neurotoxoplasmosis is generally associated with an increase in Cho and decreases in NAA along with the presence of lactate-lipid peaks. Gupta et al. (10) reported that MRS could provide information about definitive diagnosis, especially in brain abscess and parasitic infection, when combined with diagnostic imaging. Follow-up MRI should be used for the evaluation of response to medical treatment. In our case, we detected hemorrhagic transformation in follow-up MRI.

## Conclusion

We report MRI and MRS findings of neurotoxoplasmosis in an HIV-positive patient. When neurotoxoplasmosis is suspected in a patient with AIDS with ring enhancing lesions with edema in brain MRI, medical treatment should be performed at the earliest. The presence of lactate and lipid peak in MRS in addition to brain MRI supports the diagnosis of neurotoxoplasmosis in suspected patients with AIDS.

**Informed Consent:** Informed consent was obtained from the patient to present the case.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - P.G.Ç.; Design - P.G.Ç.; Supervision - P.G.Ç.; Resources - P.G.Ç., S.S.K.; Materials - P.G.Ç., S.S.K.; Data Collection

and/or Processing - P.G.Ç., S.S.K.; Analysis and/ or Interpretation - P.G.Ç., S.S.K.; Literature Search - P.G.Ç.; Writing Manuscript - P.G.Ç.; Critical Review - P.G.Ç., S.S.K.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Kurne A, Ozkaya G, Karlioguz K, Shorbagi A, Ustaçelebi S, Karabudak R, et al. The colorful clinical spectrum of cerebral toxoplasmosis in five HIV positive cases: what comes out of Pandora's box? Mikrobiyol Bul 2006; 40: 85-92.
2. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363: 1965-76.
3. Naqi R, Azeemuddin M, Ahsan H. Cerebral toxoplasmosis in a patient with acquired immunodeficiency syndrome. J Pak Med Assoc 2010; 60: 316-8.
4. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327: 1643-8.
5. Berry. Diagnostic Radiology : Neuroradiology: Head and neck imaging. Jaypee Brothers Medical Publishers (P) Ltd. ISBN:8180616363.
6. Ramsey RG, Gean AD. Neuroimaging of AIDS. I. Central nervous system toxoplasmosis. Neuroimaging Clin N Am 1997; 7: 171-86.
7. Garg RK, Sinha MK. Multiple ring-enhancing lesions of the brain. J Postgrad Med 2010; 56: 307-16.
8. James J, Thulaseedharan NK. Ring enhancing lesions in the brain of an HIV infected patient: A diagnostic challenge. Pan Afr Med J 2017; 26: 185.
9. Kumar GG, Mahadevan A, Guruprasad AS, Kovoov JM, Satishchandra P, Nath A, et al. Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging 2010; 31: 1469-72.
10. Gupta RK, Jobanputra KJ, Yadav A. MR spectroscopy in brain infections. Neuroimaging Clin N Am 2013; 23: 475-98.

# A Case of Spinal Thoracic Empyema Following Epidural Injection

## Epidural Enjeksiyon Sonrası Gelişen Spinal Torakal Ampiyem Olgusu

● Fergane Memmodova<sup>1</sup>, ● Esengül Liman<sup>1</sup>, ● Ufuk Emre<sup>1</sup>, ● Yeşim Karagöz<sup>2</sup>, ● Veysel Antar<sup>3</sup>, ● Orhan Yağız<sup>1</sup>

<sup>1</sup>Istanbul Training and Research Hospital, Clinic of Neurology, İstanbul, Turkey

<sup>2</sup>Istanbul Training and Research Hospital, Clinic of Radiology, İstanbul, Turkey

<sup>3</sup>Istanbul Training and Research Hospital, Clinic of Neurosurgery, İstanbul, Turkey

### ABSTRACT

Spinal thoracic empyema is a complicated, important spinal pathology that is seen sporadically or following surgery or trauma. In this report, we aimed to present a case with spinal thoracic empyema following epidural injection and to draw attention to this rare etiologic cause.

**Keywords:** Epidural injection, myelopathy, thoracic empyema

### ÖZ

Spinal torakal ampiyem cerrahiye, travmaya bağlı ya da sporadik olarak ortaya çıkan, komplike, önemli bir spinal patolojidir. Bu yazıda epidural enjeksiyon sonrası gelişen spinal torakal ampiyem olgusunu sunmak ve bu nadir etiyolojik nedene dikkat çekmek istedik.

**Anahtar Kelimeler:** Epidural enjeksiyon, miyelopati, torakal ampiyem

### Introduction

In recent years, different complications due to widely applied spinal epidural injections can be seen. In this report, we present a thoracic empyema case with paraparesis and a previous history of spinal epidural injection.

### Case Report

A 46-year-old male patient presented with complaints of numbness and weakness of the legs, and urinary incontinence. The patient stated that low back pain and numbness started about 3 months ago and that his complaints increased over the last 20 days. From the patient's medical history, it was learned that he was hospitalized due to neck pain for seven days in an algology service of another hospital approximately one year ago and underwent spinal epidural injection. The patient said that he did not benefit from this treatment, which was repeated once in every 15 days for a total of 4 times. His past medical history revealed that he had kidney stones and hypertension, and he had sequelae in his right lower extremity due to traffic accident at the age of 12 years. His family history was unremarkable except spinal muscular atrophy in the medical history of his brother. There were night sweats and about 10 kg of involuntary weight loss in the last 3 months. Neurological examination revealed 3/5 motor strength in bilateral lower extremity, positive Babinski reflex

on the left, areflexia on the lower extremities and sphincter defect. Routine laboratory tests White Blood Cell=9.53, Hemoglobin Hgb=14.8, C-reaktif protein=0.306, Sedimentation=9 mm/h) were within normal limits. Cervical spinal magnetic resonance imaging (MRI) revealed diffuse hyperintensity consistent with diffuse edema in the spinal cord and 8x5 mm wide subdural collections starting from the seventh cervical vertebra level and showing caudal extension, more prominent posteriorly. These findings were found to be consistent with subdural empyema. Thoracic spinal MRI revealed T2W hyperintense, T1W mild hypointense diffuse edematous signal changes in the central dorsal spinal cord, involving gray matter with mild expansion. Contrast-enhanced sections revealed arachnoidal and dural diffuse and prominent contrast enhancement. Appearance consistent with empyema was observed between T2-9 vertebra levels (Figure 1). In the cerebrospinal fluid (CSF) examination, glucose was 33 mg/dL (concomitant blood glucose=121 mg/dL), protein was 562.3 mg/dL, and 40 leukocytes (60-70% mononuclear leukocytes (MNL) were detected in the cell count. Pandy was (+++++) positive, acid-fast bacilli and tuberculosis (TBC) Polymerase chain reaction (PCR) were negative. Since TBC could not be excluded with CSF findings, anti-TBC treatment was initiated. In the surgery performed for thoracic empyema, the arachnoid plan was lost, clear fluid was obtained by puncture from the thoracic region, cavitory areas were observed under the tissue and sampling was performed from calcific tissues. Dexamethasone



**Address for Correspondence/Yazışma Adresi:** Fergane Memmodova, İstanbul Training and Research Hospital, Clinic of Neurology, İstanbul, Turkey


**Phone:** +90 534 679 96 29 **E-mail:** mfergane@mail.ru

**Cite this article as/Atıf:** Memmodova F, Liman E, Emre U, Karagöz Y, Antar V, Yağız O. A Case of Spinal Thoracic Empyema Following Epidural Injection. İstanbul Med J 2019; 20(2): 163-4.

**Received/Geliş Tarihi:** 28.05.2016

**Accepted/Kabul Tarihi:** 23.05.2018





**Figure 1.** T1- and T2-weighted thoracic spinal magnetic resonance images of the patient

treatment was added to anti-TBC treatment and patient was followed up. One month later, the lower extremity muscle strength of the patient improved to 4/5, however, urinary and fecal incontinence persisted.

In the late-term pathology report, it was noted that pre-operative CSF sample did not have any atypical cells and that small number of mature-looking lymphocytes, activated lymphocytes and macrophages were observed with PAP and Giemsa staining.

In the histochemical examinations of the specimen obtained during the surgery, no bacillary microorganism was observed with EZN staining and no fungal organism was observed with PAS staining. Necrotizing granulomatous inflammation was detected in the sample obtained from the intramedullary area. Lymphocytes and polymorphonuclear leukocytes were observed in the sample from intramedullary spinal fluid.

As the patient could not be reached in the follow-up, no information could be obtained about his final condition. The informed consent was obtained from the patient.

## Discussion

Spinal epidural empyema is an insidious clinical condition that can be treated by early diagnosis and intervention, but its diagnosis is often delayed. Typical clinical findings include localized back pain, fever and neurological deficits. While empyema causes myelopathy due to pressure on the spinal cord, this situation may lead to motor weakness that can be even permanent (1,2). Difficulty in diagnosis and delay in treatment of patients with atypical clinical findings lead to increased morbidity and mortality (1).

Hematogenous spread from the upper respiratory tract or a dental infection has been described as possible etiologies in some cases, but it has also been identified as a local complication of vertebral osteomyelitis (3). In the literature, although it is defined as iatrogenic after spinal epidural catheterization, spinal extradural block or interventions for discopathy, sporadic cases are also reported (4,5). In our case, we thought that spinal epidural injection performed for neck pain had a role in etiology. While spinal epidural empyema usually occurs with *Staphylococcus aureus*, *Mycobacterium tuberculosis* and Brucellosis are other common microorganisms (2). Our patient was negative for *Brucella* serology and PCR, and mycobacterial culture.

MRI is diagnostic in most cases. The homogenous contrast enhancement caused by granulomatous tissue in the MRI is seen as a mass or as a

contrast-enhancing inflammatory tissue (6). In our case, MRI revealed diffuse hyperintensity consistent with diffuse edema in the spinal cord and appearance that might be significant in terms of empyema around the cord between T2-9 vertebra levels accompanied by contrast enhancement.

Lumbar puncture is also a guiding for the detection of the agent. Low CSF glucose level compared to the concomitant blood glucose level was thought to be in favor TBC. However, regarding negative mycobacteria culture and PCR studies along with a previous history of spinal epidural injection, decreased glucose level was thought to be secondary to localized infection.

While surgical drainage and decompression with concomitant antibiotic therapy is required in most of the cases, antibiotic therapy may be sufficient in some well-selected cases. Our case also benefited from surgery and empiric antibiotics for possible bacterial microorganisms and TBC.

## Conclusion

In case of affected spinal cord and the surrounding tissue in spinal imaging of patients admitting with paraparesis, questioning epidural injection in the history is important in the differential diagnosis and treatment.

**Informed Consent:** The informed consent was obtained from the patient.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - U.E.; Design - F.M.; Supervision - U.E.; Resources - F.M.; Materials - V.A.; Data Collection and/or Processing - Y.K.; Analysis and/ or Interpretation - O.Y.; Literature Search - F.M., E.L.; Writing Manuscript - F.M.; Critical Review - U.E.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors stated that they did not receive financial support for this study.

## References

1. Nussbaum ES, Rigamonti D. Spinal epidural abscess: A report of 40 cases and review. *Surgical Neurology* 1992; 38: 225-31.
2. Karaarslan G, Akalın Y. Iatrogenic reactive inflammation with thick membrane mimicking spinal epidural abscess after lumbar disc surgery: A case report and literature review. *Türk Nöroşirürji Dergisi* 2011; 21: 34-8.
3. Baker AS, Ojemann RG, Swartz MN, Richardson EP. Spinal epidural abscess. *N Engl J Med* 1975; 293: 463-8.
4. Sarubbi FA, Vasquez JE. Spinal epidural abscess associated with the use of temporary epidural catheters: report of two cases and review. *Clinical Infectious Diseases* 1997; 25: 1155-8.
5. John F, Ferguson JF, Kirsch WM. Epidural empyema following thoracic extradural block case reports and technical notes. *J Neurosurg* 1974; 41: 762-4.
6. Köksal V, Güçer H. Thoracic spinal epidural empyema presentation progressive paraparesis in a healthy individual and surgical treatment: Case report. *Türk Nöroşirürji Dergisi* 2011; 21: 60-3.

# Postoperative Fibrin Reaction and Descemet Membrane Detachment: A Case Report

## Postoperatif Fibrin Reaksiyon ve Descemet Membranı Dekolmanı: Olgu Sunumu

İD Mustafa Suat Alıkma, İD Erkan Ünsal, İD Tülay Akçetin, İD Mehmet Özgür Çubuk, İD Kadir Eltutar

İstanbul Training and Research Hospital, Clinic of Ophthalmology, İstanbul, Turkey

### ABSTRACT

An 85-year-old male patient who underwent phacoemulsification and intraocular lens implantation surgery in the right eye one week ago was admitted to our clinic for first week control. The patient stated that his vision had decreased slowly from post-operative day 1. Anterior segment examination revealed corneal edema, wrinkle in Descemet membrane, anterior chamber fibrin reaction and pseudophakic in the right eye. The left eye was phakic. Visual acuity (VA) was counting fingers at 3 meters in the right and 0.1 in the left eye. Intraocular pressure (IOP) was 14 mmHg in both right and left eyes. In the fundus examination, the right retina could not be evaluated clearly. In ultrasonography examination, the right retina was attached. Fundus examination of the left eye was normal. In the patient's recorded notes on postoperative day 1, VA of the right eye was 0.4 and IOP was 14 mmHg, and the anterior segment examination revealed clear cornea and quiet anterior chamber. In the postoperative first week, 25 µg/mL 0.1 cc tissue plasminogen activator injection was performed due to fibrin reaction in the anterior chamber. As wrinkle in Descemet membrane and corneal edema persisted despite the regression of fibrin one day after injection, anterior segment optical coherence tomography (OCT) was performed for suspected Descemet membrane detachment. Total Descemet membrane detachment was observed in OCT. Sulfur hexafluoride (SF6) was injected into the anterior chamber to treat Descemet membrane detachment. It was observed that corneal edema and keratic stria disappeared, VA increased to 0.3, IOP was 14 mmHg, cornea was clear, there was gas in the anterior chamber and the fibrin was completely regressed on the first day after SF6 injection. In this study, we aimed to present a case with total Descemet membrane detachment with accompanying postoperative fibrin membrane and our successful treatment.

**Keywords:** Descemet membrane detachment, fibrin reaction, phacoemulsification, tPA

### ÖZ

Bir hafta önce sağ gözünden fakoemülsifikasyon ve göz içi lens cerrahisi olan 85 yaşındaki erkek hasta, tarafımıza 1. hafta kontrolü için başvurdu. Hasta ameliyatın 1. gününden itibaren görmesinin yavaşça azaldığını ifade etti. Ön segment muayenesinde sağ gözde kornea ödemi, Descemet membranında kırışıklık, ön kamarada fibrin reaksiyon ve psö dofakik izlendi. Sol göz fakik idi. Görme keskinliği (GK) sağda 3 metreden parmak sayma (mps), solda 0,1 seviyesinde, göz içi basıncı (GİB) sağ ve solda 14 mmHg olarak izlendi. Fundus muayenesinde sağ retina net olarak değerlendirilemedi. Ultrasonografi'de sağ retina yatışık izlendi. Sol göz fundus muayenesi doğal gözlendi. Hastanın postoperatif 1. gün kontrolünde kaydedilmiş notlarında sağ göz GK seviyesi 0,4, GİB 14 mmHg idi, ön segment muayenesinde korneanın saydam ve ön kamaranın sakin olduğu izlendi. Postoperatif 1. haftada ön kamarada fibrin reaksiyon olması nedeniyle 25 µg/mL 0,1 cc doku plazminojen aktivatörü enjeksiyonu uygulandı. Enjeksiyondan 1 gün sonra fibrinin gerilemesine rağmen Descemet membran kırışıklığının ve kornea ödeminin aynı şekilde devam etmesi nedeniyle Descemet membran dekolmanı şüphesiyle ön segment optik koherans tomografi (OCT) çekildi. Çekilen OCT'de total Descemet membran dekolmanı izlendi. Descemet membran dekolmanını tedavi etmek amaçlı ön kamaraya sülfür hekzaflorür (SF6) enjeksiyonu uygulandı. SF6 enjeksiyonu sonrası ilk gün kornea ödeminin ve keratik strianın kaybolduğu, GK'nin 0,3 seviyesine çıktığı, GİB'nin 14 mmHg, korneanın saydam olduğu, ön kamarada gaz olduğu ve fibrinin tamamen gerilemiş olduğu gözlendi. Bu çalışmamızda postoperatif fibrin membrana eşlik eden total Descemet membran dekolmanı olan bir olguyu ve başarılı olan tedavimizi sunmayı amaçladık.

**Anahtar Kelimeler:** Descemet membran dekolmanı, fibrin reaksiyon, fakoemülsifikasyon, tPA



Address for Correspondence/Yazışma Adresi: Mustafa Suat Alıkma, İstanbul Training and Research Hospital, Clinic of Ophthalmology, İstanbul, Turkey  
Phone: +90 532 171 55 71 E-mail: m.suatalikma@gmail.com ORCID ID: orcid.org/0000-0002-3621-1892

Cite this article as/Atıf: Alıkma MS, Ünsal E, Akçetin T, Çubuk MÖ, Eltutar. Postoperative Fibrin Reaction and Descemet Membrane Detachment: A Case Report. İstanbul Med J 2019; 20(2): 165-8.

Received/Geliş Tarihi: 20.05.2017  
Accepted/Kabul Tarihi: 28.05.2018

## Introduction

Cataract surgery has become a less aggressive surgery in the light of recent surgical techniques and accompanying technological advances. Over the years, the incisions got smaller in the surgical techniques, thus resulting in less postoperative inflammation and astigmatism (1). At the same time, intraocular pressure (IOP) has become more stable during surgery as an advantage of surgery in a closed environment, and as a result, complications such as choroidal bleeding have become less common (2).

Despite all these advances in surgical technique, Descemet membrane detachment may occur due to surgical instruments entering the eye from the corneal incision. Progressive post-operative corneal edema is an alerting factor for the surgeon (3). The definitive diagnosis is made by anterior segment optical coherence tomography (OCT) (4). Sterile air, sulfur hexafluoride (SF<sub>6</sub>) gas and perfluoropropane (C<sub>3</sub>F<sub>8</sub>) gas can be injected into the anterior chamber for the treatment of Descemet membrane detachment (5-7).


Post-operative inflammation can be controlled by the use of anti-inflammatory drugs that suppress inflammation in the eye. Antibiotic treatment in addition to anti-inflammatory treatment is important for endophthalmitis prophylaxis (8). In addition to surgical trauma, BSS solution used to generate volume during surgery, molecular structures and production techniques of viscoelastic substances are also effective in the development of post-operative inflammation (9).

In this study, we aimed to present a case with Descemet membrane detachment and accompanying fibrin reaction after cataract surgery.


## Case Report

An 85-year-old male patient who underwent phacoemulsification surgery in his right eye with a diagnosis of nuclear cataract was discharged on the first day after surgery with clear cornea, (+1) cell in the anterior chamber and normal IOP. Moxifloxacin eye drop seven times a day (Avelox, Alcon) and prednisolone eye drop seven times a day (Pred Forte, Allergan) were prescribed after discharge. The patient was called for control examination after 1 week. In the post-operative first week control, it was observed that the cornea was edematous, there were keratic striae, the anterior chamber details could not be selected clearly and there was fibrin reaction in the anterior chamber (Figure 1). Visual acuity (VA) was counting fingers at 3 meters and IOP was 14 mmHg. Posterior segment examination with indirect ophthalmoscope could not be performed due to corneal edema and fibrin membrane. In the fundus examination, only normal retinal reflection could be observed. In ultrasonography examination, the retina was attached and the vitreous was normal. The patient stated that he had seen well on the morning after the surgery, but that VA decreased slowly within one week. The absence of these findings on the morning of post-operative day one and the detection of these findings after 1 week confirmed the statements of the patient. The patient had no complaints of pain, but he had complaints of stinging and burning. Endophthalmitis was considered initially, however, this diagnosis could not be made due to lack of pain and presence of normal vitreous. Because of fibrin reaction, 25 µg/mL 0.1 cc alteplase [tissue plasminogen activator (tPA), Actilyse,


Boehringer Ingelheim Pharmaceuticals Inc., Germany)] was injected into the anterior chamber initially. On the first day after injection, fibrin reaction and flare were observed to regress. However, it was thought that there might be Descemet membrane detachment due to persistence of keratic striae and corneal edema (6,10). An anterior segment OCT (3D-2000 Series, Topcon, Japan) was performed to support this diagnosis. Descemet membrane detachment was detected in OCT (Figure 2). The cause of progressive corneal edema and keratic striae was thought to be Descemet membrane detachment. 0.05 cc of pure



**Figure 1.** Corneal edema, keratic striae and fibrin reaction in the anterior chamber




**Figure 2.** Descemet membrane detachment in the anterior chamber in optical coherence tomography



**Figure 3.** Gas seen after injection of sulfur hexafluoride 6 into the anterior chamber





**Figure 4.** Regressed Descemet membrane detachment after the injection of sulfur hexafluoride 6 into anterior chamber and its visualization in optical coherence tomography

SF6 gas (Vefa Medical, Turkey) was injected into the anterior chamber. On the evening of the injection, the patient was ensured to lie on his back and to look at the ceiling. On the next day, although there was air-fluid limit just above the optical axis, it was found that the VA was 0.3, corneal edema regressed and keratic striae decreased (Figure 3). The weekly examinations showed that the gas in the anterior chamber was slowly absorbed, the fibrin reaction in the anterior chamber did not develop again, and the cornea remained normal. The control OCT also confirmed that Descemet membrane was attached (Figure 4). Written informed consent was obtained from the patient for this study.

## Discussion

In case of dominant post-operative inflammation for various reasons, fibrin reaction may be observed in the anterior chamber depending on the number of cells and severity of inflammation (11). Therefore, the possibility of post-operative fibrin reaction is higher in patients with uveitis (12). Reaction time in the anterior chamber advice the surgeon whether the reaction is sterile or infective. In case of intense cell and fibrin reaction in the anterior chamber on post-operative day one, toxic anterior segment syndrome (TASS) is considered initially (13). TASS is not infective and responds well to topical and systemic steroids (14,15). In the reaction occurring later in the post-operative period, infective causes are more likely. Infective reasons should be considered in the anterior chamber reactions, especially after the post-operative day four (16). TASS has painless anterior chamber reaction and hypopion, whereas eye pain and perilimbal injection are accompanied to this situation in infective anterior chamber reactions (14). In our patient, we suspected infective anterior chamber reaction due to the formation of anterior chamber reaction in the late period and presence of accompanying (+++++) cells in the anterior chamber. However, we thought that the patient could have an inflammatory event due to the lack of hyperemia in his conjunctiva, lack of ciliary injection and pain. Since we considered an inflammatory event in the patient, we injected tPA into the anterior chamber, which can be used to treat the fibrin reaction (17). Although the dose of injected tPA was different in many studies, we used the same treatment dose in another study conducted in our country (18). While the fibrin reaction and flare were regressed with treatment, we suspected endothelial insufficiency due to Descemet wrinkles and corneal edema, and performed anterior segment OCT. We detected Descemet membrane detachment in the OCT. We injected 0.05

cc of SF6 gas into the anterior chamber to treat Descemet membrane detachment. As a result, observation of fibrin reaction and cell in the anterior chamber in the post-operative period may be predictive of two different clinical entities according to time. TASS was observed one week after surgery in our patient, even though it is an expected finding in the post-operative day one. Ciliary injection, pain, and hyperemia in anterior chamber reactions also guide the ophthalmologist about the severity of the situation.

## Conclusion

In patients with a prediagnosis of TASS, the observation of keratic striae, as well as corneal edema, may give the physician an idea about accompanying Descemet membrane detachment. In this situation, it is possible to treat Descemet membrane detachment with sterile air, SF6 gas and C3F8 gas injected into the anterior chamber.

**Informed Consent:** Written informed consent was obtained from the patient for this study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Design - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Supervision - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Resources - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Materials - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Data Collection and/or Processing - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Analysis and/or Interpretation - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Literature Search - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Writing Manuscript - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.; Critical Review - M.S.A., E.Ü., T.A., M.Ö.Ç., K.E.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

- Gözüm N. Katarakt ve tedavisi. Klinik gelişim 2012; 25: 12-5.
- Can İ, Takmaz T, Nacaroglu ŞA, Genç İ, Soyugelen G. Bimanuel küçük kesili katarakt cerrahisi. Glo-Kat 2007; 2: 227-35.
- Bhattacharjee H, Bhattacharjee K, Medhi J, Altaf A. Descemet's membrane detachment caused by inadvertent vancomycin injection. Indian J Ophthalmol 2008; 56: 241-3.
- Kothari S, Kothari K, Parikh RS. Role of anterior segment optical coherence tomogram in Descemet's membrane detachment. Indian J Ophthalmol 2011; 59: 303-5.
- Ellis DR, Cohen KL. Sulfur hexafluoride gas in the repair of Descemet's membrane detachment. Cornea 1995; 14: 436-7.
- Macsaï MS, Gainer KM, Chisholm L. Repair of Descemet's membrane detachment with perfluoropropane (C3F8). Cornea 1998; 17: 129-34.
- Kim IS, Shin JC, Im CY, Kim EK. Three Cases of Descemet's membrane detachment after Cataract Surgery. Yonsei Med J 2005; 46: 719-23.
- Aslan L. Prevention and treatment of bacterial endophthalmitis after cataract surgery. Clin Anal Med 214; 5: 353-7.
- Althomali TA. Viscoelastic substance in prefilled syringe as an etiology of Toxic Anterior Segment Syndrome. Cutan Ocul Toxicol 2016; 35: 237-41.



10. Kim IS, Shin JC, Im CY, Kim EK. Three cases of descemet's membrane detachment after cataract surgery. *Yonsei Med J* 2005; 46: 719-23.
11. Cunha LP, Costa-Cunha LVF, Costa CF, Bastos RR, Prata TdS, Monteiro MLR. Predictive factors for anterior chamber fibrin formation after vitreoretinal surgery. *Rev Bras Oftalmol* 2014; 73: 93-7.
12. da Rocha Lima B, Pichi F, Nucci P, Srivastava SK, Lowder CY. Fibrin reaction after uveitic cataract surgery: treatment and prevention. *Eur J Ophthalmol* 2014; 24: 626-8.
13. Öner Ö, Akova YA, Usta YB. Toxic Anterior Segment Syndrome (TASS). *Turk J Ophthalmol* 2011; 41: 407-13.
14. Dereli G, Takmaz T. Fakoemulsifikasyon sonrası toksik anterior segment sendromu. *Turk J Ophthalmol* 2013; 43: 377-80.
15. Cornut PL, Chiquet C. (Toxic anterior segment syndrome). *J Fr Ophtalmol* 2011; 34: 58-62.
16. Somani S, Grinbaum A, Slomovic AR. Postoperative endophthalmitis: incidence, predisposing surgery, clinical course and outcome. *Can J Ophthalmol* 1997; 32: 303-10.
17. Akçetin T, Eltutar K, Dinçer N, Özdemir F. Komplikszyonsuz katarakt ameliyatından sonra gelişen fibrin membran pupiller blok glokomunun intrakamaral tpa ile tedavisi: olgu sunumu. *İstanbul Med J* 2015; 16: 42-4.
18. Başarı B, Eren H, Pınarcı EY, Altan Ç, Mert S, Demirok A, et al. Katarakt ameliyatı sonrası fibrin membran tedavisinde doku plazminojen aktivatörünün klinik kullanımı. *Glo-Kat* 2012; 7: 109-12.

# Palpable Purpura in a Patient with Uncontrolled Type 2 Diabetes Mellitus: Possible Side Effect of Linagliptin

## Kontrolsüz Tip 2 Diabetes Mellitus'lu Bir Hastada Palpabl Purpura: Linagliptinin Muhtemel Yan Etkisi

Ömercan Topaloğlu, Bahri Evren, İbrahim Şahin

İnönü University Faculty of Medicine, Department of Endocrinology, Malatya, Turkey

### ABSTRACT

Linagliptin is a member of "Dipeptidyl Peptidase-4" (DPP-4) inhibitors and may be preferred for certain advantages. We present a type 2 diabetes case with developed skin findings after initiation of linagliptin. A 66-year-old type 2 diabetic woman with coronary heart disease for 10 years was admitted to our clinic with dry mouth, polydipsia and polyuria. She was on metformin, acetylsalicylic acid and nitrate treatment. The physical examination was unremarkable. On admission, blood glucose was 319 mg/dL, urine ketone was negative, serum biochemistry and arterial blood gas results were within normal limits. Linagliptin was added to treatment after glycemic regulation was achieved with intensive insulin regimen. On the second day of linagliptin treatment, palpable purpura-like lesions were seen in the lower and upper extremities. Linagliptin was considered as an etiological factor. After discontinuation of linagliptin, the lesions gradually regressed. DPP-4 inhibitors may lead to some dermatological side effects due to inhibition of other DPP enzymes. To the best of our knowledge, our case is the first case in the literature to develop palpable purpura after linagliptin treatment.

**Keywords:** Diabetes, linagliptin, palpable purpura

### ÖZ

Linagliptin, "Dipeptidil Peptidaz-4" (DPP-4) inhibitörlerinin bir üyesidir ve bazı avantajlarından dolayı tercih edilebilir. Linagliptin başlandıktan sonra deri bulguları gelişen tip 2 diyabetli bir olguyu sunuyoruz. On yıldır koroner kalp hastalığı olan 66 yaşında tip 2 diyabetli kadın hasta kliniğimize ağız kuruluğu, polidipsi ve poliüri ile başvurdu. Metformin, asetilsalisilik asit ve nitrat kullanan hastanın fizik bakışı normal sınırlardaydı. Başvuruda, kan glukozu 319 mg/dL, idrar ketonu negatif, serum biyokimya ve arteriyel kan gazı normal sınırlarda saptandı. İntensif insülin rejimi ile glisemik regülasyon sağlandıktan sonra linagliptin eklendi. Linagliptin tedavisinin 2. gününde, hastanın alt ekstremitelerinde ve kollarında palpabl purpura benzeri lezyonlar ortaya çıktı. Etiyolojik faktör olarak linagliptin düşünüldü. Linagliptin kesildikten sonra lezyonlar kademeli olarak geriledi.

DPP-4 inhibitörleri diğer DPP enzimlerinin inhibisyonu sebebiyle bazı dermatolojik yan etkilere yol açabilir. Bildiğimiz kadarıyla, bizim olgumuzda literatürde ilk defa linagliptin tedavisi sonrasında palpabl purpura gelişmiştir.

**Anahtar Kelimeler:** Diyabet, linagliptin, palpabl purpura

### Introduction

Several oral antidiabetic agents have been widely used for the management of type 2 diabetes mellitus. In clinical practice, some factors, such as age, body weight, clinical features, risk of hypoglycemia, and side effects of the drugs, lead us to choose specific agents or a combination of these agents. In addition to these factors, comorbid conditions, such as cardiovascular disorders, become more important for practitioners when choosing therapeutic agent for diabetes. Hence, cardiovascular safety studies become a prerequisite for some new oral antidiabetic drugs that have emerged in last years. One of the new classes of these agents is "Dipeptidyl Peptidase-4 inhibitors" (DPP-4 inhibitors). Studies regarding

cardiovascular safety of this class of agents have been reported in recent years (1).

Several types of DPP-4 inhibitors are available worldwide. The DPP-4 inhibitors block DPP-4 enzyme and hence inhibit degradation and increase the serum concentrations of both "Glucagon-like Peptide-1" and "Glucose-dependent Insulinotropic Peptide". Several reports showed that some side effects, such as pharyngitis, arthralgia, headache, myalgia, or pancreatitis, could be observed in patients using a member of DPP-4 inhibitor (2,3). Post-marketing reports demonstrated skin findings such as rash or Stevens-Johnson syndrome, based on therapeutic use of DPP-4 inhibitors. Some of the side effects of DPP-4 inhibitors may be due



**Address for Correspondence/Yazışma Adresi:** Ömercan Topaloğlu, İnönü University Faculty of Medicine, Department of Endocrinology, Malatya, Turkey

**Phone:** +90 505 968 18 17 **E-mail:** drhomercan@hotmail.com **ORCID ID:** orcid.org/0000-0003-3703-416X

**Cite this article as/Atıf:** Topaloğlu Ö, Evren B, Şahin İ. Palpable Purpura in a Patient with Uncontrolled Type 2 Diabetes Mellitus: Possible Side Effect of Linagliptin. İstanbul Med J 2019; 20(2): 169-71.

**Received/Geliş Tarihi:** 24.01.2018

**Accepted/Kabul Tarihi:** 23.05.2018

to the blockage of other subclasses of DPP enzyme family. Especially, some DPP-4 inhibitors have an electrophilic trap making them unstable, and these have a low selectivity against DPP-8 and DPP-9 (4). One study showed that DPP-9 enzyme was expressed in skin cells (5). However, since DPP-8 and DPP-9 enzymes are also responsible for T-cell activation, inhibition of these enzymes by DPP-4 inhibitors may cause side effects such as skin reactions (4). Therefore, the selectivity of the drug to DPP-4 enzyme becomes evident when evaluating its side effects.

Linagliptin is one of the members of DPP-4 inhibitors that have been approved by FDA in May 2011 and is often preferred due to some advantages over the others; for example, dose reduction is not needed in patients with decreased renal function. Linagliptin, a selective inhibitor for DPP-4, inhibits DPP-4 enzyme with a 40.000-fold and >10.000-fold higher activity than DPP-8 and DPP-9, respectively (6). It has a greater potency than other DPP-4 inhibitors (7). Several case reports have demonstrated some skin reactions associated with the use of DPP-4 inhibitors such as sitagliptin, vildagliptin and saxagliptin. Lower rates of skin findings associated with linagliptin use may be due to its higher selectivity. To the best of our knowledge, only one case report showed a skin reaction like blistering and ulceration after linagliptin treatment (8). We present a type 2 diabetes case with palpable purpura like lesions after the initiation of linagliptin.

## Case Report

A 66-year-old woman with a history of type 2 diabetes for ten years was admitted to our clinic with complaints of dry mouth, polydipsia and polyuria. Recently, she experienced severe emotional stress due to social issues. She also had history of coronary heart disease confirmed by coronary angiography. She did not have any other comorbid disease. She was taking metformin (1000 mg, twice a day), acetylsalicylic acid (100 mg, once a day), and oral nitrate (20 mg, twice a day) for ten years. On physical examination, vital signs were stable. Examinations of cardiovascular, pulmonary and gastrointestinal systems were normal. She had no skin rash or lesion. Routine laboratory tests were performed. White blood cell, hemoglobin (Hb), and platelet counts were 3900/ $\mu$ L, 13.6 g/dL, and  $203 \times 10^3$ / $\mu$ L, respectively. Blood glucose was 319 mg/dL and HbA1c was 5.7% (39 mmol/mol). Other biochemical tests were as follows: BUN=21.44 mg/dL, creatinine=0.78 mg/dL, ALT=25 U/L, AST=44 U/L, ALP=106 U/L, GGT=40 U/L, direct/total bilirubin=0.12/0.34 mg/dL, Na=134 mmol/L, K=5.1 mmol/L, Cl=101 mmol/L, Ca=9.3 mg/dL, P=2.9 mg/dL, albumin=3.9 g/dL, total protein=7.5 g/dL, high-density lipoprotein=43 mg/dL, low-density lipoprotein=109 mg/dL, triglyceride=110 mg/dL and total cholesterol=175 mg/dL. Coagulation parameters were as follows: INR=1, activated partial thromboplastin time=30.2 seconds. Arterial blood gas analysis revealed mild metabolic acidosis with pH=7.31,  $\text{HCO}_3^-$ =18.6, mmol/L,  $\text{pCO}_2$ =35 mmHg and  $\text{pO}_2$ =64.7 mmHg. She had no ketonuria, but glycosuria was determined as 4+. She had microalbuminuria, determined as urinary albumin/creatinine ratio 80 mg/g.

We managed the patient with the diagnosis of uncontrolled diabetes. First, we initiated a basal-bolus intensive insulin regimen with strict glucose monitoring to improve uncontrolled hyperglycemia. We also continued treatment with metformin in addition to intensive insulin

regimen. Initial insulin doses were pre-prandial 3x6 units glulisine and 1x10 units insulin glargine at 11:00 pm. We gradually increased insulin doses. The final insulin regimen doses were 3x10 units insulin glulisine and 1x16 units insulin glargine. We regulated dysglycemia of the patient. For screening, ophthalmological examination was performed and retinopathy was not detected. Linagliptin was added to the treatment on the fifth day of hospitalization to reduce the dose of insulin. We continued strict blood glucose monitoring. Palpable purpura like lesions, ranging from 0.3 to 1.5 cm in diameter, appeared in lower and upper extremities of the patient on the second day of linagliptin treatment (Figure 1). We did not take biopsy from lesions. After discontinuation of linagliptin, palpable purpura both in lower and upper extremities regressed gradually. We have received written informed consent from the patient.

## Discussion

Combination therapies are commonly used in the management of type 2 diabetes. DPP-4 inhibitors may also be added to the treatment of type 2 diabetic patients taking insulin. Some studies have showed that an increased rate of hypoglycemia can be observed in patients with type 2 diabetes who have combination therapy with DPP-4 inhibitor and insulin (9). Therefore, in patients with type 2 diabetes having intensive insulin regimen, addition of an oral DPP-4 inhibitor may obligate to change the insulin doses. In addition to hypoglycemia, several adverse events, such as skin findings, may be detected in patients given oral DPP-4 inhibitors.

Some post-marketing reports have shown that cutaneous reactions such as Stevens-Johnson syndrome are observed in patients receiving alogliptin (10). In one study, increased skin-related events were detected in patients receiving alogliptin compared with placebo; these were mostly pruritus and rash (11). Several reports have shown that bullous pemphigoid may also be observed in patients taking vildagliptin or sitagliptin (12). Sitagliptin has also been found to cause maculopapular drug eruption in some cases (13). One case report showed fixed drug eruption in a patient receiving sitagliptin therapy (14). Succurro et al. (15) reported that a patient with type 2 diabetes complained of loss of eyebrows and eyelashes 4 months after the initiation of sitagliptin/metformin combination treatment.



**Figure 1.** Palpable purpura arised on the left thigh of the patient on the second day of linagliptin

Palpable purpura are non-blanching skin lesions ranging 0.3 to 1 cm in diameter and are clinical signs of cutaneous small vessel vasculitis. A list of medications, such as penicillin, antineoplastic agents, and anticonvulsants, may incite this finding (16). Some infectious agents such as hepatitis B or C virus may also be associated with cutaneous small vessel vasculitis (16). Numerous reports have been written on the relationship of palpable purpura with drugs, however, the number of diabetic patients with palpable purpura was caused by the use of oral antidiabetic agents was limited. Leukocytoclastic vasculitis has been reported in two diabetic cases taking metformin or glyburide (17,18), however, no cases of palpable purpura associated with use of DPP-4 inhibitors were reported in the literature. Psomadakis et al. (8) reported that a 60-year-old man developed blisters on his hands as a result of linagliptin treatment. The lesions resolved after discontinuation of the drug. Repeated exposure to the drug caused two large blisters on the left foot and resulted in secondary infection. To the best of our knowledge, our case report is the first report of palpable purpura associated with linagliptin in the literature.

Although linagliptin has the highest selectivity for DPP-4 enzyme, some effects on other DPP enzymes (especially DPP-8 and DPP-9) may cause musculoskeletal and dermatological adverse reactions during treatment with linagliptin. Metformin may be implicated for the development of skin reactions, but our patient had been taking metformin for ten years. To demonstrate leukocytoclastic vasculitis histopathologically, biopsy should be taken from palpable purpura lesions. We did not take biopsy specimen and clinically observed the patient after the discontinuation of linagliptin. Then, the lesions subsided gradually. Our patient also had been taking another medication with potential for cutaneous side effects. However, linagliptin was the only drug patient started to use just before the rash. We did not challenge the patient with linagliptin after resolution of the cutaneous reaction. In such cases, occurrence of the skin lesion after a re-challenge with the same drug strongly suggests the diagnosis of a drug-related skin reaction.

New cases with skin findings thought to be associated with linagliptin should be reported, and further clinical studies examining the skin reactions of diabetic patients treated with linagliptin will clarify these issues.

### Acknowledgements

We presented this case as an abstract in "53<sup>th</sup> national congress of diabetes, 2017, Turkey".

**Informed Consent:** We have received written informed consent from the patient.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - Ö.T., B.E., İ.Ş.; Design - Ö.T., B.E., İ.Ş.; Supervision - Ö.T., B.E., İ.Ş.; Data Collection and/or Processing - Ö.T., B.E., İ.Ş.; Analysis and/or Interpretation - Ö.T., B.E., İ.Ş.; Literature Search - Ö.T.; Writing Manuscript - Ö.T.; Critical Review - Ö.T., İ.Ş.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

### References

1. Špinar J, Špinarová L, Vítovec J. The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes? *VnitrLek* 2015; 61: 976-83.
2. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. *Diabetes Res Clin Pract* 2007; 76: 132-8.
3. FDA. FDA Sitagliptin. 2009. Available at <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm183768.htm>.
4. Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. *Clin Exp Pharmacol Physiol* 2015; 42: 999-1024.
5. Gabrilovac J, Čupić B, Zapletal E, Kraus O, Jakić-Razumović J. Dipeptidylpeptidase 9 (DPP9) in human skin cells. *Immunobiology* 2017; 222: 327-42.
6. Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. *J Med Chem* 2007; 50: 6450-3.
7. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. *Expert Opin Investig Drugs* 2010; 19: 133-40.
8. Psomadakis C, Shahzad N, Katz J. Linagliptin-associated blistering and ulceration. *BMJ Case Rep* 2017; 2017. pii: bcr-2017-219998.
9. Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2010; 12: 167-77.
10. Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. *Clin Ther* 2008; 30: 499-512.
11. Nauck M, Ellis G, Fleck P, Wilson C, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. *Int J Clin Pract* 2009; 63: 46-55.
12. Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. *J Dermatol Case Rep* 2014; 8: 24-8.
13. Nakai N, Katoh N. Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: a case report and mini-review of the published work. *Allergol Int* 2014; 63: 489-91.
14. Gupta M, Gupta A. Fixed drug eruption to sitagliptin. *J Diabetes Metab Disord* 2015; 14: 18.
15. Succurro E, Palleria C, Ruffo M, Serra R, Arturi F, Gallelli L. Loss of eyebrows and eyelashes during concomitant treatment with sitagliptin and metformin. *Curr Drug Saf* 2017; 12: 10-2.
16. Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. *Am J Med* 1997; 102: 186.
17. Ben Salem C, Hmouda H, Slim R, Denguezli M, Belajouza C, Bouraoui K. Rare case of metformin-induced leukocytoclastic vasculitis. *Ann Pharmacother* 2006; 40: 1685-7.
18. Henley JK, Blackmon JA, Fraga GR, Rajpara A, Maz M. A case of glyburide-induced leukocytoclastic vasculitis. *Dermatol Online J* 2013; 19: 19619.



# Why is the Medical Symbol a Snake?

## Tıbbın Sembolü Neden Yılan?

● Ekrem Güner<sup>1</sup>, ● Kamil Gökhan Şeker<sup>1</sup>, ● Şebnem İzmir Güner<sup>2</sup>

<sup>1</sup>University of Health Sciences, İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Urology, İstanbul, Turkey

<sup>2</sup>Esenyurt University, Memorial Şişli Hospital, Clinic of Internal Medicine and Hematology, İstanbul, Turkey

### ABSTRACT

Currently, health-related professions and institutions are symbolized with an illustration of a snake wrapped around a branch of a tree, a stick or a rod. In this article, we will try to find out why the snake, which has influenced the humankind since the ancient ages and has been given place in legends and mythologies, has been depicted in ancient age reliefs, statues and coins, and has taken part in written texts, is accepted as the symbol of health and medicine in the light of ancient archaeological coin images.

**Keywords:** Asclepius, Hermes, Caduceus, Medicine, Snake, Symbol, Coin

### ÖZ

Günümüzde sağlıkla ilgili meslekler ve kurumlar, dal, sopa veya asaya sarılmış yılan resmiyle sembolize edilmektedir. Bu yazımızda antik çağdan itibaren insanı etkilemiş, efsane ve mitolojilerde geçmiş, antik dönem rölyef, heykel ve sikkelerde resmedilmiş, yazılı metinlere girmiş olan yılanın neden sağlığın ve tıbbın sembolü olarak seçildiğini antik dönem arkeolojik sikke görselleri eşliğinde ortaya çıkarmaya çalışacağız.

**Anahtar Kelimeler:** Asklepios, Hermes, Kadukeus, Tıp, Yılan, Sembol, Sikke

### Introduction

Nowadays, health-related professions and institutions are symbolized with an illustration of a snake wrapped around a branch of a tree, a stick or a rod. Although there are various animals that have protective instincts for humans or that can communicate with human beings, an association has been accepted to be present between health and this unpleasant and cold creature. Indeed, it is difficult to find any other creature other than the snake that has been attributed such negative meanings. It was once considered a God and was expected to offer remedies (1-3), and then was regarded as a scary creature that could kill humans with its poison.

The snake has influenced mankind since ancient times and has been given a place in legends and mythologies. It was also depicted in ancient age reliefs, statues and coins, and was included in written texts. In this article, we are going to discuss in the light of ancient age coin visuals why the snake is accepted as the symbol of health and medicine.

He was also depicted in antique reliefs, sculptures and coins, and was included in written texts. In this article, we will discuss why the snake is considered a symbol of health and medicine in the light of ancient coins.

### Discussion

Snake is different from other animals, as it can slough its skin off, move fast despite the absence of feet and live underground, above the ground and under water (1,4). Thanks to these characteristics, it has attracted the attention of mankind since ancient times, and it has been regarded to be holy and protecting, respected with slight fear, and even worshipped to it. (5).

Throughout history, the snake has been attributed several features such as renewal, youth, fertility, medicine, long life, immortality, common sense, precaution, physical power, potency, wisdom, farsightedness, prophecy, good luck and speed (5-10). The main reason for the association of snake with health is that it gets renewed and rejuvenated by sloughing its skin off. This is a process that symbolizes the metamorphosis among birth, life and death (4,6,11-13). Furthermore, as an animal that can live underground, above the ground and under water, snake is deemed to be a creature which knows the best about the healing power of nature that is evident in natural spring waters, flowers and herbs and thus, the symbol of health and medicine is attributed to it (14).

It is not known exactly where and when the snake first appeared in mythologies and legends, but it is observed to have taken a significant



**Address for Correspondence/Yazışma Adresi:** Kamil Gökhan Şeker, University of Health Sciences, İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Urology, İstanbul, Turkey

**Phone:** +90 505 697 21 19 **E-mail:** gkhnsaker@hotmail.com **ORCID ID:** orcid.org/0000-0003-4449-9037

**Cite this article as/Atıf:** Güner E, Şeker KG, İzmir Güner Ş. Why is the Medical Symbol a Snake? İstanbul Med J 2019; 20(2): 172-5.

**Received/Geliş Tarihi:** 21.02.2018

**Accepted/Kabul Tarihi:** 03.11.2018

role in the Eastern and Asian mythologies since 3000 B.C. Mesopotamian workpieces and structures belonging to 2800 B.C. have reliefs and legends about snakes. The most important of these is the Epic of Gilgamesh. A snake took away the jiaogulan that a hero named Gilgamesh took out of the water. Once the snake ate this plant, it sloughed its skin off and rejuvenated (5,15).

Snake is also important in the Egyptian mythology and it has preserved the holy city, Thebai. Thebai is the most prominent health center in ancient Egypt and its totem is a snake (16).

The ancient Greek world had some beliefs and mythologies from Mesopotamia and Egypt, and it accepted the snake as the symbol of eternal life. Asclepius, The God of medicine, was often portrayed in statues, reliefs and coins as experienced and at adult age, accompanied with a snake wrapped around a branch symbolizing the tree of life (17,18) (Figure 1a). This branch is his rod and the snake is usually depicted as wrapped around it (19,20) (Figure 1b). Images of isolated snakes with head up and moving forward in curls mainly symbolize the Asclepius (Figure 1c). The word Asclepius is thought to be derived from

the word “askalabos”, which means “snake” in Greek (14,21).

As the symbol of Asclepius, which is a snake, is believed to possess eternal youth as it sloughs its skin off, it was directly associated with health in the ancient Greek world (5). Asclepius was claimed to take its healing power from the snake and the people offered their vows not to Asclepius but to the snake, indeed. When Asclepius became the God of medicine over time, the figure of a snake wrapped around the accessory of the God, which is the rod, became the symbol of his healing power (22-24).

Asclepius was represented as an old and trustable man with a rod in his hand. This shows that medical education will not be short and that the training and practice processes will last so long that one will grow old and hold a rod for support. According to Asclepius, the God of medicine and health, a doctor must also be as quiet as a snake, must not reveal anyone's secret to others, and work in patience and calmness.

There is no evidence about Caduceum (Figure 2), which is a double-headed snake figure wrapped around the winged rod, Caduceus (25),



**Figure 1.** a) Asclepius with his serpent-entwined staff, Archaeological Museum of Epidaurus, Greece,

b) The Roman period, Turkey, Asia Minor, Pamphylia Region, Bronze coin issued in Perge city from 161 to 180 B.C. Front side: Daphne crowned, bearded Emperor Marcus Aurelius. Back Side: The God Asclepius is standing holding his rod wrapped with a snake,

c) The Hellenistic period, Greece. Silver tetrobol issued in Kos Island from 167 to 88 BC. Front side: Daphne crowned, bearded God Asclepius. Back side: Coiled snake with its head up



**Figure 2.** a) Statue of Hermes, From the Musei Vatican Museum, Rome, Italy,

b) The Hellenistic period, Turkey, Asia Minor, Mysia Region. Golden stater issued in Kyzikos town from 460 to 400 B.C. Front side: God Hermes, holding caduceus with his left hand. Back side: Quadripartite incus,

c) The Roman period, Turkey, Asia Minor, Phrygia Region. Bronze coin issued in Kibyra town from AD 218 to 222. Front side: Julia Soaemias. Back side: God Hermes is sitting, holding caduceus in his left hand



which belongs to another Greek God, Hermes (Mercury in Greek) (Figure 3a). In Europe, only at the end of the Middle age and in early Renaissance age, the double-headed snake wrapped around the winged rod of Hermes began to be used as a symbol associated with health (18,26-29). The first official use of Caduceum is claimed to be by the US Marine Service (29) (Figure 3b).

According to a research conducted in the US in 1992, 62% of professional medical institutions were using the snake wrapped around the rod of Hermes as a symbol, and medical commercial institutions were using the double-headed snake wrapped around Hermes' Caduceus (30) as their symbol.

However, double-headed snake figure of God Hermes is mostly not used by medical associations in Greece. Instead, the snake figure of God Asclepius that was originated from mythology serves as a symbol for several Greek medical associations (28).

Today, the single snake wrapped around the rod of Asclepius and the double-headed snake wrapped around the winged rod of Hermes are accepted as the symbols of medicine. Consequently, the common figures of both Gods, which are the snakes wrapped around a rod, were adopted as the symbol of health by health-related professions and institutions

and they used these in their logos. The figure of snake wrapped around a rod, which takes place in the logo of the World Health Organization, draws attention to the fact that it is very similar to the figure of snake wrapped around a rod, which was illustrated on ancient coins (Figure 4).

## Conclusion

Snake, which has been mentioned in legends, epics and mythologies since 3000 B.C. and which has taken place in visual or written form in ancient age statues, reliefs, coins and texts has appealed and influenced the humankind for centuries. Since the ancient Greek age, the reason for the snake to be accepted as the symbol of health has been explained in the light of the characteristics attributed to snake.

The snake's sloughing its skin off sort of means the renewal of life and rejuvenation. Throughout history, the snake has been attributed several features such as power, speed, farsightedness, good luck, healing, health and long life which are associated with the occupations that offer health and it highly deserves being the symbol of health and medicine considering the fact that even its poison is healing for the humankind.

Whether wrapped around the rod of Asclepius or Hermes, all the heroes of medicine proudly wear those snakes on their collars today as their own symbols.



**Figure 3.** a) The Early Roman period, Turkey, Asia Minor, Galatia Region. Bronze coin issued from 37 to 25 B.C. Front side: Hermes, wearing a hat and caduceus on his shoulder. Back side: Winged Caduceus (kerykeion),  
b) U.S Army Medical Department logo



**Figure 4.** a) The Early Roman period, Turkey, Asia Minor, Mysia Region, Bronze coin issued in Pergamon town from AD 100 to 200. Front side: Pegamos wearing a hat. Back side: A snake wrapped around a rod,  
b) The Hellenistic period, Turkey, Asia Minor, Mysia Region, Bronze coin issued in Pergamon town in 131 B.C. Front side: Daphne crowned, bearded God Asclepius. Back side: A snake wrapped around a rod,  
c) The remarkable similarity between the logo of the World Health Organization (WHO) and the snake wrapped around the rod of Asclepius

## References

1. Armutak A. Animal patens in the Eastern and Western Mythologies II. Reptiles, Fish, Avians and Mythological Animals. J Fac Vet Med Istanbul Univ 2004; 30: 143-57.
2. Hançerlioğlu O. İnanç Sözlüğü. Remzi Kitabevi İstanbul; 1975. pp.1-861.(In Turkish)
3. Yöndemli F. Tarih öncesinden günümüze yılan. Piramit yayıncılık; Ankara. 2004. (In Turkish)
4. Menez A. The subtle beats, Snakes from Myth to Medicine. New York: Taylor-Francis 2003; V4.
5. Campbell J. Doğu Mitolojisi, (Çev: Kudret Emiroğlu). İmge Yay Ankara; 1993.p.38. (Turkish Translate)
6. Lurker M (ED.) Snakes. In: Dictionary of gods and goddesses, devils and demons. London: Routledge. 1989. (transl. by M. O'Connell).
7. Hendel R Serpent. In: K. van der Toorn (ed.), Dictionary of deities and demons in the Bible. Leiden, New York, Köln: E.J. Brill; S 1995. pp. 1404-12.
8. Christy NP. On fear of serpents and ophiolatry. Trans Am Clin Climatol Assoc 1968; 79: 21-33.
9. Okuda J, Kiyokawa R. Snake as a symbol in medicine and pharmacy- a historical study. Yakushigaku Zasshi 2000; 35: 25-40.
10. Williams NW. Serpents, staffs, and the emblems of medicine. HolyBible, Genesis, Chapter 3, OldTestament.JAMA 1999.pp.281-475.
11. Allen N. The healing serpent in the Judaeo-Christian tradition. In: S. Kottak&H.F.J. Horstmanshoff (eds.), From Athens to Jerusalem. Rotterdam: Erasmus, 2000.pp. 203-25.
12. Bunn J T. Origin of the caduceus motif. JAMA 1967; 202: 615-9.
13. Lawrence C. The healing serpent-the snake in medical iconography. Ulster Med J 1978; 47: 134-40.
14. Rosenberg D. Dünya Mitolojisi. 4. Baskı. Ankara: İmge Kitabevi, 2006. (In Turkish)
15. Jackson, D. Gılgamış Destanı, Çev. Ahmet Antmen, Ankara: Arkadaş Yayınevi. 2013. (In Turkish)
16. Yöndemli, Fuat, Hayat ağacı ejder yılan. Nüve Kültür Merkezi ,İstanbul. 2006. (In Turkish)
17. Nayernouri T. Asclepius, Caduceus, and Simurgh as medical symbols, part I. Arch Iran Med 2010; 13: 61-8.
18. Blaeu K. The Caduceus vs. the Staff of Asclepius. 2005.
19. Bohigian GM. The staff and serpent of Asclepius. Mo Med 1997; 94: 210-1.
20. Wilcox RA, Whitham EM. The symbol of modern medicine: why one snake is more than two. Ann Intern Med 2003; 138: 673-7.
21. Kellie SM. Cult of Asclepius. The Lancet 1999; 354: 1038.
22. Leventi I. The iconography of Health in the classical years. Athens: Hellenic National Archive of Documents, 1991.p. 137.
23. van Straten F. Votives and Votaries in Greek Sanctuaries. In: Greek Religion. Ed. Buxton RGA. London: Oxford University Press, 2000.pp.247-90.
24. Caton R. The Temples and ritual of asklepios. 2<sup>nd</sup> Ed. London: C. J. Clay and Sons, 1900.
25. Larose C. The caduceus v. the staff of aesculapius. Can Med Assoc J 1979; 121: 158.
26. Retief FP, Cilliers L. History of medicine: snake and staff symbolism, and healing. S Afr Med J 2002; 92: 553-6.
27. Schouten J. The rod and serpent of Asklepios. Amsterdam, Elsevier, 1697. pp. 107-116.
28. Antoniou SA, Antoniou GA, Learney R, Grandrath FA, Antoniou AI. The rod and the serpent: history's ultimate healing symbol. World J Surg 2011; 35: 217-21.
29. Hart GD. The earliest medical use of the caduceus. Can Med Assoc J 1972; 107: 1107-10.
30. Friedlander WJ. The Golden Wand of Medicine. New York: Greenwood Press; 1992.



[illegible]